{"chunk_type":"transcript_chunk","text":"# DIP\nINTERNAL MEDICINE\n- Ep 29 (IM 1 Video)\n- Ep 30 (IM 2 Video)\n- Ep 31 (IM 3 Video)\n- Ep 32 (IM 4 Video)\n- Ep 41 (Antibiotic Guide)\n- Ep 100 (Clutch Micro)\n- Ep 104 (ACLS, Arrhythmias)\n- Ep 129 (Targeted Pulm)\n- Ep 244 (Valvular Disorders)\n- Ep 251 (Thyroid)\n- Ep 253 (Starling Forces)\n- Ep 293-NBME GI Series 1\n- Ep 294-NBME GI Series 2\n- Ep 295-NBME GI Series 3\n- Ep 298-NBME GI Series 4\n- Ep 318-NBME GI Series 5\n- Ep 319-NBME GI Series 6\n- Ep321-Clutch Metabolic Acidosis\n- Ep 331-Clutch Lung Cancer Podcast\n- Ep 332-Clutch Pleural Abnormalities/Effusions Podcast\n- Ep 333-Pressors/Inotropes for Step 2CK/3\n- Ep 339-The HY Pulmonary Embolism Podcast\n- Ep 353-The Clutch Pulmonary HTN Podcast\n- Ep 356-The Clutch UTI Podcast\n- Ep 360-The Clutch Secondary HTN Podcast\n- Ep 367-The Clutch Amyloidosis Podcast\n- Ep 376-Thyroid Cancer\n- Ep 384-IBDs and the USMLEs\n- Ep 404-The Floridly HY CXR Podcast\n- Ep 437-Infectious Populations (IVDUs)\n- Ep 439-Anion Gap Metabolic Acidosis 1\n- Ep 445-Clutch MI Complications\n- Ep 460-Floridly HY Antibiotic Review Part 1\n- Ep 461-Floridly HY Antibiotic Review Part 2\n- Ep 470-Numerical Acid Base Problems and the USMLEs\n- Ep 477-Clutch Acute Coronary Syndromes\n- Ep 492-The Clutch Septic Joint Podcast\n- Ep 496-Aortic regurgitation and some USMLE integrations\n- Ep 503-LFTs and The USMLEs\n- Ep 507-Clutch Sickle Cell Disease Part 1\n- Ep 508-Clutch Sickle Cell Disease Part 2\n- Ep 514-A Framework For Understanding Endocrine Testing\n- Ep 515-Ventilator Physiology Part 2\n- Ep 524-The Clutch Osteomyelitis Podcast\n- Ep 539-50 HY Corticosteroid facts to know for Step 1-3\n- Ep 550-The Iron Story and The USMLEs Part 1\n- Ep 552-The Iron Story and The USMLEs Part 2\n- Ep 554-What is this antibiotic used for?\n- Ep 570-The Clutch Skin and Soft Tissue Infections Podcast\n- Ep 586-Quick and Dirty Microbiology Associations\n- Ep 600-Intuition and Integrations With Select Equations\n- Ep 602-Endocrine Thinking (Stimulation and Suppression Te...)\n- Ep 605-The Extremely HY RBC Podcast\n- Ep 623-Last Minute Microbiology Review for Step 2 and 3\n- Ep 625-The 5 USMLE Gaps\nSURGERY\n- Ep 24\n- Ep 180 (Heme)\n- Ep 221 (Trauma)\n- Ep 377-GI Bleeds\n- Ep 304 (Trauma 2)\n- Ep 610-Imaging and The USMLEs (Part 1)\nOBGYN\n- Ep 22\n- Ep 118(Breast)\n- Ep239 (Risk factors)\n- Ep278(Amenorrhea)\n- Ep309(Breast Cancer)\n- Ep 338-Fetal Heart Rate Tracings\n- Ep 350-The Clutch Teratogen Podcast\n- Ep 357-Disorders of Sexual Differentiation\n- Ep 373-Progestin and Estrogen Challenge Tests\n- Ep 459-The Clutch STI Podcast\n- Ep 467-The Clutch Cervical Cancer Podcast\n- Ep 493-The Superclutch Infertility Podcast\n- Ep 531-The HY Contraceptive Podcast\nPSYCH\n- Ep 23\n- Ep 164 (Toxicology)\n- Ep 349-Psych Pharm\n- Ep 451-Serotonin Syndrome (with integrations)\n- Ep 452-NMS and Malignant Hyperthermia (vs serotonin syndr...)\n- Ep 453-Psychiatry Timelines\nPEDS\n- Ep 17\n- Ep 21\n- Ep 223 (Newborns)\n- Ep317(Breastfeeding, newborn jaundice)\n- Ep 326-Peds Cardio and Hemodynamic Changes\n- Ep 421-Pulmonary Pathophysiology Series 11\n- Ep 507-Clutch Sickle Cell Disease Part 1\n- Ep 508-Clutch Sickle Cell Disease Part 2\nNEURO\n- Ep 19 (Series 1)\n- Ep 45 (Series 2)\n- Ep 46 (Series 3)\n- Ep 47 (Series 4)\n- Ep 48 (Series 5)\n- Ep 49 (Series 6)\n- Ep 58 (Series 7)\n- Ep 59 (Series 8)\n- Ep 361-The Eye 1\n- Ep 365-The Eye 2\n- Ep 371-The Spinal Cord\n- Ep 372-Clutch Headache Podcast\n- Ep 374-Spinal Cord Lesions\n- Ep 435-Neuromuscular Junction Disorders\n- Ep 457-Horner's Syndrome\n- Ep 506-Weird but HY Spinal Cord Disorders\n- Ep 516-The Floridly HY Brain Tumor Podcast\n- Ep 543-Facial Muscle Weakness\n- Ep 546-Super HY USMLE Neurology Integrations\n- Ep 599-The Clutch Dementia Podcast\nRAPID REVIEW SERIES\n- Ep 94 (Series 1, Peds)\n- Ep 95 (Series 2, Peds)\n- Ep 119 (Series 3, IM)\n- Ep 120 (Series 4, IM/Peds)\n- Ep 121 (Series 5, IM/Peds)\n- Ep 125 (Series 6, IM)\n- Ep 126 (Series 7, IM)\n- Ep 127 (Series 8, OB)\n- Ep 128 (Series 9, IM)\n- Ep 130 (Series 10, Peds)\n- Ep 131 (Series 11, All)\n- Ep 134 (Series 12, IM)\n- Ep 141 (Series 13, IM)\n- Ep 145 (Series 14, Surgery)\n- Ep 153 (Series15, Surgery)\n- Ep 156 (Series 16, OB)\n- Ep 158(Series 17, Surgery)\n- Ep 159 (Series 18, IM)\n- Ep 163 (Series 19, Surgery)\n- Ep 166 (Series 20, Psych)\n- Ep 167 (Series 21, Cardio)\n- Ep 174 (Series 22, IM)\n- Ep 175 (Series 23, Psych)\n- Ep 177 (Series 24, OBGYN)\n- Ep 187 (Series 25)\n- Ep 189 (Series 26)\n- Ep 195 (Series 27)\n- Ep 196 (Series 28)\n- Ep 199 (Series 29)\n- Ep 202 (Series 30)\n- Ep 210 (Series 31)\n- Ep 211 (Series 32, Neuro)\n- Ep 219 (Series 33)\n- Ep 220 (Series 34)\n- Ep 225 (Series 35)\n- Ep 227 (Series 36-HY OB)\n- Ep 238 (Series 37)\n- Ep 240 (Series 38, OB/Ortho)\n- Ep 245-Series 39\n- Ep 247-Series 40\n- Ep 256-Series 41\n- Ep 258-Series 42\n- Ep 270-Series 43\n- Ep 272-Series 44\n- Ep 274-Series 45\n- Ep 282-Series 46\n- Ep 283-Series 47\n- Ep 284-Series 48 (Bone)\n- Ep 285-Series 49\n- Ep 290-Series 50\n- Ep 291-Series 51\n- Ep 297-Series 52\n- Ep 299-Series 53\n- Ep 306-Series 54\n- Ep 307-Series 55\n- Ep 312-Series 56\n- Ep 314-Series 57\n- Ep 316-Series 58\n- Ep 320-Series 59\n- Ep 324-Series 60\n- Ep 330-Series 61\n- Ep 334-Series 62\n- Ep 335-Series 63\n- Ep 336-Series 64\n- Ep 344-Series 65\n- Ep 351-Series 66\n- Ep 355-Series 67\n- Ep 358-Series 68\n- Ep 366-Series 69\n- Ep 369-Series 70\n- Ep 370-Series 71\n- Ep 380-Series 72\n- Ep 382-Series 73\n- Ep 390-Series 74\n- Ep 391-Series 75\n- Ep 394-Series 76\n- Ep 396-Series 77\n- Ep 401-Series 78\n- Ep 403-Series 79\n- Ep 405-Series 80\n- Ep 408-Series 81\n- Ep 412-Series 82\n- Ep 413-Series 83\n- Ep 415-Series 84\n- Ep 420-Series 85\n- Ep 423-Series 86\n- Ep 426-Series 87\n- Ep 427-Series 88\n- Ep 431-Series 89\n- Ep 434-Series 90\n- Ep 438-Series 91\n- Ep 442-Series 92\n- Ep 449-Series 93\n- Ep 454-Series 94\n- Ep 456-Series 95\n- Ep 462-Series 96\n- Ep 466-Series 97\n- Ep 468-Series 98\n- Ep 473-Series 99\n- Ep 476-Series 100\n- Ep 490-Series 101\n- Ep 483-Series 102\n- Ep 486-Series 103\nBIOSTATS AND ETHICS\n- Ep 123 (Ethics 1)\n- Ep 132 (Social Sciences)\n- Ep 143 (Biostats)\n- Ep 197 (Bias in Biostats)\n- Ep 337-Drug Ads\n- Ep 363-Confounding\n- Ep 364-Effect modification\nSPECIAL TOPICS/RISK FACTORS\n- Ep 36 (Ophtho)\n- Ep 37 (Risk Factors 1)\n- Ep 41 (Antibiotic Guide)\n- Ep 65 (Ventilators)\n- Ep 97 (Risk Factors, Important)\n- Ep 100 (Clutch Micro)\n- Ep 102 (Clutch Cancer)\n- Ep 111 (Clutch Pharm 1)\n- Ep 112 (Clutch Pharm 2)\n- Ep 135 (Clutch Electrolyte)\n- Ep 137 (Next Best Step 1)\n- Ep 138 (Clutch Genetic Dzs)\n- Ep 161 (Clutch Autoantibody)\n- Ep 164 (Clutch Toxicology)\n- Ep 169 (Nephrotic/Nephritic)\n- Ep 173 (Clutch Immunodeficiency)\n- Ep 184 (NBME Weird, Must Know!)\n- Ep 197 (Bias in Biostatistics)\n- Ep 198 (Hypertensive Integrations)\n- Ep 203 (Leukemias/Lymphomas)\n- Ep 204 (USMLE Military)\n- Ep 207 (Geriatrics 1)\n- Ep 208 (Transfusion Reactions)\n- Ep 215 (NBME Acetylcholine)\n- Ep 216 (Step 1 P/F)\n- Ep 221 (HY Trauma)\n- Ep 224 (Genetic Diseases 2, Chromosomes)\n- Ep 226 (The NBME and Iron Labs)\n- Ep 231 (USMLE Military 2)\n- Ep 232 (Vasculitis)\n- Ep 233 (Shock)\n- Ep 234-CLEAN SP 3 (medication/transition errors)\n- Ep 235-Admitting Patients Efficiently\n- Ep 239-OBGYN Risk Factors\n- Ep 242-USMLE Dermatology 1\n- Ep 243-The USMLEs and Water Sol. Vitamins\n- Ep 244-The NBME and Valvular Disorders\n- Ep 246-USMLE Dermatology 2\n- Ep 248-New Free 120 Q1-10 (2020)\n- Ep 249-Oxygen Content\n- Ep 250-HY Vaccine Podcast\n- Ep 251-Thyroid and The NBMEs\n- Ep 252 (Post exposure prophylaxis)\n- Ep 253 (Starling Forces and The NBMEs)\n- Ep 255-Key Drugs for Step 2CK/3\n- Ep 257-Clutch Bilirubin\n- Ep 261-USMLE Dermatology 3\n- Ep 263-Clutch CNS Infections\n- Ep 264-Clutch Heart Failure\n- Ep 265-Male Reproductive Pathologies\n- Ep 267-Normal Changes with Aging\n- Ep 269-NBME Ortho: Bone Tumors\n- Ep 273-The NBME and High Output HF\n- Ep 278- The NBME and Amenorrhea\n- Ep 279-The NBME and Prostaglandins\n- Ep 281-Fat Soluble Vitamins and the USMLEs\n- Ep 282-Risk Factors 5/Rapid Review Series 46\n- Ep 283-Risk Factors 6/Rapid Review Series 47\n- Ep 286-The Ultra HY ARDS Podcast\n- Ep 287-The Ultra HY Urinalysis Podcast\n- Ep 288-Stress Tests/TEEs on the USMLE\n- Ep 289-Alcoholism and the USMLEs\n- Ep 292-NBME Endocarditis and Myocarditis\n- Ep 300-Coronavirus/COVID-19\n- Ep 301-Diabetes and The USMLEs Part 1\n- Ep 302-Diabetes and The USMLEs Part 2\n- Ep 303-Diabetes and The USMLEs Part 3\n- Ep 304-The Floridly HY Trauma Podcast 2\n- Ep 305-Upper Limb Rapid Review 1\n- Ep 308-The Floridly HY NBME Cortisol Podcast\n- Ep 309-The Clutch Breast Cancer Podcast\n- Ep 310-The Floridly HY Knee Exam/Pathologies Podcast\n- Ep 311-Clutch CSF/Brain Imaging Podcast\n- Ep 313-The Floridly HY Hyperkalemia Podcast\n- Ep 315-The Clutch Circle of Willis Podcast\n- Ep 321-Clutch Metabolic Acidosis\n- Ep 323-Immunocompromised/Transplant Patients\n- Ep 328-Vitamin B12 Deficiency and the USMLEs\n- Ep 329-Thriving Through Transitions (Wellness)\n- Ep 331-The Clutch Lung Cancer Podcast\n- Ep 332-The Clutch Pleural Anomalies/Effusions Podcast\n- Ep 339-The HY Pulmonary Embolism Podcast\n- Ep 340-Genetic Syndromes and Cancers for the USMLEs\n- Ep 343-Paraneoplastic Syndromes and The USMLEs\n- Ep 346-Cardiovascular Pharm for Step 2CK/3 Part 1\n- Ep 347-Cardiovascular Pharm for Step 2CK/3 Part 2\n- Ep 348-The Clutch Hypercalcemia Podcast\n- Ep 349-Clutch Psych Pharm Review for the shelf exam, Step...\n- Ep 352-The Clutch Fungi Podcast for Step 2CK/3\n- Ep 357-Disorders of Sexual Differentiation\n- Ep 372-The Clutch Headache Podcast\n- Ep 375-Hardy Weinberg Made Easy\n- Ep 377-The Clutch GI Bleed Podcast\n- Ep 379-A Series of HY Elderly Vignettes for Step 1-3\n- Ep 381-Some HY Pharmacology Vignettes for Step 2CK/3\n- Ep 383-The Clutch Smoking Podcast\n- Ep 385-Anesthetic Complications and The USMLEs\n- Ep 387-Adverse Drug Reactions for Step 2CK/3\n- Ep 388-Clutch Hypocalcemia Podcast\n- Ep 392-Pulmonary Pathophysiology Series 1\n- Ep 393-Pulmonary Pathophysiology Series 2\n- Ep 395-The Clutch Diabetes Management Podcast\n- Ep 397-Pulmonary Pathophysiology Series 3\nEMED","subject":"DIP 2ec46f2986ee8056a3cedf522b3f7170","page_title":"DIP 2ec46f2986ee8056a3cedf522b3f7170","episode":"DIP 2ec46f2986ee8056a3cedf522b3f7170","section_path":["DIP 2ec46f2986ee8056a3cedf522b3f7170"],"source_doc_id":"DIP 2ec46f2986ee8056a3cedf522b3f7170","source_page":null,"source_anchor":"DIP 2ec46f2986ee8056a3cedf522b3f7170-1"}
{"chunk_type":"transcript_chunk","text":"- Ep 181 (EMED1)\n- Ep 182 (EMED2)\n- Ep 183 (EMED3)\n- Ep221(Trauma)\n- Ep 304-Trauma\n- Ep 399-The 3 Confusing Poisonings\n- Ep 571-Quick and Dirty Emergency Medicine\n- Ep 572-Quick and Dirty Emergency Medicine 2\n- Ep 574-Quick and Dirty Emergency Medicine 3\n- Ep 578-Quick and Dirty Emergency Medicine 4\nFAMILY MEDICINE\n- Ep 206 (Series 1)\n- Ep 209 (Series 2) Psych\n- Ep 212 (Series 3) GI\n- Ep 213 (Series 4) GI\n- Ep 214 (Series 5) GI\n- Ep 217 (Series 6) Pulm\nNOVEMBER 2020 CHANGES\n- Ep 228-Palliative Care 1\n- Ep 230-Quality and Safety\n- Ep 234-Medication/Care Transition Errors\n- Ep 268-Palliative Care 2\n- Ep 275-Diagnostic Errors\n- Ep 123-Ethics\n- Ep 276-Professionalism/Ethics\n- Ep 277-Infection Control/Prevention\n- Ep 325-Extremely HY Screening Guidelines\n- Ep 530-Cognitive Errors and The USMLEs\n- Ep 613-Perioperative Medicine\nOTHERS\n- Ep 236-2CK 1 day class.\n- Ep 266-ERAS Advice\n- Ep 296-Match Day 2021(Advice and Thoughts)\n- Ep 327-26 Rules for ERAS and M4 Year\n- Ep 342-Common ERAS App Mistakes\n- Ep 354-How to preround efficiently\nICU Series\n- Ep 416-Foundation (Series 1)\n- Ep 429-Crystalloid Solutions (Series 2)\nPHARMACOLOGY FOR STEP 2/3\n- Episode 484-Series 1 (Pain Control)\nFREE 120 SERIES (Step 2CK)\n- Episode 518-2024 Step 2CK Part 1\n- Episode 519-2024 Step 2CK Part 2\n- Episode 520-2024 Step 2CK Part 3\n- Episode 521-2024 Step 2CK Part 4\n- Episode 522-2024 Step 2CK Part 5\n- Episode 523-2024 Step 2CK Part 6\n- Episode 525-2024 Step 2CK Part 7\n- Episode 526-2024 Step 2CK Part 8\n- Episode 528-2024 Step 2CK Part 9\n- Episode 529-2024 Step 2CK Part 10\n- Episode 533-2024 Step 2CK Part 11\n- Episode 535-2024 Step 2CK Part 12\n- Episode 537-2024 Step 2CK Part 13\n- Episode 538-2024 Step 2CK Part 14 (final)\nFREE 137 SERIES (Step 3)\n- Episode 548-2024 Step 3 Part 1 (Q1-10)\n- Episode 549-2024 Step 3 Part 2 (Q11-20)\n- Episode 555-2024 Step 3 Part 3 (Q21-30)\n- Episode 556-2024 Step 3 Part 4 (Q31-40)\n- Episode 557-2024 Step 3 Part 5 (Q41-50)\n- Episode 558-2024 Step 3 Part 6a (Q51-54)\n- Episode 559-2024 Step 3 Part 6b (Q55-60)\n- Episode 560-2024 Step 3 Part 7 (Q61-70)\n- Episode 561-2024 Step 3 Part 8 (Q71-80)\n- Episode 562-2024 Step 3 Part 9 (Q81-91)\n- Episode 563-2024 Step 3 Part 10 (Q92-100)\n- Episode 564-2024 Step 3 Part 11a (Q101-104)\n- Episode 565-2024 Step 3 Part 11b (Q105-110)\n- Episode 566-2024 Step 3 Part 12 (Q111-120)\n- Episode 567-2024 Step 3 Part 13 (Q121-130)\n- Episode 568-2024 Step 3 Part 14 (Q131-137)","subject":"DIP 2ec46f2986ee8056a3cedf522b3f7170","page_title":"DIP 2ec46f2986ee8056a3cedf522b3f7170","episode":"DIP 2ec46f2986ee8056a3cedf522b3f7170","section_path":["DIP 2ec46f2986ee8056a3cedf522b3f7170"],"source_doc_id":"DIP 2ec46f2986ee8056a3cedf522b3f7170","source_page":null,"source_anchor":"DIP 2ec46f2986ee8056a3cedf522b3f7170-21"}
{"chunk_type":"transcript_chunk","text":"# UTI ì¹˜ë£Œ\n![image.png](UTI%20%EC%B9%98%EB%A3%8C/image.png)\n![image.png](UTI%20%EC%B9%98%EB%A3%8C/image%201.png)\n![image.png](UTI%20%EC%B9%98%EB%A3%8C/image%202.png)\n## 3. ğŸ’Š Master Rx Table (ì¹˜ë£Œ ì¡±ë³´)\n| ì§„ë‹¨ëª… | ëŒ€ìƒ (Population) | 1ì°¨ ì¹˜ë£Œì œ (Regimen) | ê¸°ê°„ | Exam Tip |\n| --- | --- | --- | --- | --- |\n| **ASB** | ì¼ë°˜ì¸/ë…¸ì¸/ë„ë‡¨ê´€ | **ì¹˜ë£Œ ì•ˆ í•¨ (X)** | - | ì¹˜ë£Œí•˜ë©´ ë‚´ì„±ê· ë§Œ í‚¤ì›€. |\n| **ASB** | **ì„ì‚°ë¶€** / ì‹œìˆ  ì „ | Nitro, Cepha | 4-7ì¼ | ì¡°ì‚° ì˜ˆë°© ìœ„í•´ í•„ìˆ˜ ì¹˜ë£Œ. |\n|  |  |  |  |  |\n| **Cystitis** | **ë‹¨ìˆœ (ê±´ê°•å¥³)** | Nitro, Fosfo, TMP | 3-5ì¼ | ì§§ê³  êµµê²Œ. Culture ë¶ˆí•„ìš”. |\n| **Cystitis** | **ë³µì¡ (ë‚¨ì ë“±)** | FQ (Cipro) | 7ì¼ | Culture í•„ìˆ˜. ì „ë¦½ì„  í™•ì¸. |\n| **Cystitis** | **ì„ì‚°ë¶€** | Cephalexin, ì•„ëª¨í´ë¼ | 7ì¼ | 3ì¼ ìš”ë²•ì€ ì¬ë°œ í”í•¨. ê¸¸ê²Œ. |\n|  |  |  |  |  |\n| **Pyelo** | **ë‹¨ìˆœ (ê±´ê°•å¥³)** | **PO** Cipro | 7ì¼ | ì™¸ë˜ ì¹˜ë£Œ ê°€ëŠ¥ (ì§‘ì— ë³´ëƒ„). |\n| **Pyelo** | **ë³µì¡ / ì„ì‚°ë¶€** | **IV** Ceftriaxone | 14ì¼ | **ë¬´ì¡°ê±´ ì…ì›**. 72hr ì—´ ì§€ì†ì‹œ CT. |\n## 4. âš¡ Exam High-Yield Summary\n1. **Sterile Pyuria (ê·  ì—†ëŠ” ë†ë‡¨):** ì†Œë³€ê²€ì‚¬ ì—¼ì¦(WBC) ìˆëŠ”ë° ë°°ì–‘ ìŒì„±? ğŸ‘‰ **Chlamydia/Gonorrhea (STD)** ì˜ì‹¬!\n2. **ë‚¨ì UTI:** ë¬´ì¡°ê±´ **Complicated**ë¡œ ê°„ì£¼í•˜ê³  ê²€ì‚¬ ëŒë ¤ë¼. (ì „ë¦½ì„ ì—¼, í•´ë¶€í•™ì  ì´ìƒ)\n3. **Recurrent UTI (ì¬ë°œì„±):** ì„±ê´€ê³„ í›„ ì¬ë°œí•˜ë©´ **ì„±ê´€ê³„ ì§í›„ ì˜ˆë°©ì  í•­ìƒì œ(1íšŒ)**ê°€ íš¨ê³¼ì .","subject":"UTI ì¹˜ë£Œ 2ef46f2986ee8096b55ccd4f633547fb","page_title":"UTI ì¹˜ë£Œ 2ef46f2986ee8096b55ccd4f633547fb","episode":"UTI ì¹˜ë£Œ 2ef46f2986ee8096b55ccd4f633547fb","section_path":["UTI ì¹˜ë£Œ 2ef46f2986ee8096b55ccd4f633547fb"],"source_doc_id":"UTI ì¹˜ë£Œ 2ef46f2986ee8096b55ccd4f633547fb","source_page":null,"source_anchor":"UTI ì¹˜ë£Œ 2ef46f2986ee8096b55ccd4f633547fb-1"}
{"chunk_type":"transcript_chunk","text":"# LM_endo 2\n**Verification (0:00~0:30 ë°›ì•„ì“°ê¸°)**\n\"Okay, let's get straight to it. You are deep in the weeds of USMLE Step 2 prep. You've gotten through the big adult systems, you're feeling okay about cardiology, pulmo, and then, uh, you hit pediatric endocrinology. Right. And the temptation is to just think, okay, same hormones, just smaller doses. Which is, I mean, it's the fastest way to get questions wrong on the exam. Exactly. Looking at this stack of notes you've pulled, it is so clear that endocrine peds isn't just scaling things down. It's, you know, it's...\"\n---\n# USMLE Step 2 Pediatric Endocrinology Deep Dive ê°•ì˜ë¡\n## 1. Introduction: ì„±ì¸ ë‚´ë¶„ë¹„í•™ê³¼ì˜ ì°¨ì´ì \nì´ ê°•ì˜ì˜ í•µì‹¬ì€ ì†Œì•„ ë‚´ë¶„ë¹„í•™ì„ ë‹¨ìˆœíˆ \"ì„±ì¸ì˜ ì¶•ì†ŒíŒ(same hormones, smaller doses)\"ìœ¼ë¡œ ìƒê°í•˜ë©´ ì‹œí—˜ì—ì„œ í‹€ë¦°ë‹¤ëŠ” ê²ƒì…ë‹ˆë‹¤. ê°€ì¥ ì¤‘ìš”í•œ í…Œë§ˆëŠ” **\"ëª¨ì²´-íƒœì•„ ì¸í„°í˜ì´ìŠ¤(Maternal-Fetal Interface)\"**ì…ë‹ˆë‹¤.\n- ì„±ì¸ ì˜í•™: ëˆˆì•ì˜ í™˜ìë¥¼ ì¹˜ë£Œí•¨.\n- ì†Œì•„ ë‚´ë¶„ë¹„í•™(íŠ¹íˆ ì‹ ìƒì•„): ì¢…ì¢… **ì–´ë¨¸ë‹ˆì˜ ìƒë¦¬í•™ì  ìƒíƒœì— ëŒ€í•œ \"ë°˜í–¥(Echo)\"**ì„ ì¹˜ë£Œí•˜ëŠ” ê²ƒì„. ì´ ì—°ê²°ê³ ë¦¬ë¥¼ ë†“ì¹˜ë©´ ì§„ë‹¨ì„ ë†“ì¹˜ê²Œ ë©ë‹ˆë‹¤.\n---\n## 2. í•´ë¶€í•™ì  êµ¬ì¡°ì™€ ê°‘ìƒì„  (Neck Anatomy & Thyroid)\n### â˜… Clinical Scenario: Midline Neck Mass\n- **ìƒí™©:** í•™ë ¹ê¸° ì•„ë™ì´ ëª© ì¤‘ì•™(midline)ì— ë©ì–´ë¦¬ê°€ ë§Œì ¸ì ¸ì„œ ë‚´ì›. ì¹¨ì„ ì‚¼í‚¬ ë•Œ ë©ì–´ë¦¬ê°€ ì›€ì§ì„.\n- **ì „í˜•ì ì¸ ìƒê°:** ê°‘ìƒì„  ì„¤ê´€ ë‚­ì¢…(Thyroglossal duct cyst) â†’ ìˆ˜ìˆ ë¡œ ì œê±°í•´ì•¼ì§€!\n- **í•¨ì •(Trap):** ë‹¨ìˆœ ë‚­ì¢…ì´ ì•„ë‹ˆë¼ **ì´ì†Œì„± ê°‘ìƒì„  ì¡°ì§(Ectopic Thyroid Tissue)**ì¼ ìˆ˜ ìˆìŒ.\n    - ë°œìƒí•™ì ìœ¼ë¡œ ê°‘ìƒì„ ì´ í˜€ ê¸°ì €ë¶€ì—ì„œ ëª©ìœ¼ë¡œ ë‚´ë ¤ì˜¤ë‹¤ê°€ ì¤‘ê°„ì— ë©ˆì¶˜ ê²ƒ.\n    - ì¤‘ìš”í•œ ì ì€ ì´ ë©ì–´ë¦¬ê°€ ì•„ì´ì˜ **ìœ ì¼í•œ ê¸°ëŠ¥ì„± ê°‘ìƒì„  ì¡°ì§**ì¼ ìˆ˜ ìˆë‹¤ëŠ” ê²ƒ.\n- **ìœ„í—˜ì„±:** í™•ì¸ ì—†ì´ ìˆ˜ìˆ ë¡œ ì œê±°í•˜ë©´ ì•„ì´ëŠ” í‰ìƒ **ì˜êµ¬ì ì¸ ê°‘ìƒì„  ê¸°ëŠ¥ ì €í•˜ì¦(Permanent Hypothyroidism)**ì„ ê°–ê²Œ ë¨. ì¬ì•™(Disaster).\n- **Next Best Step:**\n    1. ì ˆëŒ€ ë°”ë¡œ ìˆ˜ìˆ í•˜ì§€ ë§ ê²ƒ.\n    2. **ì´ˆìŒíŒŒ(Ultrasound) & TSH/T4 í™•ì¸:** ì •ìƒ ìœ„ì¹˜ì— ê°‘ìƒì„ ì´ ì¡´ì¬í•˜ëŠ”ì§€ ë¨¼ì € í™•ì¸(Map the territory)í•´ì•¼ í•¨.\n    3. ì´ì†Œì„± ì¡°ì§ì¼ ê²½ìš° ê¸°ëŠ¥ì´ ë¶ˆì™„ì „í•˜ì—¬ ì´ë¯¸ TSHê°€ ë†’ì„ ìˆ˜ ìˆìŒ(Hypothyroid).\n---\n## 3. ì„ì‹  ì¤‘ ê°‘ìƒì„  ìƒë¦¬í•™ (Maternal-Fetal Interface)\nì„ì‹ ì€ ê°‘ìƒì„ ì— ëŒ€í•œ \"ìŠ¤íŠ¸ë ˆìŠ¤ í…ŒìŠ¤íŠ¸\"ì™€ ê°™ìŠµë‹ˆë‹¤. ì„ì‹ ë¶€ì˜ ê²€ì‚¬ ìˆ˜ì¹˜ëŠ” ë¹„ì„ì‹  ê¸°ì¤€ìœ¼ë¡œëŠ” ë¹„ì •ìƒì²˜ëŸ¼ ë³´ì¼ ìˆ˜ ìˆìœ¼ë‚˜ ìƒë¦¬í•™ì ìœ¼ë¡œëŠ” ì •ìƒì…ë‹ˆë‹¤.\n### ë‘ ê°€ì§€ ì£¼ìš” í˜¸ë¥´ëª¬ì˜ ì‘ìš©\n1. **ì—ìŠ¤íŠ¸ë¡œê²(Estrogen):**\n    - ê°„ì—ì„œ **TBG(Thyroxine Binding Globulin)** ìƒì„±ì„ ì¦ê°€ì‹œí‚´.\n    - ê²°ê³¼: **Total T4 ì¦ê°€** (ë‹¨ë°±ì§ˆ ê²°í•© í˜¸ë¥´ëª¬ì´ ëŠ˜ì–´ë‚¬ìœ¼ë¯€ë¡œ). Free T4ëŠ” ì •ìƒ ìœ ì§€.\n    - â˜… ì„ì‹ ë¶€ì—ì„œ Total T4ê°€ ë†’ì€ ê²ƒì€ ìƒë¦¬í•™ì  ì •ìƒ ì†Œê²¬ì´ë¯€ë¡œ ì¹˜ë£Œí•˜ì§€ ì•ŠìŒ.\n2. **hCG (Human Chorionic Gonadotropin):**\n    - hCGì™€ TSHëŠ” ë™ì¼í•œ Alpha subunitì„ ê³µìœ í•¨ (ì‚¬ì´Œ ì§€ê°„).\n    - ì„ì‹  1ë¶„ê¸°ì— hCGê°€ í”¼í¬ë¥¼ ì¹  ë•Œ TSH ìˆ˜ìš©ì²´ë¥¼ ìê·¹(Weak TSH ì—­í• ).\n    - ê²°ê³¼: T4 ì•½ê°„ ì¦ê°€ â†’ í”¼ë“œë°±ìœ¼ë¡œ **TSH ê°ì†Œ**.\n    - ì„ìƒì  ì˜ì˜: **ì„ì‹ ì„± ì¼ê³¼ì„± ê°‘ìƒì„ ì¤‘ë…ì¦(Gestational Transient Thyrotoxicosis)**. ì…ë§ì´ ì‹¬í•œ(Hyperemesis Gravidarum) ì‚°ëª¨ì—ì„œ hCGê°€ ë§¤ìš° ë†’ì•„ ë°œìƒ ê°€ëŠ¥.\n### â˜… Graves' Disease in Pregnancy (ê·¸ë ˆì´ë¸ŒìŠ¤ë³‘ ì‚°ëª¨ ê´€ë¦¬) â†’ ëœ! ì¹˜ë£Œí•œë‹¤!\nì‚°ëª¨ê°€ ê·¸ë ˆì´ë¸ŒìŠ¤ë³‘ìœ¼ë¡œ í•­ê°‘ìƒì„ ì œ(PTU, Methimazole)ë¥¼ ë³µìš©í•´ì•¼ í•  ë•Œ ë”œë ˆë§ˆê°€ ë°œìƒí•©ë‹ˆë‹¤.\n- **ë¬¸ì œ:** ì•½ë¬¼ì´ íƒœë°˜ì„ í†µê³¼í•¨. íƒœì•„ì˜ ê°‘ìƒì„ ì€ í›¨ì”¬ ì‘ê³  ì˜ˆë¯¼í•¨.\n- **ê³¼ì‰ ì¹˜ë£Œì˜ ìœ„í—˜:** ì‚°ëª¨ ìˆ˜ì¹˜ë¥¼ ì™„ë²½í•˜ê²Œ ì •ìƒìœ¼ë¡œ ë§ì¶”ë ¤ë‹¤ íƒœì•„ì—ê²Œ ì•½ë¬¼ì´ ê³¼ë‹¤ ì „ë‹¬ë˜ë©´, íƒœì•„ì˜ ê°‘ìƒì„ ì´ ì–µì œë¨ â†’ íƒœì•„ ë‡Œí•˜ìˆ˜ì²´ê°€ TSHë¥¼ ë¿œì–´ëƒ„ â†’ **íƒœì•„ ê°‘ìƒì„ ì¢…(Fetal Goiter)** ë° ì„ ì²œì„± ê°‘ìƒì„  ê¸°ëŠ¥ ì €í•˜ì¦ ìœ ë°œ.\n- **ì „ëµ:** **\"Permissive Hyperthyroidism\" (í—ˆìš©ì  ê°‘ìƒì„  í•­ì§„)**. ì‚°ëª¨ë¥¼ ì•½ê°„ ê°‘ìƒì„  í•­ì§„ ìƒíƒœ(mildly hyperthyroid)ë¡œ ìœ ì§€í•˜ì—¬ íƒœì•„ë¥¼ ê³¼ì‰ ì¹˜ë£Œë¡œë¶€í„° ë³´í˜¸í•˜ëŠ” ì•ˆì „ì¥ì¹˜(Safety buffer)ë¥¼ ë‘ .","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-1"}
{"chunk_type":"transcript_chunk","text":"### Neonatal Thyrotoxicosis (ì‹ ìƒì•„ ê°‘ìƒì„  ì¤‘ë…ì¦)\n- **ì›ì¸:** ì‚°ëª¨ì˜ IgG í•­ì²´(TSH ìˆ˜ìš©ì²´ ìê·¹ í•­ì²´)ê°€ íƒœë°˜ì„ í†µê³¼í•˜ì—¬ íƒœì•„ ê°‘ìƒì„ ì„ ìê·¹.\n- **ì¦ìƒ:** ë¹ˆë§¥(Tachycardia), ë³´ì±„ëŠ” ì•„ì´(Irritability), ì²´ì¤‘ ì¦ê°€ ë¶€ì§„.\n- **ê²½ê³¼:** ì¼ì‹œì ì„(Transient). ëª¨ì²´ë¡œë¶€í„° ë°›ì€ í•­ì²´ê°€ ì‚¬ë¼ì§€ë©´ ì¢‹ì•„ì§(ìˆ˜ì£¼~ìˆ˜ê°œì›”).\n- **ì¹˜ë£Œ:** ê¸‰ì„±ê¸°ì—ëŠ” ë² íƒ€ì°¨ë‹¨ì œ(Beta-blockers)ë‚˜ ë©”í‹°ë§ˆì¡¸ë¡œ ì¦ìƒ ì¡°ì ˆ í•„ìš”.\n---\n## 4. ì¹¼ìŠ˜ ëŒ€ì‚¬ ë¯¸ìŠ¤í„°ë¦¬ (Calcium Mysteries)\n### â˜… Clinical Scenario: Seizing Newborn\n- **ìƒí™©:** ìƒí›„ 3-4ì¼ ëœ ì‹ ìƒì•„ê°€ ê²½ë ¨(Seizure/Jittery)ìœ¼ë¡œ ë‚´ì›.\n- **ê²€ì‚¬ ê²°ê³¼:** **ì €ì¹¼ìŠ˜í˜ˆì¦(Hypocalcemia)**, PTH ë‚®ê±°ë‚˜ ë¶€ì ì ˆí•˜ê²Œ ì •ìƒ(Low/Normal PTH).\n- **ê°ë³„ ì§„ë‹¨:**\n    - DiGeorge Syndrome (22q11 deletion): í‰ì„ (Thymus) ì—†ìŒ, ì‹¬ì¥ ê¸°í˜• ë™ë°˜. í•˜ì§€ë§Œ ì´ ì‹œë‚˜ë¦¬ì˜¤ì—ì„œëŠ” í‰ì„ ë„ ìˆê³  ì‹¬ì¥ë„ ì •ìƒì„.\n- **ì§„ë‹¨:** **Maternal Familial Hypocalciuric Hypercalcemia (FHH, ê°€ì¡±ì„± ì €ì¹¼ìŠ˜ë‡¨ì„± ê³ ì¹¼ìŠ˜í˜ˆì¦)**\n- **ê¸°ì „ (Mechanism):**\n    1. **ì‚°ëª¨:** ì¹¼ìŠ˜ ê°ì§€ ìˆ˜ìš©ì²´(Ca-sensing receptor)ê°€ ë‘”ê°í•¨(Set pointê°€ ë†’ìŒ). ì‚°ëª¨ëŠ” ê³ ì¹¼ìŠ˜í˜ˆì¦ì´ ìˆì§€ë§Œ ì¦ìƒì€ ì—†ìŒ(Asymptomatic).\n    2. **íƒœì•„:** ì‚°ëª¨ì˜ ë†’ì€ ì¹¼ìŠ˜ì´ íƒœë°˜ì„ í†µê³¼í•´ íƒœì•„ì—ê²Œ ì „ë‹¬ë¨. íƒœì•„ì˜ ë¶€ê°‘ìƒì„ (Parathyroid)ì€ \"ì¹¼ìŠ˜ì´ ì¶©ë¶„í•˜ë„¤\"ë¼ê³  ìƒê°í•˜ê³  **í™œë™ì„ ë©ˆì¶¤(Suppressed/Dormant)**.\n    3. **ì¶œìƒ:** íƒ¯ì¤„ì´ ëŠê¸°ë©° ì¹¼ìŠ˜ ê³µê¸‰ ì¤‘ë‹¨. í•˜ì§€ë§Œ ì•„ê¸°ì˜ ë¶€ê°‘ìƒì„ ì€ ì—¬ì „íˆ ì ë“¤ì–´ ìˆìŒ.\n    4. **ê²°ê³¼:** ì•„ê¸°ì˜ ì¹¼ìŠ˜ ìˆ˜ì¹˜ê°€ ê¸‰ë½í•˜ë©° ê²½ë ¨ ë°œìƒ.\n- **í™•ì§„ ë°©ë²•:** **ì‚°ëª¨ì˜ ì†Œë³€**ì„ ê²€ì‚¬í•¨. ì‚°ëª¨ì˜ ì†Œë³€ ì¹¼ìŠ˜ì´ ë§¤ìš° ë‚®ìŒ (Low urine calcium).\n- **ì¹˜ë£Œ:** ì•„ê¸°ì˜ ë¶€ê°‘ìƒì„ ì´ ê¹¨ì–´ë‚  ë•Œê¹Œì§€ ì§€ì§€ì  ì¹˜ë£Œ(ì¹¼ìŠ˜, ë¹„íƒ€ë¯¼ D).\n---\n## 5. ë¶€ì‹  ì§ˆí™˜ (Adrenal Glands - CAH)\nì„ ì²œì„± ë¶€ì‹  ê³¼í˜•ì„±(CAH)ì—ì„œ ê°€ì¥ í”í•œ 21-hydroxylase ê²°í•(ì €í˜ˆì••, ê³ ì¹¼ë¥¨í˜ˆì¦) ì™¸ì—, **ê³ í˜ˆì••**ì„ ìœ ë°œí•˜ëŠ” ìœ í˜•ì„ êµ¬ë³„í•˜ëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤.\n### ê³ í˜ˆì••ì„ ìœ ë°œí•˜ëŠ” CAH ìœ í˜• (Hypertensive Forms)\n| ìœ í˜• | íš¨ì†Œ ê²°í• | ì£¼ìš” íŠ¹ì§• ë° ê¸°ì „ | ì„±ì  ë°œë‹¬ (Sexual Development) |\n| --- | --- | --- | --- |\n| **11Î²-Hydroxylase Deficiency** | 11Î²-OH | ëŒì´ í•˜ë¥˜ì— ìˆìŒ.<br>DOC(11-Deoxycorticosterone) ì¶•ì .<br>DOCëŠ” ì•Œë„ìŠ¤í…Œë¡ ì²˜ëŸ¼ ì‘ìš© â†’ ì—¼ë¶„/ìˆ˜ë¶„ ì €ë¥˜ â†’ **ê³ í˜ˆì••, ì €ì¹¼ë¥¨í˜ˆì¦** | **ë‚¨ì„±íšŒ(Virilization)**<br>(ì•ˆë“œë¡œê² ê²½ë¡œë¡œ ë„˜ì¹¨)<br>ì—¬ì•„ì˜ ëª¨í˜¸í•œ ì„±ê¸°(Ambiguous genitalia) |\n| **17Î±-Hydroxylase Deficiency** | 17Î±-OH | ì„±í˜¸ë¥´ëª¬ ìƒì„± ë¶ˆê°€.<br>ë¯¸ë„¤ë„ì½”ë¥´í‹°ì½”ì´ë“œ ê³¼ì‰ â†’ **ê³ í˜ˆì••, ì €ì¹¼ë¥¨í˜ˆì¦** | **ì„±ì  ìœ ì¹˜ì¦(Sexually Infantile)**<br>ì‚¬ì¶˜ê¸° ì—†ìŒ, ì„±í˜¸ë¥´ëª¬ ì—†ìŒ |\n### â˜… Pharmacology Pearl: Etomidate\n- ë§ˆì·¨ ìœ ë„ì œì¸ **Etomidate**ëŠ” **11Î²-Hydroxylaseë¥¼ ì–µì œ**í•¨.\n- ìœ ì „ì  ì§ˆí™˜ê³¼ ìœ ì‚¬í•œ íš¨ê³¼ë¥¼ ëƒ„(Cortisol ìƒì„± ì°¨ë‹¨).\n- **ì£¼ì˜:** íŒ¨í˜ˆì¦(Sepsis)ì´ë‚˜ ë¶€ì‹  ì˜ˆë¹„ë ¥(Adrenal reserve)ì´ ë–¨ì–´ì§„ í™˜ìì—ê²Œ ì‚¬ìš©í•˜ë©´ **ê¸‰ì„± ë¶€ì‹  ë¶€ì „(Acute Adrenal Crisis)**ì„ ìœ ë°œí•  ìˆ˜ ìˆìœ¼ë¯€ë¡œ ê¸ˆê¸°(Contraindication).\n---\n## 6. ì†Œì•„ ë‹¹ë‡¨ë³‘ (Pediatric Diabetes)\n### íŒ¨ëŸ¬ë‹¤ì„ì˜ ë³€í™”\n- ê³¼ê±°: ì†Œì•„ = 1í˜• ë‹¹ë‡¨.\n- í˜„ì¬: ë¹„ë§Œ ìœ í–‰ìœ¼ë¡œ ì²­ì†Œë…„ ë° ì†Œì•„ì—ì„œ 2í˜• ë‹¹ë‡¨ ê¸‰ì¦. 1í˜•ê³¼ 2í˜•ì„ êµ¬ë³„í•˜ëŠ” ê²ƒì´ í•„ìˆ˜ì .\n### êµ¬ë³„ ë°©ë²•: C-Peptide & Antibodies\n1. **C-Peptide:** ì¸ìŠë¦°ì´ ë§Œë“¤ì–´ì§ˆ ë•Œ 1:1ë¡œ ìƒì„±ë˜ëŠ” ì—°ê²° ì¡°ê°(Wrapper). ë‚´ì¸ì„± ì¸ìŠë¦° ìƒì„±ì˜ ì§€í‘œ.\n    - **1í˜• ë‹¹ë‡¨:** ê³µì¥ì´ ë¶ˆíƒ. ì¸ìŠë¦° ì—†ìŒ â†’ **C-Peptide ë‚®ê±°ë‚˜ ì—†ìŒ**.\n    - **2í˜• ë‹¹ë‡¨:** ì¸ìŠë¦° ì €í•­ì„±. ì·Œì¥ì´ ê³¼ë¡œí•¨ â†’ ì¸ìŠë¦° ë†’ìŒ â†’ **C-Peptide ë†’ìŒ**.\n2. **ìê°€í•­ì²´ (Autoantibodies):**\n    - **1í˜•:** GAD65, IA-2 ë“± í•­ì²´ ì–‘ì„±.\n    - **2í˜•:** í•­ì²´ ìŒì„±.\n### MODY (Maturity Onset Diabetes of the Young)","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-21"}
{"chunk_type":"transcript_chunk","text":"- íŠ¹ì§•: ì Šì€ ë‚˜ì´, ê²½ë¯¸í•œ ê³ í˜ˆë‹¹, **ê°•í•œ ê°€ì¡±ë ¥**, ë¹„ë§Œ ì•„ë‹˜, í•­ì²´ ìŒì„±.\n- ì›ì¸: ë‹¨ì¼ ìœ ì „ì ëŒì—°ë³€ì´(Monogenic defect). ìê°€ë©´ì—­ ì•„ë‹˜.\n- ì¹˜ë£Œ: ì¼ë¶€ ìœ í˜•(MODY 1)ì€ ì¸ìŠë¦° ëŒ€ì‹  **ì„¤í¬ë‹ìš°ë ˆì•„(Sulfonylureas)**ì— ë°˜ì‘ì´ ì¢‹ìŒ.\n---\n## 7. Rapid Fire Recap (í•µì‹¬ ìš”ì•½)\nê°•ì˜ ë‚´ìš©ì„ 5ê°€ì§€ í•µì‹¬ í¬ì¸íŠ¸ë¡œ ì •ë¦¬í•©ë‹ˆë‹¤.\n1. **Midline Neck Mass:** ì ˆëŒ€ ë°”ë¡œ ì ˆì œí•˜ì§€ ë§ˆë¼. **ì´ˆìŒíŒŒì™€ TSH**ë¡œ ì´ì†Œì„± ê°‘ìƒì„  ì—¬ë¶€ë¥¼ ë¨¼ì € í™•ì¸í•´ë¼.\n2. **Pregnancy Thyroid Physiology:** Estrogenì€ TBGë¥¼ ë†’ì—¬ Total T4ë¥¼ ë†’ì´ê³ , hCGëŠ” TSHë¥¼ í‰ë‚´ë‚´ì–´ TSHë¥¼ ë‚®ì¶˜ë‹¤. Gravesë³‘ ì‚°ëª¨ ì¹˜ë£Œ ì‹œ íƒœì•„ì˜ ê°‘ìƒì„  ì €í•˜ë¥¼ ë§‰ê¸° ìœ„í•´ ì‚°ëª¨ë¥¼ ì•½ê°„ í•­ì§„ ìƒíƒœë¡œ ìœ ì§€í•´ë¼.\n3. **Seizing Newborn:** ì €ì¹¼ìŠ˜í˜ˆì¦ + ë‚®ì€/ì •ìƒ PTH ì‹ ìƒì•„ë¥¼ ë³´ë©´ **ì—„ë§ˆì˜ ì†Œë³€ ì¹¼ìŠ˜**ì„ í™•ì¸í•´ë¼(Maternal FHH).\n4. **Adrenal Hypertension:** ê³ í˜ˆì•• + ë‚¨ì„±í™”(Virilization) = **11Î²-hydroxylase ê²°í•**. ê³ í˜ˆì•• + ì„±ì  ë¯¸ì„±ìˆ™ = **17Î±-hydroxylase ê²°í•**. (EtomidateëŠ” 11Î² íš¨ì†Œë¥¼ ì°¨ë‹¨í•¨).\n5. **Pediatric Diabetes:** ë‚˜ì´ë‚˜ ì²´í˜•ë§Œ ë³´ì§€ ë§ê³  **C-Peptideì™€ í•­ì²´**ë¥¼ í†µí•´ 1í˜•ê³¼ 2í˜•ì„ êµ¬ë³„í•´ë¼. MODY(ê°•í•œ ê°€ì¡±ë ¥, í•­ì²´ ìŒì„±) ê°€ëŠ¥ì„±ë„ ì—¼ë‘ì— ë‘¬ë¼.\n**Final Thought:** ì†Œì•„ê³¼ í™˜ìëŠ” ì¢…ì¢… **ì–´ë¨¸ë‹ˆì˜ ê±°ìš¸(Mirror of the mother)**ì…ë‹ˆë‹¤. ì„¤ëª…ë˜ì§€ ì•ŠëŠ” ì‹ ìƒì•„ì˜ ì¦ìƒì„ ë³¼ ë•Œ í•­ìƒ ëª¨ì²´ì˜ ìƒíƒœë¥¼ ì—­ì¶”ì (Trace the pathway)í•´ë³´ì„¸ìš”.\n**Verification (0:00~0:30):**\n\"Welcome back to the deep dive. Today we are putting on our white coats and, uh, walking straight into the clinic. We have a very, very specific mission. We've taken this massive stack of high yield endocrine review materials. I'm talking charts, clinical algorithms, the latest guidelines, and we are going to synthesize them into a singular operational framework. And this is all for USMLE Step 2 preparation. And our focus today is exclusively on the pancreas. The pancreas, you know, for a lot of students just starting out, the mental model of the pancreas is, well, it's pretty simple.\"\n---\n# ğŸ©º USMLE Step 2: The Pancreas Operational Framework\n## 1. Introduction: The Mental Model Shift\nUSMLE Step 2 ì‹œí—˜ì€ ë‹¨ìˆœí•œ ìƒë¦¬í•™(ì¸ìŠë¦° íŒí”„ ê°œë…)ì„ ë„˜ì–´ **ì„ìƒ ê´€ë¦¬(Clinical Management)**ì™€ **ë¯¸ë¬˜í•œ ì„ ë³„ ê°€ì´ë“œë¼ì¸(Screening Guidelines)**ì— ì´ˆì ì„ ë§ì¶¥ë‹ˆë‹¤.\nì´ ê°•ì˜ëŠ” ê²‰ë³´ê¸°ì— ë¹„ìŠ·í•´ ë³´ì´ì§€ë§Œ ì™„ì „íˆ ë‹¤ë¥¸ ì¹˜ë£Œê°€ í•„ìš”í•œ í™˜ìë“¤ì„ êµ¬ë³„í•˜ëŠ” **\"Grey Area(ì„ìƒì  íŒë‹¨)\"** ëŠ¥ë ¥ì„ í‚¤ìš°ëŠ” ê²ƒì„ ëª©í‘œë¡œ í•©ë‹ˆë‹¤.\n**ğŸ“‹ ê°•ì˜ ë¡œë“œë§µ:**\n1. **Framework:** ë‹¹ë‡¨ë³‘ ì•„í˜•(Subtypes) ë¶„ë¥˜ ë° êµ¬ë³„ë²•\n2. **Diagnosis & Screening:** ìˆ˜ì¹˜, ì»·ì˜¤í”„(Cut-offs), ê°€ì´ë“œë¼ì¸\n3. **Health Maintenance:** ëª¨ë“  ë‹¹ë‡¨ í™˜ì ë°©ë¬¸ ì‹œ í™•ì¸í•´ì•¼ í•  ì •ì‹ ì  ì²´í¬ë¦¬ìŠ¤íŠ¸\n4. **Complications:** ì‹ ê²½ë³‘ì¦(Neuropathy)ê³¼ ìœ„ë§ˆë¹„(Gastroparesis) ì‹¬ì¸µ ë¶„ì„\n5. **Acute Decompensation:** ë‹¹ë‡¨ë³‘ì„± ì¼€í†¤ì‚°ì¦(DKA)\n---\n## 2. Building the Framework: Subtypes of Diabetes\nâ˜… **í•µì‹¬ ê·œì¹™:** í™˜ìì˜ ë‚˜ì´ë§Œ ë³´ê³  ë‹¹ë‡¨ë³‘ ìœ í˜•ì„ ê°€ì •í•˜ì§€ ë§ˆì‹­ì‹œì˜¤(ì†Œì•„ ë¹„ë§Œ ì¦ê°€ë¡œ ì†Œì•„ 2í˜• ë‹¹ë‡¨ ê¸‰ì¦). \"ìƒí™”í•™ì  ì¦ê±°\"ë¥¼ í†µí•´ ì¼€ì´ìŠ¤ë¥¼ êµ¬ì¶•í•´ì•¼ í•©ë‹ˆë‹¤.\n### ğŸ§¬ C-Peptide: The Key Differentiator\n- ì·Œì¥ì€ Pro-insulinì„ ë§Œë“¤ê³ , ì´ê²ƒì´ ë¶„í•´ë˜ì–´ **Insulin**ê³¼ **C-Peptide**ê°€ 1:1 ë¹„ìœ¨ë¡œ í˜ˆë¥˜ë¡œ ë°©ì¶œë©ë‹ˆë‹¤.\n- **C-Peptide ì¸¡ì •** = ë‚´ì¸ì„± ì¸ìŠë¦°(Endogenous Insulin) ìƒì‚°ëŸ‰ ì¸¡ì •.\n| êµ¬ë¶„ | Type 1 Diabetes (ìê°€ë©´ì—­) | Type 2 Diabetes (ì €í•­ì„±) |\n| --- | --- | --- |\n| **ê¸°ì „** | ìê°€ë©´ì—­ ê³µê²©ìœ¼ë¡œ ë² íƒ€ì„¸í¬ íŒŒê´´ (Factory burned down) | ì¸ìŠë¦° ì €í•­ì„±(Shipping blocked) â†’ ì·Œì¥ì´ ë³´ìƒì ìœ¼ë¡œ ì¸ìŠë¦° ê³¼ë‹¤ ë¶„ë¹„ |\n| **ì„ìƒ ì–‘ìƒ** | ê¸‰ì„±(Acute), ì‹¬í•œ ë‹¤ë‡¨/ë‹¤ìŒ, ì²´ì¤‘ ê°ì†Œ, DKAë¡œ ë‚´ì› | ì„œì„œíˆ ì§„í–‰(Insidious), ë¬´ì¦ìƒì¼ ìˆ˜ ìˆìŒ |\n| **â˜… C-Peptide** | **Undetectable (ê²€ì¶œ ë¶ˆê°€) / ë§¤ìš° ë‚®ìŒ** | **Normal or Elevated (ì´ˆê¸°)** |\n| **Antibodies** | **Positive** (GAD65 - Glutamic Acid Decarboxylase) | **Negative** |\n### ğŸ§© The Curveball: Monogenic Diabetes (MODY)","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-41"}
{"chunk_type":"transcript_chunk","text":"- **ì‹œë‚˜ë¦¬ì˜¤:** ì Šê³  ë§ˆë¥¸ í™˜ì(24ì„¸, BMI 21), ê²½ë¯¸í•œ ê³ í˜ˆë‹¹.\n- **í•¨ì •:** 1í˜•ì²˜ëŸ¼ ë³´ì´ì§€ë§Œ(ì Šê³  ë§ˆë¦„), í•­ì²´ ê²€ì‚¬ê°€ ìŒì„±ì…ë‹ˆë‹¤.\n- **íŠ¹ì§•:**\n    - GAD65 Antibodies: **Negative** (ìê°€ë©´ì—­ ì•„ë‹˜)\n    - C-Peptide: **Detectable** (ì¸ìŠë¦° ìƒì‚°ì€ í•¨, ë¶„ë¹„ ê¸°ì „ì˜ ìœ ì „ì  ê²°í•¨ - Software problem)\n    - ê°€ì¡±ë ¥: **Autosomal Dominant (ìƒì—¼ìƒ‰ì²´ ìš°ì„±)** - 3ì„¸ëŒ€ì— ê±¸ì¹œ ìˆ˜ì§ ê°ì—¼ íŒ¨í„´.\n- **ì¹˜ë£Œ:** ì¸ìŠë¦° ì£¼ì‚¬ê°€ í•„ìš” ì—†ëŠ” ê²½ìš°ê°€ ë§ìŒ. ì„¤í¬ë‹ìš°ë ˆì•„(Sulfonylureas)ì— ë°˜ì‘ì´ ì¢‹ìŒ.\n---\n## 3. Diagnosis and Screening Game\n### ğŸ•µï¸â€â™‚ï¸ Who to Screen? (USPSTF Guidelines)\n- **ê¸°ë³¸:** 35~70ì„¸ ì„±ì¸ ì¤‘ ê³¼ì²´ì¤‘ ë˜ëŠ” ë¹„ë§Œ(BMI > 25)ì¸ ê²½ìš°.\n- **â˜… 35ì„¸ ë¯¸ë§Œ ì˜ˆì™¸ ì¡°í•­ (Under 35 Exception):** ê³¼ì²´ì¤‘ì´ë©´ì„œ ì¶”ê°€ ìœ„í—˜ ìš”ì¸ì´ ìˆëŠ” ê²½ìš° ì¦‰ì‹œ ì„ ë³„ ê²€ì‚¬.\n    - **HIV ê°ì—¼:** ë°”ì´ëŸ¬ìŠ¤ ìì²´ì˜ ì—¼ì¦ ë° í•­ë ˆíŠ¸ë¡œë°”ì´ëŸ¬ìŠ¤ì œ(ì•½ë¬¼)ì˜ ëŒ€ì‚¬ ë…ì„±.\n    - **ë‚­í¬ì„± ì„¬ìœ ì¦ (Cystic Fibrosis)**\n    - **ì¥ê¸° ì´ì‹ í›„ (Post-organ transplantation):** ë©´ì—­ì–µì œì œ(Tacrolimus, Cyclosporine, â˜…Steroids) ì‚¬ìš© ë•Œë¬¸. ìŠ¤í…Œë¡œì´ë“œëŠ” ê°„ì˜ í¬ë„ë‹¹ ìƒì„±ì„ ë†’ì´ê³  ê·¼ìœ¡ì˜ ì¸ìŠë¦° ì €í•­ì„±ì„ ìœ ë°œí•¨.\n    - **ì„ì‹  ê³„íš ì¤‘ì¸ ì—¬ì„±:** PCOS, ê°€ì¡±ë ¥ ë“± ìœ„í—˜ ìš”ì¸ì´ ìˆë‹¤ë©´ ì„ì‹  ì „ ê²€ì‚¬ í•„ìˆ˜.\n### ğŸ“Š Diagnostic Cut-offs (ìˆ˜ì¹˜ ì•”ê¸° í•„ìˆ˜)\n1. **Hemoglobin A1c:**\n    - **Diabetes:** â‰¥ 6.5%\n    - Pre-diabetes: 5.7% ~ 6.4%\n2. **Fasting Plasma Glucose (8ì‹œê°„ ê³µë³µ):**\n    - **Diabetes:** â‰¥ 126 mg/dL (ë§ë§‰ë³‘ì¦ ìœ ë³‘ë¥ ì´ ê¸‰ì¦í•˜ëŠ” êµ¬ê°„)\n    - Pre-diabetes: 100 ~ 125 mg/dL\n3. **Random Glucose (ìœ ì¦ìƒ í™˜ì):**\n    - **Diabetes:** â‰¥ 200 mg/dL + ê³ í˜ˆë‹¹ ì¦ìƒ (ë‹¤ìŒ, ë‹¤ë‡¨, ì²´ì¤‘ê°ì†Œ)\n4. **â˜… OGTT (75g ê²½êµ¬ í¬ë„ë‹¹ ë¶€í•˜ ê²€ì‚¬):**\n    - **Diabetes:** 2ì‹œê°„ í›„ í˜ˆë‹¹ â‰¥ 200 mg/dL\n    - **ì„ìƒì  ì˜ì˜:** **PCOS(ë‹¤ë‚­ì„± ë‚œì†Œ ì¦í›„êµ°)** í™˜ìì—ê²Œ ê°€ì¥ ë¯¼ê°í•œ(Most Sensitive) ê²€ì‚¬. PCOS í™˜ìëŠ” ê³µë³µ í˜ˆë‹¹ì´ë‚˜ A1cê°€ ì •ìƒì´ë¼ë„ ì‹í›„ ì¸ìŠë¦° ì €í•­ì„±ì´ ì‹¬í•  ìˆ˜ ìˆìŒ.\n---\n## 4. Health Maintenance Checklist (The Visit)\nëª¨ë“  ë°©ë¬¸ ì‹œ í™•ì¸í•´ì•¼ í•  ì‹œìŠ¤í…œ ì ê²€ ì‚¬í•­ì…ë‹ˆë‹¤.\n### ğŸ¯ Glycemic Control Goals\n- **ì¼ë°˜ ì„±ì¸:** A1c â‰¤ 7%\n- **â˜… ë…¸ì¸/ë™ë°˜ì§ˆí™˜ì:** A1c â‰¤ 8%\n    - ì´ìœ : **ì €í˜ˆë‹¹(Hypoglycemia)**ì´ ë” ìœ„í—˜í•¨. ë‚™ìƒ(ê³ ê´€ì ˆ ê³¨ì ˆ), ì–´ì§€ëŸ¬ì›€, ë¶€ì •ë§¥ ìœ ë°œ ê°€ëŠ¥. ì¹˜ë£Œê°€ ì§ˆë³‘ë³´ë‹¤ ë” ìœ„í—˜í•  ìˆ˜ ìˆìŒ.\n### ğŸ›¡ï¸ Organ Protection Screening\n1. **Nephropathy (ì‹ ì¥):**\n    - ê²€ì‚¬: ì—° 1íšŒ **Random Urine Albumin-to-Creatinine Ratio (UACR)**.\n    - ê¸°ì¤€: < 30 mg/g (ì •ìƒ). ê·¸ ì´ìƒì€ ë¯¸ì„¸ì•Œë¶€ë¯¼ë‡¨(Microalbuminuria) â†’ ACE ì–µì œì œ ì‚¬ìš© ê³ ë ¤.\n2. **Retinopathy (ëˆˆ):**\n    - ê²€ì‚¬: ì•ˆê³¼ ì „ë¬¸ì˜ì— ì˜í•œ ì‚°ë™ ê²€ì‚¬(Dilated eye exam).\n    - **â˜… ì‹œê¸° (ì‹œí—˜ ë¹ˆì¶œ):**\n        - **Type 2:** ì§„ë‹¨ **ì¦‰ì‹œ (Right away)** (ì§„ë‹¨ ì „ ì´ë¯¸ ê³ í˜ˆë‹¹ ê¸°ê°„ì´ ê¸¸ì—ˆìŒ).\n        - **Type 1:** ì§„ë‹¨ í›„ **5ë…„ ë’¤**ë¶€í„° (ë§ë§‰ë³‘ì¦ ë°œìƒì— ì‹œê°„ì´ ê±¸ë¦¼).\n3. **Neuropathy (ì‹ ê²½):**\n    - ê²€ì‚¬: ì—° 1íšŒ ë°œ ê²€ì‚¬ (Monofilament + Tuning fork).\n4. **Cardiovascular (ì‹¬í˜ˆê´€):**\n    - í˜ˆì•• ì¡°ì ˆ (<130/80), ì§€ì§ˆ ê´€ë¦¬(Statins), ê¸ˆì—°, ì•„ìŠ¤í”¼ë¦° ë“±. ë‹¹ë‡¨ í™˜ìì˜ ì£¼ ì‚¬ë§ ì›ì¸ì€ ì‹¬ì¥ ì§ˆí™˜ì„.\n---\n## 5. Complications Deep Dive ğŸ¦µğŸ§ ğŸ¤¢\n### âš¡ Neuropathy (ì‹ ê²½ë³‘ì¦)\në‹¨ìˆœíˆ \"ë°œ ì €ë¦¼\"ì´ ì•„ë‹™ë‹ˆë‹¤.\n1. **Cardiovascular Autonomic Neuropathy (DAN):**\n    - **Resting Tachycardia:** ë¯¸ì£¼ì‹ ê²½(Vagal tone) ì†Œì‹¤ë¡œ ì‹¬ë°•ìˆ˜ ì¦ê°€.\n    - **Loss of Nocturnal Dipping:** ë°¤ì— í˜ˆì••ì´ ë–¨ì–´ì§€ì§€ ì•ŠìŒ.\n    - **Postural Hypotension:** ê¸°ë¦½ì„± ì €í˜ˆì••.\n2. **Genitourinary (ë¹„ë‡¨ìƒì‹ê¸°):**\n    - ë°œê¸° ë¶€ì „, ì—­í–‰ì„± ì‚¬ì •.\n    - **Neurogenic Bladder (ì‹ ê²½ì¸ì„± ë°©ê´‘):** ë°©ê´‘ ì¶©ë§Œ ê°ê° ì†Œì‹¤ â†’ ì†Œë³€ì´ ê°€ë“ ì°¨ë„ ëª¨ë¦„ â†’ Overflow Incontinence (ì—­ë¥˜ì„± ìš”ì‹¤ê¸ˆ) â†’ ì¦ì€ ìš”ë¡œê°ì—¼(UTI).\n3. **Peripheral Neuropathy (ë§ì´ˆ):**\n    - **ê²€ì‚¬ ë„êµ¬:**\n        - **Monofilament (10g force):** ì••ê°(Pressure sensation) ì¸¡ì •. ê¶¤ì–‘(Ulcer) ë°œìƒ ìœ„í—˜ ì˜ˆì¸¡ì— ì¤‘ìš”.\n        - **Tuning Fork:** ì§„ë™ê°ê°(Vibratory sense) ì¸¡ì •. ëŒ€ì„¬ìœ  ì‹ ê²½ ì†ìƒì˜ ì´ˆê¸° ì§•í›„.\n    - **Charcot Arthropathy:** ê°ê° ì†Œì‹¤ë¡œ ì¸í•œ ë¼ˆì™€ ê´€ì ˆì˜ íŒŒê´´. **\"Rocker bottom foot\"** ë³€í˜• ìœ ë°œ.\n### ğŸ¤¢ Gastroparesis (ìœ„ë§ˆë¹„)","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-61"}
{"chunk_type":"transcript_chunk","text":"- **ì •ì˜:** ë¯¸ì£¼ì‹ ê²½ ì†ìƒìœ¼ë¡œ ìœ„ ë°°ì¶œì´ ì§€ì—°ë¨.\n- **ì¦ìƒ:** ì˜¤ì‹¬, êµ¬í† , ì¡°ê¸° í¬ë§Œê°.\n- **â˜… \"A-ha\" Vignette Clue (ì‹œí—˜ ê²°ì •ì  ë‹¨ì„œ):**\n    - ì¸ìŠë¦° ì˜ì¡´ì„± ë‹¹ë‡¨ í™˜ìê°€ ì‹í›„ ì˜¤ì‹¬/êµ¬í† ë¥¼ í˜¸ì†Œí•˜ë©° **\"ì‹í›„ ì €í˜ˆë‹¹(Post-prandial Hypoglycemia)\"**ì„ ê²ªìŒ.\n    - **ê¸°ì „ (Mismatch):** ì†íš¨ì„± ì¸ìŠë¦°ì€ íˆ¬ì—¬ë˜ì–´ ì‘ìš©(Peak)í•˜ì§€ë§Œ, ìœ„ë§ˆë¹„ë¡œ ìŒì‹ì€ ì†Œí™”/í¡ìˆ˜ë˜ì§€ ì•ŠìŒ â†’ í˜ˆë‹¹ì„ ì˜¬ë¦´ ìŒì‹ì´ ì—†ëŠ”ë° ì¸ìŠë¦°ë§Œ ì‘ìš©í•˜ì—¬ ì €í˜ˆë‹¹ ë°œìƒ.\n---\n## 6. Acute Decompensation: DKA (Diabetic Ketoacidosis)\n### ğŸš¨ Clinical Presentation\n- **í™˜ì:** ì£¼ë¡œ ì Šì€ 1í˜• ë‹¹ë‡¨ í™˜ì (Brittle diabetes).\n- **ì´ˆê¸° ì¦ìƒ:** ê·¹ì‹¬í•œ ë‹¤ë‡¨, ë‹¤ìŒ, **ì‹œë ¥ ì €í•˜(Blurred Vision)**.\n    - *ì‹œë ¥ ì €í•˜ ì´ìœ :* ê³ í˜ˆë‹¹ìœ¼ë¡œ ì¸í•œ ì‚¼íˆ¬ì•• ë³€í™”ë¡œ ìˆ˜ì •ì²´(Lens)ì˜ ìˆ˜ë¶„ì´ ë¹ ì ¸ë‚˜ê°€ ëª¨ì–‘ì´ ë³€í•¨ (êµ´ì ˆë¥  ë³€í™”).\n- **í›„ê¸° ì¦ìƒ:** ì¿ ìŠ¤ë§ˆìš¸ í˜¸í¡(Kussmaul respirations), ê³¼ì¼ ëƒ„ìƒˆ(Fruity breath), ì˜ì‹ ë³€í™”.\n### ğŸ’¡ Interesting Concept: Stress Hyperglycemia\n- íŠ¸ë¼ìš°ë§ˆë‚˜ ìˆ˜ìˆ  í›„ í™˜ìì˜ í˜ˆë‹¹ ìƒìŠ¹ì€ **ìƒì¡´ ê¸°ì „(Survival mechanism)**ì¼ ìˆ˜ ìˆìŒ.\n- ë¶€ìƒ ì‹œ ë©´ì—­ ì²´ê³„ì™€ ë‡Œì— ì—°ë£Œë¥¼ ê³µê¸‰í•˜ê¸° ìœ„í•´ ì‹ ì²´ê°€ ì˜ë„ì ìœ¼ë¡œ ì¸ìŠë¦° ì €í•­ì„±ì„ ë†’ì—¬ í˜ˆë‹¹ì„ ì˜¬ë¦¼. ì´ëŠ” ì§ˆë³‘ì´ ì•„ë‹ˆë¼ ì ì‘ ë°˜ì‘ì„.\n---\n## ğŸ”¥ Rapid Fire Recap: The \"Must-Knows\"\n1. **Subtypes:** ë‚˜ì´ê°€ ì•„ë‹ˆë¼ **ìƒí™”í•™ì  ì¦ê±°(C-peptide, Antibodies)**ë¡œ êµ¬ë¶„í•˜ë¼.\n2. **Screening:** 35-70ì„¸ ê³¼ì²´ì¤‘ì´ ê¸°ë³¸ì´ì§€ë§Œ, **HIV, ë‚­í¬ì„± ì„¬ìœ ì¦, ì´ì‹ í™˜ì, PCOS**ëŠ” 35ì„¸ ë¯¸ë§Œì´ë¼ë„ ì„ ë³„ ê²€ì‚¬í•˜ë¼.\n3. **PCOS:** ì§„ë‹¨ì„ ìœ„í•´ **OGTT**ë¥¼ ì‚¬ìš©í•˜ë¼ (ê°€ì¥ ë¯¼ê°í•¨).\n4. **Gastroparesis:** ì¸ìŠë¦° ì˜ì¡´ í™˜ìì˜ **ì‹í›„ ì €í˜ˆë‹¹ + ì†Œí™”ê¸° ì¦ìƒ**ì„ ì°¾ì•„ë¼.\n5. **Neuropathy:** MonofilamentëŠ” ê¶¤ì–‘ ìœ„í—˜ì„, Tuning forkëŠ” ì§„ë™ ê°ê°ì„ ë³¸ë‹¤.\n6. **Retinopathy:** 2í˜• ë‹¹ë‡¨ëŠ” ì§„ë‹¨ ì¦‰ì‹œ, 1í˜• ë‹¹ë‡¨ëŠ” 5ë…„ í›„ ê²€ì‚¬í•œë‹¤.\n**Final Thought:** \"Insulin resistance is a fundamental response to injury and stress.\" (ì¸ìŠë¦° ì €í•­ì„±ì€ ì†ìƒê³¼ ìŠ¤íŠ¸ë ˆìŠ¤ì— ëŒ€í•œ ê·¼ë³¸ì ì¸ ë°˜ì‘ì´ë‹¤.)\nì œê³µí•´ì£¼ì‹  ì˜¤ë””ì˜¤ íŒŒì¼ `DKA_Protocols_and_Diabetes_Pharmacology.m4a`ë¥¼ ë¶„ì„í•˜ì—¬, USMLE Step 2 ì¤€ë¹„ë¥¼ ìœ„í•œ ë§ì¶¤í˜• ê°•ì˜ë¡ì„ ì‘ì„±í–ˆìŠµë‹ˆë‹¤. ìš”ì²­í•˜ì‹  ëŒ€ë¡œ **Hallucination ë°©ì§€ë¥¼ ìœ„í•´ ì˜¤ë””ì˜¤ì— í¬í•¨ëœ ë‚´ìš©ë§Œ**ì„ ê¸°ë°˜ìœ¼ë¡œ ì‘ì„±í–ˆìœ¼ë©°, 0:00~0:30 êµ¬ê°„ì˜ ê²€ì¦(Verification)ì„ ë¨¼ì € ì œì‹œí•©ë‹ˆë‹¤.\n---\n### **Verification: Audio Dictation (0:00 ~ 0:30)**\n\"Welcome back to the deep dive. We are back in the trenches today for part two of our diabetes series. If you were with us for part one, you know we covered the broad strokes: the screening, the diagnosis, really the basic definitions. But today... today is specifically for the learner who is staring down the barrel of USMLE Step 2. That's exactly right. We're moving past the 'what is diabetes' phase. That's in the rear view mirror. Today is all about the how. How do we manage the acute crisis? How do you navigate this... I mean this absolute explosion of new drug classes?\"\n---\n# USMLE Step 2 Deep Dive: Diabetes Pharmacology & Acute Management\nì´ ê°•ì˜ëŠ” ë‹¨ìˆœíˆ ë‹¹ë‡¨ë³‘ì˜ ì •ì˜ë¥¼ ë„˜ì–´ì„œ, **USMLE Step 2**ë¥¼ ëª©ì „ì— ë‘” í•™ìŠµìë¥¼ ìœ„í•´ **\"How(ì–´ë–»ê²Œ ê´€ë¦¬í•  ê²ƒì¸ê°€)\"**ì— ì§‘ì¤‘í•©ë‹ˆë‹¤. ê¸‰ì„± ìœ„ê¸° ê´€ë¦¬(DKA/HHS)ë¶€í„° ë³µì¡í•œ ì•½ë¦¬í•™, ê·¸ë¦¬ê³  í•©ë³‘ì¦ ê´€ë¦¬ê¹Œì§€ ë‹¤ë£¹ë‹ˆë‹¤.\n## 1. The Acute Crisis: DKA vs. HHS ğŸš¨\nì‘ê¸‰ì‹¤(ER) ì„¸íŒ…ì—ì„œ ê°€ì¥ ë¨¼ì € ë§ˆì£¼í•˜ê²Œ ë˜ëŠ” ë‘ ê°€ì§€ ì¹˜ëª…ì ì¸ ê¸‰ì„± í•©ë³‘ì¦ì…ë‹ˆë‹¤. ë³‘íƒœìƒë¦¬ë¥¼ ì´í•´í•˜ë©´ ì¹˜ë£Œ í”„ë¡œí† ì½œì´ ì§ê´€ì ìœ¼ë¡œ ì´í•´ë©ë‹ˆë‹¤.","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-81"}
{"chunk_type":"transcript_chunk","text":"### A. Diabetic Ketoacidosis (DKA) - Type 1 ìœ„ì£¼\n- **Pathophysiology (The Triad):**\n    1. **Hyperglycemia (ê³ í˜ˆë‹¹)**\n    2. **Ketosis (ì¼€í†¤ì¦):** ì¸ìŠë¦° ê²°í• â†’ ì„¸í¬ê°€ ë‹¹ì„ ëª» ì”€ â†’ ì§€ë°© ë¶„í•´(Lipolysis) â†’ ìœ ë¦¬ì§€ë°©ì‚°(Free Fatty Acids) ê°„ìœ¼ë¡œ ì´ë™ â†’ ì¼€í†¤ì²´(Ketone bodies) ìƒì„±.\n        - ì£¼ìš” ì¼€í†¤: Acetoacetate, **Beta-hydroxybutyrate (â˜… Acidosisì˜ ì£¼ë²”)**.\n    3. **Acidosis (ì‚°ì¦):** ì¼€í†¤ ì¶•ì  â†’ H+ ì´ì˜¨ ë°©ì¶œ â†’ Bicarbonateê°€ ë²„í¼ë§í•˜ë ¤ë‹¤ ê³ ê°ˆë¨ â†’ **Anion Gap Metabolic Acidosis**.\n- **Clinical Presentation:** ë‹¤ë‡¨(Polyuria), ë‹¤ìŒ(Polydipsia), ë³µí†µ(Abdominal pain), blurry vision â˜… , êµ¬ì—­/êµ¬í† (N/V), **Kussmaul respirations** (CO2ë¥¼ ë‚ ë ¤ ë³´ë‚´ë ¤ëŠ” ê¹Šê³  ë¹ ë¥¸ í˜¸í¡), **Fruity odor** (Acetone ëƒ„ìƒˆ).\n### B. Hyperosmolar Hyperglycemic State (HHS) - Type 2 ìœ„ì£¼\n- **íŠ¹ì§•:** ì•½ê°„ì˜ ì¸ìŠë¦°ì€ ë‚¨ì•„ìˆì–´ì„œ Ketogenesis(ì¼€í†¤ ìƒì„±)ëŠ” ì–µì œí•¨. ë”°ë¼ì„œ Acidosisë‚˜ Anion Gapì€ ì—†ìŒ.\n- **ë¬¸ì œì :** í˜ˆë‹¹ì´ **800~1000 mg/dL** ì´ìƒìœ¼ë¡œ ì¹˜ì†ŸìŒ â†’ ì—„ì²­ë‚œ ê³ ì‚¼íˆ¬ì••(Hyperosmolarity) â†’ ì‹¬ê°í•œ íƒˆìˆ˜.\n- **ì¦ìƒ:** **Neurologic signs** (Confusion, Lethargy, Coma)ê°€ í›¨ì”¬ ëšœë ·í•¨.\n---\n## 2. Management Protocol: The \"How-To\" ğŸ¥\nDKAì™€ HHS ì¹˜ë£Œì˜ í•µì‹¬ì€ ìˆœì„œì…ë‹ˆë‹¤. **Fluid â†’ Potassium â†’ Insulin** ìˆœì„œë¥¼ ê¸°ì–µí•˜ì„¸ìš”.\n### Step 1: Fluids (ìˆ˜ë¶„ ê³µê¸‰) ğŸ’§\n- í™˜ìëŠ” ì—„ì²­ë‚œ íƒˆìˆ˜ ìƒíƒœ(Osmotic diuresisë¡œ ì¸í•´ 5~10L ë¶€ì¡±).\n- **ì²« ì¡°ì¹˜:** **Isotonic Saline (Normal Saline)** Bolus (1~2L in first 1-2 hrs)ë¡œ í˜ˆê´€ ë‚´ ë³¼ë¥¨(Intravascular volume) íšŒë³µ.\n### Step 2: The Potassium Trap (â˜… High Yield) ğŸŒ\n- ê°€ì¥ ì¤‘ìš”í•œ ë³´ë“œ ë¬¸ì œ í¬ì¸íŠ¸ì…ë‹ˆë‹¤. ì´ˆê¸° ë© ê²°ê³¼ì—ì„œ í¬íƒ€ìŠ˜(K+)ì´ ì •ìƒì´ê±°ë‚˜ ë†’ì•„ ë³´ì—¬ë„ **ì ˆëŒ€ë¡œ ì†ì§€ ë§ˆì„¸ìš”(Total body depletion ìƒíƒœ)**.\n- Acidosisë¡œ ì¸í•´ ì„¸í¬ ë‚´ì˜ K+ê°€ í˜ˆì•¡ìœ¼ë¡œ ë¹ ì ¸ë‚˜ì˜¨ ìƒíƒœì…ë‹ˆë‹¤. ì¸ìŠë¦°ì„ ì£¼ë©´ K+ê°€ ë‹¤ì‹œ ì„¸í¬ ì•ˆìœ¼ë¡œ ê¸‰ê²©íˆ ë“¤ì–´ê°€ **Fatal Arrhythmia**ë¥¼ ìœ ë°œí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n- ì‹¤ì œë¡œëŠ” hypokalemiaì¸ë° ê²€ì‚¬ìƒ ë†’ì•„ë³´ì´ëŠ” ì°©ê°ì¸ê²ƒ.\n- **Algorithm (Rule of 3.3):**\n    - **K+ < 3.3:** **Insulin ê¸ˆì§€!** K+ë¥¼ ë¨¼ì € ë³´ì¶©.\n    - **K+ 3.3 ~ 5.2:** K+ë¥¼ ë³´ì¶©í•˜ë©´ì„œ Insulin ì‹œì‘.\n    - **K+ > 5.2:** Insulin ì‹œì‘ (K+ ëª¨ë‹ˆí„°ë§).\n### Step 3: Insulin ğŸ’‰\n- **IV Regular Insulin** (0.1 units/kg/hr) ì‚¬ìš©.\n- **ëª©í‘œ:** í˜ˆë‹¹ì„ ì‹œê°„ë‹¹ 50~75 mg/dLì”© ì²œì²œíˆ ë‚®ì¶¤. ë„ˆë¬´ ë¹¨ë¦¬ ë‚®ì¶”ë©´ **Cerebral Edema (ë‡Œë¶€ì¢…)** ìœ„í—˜!\n- **Closing the Gap:** í˜ˆë‹¹ì´ 200~250 mg/dLê¹Œì§€ ë–¨ì–´ì ¸ë„ Anion Gapì´ ë‹«íˆì§€ ì•Šì•˜ë‹¤ë©´(Acidosis í•´ê²° ì•ˆ ë¨), ì¸ìŠë¦°ì„ ë„ì§€ ë§ê³  **IV fluidsì— Dextrose(D5W)ë¥¼ ì¶”ê°€**í•´ì„œ ì¸ìŠë¦°ì„ ê³„ì† ì£¼ì…í•´ì•¼ í•¨ (Sugarë¥¼ ë¨¹ì—¬ê°€ë©° ì¸ìŠë¦°ì„ ì¤Œ).\n### Step 4: Transition\n- Gapì´ ë‹«íˆê³  í™˜ìê°€ ì‹ì‚¬ ê°€ëŠ¥í•˜ë©´ í”¼í•˜(SubQ) ì¸ìŠë¦°ìœ¼ë¡œ ì „í™˜.\n- **Overlap bridge:** IV ë„ê¸° 1~2ì‹œê°„ ì „ì— SubQ(Long-acting)ë¥¼ ì¤˜ì„œ ì¸ìŠë¦° ê³µë°±ì„ ë§‰ì•„ì•¼ í•¨(Rebound DKA ë°©ì§€).\n---\n## 3. Pharmacology: The Drug Classes ğŸ’Š\nì•½ë¬¼ ê¸°ì „, ë¶€ì‘ìš©, ê¸ˆê¸° ì‚¬í•­ì„ ì™„ë²½íˆ ë§¤ì¹­í•´ì•¼ í•©ë‹ˆë‹¤.\n| **ì•½ë¬¼ ê³„ì—´** | **ê¸°ì „ ë° íŠ¹ì§•** | **â˜… Key Side Effects / Notes** |\n| --- | --- | --- |\n| **Biguanides**\n(Metformin) | **1st Line.** ê°„ì˜ í¬ë„ë‹¹ ìƒì„±(Gluconeogenesis) ì–µì œ. ì¸ìŠë¦° ê°ìˆ˜ì„± ê°œì„ . | â€¢ **Lactic Acidosis:** ì‹ ì¥/ê°„ ê¸°ëŠ¥ ì €í•˜ ì‹œ ìœ„í—˜.\nâ€¢ **eGFR < 30:** ê¸ˆê¸° (Contraindication).\nâ€¢ GI Upset (ì„¤ì‚¬ ë“±), B12 ê²°í•.\nâ€¢ **Weight Neutral** (ì•½ê°„ì˜ ê°ì†Œ). |\n| **Sulfonylureas**\n(Glipizide, Glimepiride, Glyburide) (ëˆì—†ìœ¼ë©´) | ì·Œì¥ ë² íƒ€ì„¸í¬ ìê·¹ (K+ ì±„ë„ ì°¨ë‹¨ â†’ Ca ìœ ì… â†’ ì¸ìŠë¦° ë¶„ë¹„). \"Squeeze the pancreas.\" | â€¢ **Hypoglycemia** (ê°€ì¥ í° ìœ„í—˜).\nâ€¢ **Weight Gain**.\nâ€¢ **Glyburide:** ì‹ ë¶€ì „ í™˜ì ê¸ˆê¸° (í™œì„± ëŒ€ì‚¬ì²´ ì¶•ì ). |\n| **TZDs**\n(Pioglitazone) | **PPAR-gamma agonist** (í•µ ìˆ˜ìš©ì²´). ì¸ìŠë¦° ë¯¼ê°ë„ ì¦ê°€. | â€¢ **Fluid Retention/Edema:** **CHF Class 3/4 í™˜ì ì ˆëŒ€ ê¸ˆê¸°!**\nâ€¢ ê³¨ì ˆ ìœ„í—˜ ì¦ê°€, ì²´ì¤‘ ì¦ê°€.\nâ€¢ ë°©ê´‘ì•” ì´ìŠˆ(ê³¼ê±°). |\n| **GLP-1 Agonists**\n(-tides: Exenatide, Liraglutide, Semaglutide) | \"The Darlings.\" í¬ë„ë‹¹ ì˜ì¡´ì„± ì¸ìŠë¦° ë¶„ë¹„â†‘, ê¸€ë£¨ì¹´ê³¤â†“, ìœ„ ë°°ì¶œ ì§€ì—°. | â€¢ **Weight Loss** (Satiety ì¦ê°€).\nâ€¢ **CV Benefit** (ì‹¬í˜ˆê´€ ë³´í˜¸).\nâ€¢ GI ë¶€ì‘ìš©(N/V) í”í•¨.\nâ€¢ **Contraindication:** Medullary Thyroid Cancer (MEN 2) ê³¼ê±°ë ¥/ê°€ì¡±ë ¥. |\n| **DPP-4 Inhibitors**\n(-gliptins: Sitagliptin, Linagliptin) | GLP-1 ë¶„í•´ íš¨ì†Œ ì–µì œ. GLP-1 íš¨ê³¼ ì—°ì¥. | â€¢ Weight Neutral, ì˜ ê²¬ë”¤(Gentle).\nâ€¢ Pancreatitis ìœ„í—˜ì„±(ì•½í•¨).\nâ€¢ ì‹¬ë¶€ì „ ìœ„í—˜ ì‹ í˜¸(Saxagliptin). |\n| **SGLT2 Inhibitors**\n(-flozins: Empagliflozin, Dapagliflozin) | ì‹ ì¥(PCT)ì—ì„œ í¬ë„ë‹¹ ì¬í¡ìˆ˜ ì°¨ë‹¨ â†’ ì†Œë³€ìœ¼ë¡œ ë‹¹ ë°°ì¶œ. | â€¢ **Weight Loss**, í˜ˆì•• ê°ì†Œ.\nâ€¢ **Renal & Cardiac Protective** (CKD, HF í™˜ìì— ê°•ë ¥ ì¶”ì²œ).\nâ€¢ **UTI, Yeast Infection** (ê³°íŒ¡ì´ ê°ì—¼).\nâ€¢ â˜… **Euglycemic DKA:** í˜ˆë‹¹ì´ ì •ìƒì´ì§€ë§Œ DKA ë°œìƒ ê°€ëŠ¥. |\n---","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-101"}
{"chunk_type":"transcript_chunk","text":"## 4. Insulin Types & Strategy ğŸ’‰\n### **Types**\n- **Basal (Long-acting):** Glargine, Degludec. \"Peakless\" (í”¼í¬ ì—†ì´ 24ì‹œê°„ ì§€ì†). ë°°ê²½ ì¸ìŠë¦° ìš”êµ¬ëŸ‰ ì»¤ë²„.\n- **Bolus (Rapid-acting):** Lispro, Aspart, Glulisine. ì‹ì‚¬ ì§ì „ íˆ¬ì—¬. 15ë¶„ ë‚´ ì‘ìš© ì‹œì‘.\n- Intermediate (NPH): peakìˆìŒ. ì˜ ì•ˆì”€. hypoglycemiaìœ„í—˜.\n- RI: ì˜ ì•ˆì”€. DKA, HHS ë•Œ ì”€. Inpatient IV drip ë•ŒëŠ” ì”€.\n### **Management Strategy**\n- **Inpatient (ì…ì› í™˜ì):** ê²½êµ¬ì•½(Oral meds)ì€ ëŠìŠµë‹ˆë‹¤.\n    - **Basal-Bolus ìš”ë²•**ì´ Sliding Scale ë‹¨ë… ìš”ë²•ë³´ë‹¤ í›¨ì”¬ ìš°ì›”í•©ë‹ˆë‹¤.\n    - **Correction Scale:** ì‹ì „ í˜ˆë‹¹ì— ë”°ë¼ ì¶”ê°€ë¡œ ì£¼ëŠ” ì¸ìŠë¦°.\n---\n## 5. T2DM Outpatient Management Algorithm (ì™¸ë˜ ì¹˜ë£Œ ì•Œê³ ë¦¬ì¦˜) ğŸš€\në‹¨ìˆœíˆ ì•½ë¬¼ ì¢…ë¥˜ë¥¼ ì•„ëŠ” ê²ƒë³´ë‹¤ **\"ì–´ë–¤ í™˜ìì—ê²Œ ë¬´ì—‡ì„ ë¨¼ì € ì“¸ ê²ƒì¸ê°€?\"**ë¥¼ ê²°ì •í•˜ëŠ” ê²ƒì´ ì‹œí—˜ì˜ í•µì‹¬ì…ë‹ˆë‹¤.\n- ê°œì¸í™”ëœ hba1c ëª©í‘œ\n    - ì¼ë°˜ì ìœ¼ë¡œ 7%\n    - ê±´ê°•í•˜ê³  ì Šì€ í™˜ì 6.5%\n    - comorbididities, ë…¸ì¸ 8%\n### 1.1  Step 1: The Anchor (1ë‹¨ê³„: ì‹œì‘ì€ ë©”íŠ¸í¬ë¥´ë¯¼)\n- **Standard of Care:** ì§„ë‹¨ ì¦‰ì‹œ ìƒí™œìŠµê´€ êµì •(Lifestyle)ê³¼ í•¨ê»˜ **Metformin**ì„ ì‹œì‘í•©ë‹ˆë‹¤.\n- **ì˜ˆì™¸ (Exceptions):**\n    - eGFR < 30 (CKD stage 4, 5).\n    - Acidosis risk (ì‹¬í•œ ê°„ë¶€ì „ ë“±).\n### 1.2. Step 2: Escalation Strategy (2ë‹¨ê³„: ì•½ë¬¼ ì¶”ê°€) ğŸ“ˆ\n3ê°œì›” ë’¤ A1cê°€ ëª©í‘œ(ì£¼ë¡œ < 7%)ì— ë„ë‹¬í•˜ì§€ ëª»í–ˆë‹¤ë©´, **ë‘ ë²ˆì§¸ ì•½ì œ**ë¥¼ ì¶”ê°€í•©ë‹ˆë‹¤. ì´ë•Œ ì„ íƒ ê¸°ì¤€ì€ **ë™ë°˜ ì§ˆí™˜(Comorbidities)**ì…ë‹ˆë‹¤.\n| **í™˜ìì˜ ë™ë°˜ ì§ˆí™˜ (Comorbidity)** | **ì¶”ì²œ ì•½ë¬¼ (Drug of Choice)** | **ì´ìœ  (Rationale)** |\n| --- | --- | --- |\n| **Heart Failure (ì‹¬ë¶€ì „)** ğŸ«€ | **SGLT-2 Inhibitor** (Empagliflozin ë“±) | ì‹¬ë¶€ì „ ì…ì› ë° ì‚¬ë§ë¥  ê°ì†Œ ì…ì¦. |\n| **CKD (ë§Œì„± ì‹ ë¶€ì „)** ì½©íŒ¥ | **SGLT-2 Inhibitor** | ì‹ ì¥ ê¸°ëŠ¥ ì•…í™” ì§€ì—° (Nephroprotection). |\n| **ASCVD (ì£½ìƒê²½í™” ì‹¬í˜ˆê´€ì§ˆí™˜)** ğŸ©¸\n(MI, Stroke, CAD ë³‘ë ¥) | **GLP-1 Agonist** or **SGLT-2 Inhibitor** | ì£¼ìš” ì‹¬í˜ˆê´€ ì‚¬ê±´(MACE) ì˜ˆë°© íš¨ê³¼. |\n| **Obesity (ë¹„ë§Œ)** âš–ï¸ | **GLP-1 Agonist** (Semaglutide ë“±) | ê°•ë ¥í•œ ì²´ì¤‘ ê°ëŸ‰ íš¨ê³¼. |\n| **Cost Issues (ë¹„ìš© ë¬¸ì œ)** ğŸ’¸ | **Sulfonylurea** or **TZD** | ì•½ê°’ì´ ë§¤ìš° ì €ë ´í•¨ (ë‹¨, ì €í˜ˆë‹¹/ì²´ì¤‘ì¦ê°€ ìœ„í—˜ ê°ìˆ˜). |\n### 1.3. â˜… The \"Insulin First\" Rule (ì–¸ì œ ë°”ë¡œ ì¸ìŠë¦°ì„ ì“°ëŠ”ê°€?) ğŸš¨\nê²½êµ¬ ì•½ë¬¼ì„ ê±´ë„ˆë›°ê³  **ì§„ë‹¨ ì¦‰ì‹œ ì¸ìŠë¦°**ì„ ì¨ì•¼ í•˜ëŠ” ê²½ìš°ì…ë‹ˆë‹¤.\n- **ê¸°ì¤€ (Criteria):**\n    1. **ì²˜ìŒì— HbA1c > 10%**\n    2. **Random Glucose > 300 mg/dL**\n    3. **Severe Symptoms (Catabolic State):** ë‹¤ìŒ(Polydipsia), ë‹¤ë‡¨(Polyuria), **ì²´ì¤‘ ê°ì†Œ(Weight loss)**.\n- **ì´ìœ :** í¬ë„ë‹¹ ë…ì„±(Glucotoxicity)ì´ ë„ˆë¬´ ì‹¬í•´ ê²½êµ¬ ì•½ë¬¼ì´ ë“£ì§€ ì•Šê±°ë‚˜, ì·Œì¥ ë² íƒ€ì„¸í¬ê°€ ê±°ì˜ ê³ ê°ˆëœ ìƒíƒœ(Catabolic)ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤. ì¼ë‹¨ ì¸ìŠë¦°ìœ¼ë¡œ ë¶ˆì„ ëˆ ë’¤(Break toxicity), ë‚˜ì¤‘ì— ê²½êµ¬ì•½ìœ¼ë¡œ ì „í™˜(De-escalate)ì„ ê³ ë ¤í•©ë‹ˆë‹¤.\n- ê²½êµ¬ì•½ìœ¼ë¡œ ë¶ˆì¶©ë¶„í•˜ì—¬ ë³´ì¶©í•˜ëŠ” ê²½ìš°\n    - Basal ì¶”ê°€ë¶€í„° ì‹œì‘í•œë‹¤.\n---\n## 6. Diabetic Nephropathy","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-121"}
{"chunk_type":"transcript_chunk","text":"### 1. Pathophysiology: The Pressure Cooker (ê¸°ì „)\nê°•ì‚¬ëŠ” ì‹ ì¥ ì†ìƒì˜ ì‹œì‘ì„ **'ì••ë ¥ì†¥(Pressure Cooker)'**ì— ë¹„ìœ í•˜ì—¬ ì„¤ëª…í•©ë‹ˆë‹¤.\n- **Hyperfiltration (ê³¼ì—¬ê³¼):**\n    - ì´ˆê¸° ë‹¨ê³„ì—ì„œ ê³ í˜ˆë‹¹ì€ ì‹ ì¥ìœ¼ë¡œ ê°€ëŠ” í˜ˆë¥˜ë¥¼ ì¦ê°€ì‹œí‚µë‹ˆë‹¤.\n    - ì´ë¡œ ì¸í•´ ì‚¬êµ¬ì²´(Glomerulus) ë‚´ë¶€ì˜ ì••ë ¥ì´ ë†’ì•„ì§€ê³ , ì‹ ì¥ì€ í‰ì†Œë³´ë‹¤ ë” ë§ì€ ì¼ì„ í•˜ê²Œ ë©ë‹ˆë‹¤(Hyperfiltration).\n- **Damage (ì†ìƒ):**\n    - ë†’ì€ ì••ë ¥ì´ ì§€ì†ë˜ë©´ ì‚¬êµ¬ì²´ ê¸°ì €ë§‰ì´ ì†ìƒë˜ê³ , ê²°êµ­ êµ¬ë©ì´ ì»¤ì ¸ì„œ ë‹¨ë°±ì§ˆ(ì•Œë¶€ë¯¼)ì´ ì†Œë³€ìœ¼ë¡œ ìƒˆì–´ ë‚˜ì˜¤ê²Œ ë©ë‹ˆë‹¤.\n    - ì´ê²ƒì´ ë°”ë¡œ **Microalbuminuria (ë¯¸ì„¸ì•Œë¶€ë¯¼ë‡¨)**ì…ë‹ˆë‹¤.\n### 2. Screening: Catching it Early (ì„ ë³„ ê²€ì‚¬) ğŸ•µï¸â€â™‚ï¸\nê°€ì¥ ì¤‘ìš”í•œ ê²ƒì€ ì‹ ì¥ ê¸°ëŠ¥(Cr)ì´ ë–¨ì–´ì§€ê¸° **ì „**ì—, ë¯¸ì„¸í•œ ì†ìƒ ì§•í›„ë¥¼ ì°¾ì•„ë‚´ëŠ” ê²ƒì…ë‹ˆë‹¤.\n- **The Test:** **Spot Urine Albumin/Creatinine Ratio (UACR)**\n    - â˜… **Dipstick is Useless:** ì¼ë°˜ ì†Œë³€ê²€ì‚¬ ìŠ¤í‹±(Dipstick)ì€ 'ë¯¸ì„¸' ì•Œë¶€ë¯¼ë‡¨ë¥¼ ì¡ì•„ë‚´ì§€ ëª»í•©ë‹ˆë‹¤. ë°˜ë“œì‹œ **UACR** ì •ëŸ‰ ê²€ì‚¬ë¥¼ í•´ì•¼ í•©ë‹ˆë‹¤.\n- **The Cutoff:**\n    - **Normal:** < 30 mg/g\n    - **Microalbuminuria (Moderately increased):** **30 - 300 mg/g**\n    - **Macroalbuminuria (Severely increased):** > 300 mg/g\n    - **ì§„ë‹¨ ê¸°ì¤€:** UACRì´ **30 mg/g ì´ìƒ**ì´ë©´ ë‹¹ë‡¨ë³‘ì„± ì‹ ì¦ì˜ ì´ˆê¸° ì§•í›„ë¡œ ê°„ì£¼í•©ë‹ˆë‹¤.\n- **When to Screen (ê²€ì‚¬ ì‹œê¸°):**\n    - **Type 2 DM:** **ì§„ë‹¨ ì¦‰ì‹œ (At diagnosis)** ì‹œì‘í•˜ì—¬ ë§¤ë…„ ê²€ì‚¬. (ì œ2í˜•ì€ ì§„ë‹¨ ì‹œì ì— ì´ë¯¸ ì•“ì€ ì§€ ì˜¤ë˜ë˜ì—ˆì„ ìˆ˜ ìˆê¸° ë•Œë¬¸).\n    - **Type 1 DM:** **ì§„ë‹¨ 5ë…„ í›„**ë¶€í„° ì‹œì‘. (ê¸‰ì„± ë°œë³‘ì´ë¯€ë¡œ ì´ˆê¸° 5ë…„ì€ ì‹ ì¥ í•©ë³‘ì¦ì´ ë“œë¬¾).\n### 3. Treatment: Turning Down the Pressure (ì¹˜ë£Œ) ğŸ’Š\nì¹˜ë£Œì˜ í•µì‹¬ì€ ì‚¬êµ¬ì²´ ë‚´ë¶€ì˜ ì••ë ¥ì„ ë‚®ì¶°ì„œ ì½©íŒ¥ì„ ë³´í˜¸í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤.\n### 3.1. ACE Inhibitors & ARBs (The Gold Standard) ğŸ†\n- **ì•½ë¬¼:** Lisinopril, Losartan ë“±.\n- **Indication (ì ì‘ì¦):**\n    - **ê³ í˜ˆì••ì´ ì—†ë”ë¼ë„(Normotensive)**, **ë¯¸ì„¸ì•Œë¶€ë¯¼ë‡¨(Microalbuminuria)ê°€ ê²€ì¶œë˜ë©´ ë¬´ì¡°ê±´ ì‹œì‘**í•©ë‹ˆë‹¤.\n    - ì´ëŠ” í˜ˆì•• ì¡°ì ˆ ëª©ì ì´ ì•„ë‹ˆë¼ ì‹ ì¥ ë³´í˜¸ ëª©ì ì…ë‹ˆë‹¤.\n- **Mechanism (ê¸°ì „):**\n    - **Efferent Arteriole Dilation (ìˆ˜ì¶œ ì†Œë™ë§¥ í™•ì¥):** ë‚˜ê°€ëŠ” í˜ˆê´€ì„ ë„“í˜€ì£¼ì–´ ì‚¬êµ¬ì²´ ë‚´ë¶€ì˜ ì••ë ¥ì„ ë–¨ì–´ëœ¨ë¦½ë‹ˆë‹¤. (ë§ˆì¹˜ ëŒì˜ ìˆ˜ë¬¸ì„ ì—´ì–´ ìˆ˜ìœ„ë¥¼ ë‚®ì¶”ëŠ” ì›ë¦¬).\n### 3.2. í˜ˆë‹¹ ì¡°ì ˆ SGLT-2 Inhibitors (The New Champion) ğŸŒŸ\n- **ì•½ë¬¼:** Empagliflozin, Dapagliflozin ë“±.\n- **Role:** ìµœê·¼ ê°€ì´ë“œë¼ì¸ì—ì„œ **CKD ì§„í–‰ì„ ëŠ¦ì¶”ëŠ” íš¨ê³¼**ê°€ ì…ì¦ë˜ì–´, ACEi/ARBì™€ í•¨ê»˜ ì‹ ì¥ ë³´í˜¸ì˜ í•µì‹¬ ì¶•ìœ¼ë¡œ ë¶€ìƒí–ˆìŠµë‹ˆë‹¤.\n    - íŠ¹íˆ eGFRì´ ë–¨ì–´ì ¸ ìˆëŠ” í™˜ìì—ê²Œë„ ì‹ ì¥ ë³´í˜¸ íš¨ê³¼(Renoprotective)ê°€ ê°•ë ¥í•©ë‹ˆë‹¤.\n---\n## ğŸ’¡ Clinical Pearl (ì‹œí—˜ì— ë‚˜ì˜¤ëŠ” í¬ì¸íŠ¸)\n- **Scenario:** í˜ˆì•• 120/80ì¸ ë‹¹ë‡¨ í™˜ìì˜ ì†Œë³€ ê²€ì‚¬ì—ì„œ UACRì´ 45 mg/gì´ ë‚˜ì™”ë‹¤. ì¡°ì¹˜ëŠ”?\n    - **ì •ë‹µ:** **Lisinopril (ACEi) ì‹œì‘.** (í˜ˆì••ì´ ì •ìƒì´ë¼ë„ ë‹¨ë°±ë‡¨ê°€ ìˆìœ¼ë©´ ì”ë‹ˆë‹¤.)\n- **Contraindication:** ë§Œì•½ í™˜ìê°€ ì„ì‹  ê³„íšì´ ìˆê±°ë‚˜ ì„ì‹  ì¤‘ì´ë¼ë©´?\n    - ACEi/ARBëŠ” ê¸ˆê¸°ì…ë‹ˆë‹¤.\n---\n## 7. Metabolic syndrome\n- 5ê°€ì§€ì¤‘ 3ê°€ì§€ì´ìƒ\n1. **Abdominal Obesity (ë³µë¶€ ë¹„ë§Œ):**\n    - ê°€ì¥ ì¤‘ìš”í•œ ì§€í‘œì…ë‹ˆë‹¤. ë‚´ì¥ ì§€ë°©(Visceral fat)ì´ ì¸ìŠë¦° ì €í•­ì„±ì˜ í•µì‹¬ì´ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤.\n    - â™‚ï¸ **Men:** > 40 inches\n    - â™€ï¸ **Women:** > 35 inches\n2. **Hypertriglyceridemia (ê³ ì¤‘ì„±ì§€ë°©):**\n    - **> 150 mg/dL**. (í˜¹ì€ ì•½ë¬¼ ë³µìš© ì¤‘).\n3. **Low HDL (ë‚®ì€ HDL):**\n    - â™‚ï¸ **Men:** < 40 mg/dL\n    - â™€ï¸ **Women:** < 50 mg/dL\n4. **Hypertension (ê³ í˜ˆì••):**\n    - **> 130 / 85 mmHg**. (ì¼ë°˜ì ì¸ ê³ í˜ˆì•• ì§„ë‹¨ ê¸°ì¤€ì¸ 130/80ê³¼ ë¯¸ì„¸í•˜ê²Œ ë‹¤ë¥´ë‹ˆ ì£¼ì˜! ìˆ˜ì¶•ê¸° 130, ì´ì™„ê¸° 85).\n5. **Hyperglycemia (ê³ í˜ˆë‹¹):**\n    - **Fasting Glucose > 100 mg/dL**. (ë‹¹ë‡¨ë³‘ ì§„ë‹¨ ê¸°ì¤€ì¸ 126ë³´ë‹¤ ë‚®ìŠµë‹ˆë‹¤. ì¦‰, **Pre-diabetes** ë‹¨ê³„ë¶€í„° í¬í•¨ë©ë‹ˆë‹¤).\n- Why do we care? (ì„ìƒì  ì˜ì˜) ğŸš‘\n    - d/t insulin resistance\n    - **Cardiovascular Risk:** ì‹¬í˜ˆê´€ ì§ˆí™˜ ë°œìƒ ìœ„í—˜ì´ 2ë°° ì´ìƒ ì¦ê°€í•©ë‹ˆë‹¤.\n    - **Type 2 Diabetes:** ë‹¹ë‡¨ë³‘ ë°œìƒ ìœ„í—˜ì´ 5ë°° ì´ìƒ ì¦ê°€í•©ë‹ˆë‹¤.\n    - **NASH (Non-alcoholic Steatohepatitis):** ë¹„ì•Œì½”ì˜¬ì„± ì§€ë°©ê°„ì—¼ê³¼ ë§¤ìš° ê°•ë ¥í•˜ê²Œ ì—°ê´€ë˜ì–´ ìˆìŠµë‹ˆë‹¤. (ALT > AST íŒ¨í„´).\n## 8. Hypoglycemia (ì €í˜ˆë‹¹) ğŸ“‰\n### 1. Definition & Whipple's Triad","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-141"}
{"chunk_type":"transcript_chunk","text":"- í˜ˆë‹¹ **< 70 mg/dL**.\n- **Whipple's Triad:**\n    1. ì €í˜ˆë‹¹ ì¦ìƒ (Sweating, tremor, confusion).\n    2. ì‹¤ì œ ë‚®ì€ í˜ˆë‹¹ ìˆ˜ì¹˜.\n    3. í¬ë„ë‹¹ íˆ¬ì—¬ í›„ ì¦ìƒ í˜¸ì „.\n- symptoms\n    - adrenergic : epinephrine, norepinephrine ì¦ê°€. ë¶ˆì•ˆ, ê¸´ì¥, ë•€\n    - neuroglycopenic: ë‡Œê°€ ë‹¹ì´ ì—†ì–´ì„œ ë‚˜íƒ€ë‚˜ëŠ” ì¦ìƒ.\n### 2. Treatment\n- **Awake:** ì£¼ìŠ¤ë‚˜ ì‚¬íƒ• ë“± ë¹ ë¥¸ íƒ„ìˆ˜í™”ë¬¼ ì„­ì·¨ (\"Rule of 15\").\n- **Unconscious (IV access O):** **IV Dextrose (D50)**. (ê°€ì¥ í™•ì‹¤í•¨).\n- **Unconscious (IV access X):** **IM Glucagon** (ê·¼ìœ¡ ì£¼ì‚¬).\n### 3. â˜… Diagnostic Workup (The Detective Work) ğŸ•µï¸â€â™‚ï¸\në‹¹ë‡¨ê°€ ì—†ëŠ” í™˜ìê°€ ì €í˜ˆë‹¹ìœ¼ë¡œ ì™”ì„ ë•Œ, ì›ì¸(ì¸ìŠë¦°ì¢… vs ì™¸ë¶€ ì£¼ì… vs ì•½ë¬¼)ì„ ê°ë³„í•˜ëŠ” ì•Œê³ ë¦¬ì¦˜ì…ë‹ˆë‹¤.\n| **Condition** | **Insulin** | **C-Peptide â˜…** | **Pro-insulin** | **Sulfonylurea Screen** |\n| --- | --- | --- | --- | --- |\n| **Exogenous Insulin** (ì£¼ì‚¬ íˆ¬ì—¬) | â¬†ï¸ High | **â¬‡ï¸ Low** | â¬‡ï¸ Low | (-) |\n| **Insulinoma** (ì¢…ì–‘) | â¬†ï¸ High | **â¬†ï¸ High** | â¬†ï¸ High | (-) |\n| **Sulfonylurea Abuse** (ì•½ë¬¼ ë³µìš©) | â¬†ï¸ High | **â¬†ï¸ High** | Normal | **(+) Positive** |\n## âš¡ Rapid Fire Recap (Must-Know Summary)\nì˜¤ë””ì˜¤ ë§ˆì§€ë§‰ì— ì •ë¦¬ëœ, **Step 2 ì‹œí—˜ì¥ì— ë“¤ì–´ê°€ê¸° ì „ ë°˜ë“œì‹œ ê¸°ì–µí•´ì•¼ í•  ë‚´ìš©**ì…ë‹ˆë‹¤.\n1. **DKA/HHS 1ìˆœìœ„ ì¹˜ë£Œ:** **Fluids (ìˆ˜ì•¡)**ì´ ë¨¼ì €ë‹¤! (1-2L Normal Saline).\n2. **Insulin ì „ K+ í™•ì¸:** K < 3.3ì´ë©´ **ì¸ìŠë¦° ì£¼ì§€ ë§ˆë¼(Hold)**. í™˜ì ì£½ëŠ”ë‹¤. 3.3 ë„˜ìœ¼ë©´ ì£¼ë©´ì„œ ì¸ìŠë¦° ì¤€ë‹¤. 5.2 ë„˜ìœ¼ë©´ ì¤€ë‹¤.\n3. **Metformin:** ì‹ ì¥ ê¸°ëŠ¥ í™•ì¸ (**GFR < 30 ê¸ˆê¸°**, Lactic Acidosis ìœ„í—˜).\n4. **Sulfonylureas:** ì €í˜ˆë‹¹ê³¼ ì²´ì¤‘ ì¦ê°€ì˜ ì£¼ë²”.\n5. **TZDs:** ì‹¬ë¶€ì „(CHF) í™˜ìì—ê²Œ **ê¸ˆê¸°**. (ë¶€ì¢… ìœ ë°œ).\n6. **SGLT-2 Inhibitors:** ì†Œë³€ìœ¼ë¡œ ë‹¹ ë°°ì¶œ. **UTI/Yeast infection** ì£¼ì˜. **Euglycemic DKA** ê°€ëŠ¥ì„± ì—¼ë‘.\n7. ì‹¬í˜ˆê´€ê³„, ì½©íŒ¥, ì‹¬ë¶€ì „ ìˆìœ¼ë©´ metformin ë‹¤ìŒë‹¨ê³„ë¡œ SGLT-2 inh.\n8. **Microalbuminuria:** 30~300 êµ¬ê°„ì—ì„œ ë°œê²¬ë˜ë©´ **ACEi/ARB** ì‹œì‘. (Efferent arteriole í™•ì¥).\n9. **Hypoglycemia Workup:** C-peptideë¥¼ í™•ì¸í•´ì„œ **Insulinoma(High)**ì™€ **ì™¸ë¶€ ì£¼ì‚¬(Low)**ë¥¼ êµ¬ë³„í•˜ë¼.\n**Verification (Dictation: 0:00~0:30)**\n\"Welcome back to the deep dive. Today we are doing something uh very specific and frankly something that I know keeps a lot of you up at night. We are tackling a beast of a topic. We are looking at the adrenal gland and we specifically designed this for the USMLE Step 2 learner. It's a beast but you know it's a tameable one. And that's our goal today. We are not just reading a textbook, we've pulled together, I mean, a mass of stack of high yield review materials...\"\n---\n# ğŸ¥ Deep Dive: USMLE Step 2ë¥¼ ìœ„í•œ Adrenal Pathology (ë¶€ì‹  ë³‘ë¦¬í•™)\n## 1. Introduction: Taming the Beast ğŸ¦\n- **Goal:** USMLE Step 2 ë° ì‹¤ì œ ì„ìƒì„ ìœ„í•œ Mental Framework êµ¬ì¶•.\n- **í•µì‹¬ í¬ì¸íŠ¸:** ë‹¨ìˆœ ì•”ê¸°ë¥¼ ë„˜ì–´, **\"Next Best Step\"** (ë‹¤ìŒ ë‹¨ê³„ëŠ” ë¬´ì—‡ì¸ê°€?)ì„ ì´í•´í•˜ëŠ” ê²ƒì´ ëª©í‘œ.\n- **Adrenal Gland (ë¶€ì‹ ):** ì•½ 4gì˜ ì‘ì€ ê¸°ê´€ì´ì§€ë§Œ, Salt, Sugar, Blood Pressure, Stress ë°˜ì‘ì„ ì¡°ì ˆí•˜ëŠ” High-stakes organ.\n- **ê¸°ë³¸ ìƒë¦¬í•™ Mnemonic:**\n    - ğŸ§‚ **Salt** (Mineralocorticoids/Aldosterone)\n    - ğŸ­ **Sugar** (Glucocorticoids/Cortisol)\n    - ğŸ’ **Sex** (Androgens)\n    - ğŸš€ **Speed** (Catecholamines)\n- **ë¶„ë¥˜ (Categories):**\n    1. **Adrenal Excess** (ê³¼ë‹¤) -> Functional masses.\n    2. **Adrenal Masses** (íŠ¹íˆ Pheochromocytoma).\n    3. **Adrenal Insufficiency** (ë¶€ì¡±).\n---\n## 2. Adrenal Excess: The Functional Masses ğŸ“ˆ\n**ì„ìƒ ì–‘ìƒ (Clinical Presentation):** ì „ì‹  ì¦ìƒ(ì¡°ì ˆë˜ì§€ ì•ŠëŠ” HTN, ì²´í˜• ë³€í™” ë“±) ë˜ëŠ” **Incidentaloma**(CT ë“±ì—ì„œ ìš°ì—°íˆ ë°œê²¬ëœ ì¢…ì–‘)ë¡œ ë‚´ì›.\n**Incidentaloma ë°œê²¬ ì‹œ ì „ëµ:**\n- ì¦‰ì‹œ ë‘ ê°€ì§€ ì§ˆë¬¸ì„ ë˜ì ¸ì•¼ í•¨:\n    1. Is it cancer? (ì•”ì¸ê°€?)\n    2. Is it functional? (í˜¸ë¥´ëª¬ì„ ë¶„ë¹„í•˜ëŠ”ê°€?)\n- **The Golden Rule:** â˜… **Biochemistry before Biopsy.** (ìƒê²€ ì „ ìƒí™”í•™ ê²€ì‚¬ í•„ìˆ˜)\n    - *ì£¼ì˜:* ìƒí™”í•™ì  í™•ì¸ ì—†ì´ Pheochromocytomaë¥¼ ìƒê²€(Biopsy)í•˜ë©´, Adrenalineì´ ëŒ€ëŸ‰ ë°©ì¶œë˜ì–´ Hypertensive Crisisë¡œ í™˜ìê°€ ì‚¬ë§í•  ìˆ˜ ìˆìŒ.","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-161"}
{"chunk_type":"transcript_chunk","text":"### A. ğŸ§‚ Salt: Primary Hyperaldosteronism (Conn Syndrome)\n- **Classic Vignette:** 3ê°€ì§€ ì´ìƒì˜ ì•½ë¬¼(Diuretic í¬í•¨)ì—ë„ ì¡°ì ˆë˜ì§€ ì•ŠëŠ” **Resistant Hypertension** + **Hypokalemia** (ê·¼ìœ¡ ê²½ë ¨, ìœ„ì•½ê°).\n- **í•µì‹¬ ê°œë…: Aldosterone Escape**\n    - ë†’ì€ Aldosteroneì€ Na+ ì¬í¡ìˆ˜ & K+ ë°°ì¶œì„ ìœ ë°œí•¨.\n    - ì´ˆê¸°ì—ëŠ” ë¬¼ì´ Na+ë¥¼ ë”°ë¼ê°€ Volume expansionì´ ì¼ì–´ë‚¨.\n    - **Why no edema? (ì™œ ë¶€ì¢…ì´ ì—†ëŠ”ê°€?):** ì‹¬ë°©ì´ ëŠ˜ì–´ë‚˜ë©´ì„œ **ANP**ê°€ ë¶„ë¹„ë˜ì–´ ì‹ ì¥ì—ì„œ ê°•ì œë¡œ Sodium/Waterë¥¼ ë°°ì¶œì‹œí‚´ (Pressure Natriuresis).\n    - *ê²°ê³¼:* ê³ í˜ˆì••ì€ ìˆì§€ë§Œ ë¶€ì¢…(Edema)ì€ ì—†ìŒ. (Edemaê°€ ìˆë‹¤ë©´ Heart Failureë‚˜ Cirrhosisë¥¼ ì˜ì‹¬).\n- **Labs:** **Hypokalemia** + **Metabolic Alkalosis**. (HypokalemiaëŠ” Diuretic ì‚¬ìš© ì „ê¹Œì§€ëŠ” ì •ìƒì¼ ìˆ˜ë„ ìˆìŒ). í™˜ìê°€ normal-normallow potassium levelë¡œ ë‚´ì›í•  ìˆ˜ ìˆìœ¼ë‚˜, ì´ë‡¨ì œì— ê³¼í•˜ê²Œ hypokalemiaë°˜ì‘í•¨.\n- **Diagnostic Algorithm (ì§„ë‹¨ ìˆœì„œ):**\n    1. **Screen:** Aldosterone/Renin Ratio.\n        - High Aldo + Low Renin (Suppressed).\n        - **Positive Screen:** Ratio > 20 (ë‹¨, absolute Aldo > 15 ng/dL).\n    2. **Confirm:** Salt Loading Test.\n        - ì†Œê¸ˆ ë¶€í•˜(ì‹ì‚¬ ë˜ëŠ” IV Saline)ë¥¼ ì£¼ì—ˆì„ ë•Œ Aldosteroneì´ ì–µì œë˜ì§€ ì•Šìœ¼ë©´ ì–‘ì„±.\n    3. **Localize:** CT Scan.\n        - *í•¨ì •:* CTì—ì„œ Massê°€ ë³´ì¸ë‹¤ê³  ë¬´ì¡°ê±´ ê·¸ìª½ì´ ì›ì¸ì´ ì•„ë‹˜ (ë¹„ê¸°ëŠ¥ì„± ì¢…ì–‘ì¼ ìˆ˜ ìˆìŒ).\n        - 40ì„¸ ë„˜ëŠ”í™˜ìì—ì„œëŠ” non functioning incidentalomaê°€ ë§ìŒ. ê·¸ëƒ¥ lumpê°€ ë³´ì¸ë‹¤ê³  ë—ëŠ”ë° ì‚¬ì‹¤ ì•„ë¬´ê²ƒë„ ì•„ë‹ˆì—ˆì„ ìˆ˜ ìˆìŒ. 40ì„¸ ë„˜ì—ˆìœ¼ë©´ ë©ì–´ë¦¬ìˆë‹¤ê³  ê·¸ëƒ¥ ë¬´ì§€ì„± ë–¼ê¸° ì•ˆë¨!\n    4. **Differentiate:** â˜… **Adrenal Venous Sampling (AVS).**\n        - ìˆ˜ìˆ  ì „ Gold Standard. ì–‘ìª½ ì •ë§¥ì—ì„œ í˜¸ë¥´ëª¬ì„ ì±„ì·¨í•˜ì—¬ **Unilateral Adenoma**ì¸ì§€ **Bilateral Hyperplasia**ì¸ì§€ êµ¬ë³„.\n- **Treatment:**\n    - **Unilateral Adenoma:** Surgical resection (ìˆ˜ìˆ ì  ì ˆì œ, ì™„ì¹˜ ê°€ëŠ¥).\n    - **Bilateral Hyperplasia:** **Mineralocorticoid Receptor Antagonists (MRAs)**ë¡œ ì•½ë¬¼ ì¹˜ë£Œ.\n        - *Spironolactone:* Androgen ìˆ˜ìš©ì²´ë„ ì°¨ë‹¨í•˜ì—¬ Gynecomastia, Libido ê°ì†Œ ë¶€ì‘ìš© ìˆìŒ.\n        - *Eplerenone:* ë¶€ì‘ìš©ì´ ì ì€ ëŒ€ì²´ ì•½ë¬¼.\n### B. ğŸ­ Sugar: Cushing Syndrome (Hypercortisolism)\n- **Presentation:** Central obesity, Moon facies, Buffalo hump, â˜… **Wide Purple Striae (>1cm)**, Easy bruising.\n    - *êµ¬ë³„ì :* **Proximal Muscle Weakness** (ê³„ë‹¨ ì˜¤ë¥´ê¸° í˜ë“¦, ë¨¸ë¦¬ ë¹—ê¸° í˜ë“¦) - ë‹¨ë°±ì§ˆ ë¶„í•´(Catabolic effect) ë•Œë¬¸.\n- **Diagnosis (The 2 out of 3 Rule):** ë‹¤ìŒ ì„ ë³„ ê²€ì‚¬ ì¤‘ 2ê°€ì§€ê°€ ì–‘ì„±ì´ì–´ì•¼ í™•ì§„.\n    1. **24-hour Urinary Free Cortisol.**\n    2. **Late Night Salivary Cortisol:** ì¼ì£¼ê¸° ë¦¬ë“¬(Diurnal rhythm) ì†Œì‹¤ í™•ì¸ (ìì •ì— Cortisolì´ ë†’ìœ¼ë©´ ë¹„ì •ìƒ).\n    3. **Low-dose Dexamethasone Suppression Test:** ì •ìƒì´ë¼ë©´ ACTHê°€ ì–µì œë˜ê³  ë”°ë¼ì„œ, ë‹¤ìŒë‚  ì•„ì¹¨ ì½”í‹°ì†”ë„ ì–µì œë˜ì–´ì•¼ í•˜ë‚˜, Cushingì€ ì•„ì¹¨ ì½”í‹°ì†”ì´ ì–µì œë˜ì§€ ì•ŠìŒ.\n- **ì›ì¸ ê°ë³„ (ACTH Level):**\n    - **Low ACTH:** Primary Adrenal problem (Tumor).\n        - low DHEAë‘ ë™ë°˜ë˜ëŠ” ê²½ìš° ë§ìŒ (DHEAë„ ACTHì˜ ìê·¹ì„ ë°›ê¸° ë•Œë¬¸)\n        - iatrogenic ë¨¼ì € ë°˜ë“œì‹œ rule out â˜… â˜…  Low ACTH, low DHEA\n    - **High ACTH:** ACTH-dependent (Pituitary or Ectopic).\n- **High-Dose Dexamethasone Suppression Test (High ACTHì¸ ê²½ìš°):**\n    - **Cushing Disease (Pituitary Adenoma):** ì–´ëŠ ì •ë„ Feedbackì´ ë‚¨ì•„ ìˆì–´ High-doseì—ì„œ ì–µì œë¨ (>50%).\n    - **Ectopic ACTH (ì˜ˆ: Small Cell Lung Cancer):** ììœ¨ì  ë¶„ë¹„. High-doseì—ì„œë„ **ì–µì œë˜ì§€ ì•ŠìŒ**. hyperpigmentation â˜… (addisonì²˜ëŸ¼)\n- **Ectopic (Lung Cancer) ì„ìƒ íŒíŠ¸:**\n    - ê¸‰ê²©í•œ ì§„í–‰, ë¹„ë§Œë³´ë‹¤ëŠ” Cachexia(ë©”ë§ˆë¦„), ì‹¬í•œ Hyperpigmentation, ë§¤ìš° ë†’ì€ ACTH ìˆ˜ì¹˜.\n### C. ğŸš€ Speed: Pheochromocytoma (Medullary Tumor)\n- **Chromaffin Cells ì¢…ì–‘:** Catecholamines (Epi, Norepi, Dopamine) ë¶„ë¹„.\n- **Classic Triad (3 P's):**\n    1. **P**aroxysmal Headache (ë°œì‘ì  ë‘í†µ).\n    2. **P**alpitations/Tachycardia.\n    3. **P**erspiration (ë°œí•œ).\n    - *í•µì‹¬:* ì¦ìƒì´ **Paroxysmal** (ì™”ë‹¤ ê°”ë‹¤ í•¨) í•˜ë‹¤ëŠ” ê²ƒ.\n- **Diagnosis:**\n    - Screen: Plasma Free Metanephrines (ë¯¼ê°ë„ ë†’ìŒ).\n    - Confirm: 24-hour Urine Metanephrines.\n- **ê°ë³„ í¬ì¸íŠ¸:**\n    - **Thyroid Storm:** ê³ ì—´(Hyperpyrexia) ë™ë°˜.\n    - **Pheo:** ë•€ì€ ë‚˜ì§€ë§Œ **FeverëŠ” ê±°ì˜ ì—†ìŒ**.\n- **Triggers:** ìˆ˜ìˆ /ë§ˆì·¨ ìœ ë„(Induction), ë³µì•• ìƒìŠ¹ ë“±.\n- **Treatment Rule:** â˜… **A before B**\n    - **Alpha-blocker FIRST** (Phenoxybenzamine) - í˜ˆê´€ ì´ì™„.\n    - **Beta-blocker SECOND** - ì‹¬ë°•ìˆ˜ ì¡°ì ˆ.\n    - *ì´ìœ :* Beta-blockerë¥¼ ë¨¼ì € ì“°ë©´, í˜ˆê´€ ìˆ˜ì¶• ì‘ìš©(Alpha)ë§Œ ë‚¨ì•„ **Unopposed Alpha Stimulation**ìœ¼ë¡œ í˜ˆì••ì´ í­ë“±í•˜ì—¬ ì‚¬ë§ ê°€ëŠ¥.\n---\n## 3. Adrenal Insufficiency (The \"Too Little\") ğŸ“‰\n**ë¶„ë¥˜:** Primary (ë¶€ì‹  ìì²´ íŒŒê´´), Secondary (ë‡Œí•˜ìˆ˜ì²´), Tertiary (ì‹œìƒí•˜ë¶€).\n### A. Primary Adrenal Insufficiency (Addison's Disease)\n- **Pathology:** Adrenal cortexì˜ íŒŒê´´. **Cortisol**, **Aldosterone**, **Androgens** ëª¨ë‘ ê²°í•.\n- **Etiology (ì›ì¸):**\n    - *ì„ ì§„êµ­:* Autoimmune Adrenalitis.\n    - *ê°œë°œë„ìƒêµ­/ì „ì„¸ê³„:* **Tuberculosis (TB)** (CTìƒ ì„íšŒí™”ëœ ë¶€ì‹ ).\n- **Symptoms & Labs:**\n    - **Hyperpigmentation:** ë†’ì€ ACTH (POMC -> MSH ìê·¹) ë•Œë¬¸. ì†ë°”ë‹¥ ì£¼ë¦„, êµ¬ê°• ì ë§‰ ì°©ìƒ‰.\n    - **Salt Craving:** Aldosterone ê²°í• ë•Œë¬¸.\n    - **Electrolytes:** â˜… **Hyponatremia + Hyperkalemia** (Na ë²„ë¦¬ê³  K ì €ì¥).\n    - **Acidosis:** Non-anion gap metabolic acidosis.\n    - **Eosinophilia:** Cortisolì´ ì—†ì–´ì„œ Eosinophilì´ ì¦ê°€.\n    - **ì—¬ì„±:** ì²´ëª¨(Axillary/pubic hair) ì†Œì‹¤ ë° ì„±ìš• ê°ì†Œ (Adrenal androgen ê²°í•).\n    - SIADH. ADH ì¦ê°€.\n### B. Secondary/Tertiary Adrenal Insufficiency\n- **Etiology:** ë§Œì„± ìŠ¤í…Œë¡œì´ë“œ ì‚¬ìš© í›„ ì¤‘ë‹¨ (ê°€ì¥ í”í•œ ì˜ì¸ì„± ì›ì¸).\n- **í•µì‹¬ ì°¨ì´ì :** **Aldosteroneì€ ì •ìƒ (INTACT)** (RAASì— ì˜í•´ ì¡°ì ˆë˜ë¯€ë¡œ).\n    - ë”°ë¼ì„œ Hyperkalemiaë‚˜ Salt cravingì´ ì—†ìŒ.\n    - **No Hyperpigmentation** (ACTHê°€ ë‚®ìœ¼ë¯€ë¡œ).\n    - ì¦ìƒì´ ëª¨í˜¸í•¨ (í”¼ë¡œ, ìœ„ì•½ê°, ì˜¤ì‹¬).\n### C. Diagnostic Algorithm\n1. basal cortisol, basal ACTH ì¸¡ì •\n    1. cortisolì´ 3ë°‘ìœ¼ë¡œ ë‚®ìœ¼ë©´ í™•ì§„\n    2. cortisolì´ 3-8ë¡œ ì• ë§¤í•˜ë©´?\n2. ACTH (cosynotropin) stimulationê²€ì‚¬: cortisol ë°˜ì‘ì—¬ë¶€ë¡œ AI ìì²´ë¥¼ í™•ì§„\n    1. ì •ìƒ: ACTHíˆ¬ì—¬ í›„ ì½”í‹°ì†”ì´ ëœ¬ë‹¤.\n    2. ë¹„ì •ìƒ: ACTHíˆ¬ì—¬ í›„ì—ë„ cortisolì´ ë‚®ë‹¤. ì˜¤ë¡œì§€ AI í™•ì§„ì´ë©° êµ¬ì²´ì ì¸ AI ìœ í˜• ë¶„ë¥˜ì— ì“°ì§€ ì•ŠìŒ! â˜… â˜… \n    note: primary, secondary, tertiary ëª¨ë‘ ACTH ìê·¹ê²€ì‚¬ì— ì½”í‹°ì†”ì´ ë°˜ì‘ì•ˆí•œë‹¤. í‘œë©´ì ìœ¼ë¡œ adrenal glandì— ë¬¸ì œ ì—†ëŠ” secondary, tertiary AIë„ ACTHìê·¹ ê²€ì‚¬ì— ë°˜ì‘í•˜ì§€ ì•ŠëŠ”ë‹¤!\n3. ACTH high (primary AI) vs ACTH low (secondary, tertiary AI): ACTHìˆ«ìë¡œ AI ìœ í˜•ì„ ë¶„ë¥˜í•œë‹¤.\n### D. ğŸš¨ Adrenal Crisis (Acute Insufficiency)\n- **Scenario:** ë¶€ì‹  ê¸°ëŠ¥ì´ ì €í•˜ëœ í™˜ìê°€ í° ìŠ¤íŠ¸ë ˆìŠ¤(ìˆ˜ìˆ , ê°ì—¼, ì™¸ìƒ)ë¥¼ ë°›ê±°ë‚˜ ìŠ¤í…Œë¡œì´ë“œë¥¼ ê°‘ìê¸° ì¤‘ë‹¨í–ˆì„ ë•Œ.\n- **Precipitants (ìœ ë°œ ìš”ì¸):**\n    - **Waterhouse-Friderichsen Syndrome:** Meningococcemia (*Neisseria meningitidis*)ì— ì˜í•œ ì–‘ì¸¡ ë¶€ì‹  ì¶œí˜ˆ.\n    - **Etomidate:** ë§ˆì·¨ ìœ ë„ì œ. 11-beta-hydroxylaseë¥¼ ì–µì œí•˜ì—¬ íŒ¨í˜ˆì¦ í™˜ìì—ì„œ ìœ„ê¸° ìœ ë°œ ê°€ëŠ¥.\n- **Presentation:**\n    - **Refractory Shock:** ìˆ˜ì•¡ê³¼ ìŠ¹ì••ì œ(Pressors)ì— ë°˜ì‘í•˜ì§€ ì•ŠëŠ” ì‡¼í¬.\n    - Acute abdomenê³¼ ìœ ì‚¬í•œ ì‹¬í•œ ë³µí†µ, êµ¬í† .\n    - Hypotension, Hypoglycemia.\n- **Management (ì¹˜ë£Œ):**\n    - â˜… **ê²€ì‚¬ ê²°ê³¼ë¥¼ ê¸°ë‹¤ë¦¬ì§€ ë§ ê²ƒ (Do NOT wait for labs).**\n    - **ì¦‰ê°ì ì¸ ì²˜ì¹˜:**\n        1. **IV Hydrocortisone** (Stress dose - Glucocorticoid & Mineralocorticoid íš¨ê³¼ ëª¨ë‘ ìˆìŒ).\n        2. Aggressive IV Fluids (Normal Saline).\n---","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-181"}
{"chunk_type":"recap_summary","text":"## 4. Rapid Fire Recap ğŸ”¥ (ì¡±ë³´ ì •ë¦¬)\n1. **Conn Syndrome ì§„ë‹¨ (Rule of 2):**\n    - Screen: Aldo/Renin Ratio > 20.\n    - Confirm: Salt Loading Test (ì–µì œ ì‹¤íŒ¨).\n2. **Cushing Screening (2 out of 3 Rule):**\n    - ë‹¤ìŒ ì¤‘ 2ê°œ ì–‘ì„± í•„ìš”: 24hr Urine, Late Night Saliva, Low-Dose Dex.\n3. **The Great Electrolyte Split (ì „í•´ì§ˆ ì°¨ì´):**\n    - **Conn's:** High BP, Low K+, High Na+.\n    - **Addison's:** Low BP, High K+, Low Na+.\n4. **Pigmentation Clue (ìƒ‰ì†Œì¹¨ì°© íŒíŠ¸):**\n    - Hyperpigmentation = **High ACTH** (Primary AI ë˜ëŠ” Ectopic Cushing's).\n    - No Pigmentation = Secondary AI ë˜ëŠ” Pituitary Cushing's.\n5. **Refractory Signs (ì¹˜ë£Œ ë¶ˆì‘ ì§•í›„):**\n    - 3ê°€ì§€ ì•½ì œì—ë„ ì•ˆ ë“£ëŠ” HTN = **Conn Syndrome.**\n    - ìˆ˜ì•¡/ìŠ¹ì••ì œì— ì•ˆ ë“£ëŠ” Hypotension = **Adrenal Crisis.**\n6. **Iatrogenic Warning (ì˜ì¸ì„± ê²½ê³ ):**\n    - ì˜ì‚¬ê°€ ë§Œë“œëŠ” ê°€ì¥ í”í•œ ë¶€ì‹  ë¬¸ì œ = ë§Œì„± ìŠ¤í…Œë¡œì´ë“œ ì‚¬ìš©ìœ¼ë¡œ ì¸í•œ **Secondary Adrenal Insufficiency**.\n    - *ê¸°ì–µí•  ê²ƒ:* ì–µì œëœ ë¶€ì‹ ì€ ìˆ˜ìˆ /ì§ˆë³‘ ì‹œ ìŠ¤íŠ¸ë ˆìŠ¤ ë°˜ì‘ì„ ëª»í•˜ë¯€ë¡œ ë°˜ë“œì‹œ **Stress-dose Steroids**ë¥¼ ì¤˜ì•¼ í•¨!\n## 0:00~0:30 êµ¬ê°„ ë°›ì•„ì“°ê¸° (Dictation Verification)\n\"Welcome back to the deep dive. So we're picking up right where we left off with our exploration of the endocrine system. Yep, part two. And if you were with us for the last session, we kind of laid out the general rules, the physiology, the feedback loops, you know, how it all hums when it's working right. Right. But today, today the vibe uh it changes completely. It really does. We're shifting from how things work to what happens when things grow. We're talking about mass effects.\"\n---\n# ğŸ§ Deep Dive: Thyroid Nodules, Adrenal Tumors, & MEN Syndromes\n## 1. Introduction: From Physiology to Pathology\n- ì´ë²ˆ ì„¸ì…˜ì˜ ë¶„ìœ„ê¸°ëŠ” ì´ì „(Physiology)ê³¼ëŠ” ì™„ì „íˆ ë‹¤ë¦…ë‹ˆë‹¤. \"How it works\"ì—ì„œ **\"What happens when things grow\"**ë¡œ ì „í™˜ë©ë‹ˆë‹¤.\n- ì£¼ìš” í…Œë§ˆ: **Mass Effects** (ì¢…ì–‘, ê²°ì ˆì´ ì»¤ì§€ë©´ì„œ ìƒê¸°ëŠ” ë¬¸ì œë“¤).\n- ë‹¤ë£¨ëŠ” ë‚´ìš©ì´ ë§ˆì¹˜ \"ê³µí¬ ì˜í™” ìºìŠ¤íŒ…(Horror movie cast)\"ì²˜ëŸ¼ ë“¤ë¦´ ìˆ˜ ìˆìŠµë‹ˆë‹¤ (ì˜ˆ: Neuroma, Thyroid storm ë“±).\n- **ëª©í‘œ:** ë‹¨ìˆœí•œ ì§ˆë³‘ ë‚˜ì—´ì´ ì•„ë‹ˆë¼, **Framework(ì‚¬ê³ ì˜ í‹€)**ë¥¼ ë§Œë“œëŠ” ê²ƒ. ì–¸ì œ ìŠ¤ìº”í•˜ê³ , ì–¸ì œ ìƒê²€(Biopsy)í•˜ê³ , ì–¸ì œ ì™¸ê³¼ì˜ë¥¼ ë¶€ë¥¼ì§€ ê²°ì •í•˜ëŠ” **Algorithm**ì„ ìµíˆëŠ” ê²ƒì´ í•µì‹¬ì…ë‹ˆë‹¤.\n---\n## 2. Thyroid Nodules: The Algorithm (ê°‘ìƒì„  ê²°ì ˆ ì ‘ê·¼ë²•)","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-199"}
{"chunk_type":"transcript_chunk","text":"ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤: í™˜ìê°€ ëª©ì— ë©ì–´ë¦¬(Lump)ê°€ ë§Œì ¸ì ¸ì„œ ë‚´ì›í–ˆìŠµë‹ˆë‹¤. ë³¸ëŠ¥ì ìœ¼ë¡œëŠ” ë°”ë¡œ ë°”ëŠ˜ì„ ì°”ëŸ¬ í™•ì¸í•˜ê³  ì‹¶ì§€ë§Œ, **Endocrinologyì—ì„œëŠ” ê·¸ê²ƒì´ í‹€ë¦° ì ‘ê·¼ì…ë‹ˆë‹¤.**\n### â˜… Step 1: The Gatekeeper - TSH Level\nê°€ì¥ ë¨¼ì € í™•ì¸í•´ì•¼ í•  ê²ƒì€ **TSH ìˆ˜ì¹˜**ì…ë‹ˆë‹¤.\n- **TSHê°€ ë‚®ë‹¤ (Low TSH):**\n    - ë‡Œê°€ ê°‘ìƒì„  ìê·¹ì„ ë©ˆì·„ë‹¤ëŠ” ëœ»ì…ë‹ˆë‹¤.\n    - ì¦‰, ê²°ì ˆ(Nodule)ì´ ìŠ¤ìŠ¤ë¡œ í˜¸ë¥´ëª¬ì„ ë¿œì–´ë‚´ê³  ìˆë‹¤ëŠ” ì˜ë¯¸ì…ë‹ˆë‹¤. -> **\"Hot\" Nodule** ğŸ”¥\n    - **â˜… Key Insight:** \"Hot nodule\"ì€ ê±°ì˜ ì ˆëŒ€ì ìœ¼ë¡œ **ì•…ì„±(Malignant)ì´ ì•„ë‹™ë‹ˆë‹¤.** (Hyper-functioning nodule is rarely cancer).\n    - **Action:** **Radioactive Iodine Scintigraphy (í•µì˜í•™ ìŠ¤ìº”)**ì„ ì‹œí–‰í•©ë‹ˆë‹¤. ìŠ¤ìº”ìƒ í¬ë¦¬ìŠ¤ë§ˆìŠ¤ íŠ¸ë¦¬ì²˜ëŸ¼ ë°ê²Œ ë¹›ë‚˜ë©´(Light up), ì•” ê±±ì •ì€ ì ‘ì–´ë‘ê³  **Hyperthyroidism(ê°‘ìƒì„  í•­ì§„ì¦)** ì¹˜ë£Œë¥¼ í•˜ë©´ ë©ë‹ˆë‹¤. **Biopsy í•˜ì§€ ë§ˆì„¸ìš”!**\n- **TSHê°€ ì •ìƒ í˜¹ì€ ë†’ë‹¤ (Normal/High TSH):**\n    - ê²°ì ˆì´ ê¸°ëŠ¥ì„ í•˜ì§€ ì•ŠëŠ”ë‹¤ëŠ” ëœ»ì…ë‹ˆë‹¤. -> **\"Cold\" Nodule** â„ï¸\n    - ì´ ê²½ìš° ì•…ì„±ì˜ ê°€ëŠ¥ì„±ì´ ìˆìœ¼ë¯€ë¡œ í•´ë¶€í•™ì  êµ¬ì¡°ë¥¼ ë´ì•¼ í•©ë‹ˆë‹¤.\n    - **Action:** **Ultrasound (ì´ˆìŒíŒŒ)** ì‹œí–‰.\n### Step 2: Ultrasound Features (The Ugly Check)\nì´ˆìŒíŒŒì—ì„œ ë‹¨ìˆœíˆ í¬ê¸°ë§Œ ë³´ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ **\"Ugly Features\"**ë¥¼ ì°¾ìŠµë‹ˆë‹¤.\n- Microcalcifications (ë¯¸ì„¸ì„íšŒí™”)\n- Irregular borders (ë¶ˆê·œì¹™í•œ ê²½ê³„ - ì¹¨ë²”í•˜ëŠ” ëª¨ì–‘)\n- Increased vascularity (í˜ˆë¥˜ ì¦ê°€)\n### Step 3: FNA (Fine Needle Aspiration)\n- **ì–¸ì œ í•˜ëŠ”ê°€?:** TSHê°€ ì •ìƒ/ë†’ìŒ **AND** ì´ˆìŒíŒŒì—ì„œ \"Ugly\"í•˜ê±°ë‚˜ í¬ê¸°ê°€ í´ ë•Œ (>1cm).\n- ì´ë•Œ ë¹„ë¡œì†Œ ë°”ëŠ˜ë¡œ ì°”ëŸ¬ ì•”ì¸ì§€ í™•ì¸í•©ë‹ˆë‹¤.\n### Step 4: ìˆ˜ìˆ  (lobectomy vs total thyroidectomy)\n- ê¸°ì¤€ 1cm\n- total thyroidectomy í›„ serum thyroglobulinìœ¼ë¡œ ì¶”ì ê²€ì‚¬ ê°€ëŠ¥\n- Adjunctant therapy: Radioiodine ablation and/or suppressive doses of thyroid hormones.\n    - Suppressive doses of thyroid hormone: ì¬ë°œ ê°€ëŠ¥ì„±ì´ ìˆìœ¼ë©´ levothyroxineì„ ì¼ë¶€ëŸ¬ ë†’ê²Œ ì¤Œ â†’ TSHê°€ ë‚®ê²Œ ìœ ì§€ë˜ë„ë¡.\n---\n## 3. Pediatric Trap: Thyroglossal Duct Cyst ğŸ‘…\nì†Œì•„ê³¼ì—ì„œ ìì£¼ ë‚˜ì˜¤ëŠ” í•¨ì • ë¬¸ì œì…ë‹ˆë‹¤.\n- **ìœ„ì¹˜:** Midline neck mass (ëª© ì •ì¤‘ì•™).\n- **ë°œìƒí•™:** ê°‘ìƒì„ ì€ í˜€ ê¸°ì €ë¶€(Base of tongue)ì—ì„œ ì‹œì‘í•´ ëª© ì•„ë˜ë¡œ ë‚´ë ¤ì˜µë‹ˆë‹¤. ì´ ê²½ë¡œì— ë‚¨ì€ í”ì ì…ë‹ˆë‹¤.\n- **íŠ¹ì§•:** í˜€ë¥¼ ë‚´ë°€ê±°ë‚˜ ì¹¨ì„ ì‚¼í‚¤ë©´ ë©ì–´ë¦¬ê°€ **ìœ„ë¡œ ì›€ì§ì…ë‹ˆë‹¤ (Moves up)**.\n- **â˜… Critical Step before Surgery:**\n    - ë¬´í„±ëŒ€ê³  ì˜ë¼ë‚´ë©´ ì•ˆ ë©ë‹ˆë‹¤. ì´ ë‚­ì¢…ì´ **ì•„ì´ì˜ \"ìœ ì¼í•œ\" ê°‘ìƒì„  ì¡°ì§(Ectopic thyroid)**ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n    - í™•ì¸í•˜ì§€ ì•Šê³  ì œê±°í•˜ë©´ ì•„ì´ëŠ” í‰ìƒ **Hypothyroidism(ê°‘ìƒì„  ê¸°ëŠ¥ ì €í•˜ì¦)**ì´ ë©ë‹ˆë‹¤.\n    - ìˆ˜ìˆ  ì „ ë°˜ë“œì‹œ **Ultrasound**ë‚˜ **Nuclear scan**ìœ¼ë¡œ ì •ìƒ ìœ„ì¹˜ì— ê°‘ìƒì„ ì´ ìˆëŠ”ì§€ í™•ì¸í•´ì•¼ í•©ë‹ˆë‹¤.\n---\n## 4. Thyroid Malignancies & Emergencies\n### A. Thyroid Lymphoma & Hashimoto's\n- **ì—°ê´€ì„±:** ë§Œì„±ì ì¸ ì—¼ì¦(Chronic inflammation)ì€ ì„¸í¬ ë³€ì´ì˜ ì˜¨ìƒì…ë‹ˆë‹¤. ì˜¤ë«ë™ì•ˆ **Hashimoto's thyroiditis**ë¥¼ ì•“ë˜ í™˜ìì—ê²Œì„œ ë°œìƒ ìœ„í—˜ì´ ë†’ìŠµë‹ˆë‹¤.\n- **ì¦ìƒ:**\n    - **Rapid growth:** ê°‘ìê¸° ëª©ì´ ë¹ ë¥´ê²Œ ë¶“ìŠµë‹ˆë‹¤.\n    - **Firm/Woody:** ë”±ë”±í•˜ê²Œ ë§Œì ¸ì§‘ë‹ˆë‹¤.\n    - **Compressive symptoms:** ëª©ì´ ì¡¸ë¦¬ëŠ” ëŠë‚Œ, ì‚¼í‚´ ê³¤ë€.\n- **â˜… Pemberton Sign:**\n    - í™˜ìì—ê²Œ ì–‘íŒ”ì„ ë¨¸ë¦¬ ìœ„ë¡œ ë“¤ê²Œ í•©ë‹ˆë‹¤ (\"Touchdown sign\").\n    - ê±°ëŒ€í•´ì§„ ê°‘ìƒì„ ì´ í‰ê³½ ì…êµ¬(Thoracic inlet)ë¥¼ ë§‰ì•„ ì •ë§¥ í™˜ë¥˜ë¥¼ ì°¨ë‹¨í•©ë‹ˆë‹¤.\n    - ê²°ê³¼: ì–¼êµ´ì´ ë¹¨ê°œì§€ê³ (Plethora), ì–´ì§€ëŸ¬ì›€ì„ ëŠë‚ë‹ˆë‹¤. -> **ì‘ê¸‰ ì˜ìƒ ì´¬ì˜ ë° ìˆ˜ìˆ  ê³ ë ¤.**\n### B. Thyroid Storm (ê°‘ìƒì„  í­í’) ğŸŒªï¸","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-209"}
{"chunk_type":"transcript_chunk","text":"- ì§„ì •í•œ ë‚´ë¶„ë¹„ ì‘ê¸‰ ìƒí™© (Medical Emergency). Thyrotoxicosisê°€ ë ˆë²¨ 11ë¡œ ì¹˜ì†Ÿì€ ìƒíƒœ.\n- **Trigger:** ìˆ˜ìˆ , ì™¸ìƒ, ê°ì—¼, í˜¹ì€ ë¶„ë§Œ(Childbirth).\n- **ì¦ìƒ:**\n    - High Fever (ê³ ì—´)\n    - Massive Tachycardia (ì‹¬ë°•ìˆ˜ 140-160)\n    - Agitation, Delirium (í¥ë¶„, ì„¬ë§ - ë¯¸ì³ ë‚ ë›°ëŠ” ìƒíƒœ)\n| **êµ¬ë¶„** | **Thyroid Storm (ê°‘ìƒì„  í­í’)** | **Malignant Hyperthermia (ì•…ì„± ê³ ì—´ì¦)** |\n| --- | --- | --- |\n| **ê³µí†µì ** | ìˆ˜ìˆ  í›„ ë°œìƒ ê°€ëŠ¥, ê³ ì—´, ë¹ˆë§¥ | ìˆ˜ìˆ  í›„ ë°œìƒ ê°€ëŠ¥(ë§ˆì·¨ì œ), ê³ ì—´, ë¹ˆë§¥ |\n| **ì°¨ì´ì ** | **â˜… No Rigidity (ê²½ì§ ì—†ìŒ)** \n (ë–¨ë¦¼ì´ë‚˜ Lid lagì€ ìˆì„ ìˆ˜ ìˆìŒ) | **Rigidity (ì „ì‹  ê·¼ìœ¡ ê°•ì§)** |\n| **ì¹˜ë£Œ** | Cooling, Beta-blockers, Steroids | Dantrolene |\n---\n## 5. Adrenal Tumors: The Stress Glands\n### A. Pheochromocytoma (The Great Mimic)\n- ë¶€ì‹  ìˆ˜ì§ˆ(Medulla)ì˜ ì¢…ì–‘ìœ¼ë¡œ, **Catecholamine (Epinephrine/Norepinephrine)**ì„ ë¿œì–´ëƒ…ë‹ˆë‹¤.\n- **ì¦ìƒ: The Classic Triad + HTN**\n    1. **H**eadache (ë‘í†µ)\n    2. **S**weating (ë°œí•œ - í™˜ìê°€ ë•€ì— í ë»‘ ì –ìŒ)\n    3. **P**alpitations (ë‘ê·¼ê±°ë¦¼ - ì‹¬ì¥ì´ íŠ€ì–´ë‚˜ì˜¬ ê²ƒ ê°™ìŒ)\n    - ì´ ì¦ìƒë“¤ì´ **ë°œì‘ì (Paroxysmal/Spells)**ìœ¼ë¡œ ë‚˜íƒ€ë‚©ë‹ˆë‹¤.\n- **ì§„ë‹¨ (Dx):**\n    - ë‹¨ìˆœ ì•„ë“œë ˆë‚ ë¦° ìˆ˜ì¹˜ê°€ ì•„ë‹ˆë¼ **Metanephrines (ë¶„í•´ ì‚°ë¬¼)**ì„ í˜ˆì•¡(Plasma)ì´ë‚˜ ì†Œë³€(Urine)ì—ì„œ ì¸¡ì •í•©ë‹ˆë‹¤.\n    - **ì´ìœ :** ì•„ë“œë ˆë‚ ë¦°ì€ ê¸ˆë°© ì‚¬ë¼ì§€ì§€ë§Œ, MetanephrinesëŠ” ë°œì‘ ì‚¬ì´ì—ë„ ìˆ˜ì¹˜ê°€ ë†’ê²Œ ìœ ì§€ë˜ê¸° ë•Œë¬¸ì…ë‹ˆë‹¤ (More reliable).\n### B. Neuroblastoma (Pediatric) ğŸ‘¶\n- ì†Œì•„ì—ì„œ ê°€ì¥ í”í•œ ë‘ê°œê°• ì™¸ ê³ í˜• ì¢…ì–‘(Extracranial solid tumor).\n- **ê¸°ì›:** Neural Crest cells (ë¶€ì‹ ).\n- **íŠ¹ì§•:**\n    - **Irregular mass crosses midline:** ë³µë¶€ ë©ì–´ë¦¬ê°€ ì •ì¤‘ì„ (Midline)ì„ ë„˜ì–´ê°‘ë‹ˆë‹¤. (Wilms tumorëŠ” ì½©íŒ¥ ì¢…ì–‘ì´ë¼ ì•ˆ ë„˜ì–´ê°).\n    - **â˜… Opsoclonus-Myoclonus Syndrome:** \"Dancing eyes, Dancing feet.\" ì•„ì´ì˜ ëˆˆì´ ì œë©‹ëŒ€ë¡œ ì›€ì§ì´ê³  íŒ”ë‹¤ë¦¬ê°€ ì”°ë£©ê±°ë¦½ë‹ˆë‹¤.\n### C. Incidentaloma (ìš°ì—°íˆ ë°œê²¬ëœ ì¢…ì–‘)\n- CT ì°ë‹¤ê°€ ìš°ì—°íˆ ë¶€ì‹  ë©ì–´ë¦¬ë¥¼ ë°œê²¬í•œ ê²½ìš°.\n- **ì ‘ê·¼ë²•:**\n    - ê¸°ëŠ¥ì„ í•˜ëŠ”ê°€? (Hot/Functioning) -> ì¡°ì¹˜ í•„ìš”.\n    - ëª¨ì–‘ì´ í‰í•œê°€? (Ugly/Large) -> ì¡°ì¹˜ í•„ìš”.\n    - ì‘ê³  ê¸°ëŠ¥ì´ ì—†ë‹¤ë©´? -> ì§€ì¼œë³¸ë‹¤ (Watch).\n    - **ì£¼ì˜:** ë¶€ì‹  ì¢…ì–‘ì€ í•¨ë¶€ë¡œ **Biopsy í•˜ì§€ ì•ŠìŠµë‹ˆë‹¤.** (Pheoì¼ ê²½ìš° ë°”ëŠ˜ë¡œ ì°Œë¥´ë©´ Adrenal Crisis ìœ ë°œ ê°€ëŠ¥).\n---\n## 6. MEN Syndromes (Alphabet Soup) ğŸ§¬\nìœ ì „ì„± ë‚´ë¶„ë¹„ ì¢…ì–‘ ì¦í›„êµ°ì…ë‹ˆë‹¤. í—·ê°ˆë¦¬ê¸° ì‰¬ìš°ë‹ˆ íŒ¨í„´ì„ ì™¸ì›Œì•¼ í•©ë‹ˆë‹¤.\n### MEN 1 (The 3 P's)\n1. **P**ituitary adenoma (ë‡Œí•˜ìˆ˜ì²´ ì¢…ì–‘)\n2. **P**arathyroid hyperplasia (ë¶€ê°‘ìƒì„  ì¦ì‹ -> ê³ ì¹¼ìŠ˜í˜ˆì¦)\n3. **P**ancreas tumors (ì·Œì¥ ì¢…ì–‘)\n    - Gastrinoma (Zollinger-Ellison): ìœ„ì‚° ê³¼ë‹¤, ë‹¤ë°œì„± ê¶¤ì–‘.\n    - VIPoma: **W**atery **D**iarrhea, **H**ypokalemia, **A**chlorhydria (WDHA syndrome).\n### MEN 2 (The RET Proto-oncogene)\nMEN 2Aì™€ 2B ëª¨ë‘ **RET ìœ ì „ì ëŒì—°ë³€ì´**ì™€ ê´€ë ¨ ìˆìœ¼ë©°, ë‘ ê°€ì§€ ê³µí†µ ì¢…ì–‘ì„ ê°€ì§‘ë‹ˆë‹¤:\n- **ê³µí†µ:** **Medullary Thyroid Cancer (MTC)** & **Pheochromocytoma**.\n| **êµ¬ë¶„** | **MEN 2A** | **MEN 2B** |\n| --- | --- | --- |\n| **ì¶”ê°€ íŠ¹ì§•** | **Parathyroid Hyperplasia** \n (ë¶€ê°‘ìƒì„  ë¬¸ì œ -> ê³ ì¹¼ìŠ˜í˜ˆì¦) | **Mucosal Neuromas** (ì…ìˆ /í˜€ì— ë©ì–´ë¦¬) \n **Marfanoid Habitus** (í‚¤ í¬ê³  ë§ˆë¦„) |\n- **ì„ìƒ íŒ:** ì Šì€ í™˜ìê°€ ê°‘ìƒì„  ìˆ˜ì§ˆì•”(Medullary CA)ì´ë‚˜ ê°ˆìƒ‰ì„¸í¬ì¢…(Pheo)ì´ ìˆë‹¤ë©´ ë°˜ë“œì‹œ MEN ì¦í›„êµ°ì„ ì˜ì‹¬í•´ì•¼ í•©ë‹ˆë‹¤.\n---","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-229"}
{"chunk_type":"recap_summary","text":"## ğŸ”¥ Rapid Fire Recap: High Yield Must-Knows\n1. **Thyroid Nodule Algorithm:** TSH ë¨¼ì €! **Low TSH = Hot Nodule = No Cancer = No Biopsy.**\n2. **Thyroglossal Duct Cyst:** ìˆ˜ìˆ  ì „ **ì •ìƒ ê°‘ìƒì„  ìœ„ì¹˜ í™•ì¸(Ultrasound/Scan)** í•„ìˆ˜. (ìœ ì¼í•œ ê°‘ìƒì„ ì¼ ìˆ˜ ìˆìŒ).\n3. **Hashimoto's Risk:** ì˜¤ë˜ëœ í•˜ì‹œëª¨í†  ê°‘ìƒì„ ì—¼ í™˜ìê°€ ê°‘ìê¸° ëª©ì´ ë¶“ê³  ë”±ë”±í•´ì§€ë©´ **Thyroid Lymphoma** ì˜ì‹¬. (**Pemberton Sign** ì²´í¬).\n4. **Thyroid Storm vs Malignant Hyperthermia:** ë‘˜ ë‹¤ ê³ ì—´/ë¹ˆë§¥ì´ì§€ë§Œ, **Rigidity(ê°•ì§)ê°€ ìˆìœ¼ë©´ MH**, ì—†ìœ¼ë©´ Storm.\n5. **Pheochromocytoma:** ë‘í†µ+ë°œí•œ+ë‘ê·¼ê±°ë¦¼(Triad). ì§„ë‹¨ì€ **Metanephrines** (not just catecholamines).\n6. **Neuroblastoma (Kids):** ë±ƒì† ë©ì–´ë¦¬ê°€ ì •ì¤‘ì„ ì„ ë„˜ìŒ(Crosses midline) + ì¶¤ì¶”ëŠ” ëˆˆ/ë°œ(Opsoclonus-myoclonus).\n7. **MEN 1:** 3 P's (Pituitary, Parathyroid, Pancreas).\n8. **MEN 2:** RET ìœ ì „ì. Medullary Thyroid CA + PheoëŠ” ê¸°ë³¸.\n    - 2AëŠ” Parathyroid (ì¹¼ìŠ˜ â†‘).\n    - 2BëŠ” Mucosal Neuroma + Marfanoid.","subject":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","page_title":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","episode":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","section_path":["LM_endo 2 2f346f2986ee806b85b4c09245ef8c59"],"source_doc_id":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59","source_page":null,"source_anchor":"LM_endo 2 2f346f2986ee806b85b4c09245ef8c59-249"}
{"chunk_type":"transcript_chunk","text":"# LM_endo 1\n**Verify (ê²€ì¦):**\n> \"Welcome back to the deep dive. Today, we are absolutely on a mission. We are going to tackle one of the most high yield and let's be honest one of the trickiest areas for USMLE step two. We are going straight into the brain, right to the center of control. We are talking about the pituitary gland. The master gland. It's so small, you know, it just sits in that little bony saddle the sella turcica. But the pathology here is... it's just massive for the boards. It controls everything from growth to your stress response, reproduction.\"\n>\n---\n# USMLE Step 2 Deep Dive: ë‡Œí•˜ìˆ˜ì²´ (Pituitary Gland) ì •ë³µí•˜ê¸° ğŸ§ \n## 1. Introduction: ì„ìƒì  ì‚¬ê³ ë°©ì‹ (Clinical Framework)\nì´ë²ˆ ê°•ì˜ì˜ ëª©í‘œëŠ” ë‹¨ìˆœ ì•”ê¸°ê°€ ì•„ë‹ˆë¼, **USMLE Step 2**ì—ì„œ ìš”êµ¬í•˜ëŠ” ê²¬ê³ í•œ ì •ì‹ ì  í”„ë ˆì„ì›Œí¬(Mental Framework)ë¥¼ êµ¬ì¶•í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ì‹œí—˜ì—ì„œëŠ” ë‹¨ìˆœíˆ ì§ˆë³‘ëª…ì„ ë¬»ëŠ” ê²ƒì´ ì•„ë‹ˆë¼, í˜¼ë€ìŠ¤ëŸ¬ìš´ ì¦ìƒ ì„¸íŠ¸ë¥¼ ê°€ì§„ í™˜ìë¥¼ ì œì‹œí•˜ê³  ë‹¤ìŒ ì¤‘ ê°€ì¥ ì ì ˆí•œ ì¡°ì¹˜ëŠ” ë¬´ì—‡ì¸ì§€(Next Best Step)ë¥¼ ë¬»ìŠµë‹ˆë‹¤.\n- **í•µì‹¬ í¬ì¸íŠ¸:** í˜¸ë¥´ëª¬ ê³¼ë‹¤(Excess) vs ê²°í•(Deficiency) êµ¬ë³„\n- **ì£¼ì˜ ì‚¬í•­:** ì§„ë‹¨ ê²€ì‚¬ì˜ ì •í™•í•œ ìˆœì„œë¥¼ ì§€í‚¤ëŠ” ê²ƒì´ ì ìˆ˜ë¥¼ ì–»ëŠ” í•µì‹¬ì…ë‹ˆë‹¤. (MRIë¥¼ ë„ˆë¬´ ì¼ì° ì°ê±°ë‚˜, í™˜ìë¥¼ ë³´ì§€ ì•Šê³  ìˆ˜ì¹˜ë§Œ ì¹˜ë£Œí•˜ëŠ” í•¨ì •ì„ í”¼í•´ì•¼ í•¨)\n---\n## 2. Hyperpituitarism (ë‡Œí•˜ìˆ˜ì²´ ê¸°ëŠ¥ í•­ì§„ì¦) - Part 1: Prolactinoma ğŸ¥›\nê°€ì¥ í”í•œ ë‡Œí•˜ìˆ˜ì²´ ì¢…ì–‘ì…ë‹ˆë‹¤. í™˜ìì˜ ì„±ë³„ê³¼ ìƒíƒœì— ë”°ë¼ ì„ìƒ ì–‘ìƒì´ ì™„ì „íˆ ë‹¤ë¦…ë‹ˆë‹¤.\n### ğŸš© ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤ (Clinical Presentation)\n| í™˜ìêµ° | ì¦ìƒ (Symptoms) | ê¸°ì „ (Mechanism) |\n| --- | --- | --- |\n| **íê²½ ì „ ì—¬ì„±** (Premenopausal Women) | â€¢ **ìƒë¦¬ ë¶ˆìˆœ (Oligomenorrhea/Amenorrhea)**  â€¢ **ë¶ˆì„ (Infertility)**  â€¢ ìœ ì¦™ ë¶„ë¹„ (Galactorrhea)  â€¢ â˜… **ê³¨ë°€ë„ ê°ì†Œ** | ë†’ì€ Prolactinì´ **GnRHë¥¼ ì–µì œ**í•˜ì—¬ Hypogonadism ìœ ë°œ (ì—ìŠ¤íŠ¸ë¡œê² ê°ì†Œë¡œ ì¡°ê¸° íê²½ê³¼ ìœ ì‚¬í•œ ë¼ˆ ì†ì‹¤ ë°œìƒ) |\n| **íê²½ í›„ ì—¬ì„± & ë‚¨ì„±** (Postmenopausal / Men) | â€¢ **ì‹œì•¼ ê²°ì† (Visual Field Defect)**: â˜… **Bitemporal Hemianopsia (í„°ë„ ì‹œì•¼)**  â€¢ ë‘í†µ (Headache)  â€¢ ì„±ìš• ê°í‡´, ë°œê¸° ë¶€ì „ | ìƒë¦¬ë¼ëŠ” 'ì•ŒëŒ'ì´ ì—†ì–´ì„œ ì¢…ì–‘ì´ **Macroadenoma**ê¹Œì§€ ì»¤ì§„ í›„ ë°œê²¬ë¨. **Mass effect**ë¡œ ì‹œì‹ ê²½ êµì°¨(Optic chiasm)ë¥¼ ì••ë°•. |\n### ğŸ§ª ì§„ë‹¨ (Diagnosis): í•¨ì • í”¼í•˜ê¸°\nMRIë¥¼ ì°ê¸° ì „ì— ë°˜ë“œì‹œ í™•ì¸í•´ì•¼ í•  ìˆ˜ì¹˜ë“¤ì´ ìˆìŠµë‹ˆë‹¤.\n1. **Serum Prolactin > 200 ng/mL:** ê±°ì˜ í™•ì •ì (Virtually diagnostic)ì¸ Prolactinoma.\n2. **Gray Zone (20~200 ng/mL):** ì§„ë‹¨ì  ì˜¤ë¥˜ê°€ ë°œìƒí•˜ê¸° ì‰¬ìš´ ìœ„í—˜ êµ¬ì—­. ë°˜ë“œì‹œ ë‹¤ìŒì„ ê°ë³„í•´ì•¼ í•¨.\n### âš ï¸ í•„ìˆ˜ ê°ë³„ ì§ˆí™˜ ë° ìƒí™© (Rule outs)\nMRI ì´¬ì˜ ì „ ë°˜ë“œì‹œ ì²´í¬í•´ì•¼ í•  ë¦¬ìŠ¤íŠ¸:\n- **ì•½ë¬¼ (Medications):** í•­ì •ì‹ ë³‘ ì•½ë¬¼(Haloperidol, Risperidone ë“±) â†’ ë„íŒŒë¯¼(Prolactinì˜ ë¸Œë ˆì´í¬)ì„ ì°¨ë‹¨í•˜ì—¬ ìˆ˜ì¹˜ ìƒìŠ¹.\n- **ìƒë¦¬ì  ìš”ì¸:** ì„ì‹ , ìœ ë‘ ìê·¹, ìŠ¤íŠ¸ë ˆìŠ¤.\n- **â˜… ê°‘ìƒì„  ê¸°ëŠ¥ ì €í•˜ì¦ (Hypothyroidism):**\n    - **ê¸°ì „:** ë‚®ì€ T4 â†’ ì‹œìƒí•˜ë¶€ì—ì„œ TRH ì¦ê°€ â†’ TRHê°€ TSHë¿ë§Œ ì•„ë‹ˆë¼ **Prolactin ë¶„ë¹„ë„ ìê·¹**.\n    - **ì£¼ì˜:** ê°‘ìƒì„  ì €í•˜ì¦ í™˜ìë¥¼ Prolactinomaë¡œ ì˜¤ì¸í•˜ì—¬ ìˆ˜ìˆ í•˜ëŠ” ê²ƒì€ **ì‹¬ê°í•œ ì‹¤ìˆ˜(Massive Mistake)**.\n    - **Next Step:** TSH, Creatinine(ì‹ ë¶€ì „ ë°°ì œ), ì„ì‹  í…ŒìŠ¤íŠ¸ í™•ì¸ í›„ MRI ì´¬ì˜.\n### ğŸ’Š ì¹˜ë£Œ (Management)","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-1"}
{"chunk_type":"transcript_chunk","text":"ProlactinomaëŠ” ë…íŠ¹í•˜ê²Œë„ **ì•½ë¬¼ ì¹˜ë£Œê°€ 1ì°¨ ì¹˜ë£Œ(First-line)**ì…ë‹ˆë‹¤.\n- **1st Line:** **Dopamine Agonists** (ë„íŒŒë¯¼ì€ Prolactinì˜ ë¸Œë ˆì´í¬ ì—­í• )\n    - **Cabergoline** (ì„ í˜¸ë¨: ë¶€ì‘ìš© ì ê³  íš¨ê³¼ ì¢‹ìŒ)\n    - Bromocriptine\n    - íš¨ê³¼: ì¢…ì–‘ í¬ê¸°ë¥¼ ì¤„ì´ê³  Prolactin ìˆ˜ì¹˜ë¥¼ ì •ìƒí™”í•¨.\n- **ìˆ˜ìˆ  (Transsphenoidal Surgery):** ì•½ë¬¼ ì¹˜ë£Œì— ì‹¤íŒ¨í•˜ê±°ë‚˜, ì‹œì•¼ ê²°ì†ì´ ê¸‰ê²©íˆ ì§„í–‰ë˜ì–´ ì•½ë¬¼ ë°˜ì‘ì„ ê¸°ë‹¤ë¦´ ìˆ˜ ì—†ì„ ë•Œë§Œ ì‹œí–‰.\n---\n## 3. Hyperpituitarism - Part 2: Acromegaly (ë§ë‹¨ë¹„ëŒ€ì¦) ğŸ¦\nì„±ì¥ í˜¸ë¥´ëª¬(GH) ê³¼ë‹¤ ë¶„ë¹„ ì§ˆí™˜ì…ë‹ˆë‹¤.\n### ğŸš© ì¦ìƒ ë° ìœ„í—˜ì„±\n- **ì™¸í˜•:** ì´ë§ˆ íŠ€ì–´ë‚˜ì˜´(Frontal bossing), ë¶€ì •êµí•©, **ì»¤ì§„ ì†ê³¼ ë°œ(ë°˜ì§€ë‚˜ ì‹ ë°œ ì‚¬ì´ì¦ˆ ë³€í™”)**.\n- **â˜… So What? (ì™œ ìœ„í—˜í•œê°€):** ë‚´ì¥ ê¸°ê´€ë„ ê°™ì´ ì»¤ì§(Visceral enlargement).\n    - **ì‹¬í˜ˆê´€(CV):** **ì‹¬ë¶€ì „(Heart Failure)**, ì‹¬ê·¼ë³‘ì¦, ê³ í˜ˆì••. â†’ **ê°€ì¥ í”í•œ ì‚¬ë§ ì›ì¸**.\n    - **í˜¸í¡ê¸°:** ìˆ˜ë©´ ë¬´í˜¸í¡ì¦ (ê¸°ë„ ì—°ì¡°ì§ ë¹„ëŒ€).\n    - **ëŒ€ì‚¬:** ë‹¹ë‡¨ë³‘ (GHëŠ” ì¸ìŠë¦° ì €í•­ì„±ì„ ìœ ë°œ).\n    - **â˜… ìœ„ì¥ê´€ê³„:** **ëŒ€ì¥ì•”(Colon Cancer)** ë° ìš©ì¢… ìœ„í—˜ ì¦ê°€.\n        - **High Yield:** Acromegaly ì§„ë‹¨ ì‹œ **ëŒ€ì¥ë‚´ì‹œê²½(Colonoscopy)** ìŠ¤í¬ë¦¬ë‹ì´ í•„ìˆ˜.\n### ğŸ§ª ì§„ë‹¨ í”„ë¡œì„¸ìŠ¤ (2-Step Process)\nì„±ì¥ í˜¸ë¥´ëª¬ì€ í•˜ë£¨ ì¢…ì¼ í„ìŠ¤(pulse) í˜•íƒœë¡œ ë¶„ë¹„ë˜ë¯€ë¡œ ëœë¤ ìˆ˜ì¹˜ëŠ” ë¬´ì˜ë¯¸í•©ë‹ˆë‹¤.\n1. **ìŠ¤í¬ë¦¬ë‹ (Screening):** **IGF-1 (Insulin-like Growth Factor 1)** ì¸¡ì •. (GHì˜ í‰ê· ì¹˜ë¥¼ ë°˜ì˜í•˜ëŠ” ì•ˆì •ì ì¸ ì§€í‘œ)\n2. **í™•ì§„ (Confirmatory):** **ê²½êµ¬ ë‹¹ë¶€í•˜ ê²€ì‚¬ (Oral Glucose Suppression Test)**.\n    - ì •ìƒ: í¬ë„ë‹¹ íˆ¬ì—¬ ì‹œ GH ê°ì†Œ.\n    - Acromegaly: GHê°€ ì–µì œë˜ì§€ ì•Šê³  ë†’ê²Œ ìœ ì§€ë¨.\n3. **MRI:** í™•ì§„ í›„ì—ë§Œ ì‹œí–‰.\n### ğŸ”ª ì¹˜ë£Œ (Management)\n- **1st Line:** **ìˆ˜ìˆ  (Transsphenoidal Resection)**. (Prolactinomaì™€ ë°˜ëŒ€!)\n- **ì•½ë¬¼:** ìˆ˜ìˆ  ì‹¤íŒ¨ ì‹œ Octreotide ë“± ì‚¬ìš©.\n---\n## 4. Posterior Pituitary (í›„ì—½) - ìˆ˜ë¶„ ê· í˜• ğŸ’§\n### ğŸ…°ï¸ SIADH (ë¶€ì ì ˆ í•­ì´ë‡¨í˜¸ë¥´ëª¬ ë¶„ë¹„ ì¦í›„êµ°)\nëª¸ì´ ë¬¼ì„ ë¶€ì ì ˆí•˜ê²Œ ë§ì´ ì¬í¡ìˆ˜í•˜ì—¬ í¬ì„ë˜ëŠ” ìƒíƒœ.\n- **í™˜ì ìƒíƒœ:** **Euvolemic** (ë¶€ì¢… ì—†ìŒ, íƒˆìˆ˜ ì•„ë‹˜ - ì ë§‰ ì´‰ì´‰í•¨).\n- **ì¦ìƒ:** ì €ë‚˜íŠ¸ë¥¨í˜ˆì¦(Hyponatremia) ì†ë„ì— ë”°ë¦„ (ì˜¤ì‹¬, í˜¼ë€, ë°œì‘, í˜¼ìˆ˜).\n- **ì›ì¸ (3ëŒ€ ì¹´í…Œê³ ë¦¬):**\n    1. **CNS:** ë‡Œì¡¸ì¤‘, ì™¸ìƒ, ìˆ˜ë§‰ì—¼ ë“±.\n    2. **Lungs:** íë ´, â˜… **ì†Œì„¸í¬ íì•” (Small Cell Lung Cancer)** - ì´ì†Œì„±(Ectopic) ADH ë¶„ë¹„. (í¡ì—°ìì˜ SIADH = í‰ë¶€ CT í•„ìˆ˜)\n    3. **ì•½ë¬¼:** **SSRIs**, Carbamazepine, NSAIDs.\n- **Labs:**\n    - Serum Osmolality: **Low (< 275)** - í˜ˆì•¡ì€ ë¬½ì–´ì§.\n    - Urine Osmolality: **High (> 100)** - ì†Œë³€ì€ ë†ì¶•ë¨.\n    - Urine Na: **High (> 40)** - ì‹ ì¥ì´ ë¬¼ì„ ì¡ê³  ì†Œê¸ˆì€ ë°°ì„¤.\n- **ì¹˜ë£Œ:**\n    - ê²½ì¦: ìˆ˜ë¶„ ì œí•œ (Fluid restriction).\n    - ì¤‘ì¦(ë°œì‘ ë“±): 3% Hypertonic Saline.\n    - â˜… **ì£¼ì˜:** ë‚˜íŠ¸ë¥¨ì„ ë„ˆë¬´ ë¹¨ë¦¬ êµì •í•˜ë©´ **Osmotic Demyelination Syndrome (Locked-in Syndrome)** ë°œìƒ ìœ„í—˜. \"Correct slowly and carefully.\"\n### ğŸ…±ï¸ Diabetes Insipidus (DI) vs. Primary Polydipsia\nì†Œë³€ëŸ‰ì´ í•˜ë£¨ 3L ì´ìƒì¸ ë‹¤ë‡¨(Polyuria) í™˜ì ê°ë³„.\n- **Water Diuresis (ë¬¼ ì„¤ì‚¬) í™•ì¸:** ë¬½ì€ ì†Œë³€(Dilute urine)ì¸ì§€ í™•ì¸.\n- **â˜… ê°ë³„ í¬ì¸íŠ¸: í˜ˆì¤‘ ë‚˜íŠ¸ë¥¨ (Serum Sodium)**\n    - **Diabetes Insipidus (ìš”ë¶•ì¦):** ë¬¼ì„ ìƒì–´ë²„ë¦¼ â†’ í˜ˆì•¡ ë†ì¶• â†’ **High Sodium (Hypernatremia)**.\n    - **Primary Polydipsia (ë¬¼ ì¤‘ë…):** ë¬¼ì„ ë„ˆë¬´ ë§ì´ ë§ˆì‹¬ â†’ í˜ˆì•¡ í¬ì„ â†’ **Low Sodium (Hyponatremia)**.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-21"}
{"chunk_type":"transcript_chunk","text":"---\n## 5. Hypopituitarism (ë‡Œí•˜ìˆ˜ì²´ ê¸°ëŠ¥ ì €í•˜ì¦) ğŸ“‰\n### ğŸš© ì›ì¸ ë° íŒ¨í„´\n- **ì›ì¸:** ê±°ëŒ€ ì„ ì¢…ì˜ ì••ë°•, ë‡Œí•˜ìˆ˜ì²´ ì¡¸ì¤‘(Apoplexy), ì‰¬í•œ ì¦í›„êµ°(Sheehan's syndrome - ë¶„ë§Œ í›„ ì¶œí˜ˆ), ì¹¨ìœ¤ì„± ì§ˆí™˜(í˜ˆìƒ‰ì†Œì¹¨ì°©ì¦ ë“±).\n- **í˜¸ë¥´ëª¬ ì†Œì‹¤ ìˆœì„œ:** GH/Gonadotropins(FSH/LH) â†’ TSH â†’ ACTH ìˆœìœ¼ë¡œ ì‚¬ë¼ì§.\n### â˜… Primary vs. Secondary Adrenal Insufficiency (ë¶€ì‹  ë¶€ì „) êµ¬ë³„\nStep 2ì—ì„œ ê°€ì¥ ì¤‘ìš”í•œ ê³ ë‚œì´ë„ ê°œë…ì…ë‹ˆë‹¤. ë‘˜ ë‹¤ Cortisolì€ ë‚®ì§€ë§Œ ê²°ì •ì ì¸ ì°¨ì´ê°€ ìˆìŠµë‹ˆë‹¤.\n| íŠ¹ì§• | Primary (Addison's Disease) | Secondary (Pituitary Failure) |\n| --- | --- | --- |\n| **ë³‘ë³€ ìœ„ì¹˜** | ë¶€ì‹  (Adrenal Gland) íŒŒê´´ | ë‡Œí•˜ìˆ˜ì²´ (Pituitary) ACTH ë¶€ì¡± |\n| **Aldosterone** | **ê°ì†Œ** (ë¶€ì‹  ì „ì²´ê°€ íŒŒê´´ë¨) | **ì •ìƒ** (RAAS ì‹œìŠ¤í…œì— ì˜í•´ ì¡°ì ˆë˜ë¯€ë¡œ ACTH ë¬´ê´€) |\n| **Potassium** | **Hyperkalemia** (Aldo ë¶€ì¡±ìœ¼ë¡œ K+ ë°°ì„¤ ëª»í•¨) | **Normal** |\n| **í”¼ë¶€ (Skin)** | â˜… **Hyperpigmentation** (High ACTH â†’ MSH ìê·¹) | **Pale / Alabaster** (ì°½ë°±í•¨, MSH ìê·¹ ì—†ìŒ) |\n| **Salt Craving** | ìˆìŒ | ì—†ìŒ |\n- **ì§„ë‹¨ íŒ:** ì €í˜ˆì•• í™˜ìì—ì„œ **ì €í˜ˆë‹¹(Hypoglycemia)** + **í˜¸ì‚°êµ¬ ì¦ê°€ì¦(Eosinophilia)**ì´ ë³´ì´ë©´, ì„¤ëª…ë˜ì§€ ì•ŠëŠ” í”¼ë¡œì™€ í•¨ê»˜ **Morning Cortisol**ì„ ë°˜ë“œì‹œ ì²´í¬í•´ì•¼ í•©ë‹ˆë‹¤. (Cortisolì´ ë‚®ìœ¼ë©´ í˜¸ì‚°êµ¬ê°€ ì¡°ì§ìœ¼ë¡œ ì´ë™í•˜ì§€ ëª»í•˜ê³  í˜ˆì•¡ì— ë¨¸ë¬¾).\n---\n## ğŸï¸ Rapid Fire Recap (í•µì‹¬ ìš”ì•½) ğŸ”¥\n1. **Prolactinoma:** Serum Prolactin **> 200**. ê°‘ìƒì„ ê¸°ëŠ¥ì €í•˜ì¦(Hypothyroid) ë°°ì œ. ì¹˜ë£ŒëŠ” **Cabergoline** (ì•½ë¬¼) ë¨¼ì €.\n2. **Acromegaly:** í° ì†/í„±, ì‹¬ì¥ ë¬¸ì œ(Bad heart). ìŠ¤í¬ë¦¬ë‹ì€ **IGF-1**, í™•ì§„ì€ **Oral Glucose Suppression**. ì¹˜ë£ŒëŠ” **ìˆ˜ìˆ ** ë¨¼ì €. **ëŒ€ì¥ë‚´ì‹œê²½** í•„ìˆ˜.\n3. **SIADH:** Hyponatremia + Euvolemia + ì§„í•œ ì†Œë³€. **Small Cell Lung Cancer** (í¡ì—°ì)ì™€ SSRI ì²´í¬. ìˆ˜ë¶„ ì œí•œì´ 1ì°¨ ì¹˜ë£Œ.\n4. **DI vs Polydipsia:** í˜ˆì¤‘ ë‚˜íŠ¸ë¥¨(Serum Sodium)ì„ ë³´ë¼. High Na = **Central DI**, Low Na = **Primary Polydipsia**.\n5. **Hypopituitarism vs Primary Adrenal Insufficiency:** ë‡Œí•˜ìˆ˜ì²´ ë¬¸ì œ(Secondary)ëŠ” **Aldosterone ì •ìƒ, Potassium ì •ìƒ, í”¼ë¶€ ì°½ë°±(Pale)**.\n---\n## 6. Closing Thought: Incidentaloma (ìš°ì—°ì¢…)\nCT/MRIì—ì„œ ìš°ì—°íˆ ë°œê²¬ëœ ë‡Œí•˜ìˆ˜ì²´ ì¢…ê´´(Mass)ê°€ ìˆë‹¤ í•´ë„, í˜¸ë¥´ëª¬ ìˆ˜ì¹˜ê°€ ì •ìƒì´ë©´ **í•¨ë¶€ë¡œ ì¹˜ë£Œí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤.**\n- í•´ë¶€í•™(Anatomy)ì´ í•­ìƒ ìƒë¦¬í•™(Physiology)ê³¼ ì¼ì¹˜í•˜ëŠ” ê²ƒì€ ì•„ë‹™ë‹ˆë‹¤.\n- ë°˜ë“œì‹œ ìƒí™”í•™ì  ì¦ê±°(Biochemical proof)ë¥¼ í™•ì¸í•˜ê³  ì¹˜ë£Œë¥¼ ê²°ì •í•˜ì‹­ì‹œì˜¤. **\"Trust but verify.\"**\n**Verification: 0:00~0:30 Dictation**\n\"Welcome back to the deep dive. Today, we are locking the doors, turning off notifications, and uh, pulling out the highlighters. We are doing a dedicated high-yield study session specifically for you if you're gearing up for USMLE Step 2. That's right. We aren't just, you know, casually browsing through medical trivia today. This is not about fun facts for a cocktail party. The goal here is to take a stack of high-yield endocrine review notes, those clinical algorithms, surgical guidelines, and really just distill them into a framework you can actually use...\"\n---\n# ğŸ¦´ USMLE Step 2 Deep Dive: Parathyroid Disorders\nì´ë²ˆ ì„¸ì…˜ì€ ë‹¨ìˆœ ì•”ê¸°(Rote memorization)ë¥¼ ë„˜ì–´, ì‹œí—˜ ë‹¹ì¼ ì‹¤ì œë¡œ í™œìš©í•  ìˆ˜ ìˆëŠ” **ë…¼ë¦¬ì  ì‚¬ê³ (Mental Map)**ë¥¼ êµ¬ì¶•í•˜ëŠ” ê²ƒì„ ëª©í‘œë¡œ í•©ë‹ˆë‹¤. \"Bones, Stones, and Groans\"ë¼ëŠ” ê³ ì „ì ì¸ ì•”ê¸°ë²•ì„ ë„˜ì–´ì„œëŠ” êµ¬ì²´ì ì¸ ìˆ˜ìˆ  ì ì‘ì¦ê³¼ ê¹Œë‹¤ë¡œìš´ ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤ë¥¼ ë‹¤ë£¹ë‹ˆë‹¤.\n## 1. Introduction: The Approach","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-41"}
{"chunk_type":"transcript_chunk","text":"- **ëª©í‘œ:** ë‹¨ìˆœ ë¦¬ìŠ¤íŠ¸ ì•”ê¸°ê°€ ì•„ë‹Œ ìƒë¦¬í•™ì  ë…¼ë¦¬ ì´í•´.\n- **ì´ˆì :** ë¶€ê°‘ìƒì„ (Parathyroid gland), íŠ¹íˆ ê³ ì¹¼ìŠ˜í˜ˆì¦(Hypercalcemia), ìœ ì „ì  ë³€ì´, ìˆ˜ìˆ  ê°€ì´ë“œë¼ì¸, ê·¸ë¦¬ê³  ì‹ ë¶€ì „/ì‹ ìƒì•„ ê´€ë ¨ ì„ìƒ ë¹„ë„¤íŠ¸(Vignette).\n---\n## 2. Primary Hyperparathyroidism (ì›ë°œì„± ë¶€ê°‘ìƒì„  í•­ì§„ì¦)\n### ğŸ©º ë³‘ì¸ (Etiology)\n- **ê°€ì¥ í”í•œ ì›ì¸:** **Parathyroid Adenoma (ë‹¨ì¼ ì„ ì¢…)**ê°€ ì•½ **80~85%** ì°¨ì§€.\n- **ìœ ì „ì  ì—°ê´€ì„±:** ì Šì€ í™˜ìë‚˜ ê°€ì¡±ë ¥ì´ ìˆëŠ” ê²½ìš° **MEN Syndrome**ì„ ì˜ì‹¬í•´ì•¼ í•¨.\n    - MEN Type 1\n    - MEN Type 2A\n    - ì£¼ë¡œ ë‹¤ë°œì„± ì„  ì¦ì‹(Hyperplasia)ê³¼ ê´€ë ¨ë¨.\n### ğŸ¤’ ì„ìƒ ì–‘ìƒ (Presentation)\n- **Textbook:** Bones, Stones, Abdominal Groans, Psychiatric Overtones.\n- **Real World & Exam Trend:** â˜… **ë¬´ì¦ìƒ(Asymptomatic)**ì´ ê°€ì¥ í”í•¨.\n    - ìš°ì—°íˆ ì‹œí–‰í•œ í˜ˆì•¡ ê²€ì‚¬ì—ì„œ ì¹¼ìŠ˜ ìˆ˜ì¹˜ê°€ ë†’ê²Œ ë‚˜ì˜¤ëŠ” ê²½ìš°ê°€ ì „í˜•ì ì¸ ì‹œë‚˜ë¦¬ì˜¤.\n- **ì¦ìƒì´ ìˆëŠ” ê²½ìš°:**\n    - **Renal:** ì‹ ì¥ ê²°ì„ (Calcium Oxalate).\n    - **Bone:** ë¼ˆ í†µì¦ (Resorption).\n    - **Abdominal:** ë³€ë¹„(Constipation), ì˜¤ì‹¬, ì†Œí™”ì„± ê¶¤ì–‘.\n    - **Psych:** í”¼ë¡œê°(Fatigue), ë¸Œë ˆì¸ í¬ê·¸(Brain fog), ì‹¬í•˜ë©´ ìš°ìš¸ì¦/í˜¼ë€.\n### ğŸ©¸ ì§„ë‹¨ì  ê²€ì‚¬ ê²°ê³¼ (Lab Profile)\nì§„ë‹¨ì˜ í•µì‹¬ì€ **ìˆ˜ì¹˜ í•˜ë‚˜ê°€ ì•„ë‹ˆë¼ \"ì¡°í•©(Combination)\"**ì„ ë³´ëŠ” ê²ƒì…ë‹ˆë‹¤.\n| í•­ëª© | ê²°ê³¼ | ì˜ë¯¸ |\n| --- | --- | --- |\n| **Serum Calcium** | **High** | ê³ ì¹¼ìŠ˜í˜ˆì¦ |\n| **PTH** | **High** OR **Inappropriately Normal** | â˜… ì¹¼ìŠ˜ì´ ë†’ì€ë° PTHê°€ ì •ìƒì´ë©´ ë¹„ì •ìƒì„. |\n> â˜… Key Concept: \"Inappropriately Normal\"\nì¹¼ìŠ˜ì´ ë†’ìœ¼ë©´ ì •ìƒì ì¸ í”¼ë“œë°± ë£¨í”„ì— ì˜í•´ PTHëŠ” ì–µì œë˜ì–´ ë‚®ì•„ì•¼ í•¨. ë§Œì•½ ì¹¼ìŠ˜ì´ ë†’ì€ë° PTHê°€ ì •ìƒ ë²”ìœ„(ì¤‘ê°„ê°’ ë“±)ë¼ë©´, ë¶€ê°‘ìƒì„ ì´ ììœ¨ì ìœ¼ë¡œ ì‘ë™í•˜ê³  ìˆë‹¤ëŠ” ëœ»ì´ë¯€ë¡œ Primary Hyperparathyroidismìœ¼ë¡œ ì§„ë‹¨í•¨.\n>\n---\n## 3. The Imposter: Familial Hypocalciuric Hypercalcemia (FHH)\nê²€ì‚¬ ê²°ê³¼ê°€ Primary Hyperparathyroidismê³¼ ê±°ì˜ ë™ì¼(High Calcium, High/Normal PTH)í•˜ì—¬ \"ìœ„ëŒ€í•œ ëª¨ë°©ê¾¼(The Great Mimic)\"ì´ë¼ ë¶ˆë¦½ë‹ˆë‹¤.\n### ğŸ§¬ ê¸°ì „ ë° íŠ¹ì§•\n- **ì›ì¸:** ì¹¼ìŠ˜ ê°ì§€ ìˆ˜ìš©ì²´(Calcium-sensing receptors)ì˜ ìœ ì „ì  ê²°í•¨.\n- **Set Point:** ì‹ ì¥ê³¼ ë¶€ê°‘ìƒì„ ì˜ ì¹¼ìŠ˜ ì„¸íŠ¸ í¬ì¸íŠ¸ê°€ ë†’ê²Œ ì„¤ì •ë¨.\n- **ì‹ ì¥:** ì¹¼ìŠ˜ì„ ë°°ì¶œí•˜ì§€ ì•Šê³  ê³µê²©ì ìœ¼ë¡œ ì¬í¡ìˆ˜í•¨.\n- **ì¹˜ë£Œ:** **ìˆ˜ìˆ  ê¸ˆì§€ (Contraindicated).** ì–‘ì„± ì§ˆí™˜ì´ë¯€ë¡œ ìˆ˜ìˆ í•´ë„ ì´ë“ì´ ì—†ê³  ìœ„í—˜ë§Œ ë”°ë¦„.\n### âš–ï¸ ê°ë³„ ì§„ë‹¨ (The Tie-Breaker)\n**24-hour Urinary Calcium Excretion Test**ê°€ í•„ìˆ˜ì ì…ë‹ˆë‹¤.\n- **FHH:** ì†Œë³€ ì¹¼ìŠ˜ **ë§¤ìš° ë‚®ìŒ**. (Calcium/Creatinine clearance ratio < **0.01**)\n- **Primary Hyperparathyroidism:** ì†Œë³€ ì¹¼ìŠ˜ **ë†’ìŒ**. (Bodyê°€ ì¹¼ìŠ˜ì„ ê°ë‹¹ ëª»í•´ ì†Œë³€ìœ¼ë¡œ ë„˜ì¹¨, Ratio > **0.02**)\n- **ì„ìƒì  ì¡°ì–¸:** ìˆ˜ìˆ  ì „ ë°˜ë“œì‹œ ì†Œë³€ ê²€ì‚¬ë¥¼ í†µí•´ FHHë¥¼ ë°°ì œí•´ì•¼ í•¨ (Medical Malpractice ë°©ì§€).\n---","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-61"}
{"chunk_type":"transcript_chunk","text":"## 4. ğŸ‘¶ Clinical Vignette: The Neonatal Crash\n**ì‹œë‚˜ë¦¬ì˜¤:** ê±´ê°•í•´ ë³´ì´ëŠ” ì‹ ìƒì•„(ë‚¨ì•„)ê°€ ìƒí›„ 3ì¼ì§¸ ê²½ë ¨(Seizure), ë¹ˆí˜¸í¡, ê·¼ìœ¡ ì—°ì¶•(Spasm)ìœ¼ë¡œ ë‚´ì›.\n- **ì•„ê¸° Labs:** **Hypocalcemia (ì €ì¹¼ìŠ˜í˜ˆì¦)** + **Low PTH**.\n- **ì›ì¸:** **ì—„ë§ˆì˜ ì§„ë‹¨ë˜ì§€ ì•Šì€ FHH (Maternal FHH).**\n### ğŸ”„ ë°œìƒ ê¸°ì „\n1. **ì„ì‹  ì¤‘:** ì—„ë§ˆ(FHH)ì˜ ë†’ì€ ì¹¼ìŠ˜ì´ íƒœë°˜ì„ í†µê³¼ â†’ íƒœì•„ëŠ” ê³ ì¹¼ìŠ˜ í™˜ê²½ì— ë…¸ì¶œ.\n2. **íƒœì•„ ë°˜ì‘:** íƒœì•„ì˜ ë¶€ê°‘ìƒì„ ì€ \"ì¹¼ìŠ˜ì´ ë„ˆë¬´ ë§ë‹¤\"ê³  íŒë‹¨í•˜ì—¬ **ê¸°ëŠ¥ì´ ì–µì œë¨(Sleep mode).**\n3. **ì¶œìƒ í›„:** íƒ¯ì¤„ì´ ëŠì–´ì§€ë©° ì—„ë§ˆë¡œë¶€í„°ì˜ ì¹¼ìŠ˜ ê³µê¸‰ ì¤‘ë‹¨.\n4. **ê²°ê³¼:** ì•„ê¸°ì˜ ë¶€ê°‘ìƒì„ ì€ ì—¬ì „íˆ ì–µì œëœ ìƒíƒœë¼ PTHë¥¼ ëª» ë§Œë“¦ â†’ ê¸‰ê²©í•œ ì €ì¹¼ìŠ˜í˜ˆì¦ ë°œìƒ â†’ **Seizure.**\n5. **ì¹˜ë£Œ:** ì•„ê¸°ì˜ ë¶€ê°‘ìƒì„ ì´ ê¹¨ì–´ë‚  ë•Œê¹Œì§€ ì¹¼ìŠ˜ ë³´ì¶© (ì¼ì‹œì  í˜„ìƒ).\n---\n## 5. ìˆ˜ìˆ  ì „ êµ­ì†Œí™” (Pre-op Localization)\n- **Sestamibi Scan (Technetium-99m):**\n    - ë¶€ê°‘ìƒì„  ì„ ì¢…(Adenoma)ì€ ë¯¸í† ì½˜ë“œë¦¬ì•„ê°€ í’ë¶€í•˜ì—¬ ë°©ì‚¬ì„± ì¶”ì ìë¥¼ í¡ìˆ˜, ìŠ¤ìº”ìƒ í¬ë¦¬ìŠ¤ë§ˆìŠ¤ íŠ¸ë¦¬ì²˜ëŸ¼ ë°ê²Œ ë¹›ë‚¨.\n    - ìˆ˜ìˆ  ì „ ì ˆê°œ ìœ„ì¹˜ë¥¼ íŒŒì•…í•˜ëŠ” í‘œì¤€ ë°©ë²•.\n---\n## 6. â˜… Surgical Indications (ìˆ˜ìˆ  ì ì‘ì¦)\nì¦ìƒì´ ìˆëŠ” í™˜ìëŠ” ë¬´ì¡°ê±´ ìˆ˜ìˆ ì…ë‹ˆë‹¤. ì¤‘ìš”í•œ ê²ƒì€ **ë¬´ì¦ìƒ(Asymptomatic)** í™˜ìì˜ ìˆ˜ìˆ  ê¸°ì¤€ì…ë‹ˆë‹¤. (ë°˜ë“œì‹œ ì•”ê¸°!)\n1. **Age:** **50ì„¸ ë¯¸ë§Œ** (ì Šì€ í™˜ìëŠ” ì¥ê¸°ì  í•©ë³‘ì¦ ì˜ˆë°©ì„ ìœ„í•´ ìˆ˜ìˆ ).\n2. **Calcium Level:** ì •ìƒ ìƒí•œì¹˜ë³´ë‹¤ **1 mg/dL ì´ìƒ** ë†’ì„ ë•Œ. (ì˜ˆ: cut-off 10.2ì¸ë° 11.2 ì´ìƒì¼ ë•Œ)\n    - ê¸‰ì„± ê³ ì¹¼ìŠ˜í˜ˆì¦ ìœ„ê¸°(Dehydration, Confusion) ìœ„í—˜ ë•Œë¬¸.\n3. **Kidney (ì‹ ì¥):**\n    - **GFR < 60** (Stage 3 CKD ì´ìƒ).\n    - ì˜ìƒ ê²€ì‚¬(CT, US, X-ray)ìƒ **ê²°ì„(Stone)**ì´ë‚˜ **ì„íšŒí™”(Nephrocalcinosis)** ë°œê²¬ ì‹œ (ë¬´ì¦ìƒì´ë¼ë„).\n4. **Bone (ë¼ˆ):**\n    - **ê³¨ë‹¤ê³µì¦ (Osteoporosis):** DEXA scan T-score **< -2.5** (Lumbar, Hip, Femoral neck, Distal radius).\n    - **ì·¨ì•½ ê³¨ì ˆ (Fragility Fracture)** ë³‘ë ¥ (ì†ëª© ê³¨ì ˆ ë“±).\n5. **Urine:** 24ì‹œê°„ ì†Œë³€ ì¹¼ìŠ˜ **> 400 mg/day** (ê²°ì„ ìƒì„± ìœ„í—˜).\n---\n## 7. Secondary & Tertiary Hyperparathyroidism (ì‹ ë¶€ì „ í™˜ì)\nì£¼ë¡œ ë§Œì„± ì‹ ë¶€ì „(CKD) ë˜ëŠ” íˆ¬ì„ í™˜ìì—ê²Œ ë°œìƒí•©ë‹ˆë‹¤.\n### Secondary Hyperparathyroidism\n- **ê¸°ì „:** ì‹ ì¥ ê¸°ëŠ¥ ì €í•˜ â†’ ë¹„íƒ€ë¯¼ D í™œì„±í™” ì‹¤íŒ¨ & ì¸ì‚°(Phosphate) ë°°ì¶œ ì‹¤íŒ¨ â†’ **High Phosphate**ê°€ ì¹¼ìŠ˜ê³¼ ê²°í•©í•´ ì¹¼ìŠ˜ ìˆ˜ì¹˜ ë–¨ì–´ëœ¨ë¦¼ â†’ ë³´ìƒ ì‘ìš©ìœ¼ë¡œ **PTH ìƒìŠ¹**.\n- **íŠ¹ì§•:** ë¶€ê°‘ìƒì„ ì´ \"ì‹œí‚¤ëŠ” ëŒ€ë¡œ ì¼í•˜ëŠ”\" ìƒíƒœ.\n### Tertiary Hyperparathyroidism\n- **ê¸°ì „:** Secondary ìƒíƒœê°€ ë„ˆë¬´ ì˜¤ë˜ ì§€ì†(ë§Œì„± ìê·¹)ë˜ì–´ ë¶€ê°‘ìƒì„ ì´ **ììœ¨ì„±(Autonomous)**ì„ íšë“. \"Rogue\" ìƒíƒœê°€ ë¨.\n- **Labs:** â˜… **High Calcium**, **High Phosphate**, **Massive PTH** (>800~1000 pg/mL).\n- **ìœ„í—˜ì„±:** ì¹¼ìŠ˜ê³¼ ì¸ì‚°ì´ ëª¨ë‘ ë†’ì•„ í˜ˆì•¡ì´ í¬í™”ë¨ â†’ ì¡°ì§ì— ì„íšŒ ì¹¨ì°©.\n### ğŸš¨ Calciphylaxis (Calcific Uremic Arteriolopathy)","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-81"}
{"chunk_type":"transcript_chunk","text":"- **ì •ì˜:** í”¼ë¶€ì˜ ì‘ì€ í˜ˆê´€ë“¤ì´ ì„íšŒí™”ë˜ì–´ ë§‰íˆëŠ” ì‘ê¸‰ ìƒí™©.\n- **ì¦ìƒ:** ë³´ë¼ìƒ‰(Violet) í”¼ë¶€ ë³‘ë³€, ê´´ì‚¬(Necrosis), ê¶¤ì–‘(Gangrene). ì‚¬ë§ë¥  ë§¤ìš° ë†’ìŒ.\n- **ê¸°íƒ€ ìˆ˜ìˆ  ì ì‘ì¦:**\n    - **Calciphylaxis** ë°œìƒ ì‹œ ì¦‰ì‹œ ìˆ˜ìˆ  (Source of PTH ì œê±°).\n    - ë‚œì¹˜ì„± ë¼ˆ í†µì¦ (Intractable bone pain).\n    - **ì‹¬í•œ ê°€ë ¤ì›€ì¦ (Severe Pruritus):** í”¼ë¶€ì— ì¹¼ìŠ˜/ì¸ì‚° ì¹¨ì°©ìœ¼ë¡œ ì¸í•´ ë°œìƒ.\n---\n## 8. Post-surgical Hypoparathyroidism (ìˆ˜ìˆ  í›„ ë¶€ê°‘ìƒì„  ê¸°ëŠ¥ ì €í•˜ì¦)\n- **ì›ì¸:** ê°‘ìƒì„ /ë¶€ê°‘ìƒì„  ì ˆì œìˆ  ì¤‘ ì‹¤ìˆ˜ë¡œ ì„ ì„ ì œê±°í•˜ê±°ë‚˜ í˜ˆë¥˜ë¥¼ ì°¨ë‹¨í•¨.\n- **ì¹˜ë£Œ:** ì¹¼ìŠ˜ + ë¹„íƒ€ë¯¼ D ë³´ì¶©.\n### âš ï¸ The Danger Zone: Calcium-Phosphate Product\n- **ê³µì‹:** Serum Calcium Ã— Serum Phosphate.\n- **ëª©í‘œ:** ì´ ê°’ì„ **55 ë¯¸ë§Œ**ìœ¼ë¡œ ìœ ì§€í•´ì•¼ í•¨.\n- **ìœ„í—˜:** 55ë¥¼ ì´ˆê³¼í•˜ë©´ ì—°ì¡°ì§ ì„íšŒí™” ìœ„í—˜ ê¸‰ì¦.\n- **Basal Ganglia Calcification:**\n    - ë‡Œì˜ ê¸°ì €í•µì— ì„íšŒí™” ë°œìƒ ê°€ëŠ¥.\n    - **ì¦ìƒ:** **íŒŒí‚¨ìŠ¨ë³‘ ìœ ì‚¬ ì¦ìƒ (Parkinsonian symptoms)**, ë–¨ë¦¼(Tremor), ë¬´ë„ë³‘(Chorea) ë“± ì¶”ì²´ì™¸ë¡œ ì¦ìƒ ìœ ë°œ.\n    - ë‹¨ìˆœíˆ ì¹¼ìŠ˜ë§Œ ì£¼ëŠ” ê²ƒì´ ì•„ë‹ˆë¼ ì¸ì‚° ìˆ˜ì¹˜ë„ ì¡°ì ˆ(Phosphate binders)í•˜ëŠ” ê· í˜•ì´ í•„ìš”í•¨.\n---\n## 9. ğŸ”¥ Rapid Fire Recap\nê°•ì˜ ë§ˆì§€ë§‰ì— ì •ë¦¬ëœ í•µì‹¬ ìš”ì•½ì…ë‹ˆë‹¤.\n1. **Primary Hyperpara Labs:** High Calcium + High/Normal PTH.\n2. **FHH êµ¬ë¶„:** **Urine Calcium** (PrimaryëŠ” High, FHHëŠ” Low, Ratio < 0.01). **FHHëŠ” ìˆ˜ìˆ  ì•ˆ í•¨.**\n3. **Neonatal Seizure + Low PTH:** **Maternal FHH** (ì—„ë§ˆì˜ ê³ ì¹¼ìŠ˜ì´ íƒœì•„ ì„ ì„ ì–µì œ).\n4. **Asymptomatic ìˆ˜ìˆ  ì ì‘ì¦ (ë°˜ë“œì‹œ ì•”ê¸°):**\n    - Age < 50\n    - Calcium > 1 mg/dL above normal\n    - GFR < 60 or Stones\n    - Osteoporosis (T-score < -2.5) or Fracture\n    - Urine Calcium > 400 mg/day\n5. **Tertiary Hyperpara:** Renal failure í™˜ì, Autonomous glands, High Ca/High Phos.\n    - **ìœ„í—˜:** **Calciphylaxis** (í”¼ë¶€ ê´´ì‚¬), ì‹¬í•œ ê°€ë ¤ì›€ì¦ â†’ ìˆ˜ìˆ  í•„ìš”.\n6. **Hypopara Treatment Goal:** Calcium Ã— Phosphate product **< 55** ìœ ì§€ (Basal Ganglia ì„íšŒí™” ë° íŒŒí‚¨ìŠ¨ ì¦ìƒ ì˜ˆë°©).\n---\n### ğŸ“ Final Thought\nìˆ˜ìˆ  ì ì‘ì¦(íŠ¹íˆ ë¬´ì¦ìƒ í™˜ì)ì€ ë‹¨ìˆœí•œ ìˆ«ìê°€ ì•„ë‹ˆë¼ **ìœ„í—˜ë„ ê³„ì¸µí™”(Risk Stratification)** ë„êµ¬ì…ë‹ˆë‹¤. ì¦ìƒì´ ì—†ë”ë¼ë„ ë¼ˆì™€ ì‹ ì¥ì— ì˜êµ¬ì ì¸ ì†ìƒì´ ì˜¤ê¸° ì „ì— \"ì§€ë¶•ì´ ìƒˆê¸° ì „ì— ê³ ì¹˜ëŠ”(Preventative Medicine)\" ê°œë…ìœ¼ë¡œ ì ‘ê·¼í•´ì•¼ í•©ë‹ˆë‹¤.\n**[Verification: 0:00~0:30 Dictation]**\n\"Hello and welcome back to the deep dive. We are uh on a mission today. We are tackling the absolute beast that is the USMLE Step 2 Endocrine section. That's right. And I know usually we like to wander through topics a bit, but today is different. Today is about survival mechanisms, specifically mental frameworks. Right, we were looking at this strictly through the eyes of the learner preparing for the boards. This isn't about memorizing a huge list of facts. Yeah. It's about building a decision tree.\"\n---\n# ğŸ©º USMLE Step 2 Endocrine: The \"Deep Dive\" Frameworks\nì´ë²ˆ ë”¥ë‹¤ì´ë¸Œì—ì„œëŠ” ë‹¨ìˆœí•œ ì‚¬ì‹¤ ì•”ê¸°ê°€ ì•„ë‹Œ, **\"Next Best Step\"**ì„ ê²°ì •í•˜ê¸° ìœ„í•œ **ì˜ì‚¬ê²°ì • ë‚˜ë¬´(Decision Tree)**ë¥¼ ë§Œë“œëŠ” ë° ì§‘ì¤‘í•©ë‹ˆë‹¤. ì‹¤ì œ ì‹œí—˜ì´ë‚˜ ë³‘ë™(Wards)ì—ì„œ í™˜ìë¥¼ ë§ˆì£¼í–ˆì„ ë•Œ í•„ìš”í•œ ìƒì¡´ ë©”ì»¤ë‹ˆì¦˜ì„ ë‹¤ë£¹ë‹ˆë‹¤. ë˜í•œ, ì²­ì·¨ì ìš”ì²­ì— ë”°ë¼ **Milk-Alkali Syndrome** (ì†ŒìŠ¤ í…ìŠ¤íŠ¸ì— í•œ ì¤„ë§Œ ìˆì–´ ì œì™¸ë¨) ëŒ€ì‹  **Hypoglycemia Associated Autonomic Failure**ë¥¼ ê¹Šì´ ìˆê²Œ ë‹¤ë£¹ë‹ˆë‹¤.\n## 1. Introduction: Mental Frameworks ğŸ§ \n- **í•µì‹¬ ëª©í‘œ:** ê±°ëŒ€í•œ ì‚¬ì‹¤ë“¤ì˜ ë‚˜ì—´ì„ ì™¸ìš°ëŠ” ê²ƒì´ ì•„ë‹ˆë¼, í™˜ìê°€ ì£¼ì–´ì¡Œì„ ë•Œ **\"ë‹¤ìŒì— ë¬´ì—‡ì„ í•  ê²ƒì¸ê°€?\"**ë¥¼ ê²°ì •í•˜ëŠ” ëŠ¥ë ¥ì„ ê¸°ë¥´ëŠ” ê²ƒ.\n- **ì ‘ê·¼ ë°©ì‹:** ë‡Œí•˜ìˆ˜ì²´(Pituitary), ê°‘ìƒì„ (Thyroid), ë¶€ê°‘ìƒì„ (Parathyroid), ë¶€ì‹ (Adrenal)ì— ëŒ€í•œ í•µì‹¬ í”„ë ˆì„ì›Œí¬ë¥¼ êµ¬ì¶•í•˜ê³ , ë‹¹ë‡¨ë³‘(Diabetes) íŒŒíŠ¸ì—ì„œëŠ” ììœ¨ì‹ ê²½ê³„ ë¶€ì „(Autonomic failure)ì„ ì§‘ì¤‘ì ìœ¼ë¡œ ë¶„ì„í•©ë‹ˆë‹¤.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-101"}
{"chunk_type":"transcript_chunk","text":"---\n## 2. Pituitary Gland (ë‡Œí•˜ìˆ˜ì²´) ğŸ¯\n### ğŸ§  Prolactinoma (í”„ë¡œë½í‹´ì„ ì¢…)\nê°€ì¥ ë¨¼ì € **\"Rule of 200\"**ì„ ê¸°ì–µí•´ì•¼ í•©ë‹ˆë‹¤.\n- **ì§„ë‹¨ ê¸°ì¤€:** í˜ˆì²­ Prolactin ìˆ˜ì¹˜ê°€ **> 200**ì´ë©´ Prolactinomaì¼ í™•ë¥ ì´ ì‚¬ì‹¤ìƒ ì§„ë‹¨ì (Virtually diagnostic)ì…ë‹ˆë‹¤.\n- **âš ï¸ The Exam Trap (ì‹œí—˜ì˜ í•¨ì •):** MRIë¥¼ ì°ìœ¼ëŸ¬ í™˜ìë¥¼ ë³´ë‚´ê¸° ì „ì— ë°˜ë“œì‹œ **ë©ˆì¶°ì•¼ í•©ë‹ˆë‹¤.**\n    - **Rule Out First:**\n        1. **Renal Insufficiency (ì‹ ë¶€ì „):** Prolactinì€ ì‹ ì¥ì—ì„œ ì œê±°ë©ë‹ˆë‹¤. ì‹ ë¶€ì „ ì‹œ ìˆ˜ì¹˜ê°€ ìƒìŠ¹í•©ë‹ˆë‹¤. â†’ **Creatinine ì²´í¬.**\n        2. **Hypothyroidism (ê°‘ìƒì„ ê¸°ëŠ¥ì €í•˜ì¦):** ê°‘ìƒì„ ì´ ì‘ë™í•˜ì§€ ì•Šìœ¼ë©´ ì‹œìƒí•˜ë¶€ê°€ TRHë¥¼ ë¶„ë¹„í•©ë‹ˆë‹¤. TRHëŠ” TSHë¿ë§Œ ì•„ë‹ˆë¼ Prolactinë„ ìê·¹í•©ë‹ˆë‹¤. â†’ **TSH ì²´í¬.**\n- **Next Best Step:** MRIê°€ ì•„ë‹ˆë¼ **Creatinineê³¼ TSH í™•ì¸**ì´ ìš°ì„ ì…ë‹ˆë‹¤.\n- **ì¹˜ë£Œ (Treatment):**\n    - MRIì—ì„œ ê±°ëŒ€ì„ ì¢…(Macroprolactinoma)ì´ ë³´ì—¬ë„ ìˆ˜ìˆ (Surgery)ì´ 1ì°¨ ì¹˜ë£Œê°€ ì•„ë‹™ë‹ˆë‹¤. â˜…\n    - **1ì°¨ ì¹˜ë£Œ:** Medical therapy (Dopamine Agonists). ì˜ˆ: **Cabergoline**.\n    - ë„íŒŒë¯¼ì€ í”„ë¡œë½í‹´ì„ ì–µì œí•˜ë©°, ì•½ë¬¼ ì¹˜ë£Œë§Œìœ¼ë¡œë„ ì¢…ì–‘ í¬ê¸°ë¥¼ ì¤„ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ìˆ˜ìˆ ì€ ì•½ë¬¼ ì‹¤íŒ¨ë‚˜ ì‹œì•¼ ê²°ì†ì´ ì§€ì†ë  ë•Œì˜ \"ë°±ì—… í”Œëœ\"ì…ë‹ˆë‹¤.\n### ğŸ’§ Water Balance: SIADH vs. Diabetes Insipidus (DI)\në§ì€ ì‚¬ëŒë“¤ì´ ì–´ë ¤ì›Œí•˜ì§€ë§Œ **\"Logic Gate\"**ë¥¼ ë”°ë¥´ë©´ í•´ê²°ë©ë‹ˆë‹¤.\n1. **Step 1: Definition of Polyuria**\n    - ì†Œë³€ëŸ‰ì´ í•˜ë£¨ **3L ì´ìƒ**ì´ì–´ì•¼ ì§„ì •í•œ ë‹¤ë‡¨(True Polyuria)ì…ë‹ˆë‹¤.\n2. **Step 2: Urine Osmolality (ì†Œë³€ ì‚¼íˆ¬ì••)**\n    - **Concentrated (ë†ì¶•):** ì‚¼íˆ¬ì„± ì´ë‡¨(Osmotic diuresis). ì˜ˆ: ë‹¹ë‡¨ë³‘(Diabetes Mellitus)ì—ì„œ í¬ë„ë‹¹ì´ ë¬¼ì„ ëŒê³  ë‚˜ê°€ëŠ” ê²½ìš°.\n    - **Dilute (í¬ì„):** ë§¹ë¬¼(Pure water)ì„ ë°°ì¶œí•˜ëŠ” ê²½ìš°. ì´ê²ƒì´ **Water Diuresis**ì…ë‹ˆë‹¤.\n### âš–ï¸ DI (ìš”ë¶•ì¦) vs. Primary Polydipsia (ì¼ì°¨ì„± ë‹¤ê°ˆì¦) êµ¬ë³„ë²•\nê°€ì¥ ì¤‘ìš”í•œ ë‹¨ì„œëŠ” **Sodium (ë‚˜íŠ¸ë¥¨)** ìˆ˜ì¹˜ì…ë‹ˆë‹¤.\n| êµ¬ë¶„ | ë³‘íƒœìƒë¦¬ | Sodium (Na) ìˆ˜ì¹˜ | ë¹„ê³  |\n| --- | --- | --- | --- |\n| **Primary Polydipsia** | ë¬¼ì„ ë„ˆë¬´ ë§ì´ ë§ˆì…”ì„œ í˜ˆì•¡ì´ í¬ì„ë¨ | **Hyponatremia (ì €ë‚˜íŠ¸ë¥¨)** | Waterlogged status |\n| **Central DI** | ë‡Œì—ì„œ ADHë¥¼ ëª» ë§Œë“¦. ë¬¼ì„ ë‹¤ ìƒì–´ë²„ë¦¬ê³  í˜ˆì•¡ì´ ë†ì¶•ë¨ | **Hypernatremia (ê³ ë‚˜íŠ¸ë¥¨)** | ê°ˆì¦ ê¸°ì „ì´ ê³ ì¥ ë‚¬ì„ ìˆ˜ ìˆìŒ |\n| **Nephrogenic DI** | ì‹ ì¥ì´ ADHë¥¼ ë¬´ì‹œí•¨. ê°ˆì¦ ê¸°ì „ì€ ì •ìƒì´ë¼ ë¬¼ì„ ë§ˆì…” ë³´ìƒí•¨ | **Normal Na** | ë³´í†µ ë‚˜íŠ¸ë¥¨ ìˆ˜ì¹˜ ì •ìƒ ìœ ì§€ |\n---\n## 3. Thyroid (ê°‘ìƒì„ ) ğŸ¦‹\n### ğŸ¤° Thyroid in Pregnancy (ì„ì‹ ê³¼ ê°‘ìƒì„ )\nì„ì‹ ì€ ìƒë¦¬í•™ì ìœ¼ë¡œ **Hyperthyroidism(ê°‘ìƒì„ ê¸°ëŠ¥í•­ì§„ì¦)ì„ ëª¨ë°©(Mimic)**í•©ë‹ˆë‹¤.\n- **Estrogen ì¦ê°€:** TBG(Thyroid Binding Globulin)ë¥¼ ì¦ê°€ì‹œì¼œ **Total T4** ìˆ˜ì¹˜ë¥¼ ë†’ì…ë‹ˆë‹¤.\n- **hCG íš¨ê³¼:** hCGëŠ” TSHì™€ êµ¬ì¡°ê°€ ë¹„ìŠ·í•˜ì—¬ ê°‘ìƒì„ ì„ ìê·¹í•©ë‹ˆë‹¤. ì´ë¡œ ì¸í•´ ì‹¤ì œ **TSH ìˆ˜ì¹˜ëŠ” ë‚®ì•„ì§‘ë‹ˆë‹¤.**\n- **ì •ìƒ ì†Œê²¬:** ì„ì‚°ë¶€(íŠ¹íˆ 1ë¶„ê¸°)ëŠ” **High Total T4, Low TSH**ë¥¼ ë³´ì´ëŠ” ê²ƒì´ ì •ìƒì…ë‹ˆë‹¤. (Gestational Transient Thyrotoxicosis) â†’ ì¹˜ë£Œí•˜ì§€ ì•ŠìŠµë‹ˆë‹¤.\n### Graves' Disease in Pregnancy (ì„ì‹  ì¤‘ ê·¸ë ˆì´ë¸ŒìŠ¤ë³‘)\në§Œì•½ ì§„ì§œ ê·¸ë ˆì´ë¸ŒìŠ¤ë³‘ì´ë¼ë©´ ì¹˜ë£Œì œê°€ ë§¤ìš° ê¹Œë‹¤ë¡­ìŠµë‹ˆë‹¤.\n- **1st Trimester:** **PTU** (Methimazoleì€ ê¸°í˜• ìœ ë°œ ê°€ëŠ¥ì„± - Teratogen). \"P for Pregnancy, P for PTU\".\n- **2nd Trimester ì´í›„:** **Methimazole**ë¡œ êµì²´ (PTUëŠ” ê°„ ë…ì„± ìœ„í—˜ - Black box warning). â˜…\n### Hypothyroidism in Pregnancy (ì„ì‹  ì¤‘ ê°‘ìƒì„ ê¸°ëŠ¥ì €í•˜ì¦)","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-121"}
{"chunk_type":"transcript_chunk","text":"- **íƒœì•„ ìœ„í—˜:** íƒœì•„ì˜ ë‡Œ ë°œë‹¬ì€ ëª¨ì²´ì˜ ê°‘ìƒì„  í˜¸ë¥´ëª¬ì— ì˜ì¡´í•©ë‹ˆë‹¤.\n- **ì¡°ì¹˜:** ì„ì‹  í™•ì¸ ì¦‰ì‹œ **Levothyroxine ìš©ëŸ‰ì„ 30% ì¦ëŸ‰**í•´ì•¼ í•©ë‹ˆë‹¤. â˜…\n    - **ì ˆëŒ€ Lab ê²°ê³¼ë¥¼ ê¸°ë‹¤ë¦¬ì§€ ë§ˆì„¸ìš”.** ì¦‰ì‹œ ì¦ëŸ‰ í›„ 4ì£¼ ë’¤ TSH í™•ì¸.\n### ğŸ” Thyroid Nodules (ê°‘ìƒì„  ê²°ì ˆ)\nê²°ì ˆì´ ë§Œì ¸ì§ˆ ë•Œ ê°€ì¥ ë¨¼ì € í•´ì•¼ í•  ì¼ì€ **TSH ì¸¡ì •**ê³¼ **Ultrasound(ì´ˆìŒíŒŒ)**ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ **TSH**ê°€ ì˜ì‚¬ê²°ì •ì˜ ê°ˆë¦¼ê¸¸(Fork in the road)ì…ë‹ˆë‹¤.\n- **TSH Low (ë‚®ìŒ):** ê°‘ìƒì„ ì´ ê³¼ë‹¤í™œë™ ì¤‘. â†’ **Scintigraphy (Radioiodine scan)** ì‹œí–‰.\n    - **Hot Nodule:** ê¸°ëŠ¥ í•­ì§„ ê²°ì ˆ. ì•”ì¼ í™•ë¥  ê±°ì˜ ì—†ìŒ.\n    - **Cold Nodule:** ê¸°ëŠ¥ ì €í•˜. ì•…ì„± ê°€ëŠ¥ì„± ìˆìŒ.\n- **TSH Normal or High:** ìŠ¤ìº”ì€ ì“¸ëª¨ì—†ìŒ. â†’ ë°”ë¡œ **Ultrasound** íŠ¹ì§• í™•ì¸ í›„ ì˜ì‹¬ìŠ¤ëŸ¬ìš°ë©´ **FNA (ì„¸ì¹¨í¡ì¸ìƒê²€)** ì‹œí–‰. â˜…\n---\n## 4. Parathyroid (ë¶€ê°‘ìƒì„ ) ğŸ¦´\n### ğŸ¥› Hypercalcemia (ê³ ì¹¼ìŠ˜í˜ˆì¦)\nHigh Calciumì€ ë³´í†µ High PTH(Primary Hyperparathyroidism)ë¥¼ ì˜ë¯¸í•©ë‹ˆë‹¤. í•˜ì§€ë§Œ ìœ ì „ì  ëª¨ë°© ì§ˆí™˜ì¸ **FHH (Familial Hypocalciuric Hypercalcemia)**ë¥¼ ì£¼ì˜í•´ì•¼ í•©ë‹ˆë‹¤.\n- **ê°ë³„ í¬ì¸íŠ¸:** **Urine Calcium (ì†Œë³€ ì¹¼ìŠ˜)**.\n    - **FHH:** ì‹ ì¥ì´ ìœ ì „ì ìœ¼ë¡œ ì¹¼ìŠ˜ì„ ì¬í¡ìˆ˜(Hoarding)í•˜ë ¤ í•¨. â†’ ì†Œë³€ ì¹¼ìŠ˜ ë§¤ìš° ë‚®ìŒ. (**Calcium/Creatinine clearance ratio < 0.01**)\n    - **ìˆ˜ìˆ  ê¸ˆì§€:** FHH í™˜ìì—ê²Œ ë¶€ê°‘ìƒì„  ì ˆì œìˆ ì€ íš¨ê³¼ê°€ ì—†ìœ¼ë¯€ë¡œ ì ˆëŒ€ í•˜ë©´ ì•ˆ ë©ë‹ˆë‹¤.\n### ğŸ‘¶ Maternal FHH Scenario (ì‹¬í™”)\n- ì‚°ëª¨ê°€ FHHì¼ ê²½ìš°(ê³ ì¹¼ìŠ˜í˜ˆì¦), íƒœì•„ëŠ” ìê¶ ë‚´ì—ì„œ ê³ ì¹¼ìŠ˜ í™˜ê²½ì— ë…¸ì¶œë©ë‹ˆë‹¤.\n- íƒœì•„ì˜ ë¶€ê°‘ìƒì„ ì€ ì–µì œ(Sleep)ë©ë‹ˆë‹¤.\n- **ì¶œìƒ í›„:** ëª¨ì²´ì˜ ì¹¼ìŠ˜ ê³µê¸‰ì´ ëŠê¸°ë©´, ì•„ê¸°ì˜ ë¶€ê°‘ìƒì„ ì´ ê¹¨ì–´ë‚˜ì§€ ëª»í•´ **Severe Hypocalcemia (ë°œì‘, ê²½ë ¨)**ê°€ ë°œìƒí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤. (Transient Hypoparathyroidism)\n---\n## 5. Adrenal Gland (ë¶€ì‹ ) âš¡\n### ğŸ©¸ Hypertension & Conn's Syndrome (Primary Hyperaldosteronism)\n- **ì¦ìƒ:** ì¡°ì ˆë˜ì§€ ì•ŠëŠ” ê³ í˜ˆì•• + **Low Potassium (ì €ì¹¼ë¥¨í˜ˆì¦)**.\n- **ì„ ë³„ ê²€ì‚¬:** Aldosterone/Renin Ratio > 20.\n- **Aldosterone Escape:** â˜…\n    - ì•Œë„ìŠ¤í…Œë¡ ì€ ì†Œê¸ˆê³¼ ë¬¼ì„ ì¡ì•„ë‘ì§€ë§Œ, í™˜ìë“¤ì€ **ë¶€ì¢…(Edema)ì´ ì—†ìŠµë‹ˆë‹¤.**\n    - ì´ìœ : í˜ˆë¥˜ëŸ‰ ì¦ê°€ë¥¼ ì‹¬ì¥ì´ ê°ì§€í•˜ì—¬ **ANP (Atrial Natriuretic Peptide)**ë¥¼ ë¶„ë¹„, ì‹ ì¥ì´ ê°•ì œë¡œ ì†Œê¸ˆê³¼ ë¬¼ì„ ë°°ì¶œí•˜ê²Œ ë§Œë“­ë‹ˆë‹¤(Pressure Natriuresis). â†’ ë¶€ì¢…ì€ ì—†ì§€ë§Œ ê³ í˜ˆì••ê³¼ ì €ì¹¼ë¥¨í˜ˆì¦ì€ ë‚¨ìŠµë‹ˆë‹¤.\n### ğŸ“‰ Adrenal Insufficiency (Addison's Disease)\n- **ì¦ìƒ:** ì²´ì¤‘ ê°ì†Œ, ì˜¤ì‹¬, ê³¼ìƒ‰ì†Œì¹¨ì°©(Darker skin - ACTH ì¦ê°€ ë•Œë¬¸).\n- **Lab íŠ¹ì§•:** Conn'sì˜ ë°˜ëŒ€. **Hyponatremia (ì €ë‚˜íŠ¸ë¥¨), Hyperkalemia (ê³ ì¹¼ë¥¨)**.\n- **Hidden Pearl:** **Eosinophilia (í˜¸ì‚°êµ¬ì¦ê°€ì¦)**. ì½”ë¥´í‹°ì†”ì´ ì—†ìœ¼ë©´ í˜¸ì‚°êµ¬ê°€ ì–µì œë˜ì§€ ì•Šì•„ ìˆ˜ì¹˜ê°€ ì˜¤ë¦…ë‹ˆë‹¤. â˜…\n- **ì§„ë‹¨:** **Cosyntropin (Synthetic ACTH) Stimulation Test**.\n    - ì •ìƒ: ì½”ë¥´í‹°ì†” ë¶„ë¹„ ì¦ê°€.\n    - ë¶€ì „: ë°˜ì‘ ì—†ìŒ.\n- **ì›ì¸ ì•½ë¬¼:** **Etomidate** (ë§ˆì·¨ ìœ ë„ì œ)ëŠ” ì½”ë¥´í‹°ì†” ìƒì„± íš¨ì†Œë¥¼ ì–µì œí•˜ì—¬, ìœ„ë…í•œ í™˜ìë¥¼ ë¶€ì‹  ìœ„ê¸°(Adrenal Crisis)ë¡œ ëª°ì•„ë„£ì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n---\n## 6. Diabetes & Autonomic Failure ğŸ¬\n### âš ï¸ Hypoglycemia Associated Autonomic Failure","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-141"}
{"chunk_type":"transcript_chunk","text":"- **ê¸°ì „:** ë°˜ë³µì ì¸ ì €í˜ˆë‹¹ì´ ë°œìƒí•˜ë©´ ì‹ ì²´ì˜ ê²½ê³  ì‹œìŠ¤í…œ(ì¹´í…Œì½œì•„ë¯¼ ë¶„ë¹„ - ë–¨ë¦¼, ì‹ì€ë•€, ë‘ê·¼ê±°ë¦¼)ì´ ë¬´ëŒì§‘ë‹ˆë‹¤.\n- **ê²°ê³¼:** **Hypoglycemia Unawareness**. í™˜ìëŠ” ì „ì¡°ì¦ìƒ ì—†ì´ ë°”ë¡œ ì˜ì‹ì„ ìƒìŠµë‹ˆë‹¤.\n- **ì•…ìˆœí™˜:** í•œ ë²ˆì˜ ì €í˜ˆë‹¹ ì—í”¼ì†Œë“œê°€ ë‹¤ìŒ ë©°ì¹ ê°„ ììœ¨ì‹ ê²½ ë°˜ì‘ì„ ë‘”í™”ì‹œí‚µë‹ˆë‹¤.\n### ğŸ¤¢ Gastroparesis (ìœ„ë¬´ë ¥ì¦)\n- **ì›ì¸:** ë¯¸ì£¼ì‹ ê²½(Vagus nerve) ì†ìƒ. ìœ„ê°€ ë¹„ì›Œì§€ì§€ ì•ŠìŒ.\n- **ì¦ìƒ:** ëª‡ ì…ë§Œ ë¨¹ì–´ë„ ë°°ê°€ ë¶€ë¦„(Early satiety), ì˜¤ì‹¬.\n- **Post-prandial Hypoglycemia (ì‹í›„ ì €í˜ˆë‹¹):** â˜…\n    - **Timing Mismatch:** ì¸ìŠë¦°(ì†íš¨ì„±)ì€ 15ë¶„ ë§Œì— ì‘ìš©í•˜ì§€ë§Œ, ìœ„ë¬´ë ¥ì¦ ë•Œë¬¸ì— ìŒì‹ì€ ì†Œí™”ë˜ì§€ ì•Šê³  ìœ„ì¥ì— ë‚¨ì•„ìˆìŠµë‹ˆë‹¤.\n    - ìŒì‹ì´ í¡ìˆ˜ë˜ê¸°ë„ ì „ì— ì¸ìŠë¦°ì´ ì‘ìš©í•˜ì—¬ **ì‹ì‚¬ í›„ ì˜¤íˆë ¤ í˜ˆë‹¹ì´ ê¸‰ê²©íˆ ë–¨ì–´ì§€ëŠ”(Crash)** í˜„ìƒì´ ë°œìƒí•©ë‹ˆë‹¤.\n---\n## 7. Additional High-Yield Concepts ğŸŒŸ\n### ğŸ“‰ Subclinical Hypothyroidism\n- **ìƒíƒœ:** TSH ë†’ìŒ, T4 ì •ìƒ.\n- **ì¹˜ë£Œ ê¸°ì¤€:**\n    - **TSH > 10:** ì¹˜ë£Œí•¨.\n    - **TSH 7~10:** **ë‚˜ì´(Age)**ë¥¼ ë´…ë‹ˆë‹¤.\n        - **ì Šì€ í™˜ì (<70ì„¸):** ì¹˜ë£Œ ê³ ë ¤.\n        - **ë…¸ì¸ í™˜ì (>70ì„¸):** **\"Do Not Treat\"**. ì¹˜ë£Œê°€ ì˜¤íˆë ¤ í•´ê°€ ë  ìˆ˜ ìˆìŒ (ì‹¬ë°©ì„¸ë™-Afib, ë¼ˆ ì†ì‹¤ ìœ ë°œ). ê´€ì°°ë§Œ í•¨.\n### ğŸ¥ Euthyroid Sick Syndrome\n- **ìƒí™©:** ICUì— ìˆëŠ” ì¤‘í™˜ìì˜ ê°‘ìƒì„  ìˆ˜ì¹˜ê°€ ì—‰ë§ì„ (Low T3, Low TSH).\n- **ëŒ€ì²˜:** **\"Do Not Treat\"**.\n    - ì´ëŠ” ì‹ ì²´ì˜ ì ì‘ ë°˜ì‘(Adaptive response)ì…ë‹ˆë‹¤. ëŒ€ì‚¬ë¥¼ ëŠ¦ì¶° ìƒì¡´í•˜ë ¤ëŠ” ê¸°ì „ì…ë‹ˆë‹¤.\n    - ì´ë•Œ í˜¸ë¥´ëª¬ì„ íˆ¬ì—¬í•˜ë©´ ì‚¬ë§ë¥ (Mortality)ì´ ì¦ê°€í•©ë‹ˆë‹¤.\n---","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-161"}
{"chunk_type":"recap_summary","text":"## ğŸ”¥ Rapid Fire Recap (í•µì‹¬ ìš”ì•½)\n1. **Prolactin > 200:** MRI ì „ì— **Meds(ì•½ë¬¼), TSH, Creatinine** í™•ì¸.\n2. **Thyroid Nodule:** **TSH ë¨¼ì €**. Lowë©´ Scan, Normalì´ë©´ Biopsy.\n3. **Pregnant Hypothyroid:** ì¦‰ì‹œ **Levothyroxine 30% ì¦ëŸ‰**.\n4. **Hypercalcemia:** ìˆ˜ìˆ  ì „ **Urine Calcium** í™•ì¸í•˜ì—¬ FHH ë°°ì œ.\n5. **Sick Patient (Low Na, High K, Eosinophilia):** **Adrenal Insufficiency** ì˜ì‹¬. **Cosyntropin Test**ë¡œ í™•ì§„.\n6. **Subclinical Hypothyroid (TSH 7~10, >70ì„¸):** **ì¹˜ë£Œí•˜ì§€ ì•ŠìŒ (Watch and Wait).**\n7. **ICU Patient (Low T3/TSH):** **Euthyroid Sick Syndrome**. ì¹˜ë£Œí•˜ì§€ ì•ŠìŒ.\n**Verify (ê²€ì¦): 0:00~0:30 êµ¬ê°„ ë°›ì•„ì“°ê¸°**\n\"Welcome back to the deep dive. Today we are uh shifting gears a little bit to serve a very specific mission. We've got a lot of listeners out there prepping for the US MLE step two and the feedback's been loud and clear. Help me organize the chaos. Right. So we're stripping away the fluff. We're taking a stack of high yield review materials, clinical guidelines and pharmacology notes and we are going to build a mental framework for endocrine clinical scenarios.\"\n---\n# USMLE Step 2 Endocrinology Deep Dive: Pharmacology & Management Framework\n## 1. Introduction: The Mental Framework ğŸ§ \nê°•ì˜ëŠ” ë‹¨ìˆœí•œ ì•”ê¸°ê°€ ì•„ë‹Œ **'ë…¼ë¦¬(Logic)'**ì™€ **'í”¼ë“œë°± ë£¨í”„(Feedback Loops)'**ë¥¼ ê°•ì¡°í•˜ë©° ì‹œì‘í•©ë‹ˆë‹¤. ë‚´ë¶„ë¹„í•™(Endocrinology)ì—ì„œì˜ ì§„ë‹¨ì€ ì£¼ë¡œ ì„¤ì •(Set-up)ì— ë¶ˆê³¼í•˜ë©°, ì‹¤ì œ ì‹œí—˜ì—ì„œ ìˆ˜í—˜ìƒë“¤ì„ ë–¨ì–´ëœ¨ë¦¬ëŠ” ì§„ì§œ ë¬¸ì œëŠ” **\"ë© ê²°ê³¼ê°€ ë‚˜ì˜¨ í›„ ë¬´ì—‡ì„ í•  ê²ƒì¸ê°€(Next Step)\"**ì— ìˆìŠµë‹ˆë‹¤.\n- **Context is Everything:** ë‚´ë¶„ë¹„í•™ì—ì„œëŠ” ì •ë‹µì— ê±°ëŒ€í•œ **ë³„í‘œ(Asterisk â˜…)**ê°€ ë¶™ìŠµë‹ˆë‹¤.\n    - ì¼ë°˜ì ì¸ í™˜ìì—ê²ŒëŠ” 'Gold Standard'ì¸ ì•½ë¬¼ì´ ì„ì‹ ë¶€ì—ê²ŒëŠ” ê¸°í˜•ì„ ìœ ë°œí•  ìˆ˜(Teratogen) ìˆê³ , 30ì„¸ í™˜ìë¥¼ ì‚´ë¦¬ëŠ” ì•½ì´ 75ì„¸ í™˜ìì—ê²ŒëŠ” ì¹˜ëª…ì ì¼ ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n- **ë¡œë“œë§µ:** ë‡Œí•˜ìˆ˜ì²´(Pituitary) â†’ ê°‘ìƒì„ (Thyroid) â†’ ë¶€ì‹ (Adrenals) & ë¶€ê°‘ìƒì„ (Parathyroids) â†’ ë‹¹ë‡¨ ê´€ë¦¬(Diabetes Maintenance).\n---","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-171"}
{"chunk_type":"transcript_chunk","text":"## 2. The Pituitary: Prolactin & Water Balance ğŸ’§\n### A. Prolactinoma (The Detective Work) ğŸ•µï¸â€â™€ï¸\nProlactin ìˆ˜ì¹˜ê°€ ë†’ë‹¤ê³  í•´ì„œ ë¬´ì¡°ê±´ Prolactinoma(ì¢…ì–‘)ë¼ê³  ë‹¨ì • ì§“ê³  ì¹˜ë£Œë¥¼ ì‹œì‘í•˜ë©´ ì•ˆ ë©ë‹ˆë‹¤. **\"Rule out mimics\"**ê°€ ìš°ì„ ì…ë‹ˆë‹¤.\n- **â˜… The Mimics (í•¨ì •):**\n    - **ì„ì‹ (Pregnancy):** ê°€ì¥ ëª…ë°±í•œ ì›ì¸.\n    - **í•­ì •ì‹ ë³‘ ì•½ë¬¼(Antipsychotics):** ë„íŒŒë¯¼ ì–µì œ ê¸°ì „ ë•Œë¬¸.\n    - **ì‹ ë¶€ì „(Renal Insufficiency):** í˜¸ë¥´ëª¬ í´ë¦¬ì–´ëŸ°ìŠ¤(Clearance) ë¬¸ì œë¡œ í˜ˆì¤‘ ë†ë„ ì¶•ì . (ë‡Œí•˜ìˆ˜ì²´ì˜ ê³¼ìƒì„±ì´ ì•„ë‹˜)\n    - **ê°‘ìƒì„ ê¸°ëŠ¥ì €í•˜ì¦(Hypothyroidism):** ë‚®ì€ ê°‘ìƒì„  í˜¸ë¥´ëª¬ â†’ ì‹œìƒí•˜ë¶€ê°€ TRH ë¶„ë¹„ â†’ TRHê°€ TSHë¿ë§Œ ì•„ë‹ˆë¼ **Prolactin ë¶„ë¹„ë„ ìê·¹**. (ì´ ê²½ìš° ê°‘ìƒì„ ì„ ì¹˜ë£Œí•´ì•¼ í•¨)\n- **Diagnosis & Threshold:**\n    - **> 200 ng/mL:** ì´ ìˆ˜ì¹˜ëŠ” ê±°ì˜ í™•ì‹¤í•˜ê²Œ **Prolactinoma(ì¢…ì–‘)**ì„ ì˜ë¯¸í•©ë‹ˆë‹¤. ì•½ê°„ ìƒìŠ¹í•œ ìˆ˜ì¹˜ëŠ” ë‹¤ë¥¸ ì›ì¸ì¼ ìˆ˜ ìˆìŒ.\n- **Management Dilemma: Surgery vs. Meds ğŸ’Š**\n    - **Microprolactinoma (<10mm, ë¬´ì¦ìƒ):** **Just Watch it.** (ì¹˜ë£Œ ë¶ˆí•„ìš”).\n    - **Macroprolactinoma (>10mm) ë˜ëŠ” ì¦ìƒ(ìœ ì¦™ë¶„ë¹„, ì‹œì•¼ê²°ì†)ì´ ìˆëŠ” ê²½ìš°:**\n        - **1ì°¨ ì¹˜ë£Œ:** â˜… **Medical Management (Dopamine Agonists)**\n        - **ì•½ë¬¼ ì„ íƒ:** **Cabergoline** (ì„ í˜¸ë¨, ë¶€ì‘ìš© ì ìŒ) > Bromocriptine.\n        - **â˜… Counter-intuitive Point:** í™˜ìê°€ ì¢…ì–‘ìœ¼ë¡œ ì¸í•´ **ì‹œì•¼ ê²°ì†(Vision loss)**ì´ ìˆì–´ë„ ìˆ˜ìˆ ì´ ì•„ë‹Œ **ì•½ë¬¼(Cabergoline)**ì´ ìš°ì„ ì…ë‹ˆë‹¤. ì•½ë¬¼ì´ ì¢…ì–‘ì„ ë§¤ìš° ë¹ ë¥´ê²Œ ì¤„ì—¬ì¤ë‹ˆë‹¤. ìˆ˜ìˆ ì€ ì•½ë¬¼ ì‹¤íŒ¨ ì‹œì˜ 'Back-up plan'ì…ë‹ˆë‹¤.\n### B. Water Balance: SIADH vs. Diabetes Insipidus (DI) âš–ï¸\n\"Wet vs. Dry\" ì‹¸ì›€ì…ë‹ˆë‹¤.\n### 1. Diabetes Insipidus (DI) - \"Dry\" & High Sodium\n- **ì¹˜ë£Œ:** Desmopressin (í˜¸ë¥´ëª¬ ëŒ€ì²´).\n- **â˜… The Potential Pitfall (í™˜ì ë’¤ì§‘ê¸° ìœ„í—˜):**\n    - í™˜ìì˜ ê°ˆì¦ ê¸°ì „(Thirst mechanism)ì€ ê³¼ë„í•˜ê²Œ ì‘ë™ ì¤‘(Overdrive)ì´ë¼ ë¬¼ì„ ê³„ì† ë§ˆì‹­ë‹ˆë‹¤.\n    - ì´ë•Œ Desmopressin(ê°•ë ¥í•œ ì†Œë³€ ì–µì œ ì‹ í˜¸)ì„ íˆ¬ì—¬í•˜ë©´ ì†Œë³€ ë°°ì¶œì€ ë©ˆì¶”ì§€ë§Œ, í™˜ìê°€ ë¬¼ ë§ˆì‹œê¸°ë¥¼ ë©ˆì¶”ì§€ ì•Šì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n    - **ê²°ê³¼:** ê¸‰ê²©í•œ í˜ˆì•¡ í¬ì„(Dilution) â†’ **Iatrogenic SIADH** (ì˜ì›ì„± SIADH) â†’ ì‹¬ê°í•œ ì €ë‚˜íŠ¸ë¥¨í˜ˆì¦(Hyponatremia).\n    - **êµí›ˆ:** ì•½ ì²˜ë°© í›„ ë°˜ì‘ì„ ëª¨ë‹ˆí„°ë§í•´ì•¼ í•¨.\n### 2. SIADH - \"Wet\" & Low Sodium\n- **ì¼ë°˜ì  ì¹˜ë£Œ:** ìˆ˜ë¶„ ì œí•œ(Fluid restriction).\n- **â˜… Red Alert Scenario (ì‘ê¸‰):**\n    - í™˜ìê°€ ì €ë‚˜íŠ¸ë¥¨í˜ˆì¦ìœ¼ë¡œ ì¸í•´ **ë°œì‘(Seizures)ì´ë‚˜ í˜¼ìˆ˜(Coma)** ìƒíƒœì¸ ê²½ìš°.\n    - **ì¹˜ë£Œ:** **Hypertonic Saline (3%)**. (ìœ ë¦¬ì°½ì„ ê¹¨ê³  ì ê·¹ì ìœ¼ë¡œ ê°œì…í•´ì•¼ í•  ë•Œ)\n---\n## 3. The Thyroid: A Beast of a Topic ğŸ¦‹\n### A. Graves' Disease (Hyperthyroidism) ğŸ”¥\nì¹˜ë£Œë²•ì€ í™˜ìê°€ ëˆ„êµ¬ëƒì— ë”°ë¼ ë‹¬ë¼ì§‘ë‹ˆë‹¤. (Meds vs. RAI vs. Surgery)\n### 1. Drugs (Antithyroid Drugs)\nì„ì‹  ì—¬ë¶€ì— ë”°ë¥¸ **\"Pregnancy Switch\"** ê·œì¹™ì´ ì¤‘ìš”í•©ë‹ˆë‹¤.\n| ì‹œê¸° | ì•½ë¬¼ ì„ íƒ | ì´ìœ  (â˜… Side Effects) |\n| --- | --- | --- |\n| **ì„ì‹  1ë¶„ê¸° (1st Trimester)** | **PTU** (Propylthiouracil) | Methimazoleì€ ê¸°í˜•(**Aplasia Cutis**: ë‘í”¼ ê²°ì† ë“±) ìœ ë°œ ìœ„í—˜. |\n| **ì„ì‹  2, 3ë¶„ê¸°** | **Methimazole** | PTUëŠ” **ê°„ ë…ì„±(Hepatotoxicity)** ìœ„í—˜ì´ ìˆì–´, ê¸°ê´€ í˜•ì„±(Organogenesis)ì´ ëë‚œ í›„ì—ëŠ” ê°„ ë³´í˜¸ë¥¼ ìœ„í•´ êµì²´. |\n### 2. Radioactive Iodine (RAI) â˜¢ï¸\n- ëŒ€ë¶€ë¶„ì˜ í™˜ìë¥¼ ì˜êµ¬ì ì¸ ê°‘ìƒì„ ê¸°ëŠ¥ì €í•˜ì¦ìœ¼ë¡œ ë§Œë“¦ (í‰ìƒ ì•½ ë³µìš© í•„ìš”).\n- **â˜… Absolute Contraindication:** **Graves' Ophthalmopathy** (ëˆˆ íŠ€ì–´ë‚˜ì˜´).\n    - RAIëŠ” ê¸‰ì„± ì—¼ì¦ì„ ìœ ë°œí•˜ì—¬ ëˆˆ ì§ˆí™˜ì„ í›¨ì”¬ ì•…í™”ì‹œí‚¬ ìˆ˜ ìˆìŒ.\n    - ëˆˆ ì¦ìƒì´ ì‹¬í•˜ë©´ **ìˆ˜ìˆ (Surgery) ë˜ëŠ” ì•½ë¬¼**ë¡œ ê°€ì•¼ í•¨.\n### 3. Monitoring (Mechanism Question) ğŸ“‰","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-181"}
{"chunk_type":"transcript_chunk","text":"- ì¹˜ë£Œ í›„ í™˜ìê°€ ì¢‹ì•„ì ¸ë„ **TSHë¥¼ ë°”ë¡œ ì²´í¬í•˜ì§€ ë§ ê²ƒ.**\n- **ì´ìœ :** ë‡Œí•˜ìˆ˜ì²´ê°€ ì˜¤ë«ë™ì•ˆ ì–µì œë˜ì–´ ìˆì—ˆê¸° ë•Œë¬¸ì—(Sluggish), ìˆ˜ê°œì›”ê°„ ê¹¨ì–´ë‚˜ì§€ ì•Šì„ ìˆ˜ ìˆìŒ. TSHëŠ” ì—¬ì „íˆ ë‚®ê²Œ ë‚˜ì˜´.\n- **ì •ë‹µ:** **Free T4 & Total T3**ë¥¼ í™•ì¸í•˜ì—¬ ê³¼ë‹¤ íˆ¬ì—¬(Overdosing)ë¥¼ ë°©ì§€í•´ì•¼ í•¨.\n### B. Hypothyroidism (Low Thyroid) â„ï¸\nStandard ì¹˜ë£ŒëŠ” Levothyroxineì´ì§€ë§Œ, ë‘ ê·¸ë£¹ì—ì„œ ê·œì¹™ì´ ë°”ë€ë‹ˆë‹¤.\n### 1. The Elderly (ë…¸ì¸ í™˜ì) ğŸ‘´\n- **Mantra:** **\"Start low and go slow.\"** (25~50 mcg).\n- **ì´ìœ :** ê°‘ìƒì„  í˜¸ë¥´ëª¬ì€ ì‹¬ê·¼ ì‚°ì†Œ ìš”êµ¬ëŸ‰ì„ ì¦ê°€ì‹œí‚µë‹ˆë‹¤(Revs up the heart engine). ê´€ìƒë™ë§¥ ì§ˆí™˜ì´ ìˆëŠ” ë…¸ì¸ì—ê²Œ ê³ ìš©ëŸ‰ì„ ì£¼ë©´ **í˜‘ì‹¬ì¦(Angina), ë¶€ì •ë§¥, ì‹¬ì¥ë§ˆë¹„**ë¥¼ ìœ ë°œí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n### 2. Pregnancy (ì„ì‹ ë¶€) ğŸ¤°\n- **Action:** ì„ì‹  í…ŒìŠ¤íŠ¸ ì–‘ì„± ì¦‰ì‹œ **ìš©ëŸ‰ì„ ì¦ëŸ‰(ì•½ 30%)**í•´ì•¼ í•¨. (TSH ê²°ê³¼ ê¸°ë‹¤ë¦¬ì§€ ë§ê³  ì¦‰ì‹œ)\n- **â˜… Mechanism (The Sponge Effect):**\n    - ì„ì‹  ì¤‘ ë†’ì€ ì—ìŠ¤íŠ¸ë¡œê² â†’ ê°„ì—ì„œ **TBG (Thyroxine Binding Globulin)** ìƒì„± ì¦ê°€.\n    - TBGê°€ í˜ˆì¤‘ Free T4ë¥¼ ìŠ¤í€ì§€ì²˜ëŸ¼ ë¹¨ì•„ë“¤ì„ â†’ í™œì„± í˜¸ë¥´ëª¬ ë¶€ì¡±.\n    - íƒœì•„ì˜ ë‡Œ ë°œë‹¬ì€ 1ë¶„ê¸°ì— ëª¨ì²´ ê°‘ìƒì„  í˜¸ë¥´ëª¬ì— ì „ì ìœ¼ë¡œ ì˜ì¡´í•˜ë¯€ë¡œ ì¦‰ê°ì ì¸ ì¦ëŸ‰ì´ í•„ìˆ˜.\n---\n## 4. The Adrenals: Stress & Pressure âš¡\n### A. Hyperaldosteronism (Conn Syndrome)\n- ì¦ìƒ: ê³ í˜ˆì•• + ì €ì¹¼ë¥¨í˜ˆì¦.\n- **Management depends on counts:**\n    - **Unilateral (í•œìª½):** Adenoma â†’ **Surgery** (Cut it out).\n    - **Bilateral (ì–‘ìª½):** Hyperplasia â†’ **Medical Mgmt** (Spironolactone, Eplerenone).\n    - **â˜… Why not remove both?** ì–‘ìª½ ë¶€ì‹ ì„ ì œê±°í•˜ë©´ í™˜ìë¥¼ **Addison's Disease**(ë¶€ì‹ ë¶€ì „)ë¡œ ë§Œë“¤ê²Œ ë¨. í‰ìƒ ìŠ¤í…Œë¡œì´ë“œ ì˜ì¡´ ë° Adrenal Crisis ìœ„í—˜ì— ë¹ ëœ¨ë¦¬ëŠ” ê²ƒì€ í˜ˆì•• ì¡°ì ˆì„ ìœ„í•´ ë„ˆë¬´ í° ëŒ€ê°€ì„.\n### B. Adrenal Crisis & Septic Shock ğŸš¨\n- ì €í˜ˆì••, ì‡¼í¬ ìƒí™©. ìˆ˜ì•¡ê³¼ Hydrocortisone íˆ¬ì—¬.\n- **â˜… Pharmacology Pearl (Anesthetic Risk):**\n    - **í”¼í•´ì•¼ í•  ì•½ë¬¼:** **Etomidate**.\n    - **ì´ìœ :** EtomidateëŠ” ì‹¬ì¥ì—ëŠ” ì•ˆì •ì ì´ì§€ë§Œ, **11-beta-hydroxylase**ë¥¼ ì–µì œí•¨ (ì½”ë¥´í‹°ì†” ìƒì„±ì˜ ë§ˆì§€ë§‰ ê´€ë¬¸).\n    - ì´ë¯¸ ìŠ¤íŠ¸ë ˆìŠ¤ ìƒí™©ì¸ íŒ¨í˜ˆì¦ í™˜ìì—ê²Œ Etomidateë¥¼ ì“°ë©´ ì½”ë¥´í‹°ì†” ìƒì„±ì„ ë§‰ì•„ **ì˜ì›ì„± ë¶€ì‹  ìœ„ê¸°(Iatrogenic Adrenal Crisis)**ë¥¼ ìœ ë°œí•˜ì—¬ í™˜ìë¥¼ ë²¼ë‘ ëìœ¼ë¡œ ë°€ ìˆ˜ ìˆìŒ.\n    - **ëŒ€ì•ˆ:** Ketamine ë“± ì‚¬ìš©.\n---\n## 5. The Parathyroid & Calcium ğŸ¦´\n### A. Tertiary Hyperparathyroidism\n- **ë§¥ë½:** ë§Œì„± ì‹ ë¶€ì „(Renal Failure).\n- **ê¸°ì „:** ì˜¤ë«ë™ì•ˆ ì €ì¹¼ìŠ˜í˜ˆì¦ì— ëŒ€ì‘í•˜ë‹¤ê°€ ë¶€ê°‘ìƒì„ ë“¤ì´ **ììœ¨ì„±(Autonomous)**ì„ ê°–ê²Œ ë¨(Go rogue). ì¹¼ìŠ˜ ìˆ˜ì¹˜ê°€ êµì •ë˜ê±°ë‚˜ ì‹ ì¥ ì´ì‹ì„ í•´ë„ ìŠ¤ìœ„ì¹˜ê°€ êº¼ì§€ì§€ ì•ŠìŒ.\n- **ê²°ê³¼:** High Calcium + High PTH. â†’ **ìˆ˜ìˆ  í•„ìš”.**\n### B. Calciphylaxis & Basal Ganglia Calcification\n- **ìœ„í—˜:** Calcium x Phosphorus ê³±(Product)ì´ **55**ë¥¼ ë„˜ìœ¼ë©´ í˜ˆì•¡ì´ ê³¼í¬í™”(Supersaturated)ë¨. ë¯¸ë„¤ë„ì´ ê³ ì²´í™”(Solid rock)ë˜ì–´ ì¹¨ì „ë¨.\n- **ì¦ìƒ:** í”¼ë¶€ ê¶¤ì–‘(Ulcers) ë¿ë§Œ ì•„ë‹ˆë¼ **ë‡Œ(Basal Ganglia) ì„íšŒí™”** ê°€ëŠ¥.\n- **ê²°ê³¼:** íŒŒí‚¨ìŠ¨ë³‘ê³¼ ìœ ì‚¬í•œ ì¶”ì²´ì™¸ë¡œ ì¦ìƒ(Extrapyramidal symptoms), ë–¨ë¦¼(Tremors) ìœ ë°œ ê°€ëŠ¥.\n---","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-201"}
{"chunk_type":"transcript_chunk","text":"## 6. Diabetes Maintenance: Prevention ğŸ›¡ï¸\n### A. Neuropathy Screening ğŸ¦¶\n- **Monofilament Test:** ì •í™•íˆ **10gì˜ ì••ë ¥**ì„ ê°€í•¨.\n- **ëª©ì :** **Large nerve fibers** (ë³´í˜¸ ê°ê°)ì˜ ì†ì‹¤ì„ í…ŒìŠ¤íŠ¸.\n- í™˜ìê°€ ì´ ì••ë ¥ì„ ëª» ëŠë¼ë©´ ì‹ ë°œ ì† ìê°ˆì´ë‚˜ ë¬¼ì§‘ì„ ëŠë¼ì§€ ëª»í•´ ê¶¤ì–‘(Ulcer) â†’ ê°ì—¼ â†’ ì ˆë‹¨(Amputation)ìœ¼ë¡œ ì´ì–´ì§. \"Low tech test with high stakes implications.\"\n### B. Elderly A1C Goals ğŸ¯\n- **ëª©í‘œ:** **< 8%** (ì¼ë°˜ì ì¸ < 7% ë³´ë‹¤ ì™„í™”).\n- **â˜… Why?** ë…¸ì¸ì—ê²ŒëŠ” ê³ í˜ˆë‹¹ë³´ë‹¤ **ì €í˜ˆë‹¹(Hypoglycemia)**ì´ í›¨ì”¬ ì¹˜ëª…ì ì„.\n    - 30ì„¸ì˜ ì €í˜ˆë‹¹ = ì†ë–¨ë¦¼, ë°°ê³ í””.\n    - 80ì„¸ì˜ ì €í˜ˆë‹¹ = ì–´ì§€ëŸ¬ì›€, ë‚™ìƒ(Fall), **ê³ ê´€ì ˆ ê³¨ì ˆ(Hip fracture)** â†’ ì‚¬ë§ë¥  ê¸‰ì¦.\n    - ì—„ê²©í•œ ì¡°ì ˆ(Tight control)ì˜ ì´ë“ë³´ë‹¤ ë‚™ìƒì˜ ìœ„í—˜ì´ ë” í¼.\n---\n## 7. Rapid Fire Scenarios (Stress Test) ğŸ”¥ğŸƒâ€â™‚ï¸\nê°•ì˜ ë§ˆì§€ë§‰ì— ì§„í–‰ëœ ì‹¤ì œ ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤ ìš”ì•½ì…ë‹ˆë‹¤.\n1. **Prolactinoma (12mm) + Vision Loss:**\n    - ìˆ˜ìˆ ? **NO.**\n    - **ì •ë‹µ:** **Cabergoline** (Meds first). ì•½ë¬¼ì´ ì¢…ì–‘ì„ ë¹ ë¥´ê²Œ ì¤„ì„.\n2. **Graves' Disease + Bulging Eyes (Exophthalmos):**\n    - Radioactive Iodine? **Absolutely NOT.**\n    - **ì •ë‹µ:** **Surgery** (Thyroidectomy) ë˜ëŠ” Meds. ë°©ì‚¬ì„ ì€ ëˆˆì„ ì•…í™”ì‹œí‚´.\n3. **Graves' Disease + Pregnancy (8 weeks/1st Trimester):**\n    - Methimazole? **NO.**\n    - **ì •ë‹µ:** **PTU**ë¡œ ë³€ê²½ (íƒœì•„ ê¸°í˜• ë°©ì§€). *Note: 2ë¶„ê¸°ì— Methimazoleë¡œ ë‹¤ì‹œ ë³€ê²½(ê°„ ë³´í˜¸).*\n4. **Hypothyroidism + Positive Pregnancy Test:**\n    - ë‹¤ìŒ ì˜ˆì•½ ê¸°ë‹¤ë¦¬ê¸°? **NO.**\n    - **ì •ë‹µ:** ì¦‰ì‹œ Levothyroxine ìš©ëŸ‰ **30% ì¦ëŸ‰** (2 pills extra/week). TBG Sponge effect í¬í™”ì‹œí‚¤ê¸° ìœ„í•´.\n5. **Septic Shock + Intubation Need:**\n    - Etomidate? **Avoid it.**\n    - **ì •ë‹µ:** Ketamine ì‚¬ìš©. (EtomidateëŠ” ì½”ë¥´í‹°ì†” ì°¨ë‹¨ ìœ„í—˜).\n6. **SIADH + Seizures (Hyponatremia):**\n    - Fluid Restriction? **Not enough.**\n    - **ì •ë‹µ:** **3% Hypertonic Saline.** (ì‘ê¸‰ ìƒí™©).\n7. **85ì„¸ ë‹¹ë‡¨ í™˜ì + A1C 7.8%:**\n    - ì¸ìŠë¦° ì¦ëŸ‰? **NO.**\n    - **ì •ë‹µ:** **Leave it alone.** (ëª©í‘œëŠ” < 8%). ì €í˜ˆë‹¹ìœ¼ë¡œ ì¸í•œ ë‚™ìƒ ìœ„í—˜ì´ ë” í¼.\n---\n**Closing Thought:** ë‚´ë¶„ë¹„í•™ì€ ë‹¨ìˆœíˆ ì•½ì´ ë¬´ì—‡ì¸ì§€(What)ê°€ ì•„ë‹ˆë¼, **í™˜ìê°€ ëˆ„êµ¬ì¸ì§€(Who)**ì— ë”°ë¼ ê· í˜•ì„ ë§ì¶”ëŠ” í•™ë¬¸ì…ë‹ˆë‹¤. \"Respect the balance.\"\n# USMLE Step 2 ëŒ€ë¹„: ê°‘ìƒì„  ì§ˆí™˜ ì‹¬ì¸µ ë¶„ì„ (Thyroid Deep Dive)\n**0:00~0:30 êµ¬ê°„ ë°›ì•„ì“°ê¸° (Verification):**\n\"Welcome back to the deep dive. Today we are uh tackling a beast. It's a small butterfly-shaped beast that sits right in the middle of your neck and essentially dictates the pace of your entire existence. It really does. We are talking about the thyroid. It is small but absolutely mighty and for anyone in the medical field especially you know those of you looking down the barrel of USMLE Step 2, the thyroid is a gold mine. I mean it is arguably one of the highest yield topics in all of internal medicine.\"\n---\n## 1. Introduction: Step 1ê³¼ Step 2ì˜ ì°¨ì´ì \n- **ê°‘ìƒì„ ì˜ ì¤‘ìš”ì„±:** ëª© ì¤‘ì•™ì— ìœ„ì¹˜í•œ ë‚˜ë¹„ ëª¨ì–‘ì˜ ê¸°ê´€ìœ¼ë¡œ, ì¡´ì¬ì˜ ì†ë„ë¥¼ ê²°ì •í•˜ëŠ” ê°•ë ¥í•œ ê¸°ê´€ì…ë‹ˆë‹¤. ë‚´ê³¼ ì˜ì—­ì—ì„œ ê°€ì¥ **High Yield** ì£¼ì œ ì¤‘ í•˜ë‚˜ì…ë‹ˆë‹¤.\n- **ì ‘ê·¼ ë°©ì‹ì˜ ë³€í™”:**\n    - Step 1: ë¶„ì ìƒë¬¼í•™, ì¡°ì§í•™, í¬ê·€ ì•” ë“±ì— ì§‘ì¤‘í•©ë‹ˆë‹¤.\n    - Step 2: **ê´€ë¦¬(Management)**ì™€ **ë‹¤ìŒ ë‹¨ê³„(Next Best Step)**ê°€ í•µì‹¬ì…ë‹ˆë‹¤.\n    - ì„ìƒì  ì˜ì‚¬ê²°ì •: ë‹¨ìˆœíˆ ì§ˆë³‘ì´ ë¬´ì—‡ì¸ì§€ ì•„ëŠ” ê²ƒì„ ë„˜ì–´, \"TSHê°€ ë‚®ê³  ê²°ì ˆì´ ë§Œì ¸ì§ˆ ë•Œ, ì¡°ì§ê²€ì‚¬ë¥¼ í•  ê²ƒì¸ê°€ ìŠ¤ìº”ì„ í•  ê²ƒì¸ê°€?\"ë¥¼ ê²°ì •í•˜ëŠ” ê²ƒì´ ì ìˆ˜ë¥¼ ê°€ë¦…ë‹ˆë‹¤.\n- **ê°•ì˜ ë¡œë“œë§µ:**\n    1. ê°‘ìƒì„  í•­ì§„ì¦ (Hyperthyroidism) ë° ì§„ë‹¨ ì•Œê³ ë¦¬ì¦˜\n    2. ê°‘ìƒì„  ì €í•˜ì¦ (Hypothyroidism) ë° í•˜ì‹œëª¨í†  (Hashimoto's)\n    3. ì„ì‹  ì¤‘ ê°‘ìƒì„  ì§ˆí™˜ (ê³ ìœ„í—˜êµ°, ìƒë¦¬í•™ì  ë³€í™”)\n    4. íšŒìƒ‰ ì§€ëŒ€ (Subclinical, Nodule, Euthyroid Sick Syndrome)\n---\n## 2. ê°‘ìƒì„  í•­ì§„ì¦ (Hyperthyroidism) í”„ë ˆì„ì›Œí¬ ğŸŒ¡ï¸\n### 2.1 ì¦ìƒê³¼ ë³‘íƒœìƒë¦¬\n- **í™˜ì ë¬˜ì‚¬ (Vignette):** êµê°ì‹ ê²½ ê³¼í•­ì§„ ìƒíƒœ (Sympathetic Overdrive).\n    - **ë”ìœ„ ë¶ˆë‚´ì„±:** í•œê²¨ìš¸ì— ì°½ë¬¸ì„ ì—¬ëŠ” ì‚¬ëŒ. ë‚¨ë“¤ì€ ì¶”ì›Œí•˜ëŠ”ë° í˜¼ì ë•€ì„ í˜ë¦¼.\n    - **ì²´ì¤‘ ê°ì†Œ:** ì‹ìš•ì€ ì •ìƒì´ê±°ë‚˜ ì¦ê°€í–ˆëŠ”ë°ë„ ì‚´ì´ ë¹ ì§ (ëŒ€ì‚¬ ìš©ê´‘ë¡œê°€ ë„ˆë¬´ ëœ¨ê±°ì›€). â˜…\n    - **ê¸°íƒ€:** ì‹¬ê³„í•­ì§„(Palpitations), ë¯¸ì„¸ ì§„ì „(Tremor), ì„¤ì‚¬/ë¹ˆë²ˆí•œ ë°°ë³€(ì¥ ìš´ë™ í•­ì§„).","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-221"}
{"chunk_type":"transcript_chunk","text":"### 2.2 ëˆˆ ì¦ìƒì˜ ë¯¸ë¬˜í•œ ì°¨ì´ (Nuance) â˜…\në§ì€ í•™ìƒë“¤ì´ í˜¼ë™í•˜ëŠ” ë¶€ë¶„ì…ë‹ˆë‹¤.\n- **Lid Lag (Stare):** ì†ê°€ë½ì„ ì•„ë˜ë¡œ ë‚´ë¦´ ë•Œ ìœ—ëˆˆêº¼í’€ì´ ëŠ¦ê²Œ ë”°ë¼ì˜¤ë©° í°ììœ„(Sclera)ê°€ ë³´ì´ëŠ” í˜„ìƒ.\n    - ì›ì¸: ë†’ì€ êµê°ì‹ ê²½ í†¤ì´ ìœ—ëˆˆêº¼í’€ ê·¼ìœ¡(Muller's muscle)ì„ ìê·¹.\n    - ì˜ë¯¸: **ëª¨ë“  ì¢…ë¥˜ì˜ ê°‘ìƒì„  í•­ì§„ì¦**ì—ì„œ ë‚˜íƒ€ë‚  ìˆ˜ ìˆìŒ. (í˜ˆì¤‘ í˜¸ë¥´ëª¬ ê³¼ë‹¤ì˜ ì§•í›„ì¼ ë¿)\n- **Proptosis / Exophthalmos (ì•ˆêµ¬ ëŒì¶œ):** ì•ˆêµ¬ê°€ ë¬¼ë¦¬ì ìœ¼ë¡œ ë°–ìœ¼ë¡œ íŠ€ì–´ë‚˜ì˜¤ëŠ” í˜„ìƒ.\n    - ì›ì¸: ìê°€ë©´ì—­ ë°˜ì‘ìœ¼ë¡œ ì•ˆêµ¬ ë’¤ ê³µê°„(Retro-orbital space)ì— ê¸€ë¦¬ì½”ì‚¬ë¯¸ë…¸ê¸€ë¦¬ì¹¸ ì¶•ì  ë° ì—¼ì¦ ë°œìƒ -> ê·¼ìœ¡ê³¼ ì§€ë°©ì´ ë¶€í’€ì–´ ì•ˆêµ¬ë¥¼ ë°€ì–´ëƒ„.\n    - ì˜ë¯¸: **â˜…ê·¸ë ˆì´ë¸ŒìŠ¤ë³‘(Graves' Disease)ì— íŠ¹ì´ì (Specific)â˜…**ì¸ ì†Œê²¬.\n### 2.3 ì§„ë‹¨ ì•Œê³ ë¦¬ì¦˜ (Step 1 -> Step 2) ğŸ“‰\n- **Step 1: ìƒí™”í•™ì  í™•ì¸ (Labs)**\n    - TSH ë‚®ìŒ + Free T4/T3 ë†’ìŒ (ì¼ì°¨ì„± ê°‘ìƒì„  í•­ì§„ì¦).\n    - ë‡Œí•˜ìˆ˜ì²´ ë¬¸ì œ(ì´ì°¨ì„±)ëŠ” ë“œë¬¾ (TSH ë†’ìŒ, T4 ë†’ìŒ).\n- **Step 2: ì›ì¸ ê°ë³„ (The Crucial Pivot)**\n    - **ì§€ë¦„ê¸¸:** ë¯¸ë§Œì„± ê°‘ìƒì„ ë¹„ëŒ€(Diffuse Goiter) + ì•ˆêµ¬ ëŒì¶œ(Exophthalmos)ì´ ìˆìœ¼ë©´ ì¶”ê°€ ê²€ì‚¬ ì—†ì´ **ê·¸ë ˆì´ë¸ŒìŠ¤ë³‘** ì§„ë‹¨ ê°€ëŠ¥. (TSH ìˆ˜ìš©ì²´ í•­ì²´ ê²€ì‚¬ë¡œ í™•ì¸ ê°€ëŠ¥í•˜ì§€ë§Œ ì„ìƒì ìœ¼ë¡œ ì§„ë‹¨ ì¢…ë£Œ).\n    - **ë¶ˆí™•ì‹¤í•œ ê²½ìš°:** ë…¸ì¸ í™˜ì, ì•ˆêµ¬ ì¦ìƒ ì—†ìŒ, ê°‘ìƒì„  ë¹„ëŒ€ ë¶ˆëª…í™• -> **â˜…RAIU Scan (Radioactive Iodine Uptake, ë°©ì‚¬ì„± ìš”ì˜¤ë“œ ì„­ì·¨ìœ¨)â˜…** ì‹œí–‰.\n### 2.4 RAIU ìŠ¤ìº” í•´ì„: ê³µì¥(Factory) vs ëˆ„ì¶œ(Leak) ğŸ­\nì¹˜ë£Œ ë°©ì¹¨ì„ ê²°ì •í•˜ëŠ” ê°€ì¥ ì¤‘ìš”í•œ ê²€ì‚¬ì…ë‹ˆë‹¤.\n| êµ¬ë¶„ | RAIU ì„­ì·¨ìœ¨ | ì˜ë¯¸ | íŒ¨í„´ | ì¹˜ë£Œ |\n| --- | --- | --- | --- | --- |\n| **ê³µì¥ ê³¼ê°€ë™ (Factory Overdrive)** | **ë†’ìŒ (High)** | ê³µì¥ì´ ì›ë£Œ(ìš”ì˜¤ë“œ)ë¥¼ ì ê·¹ì ìœ¼ë¡œ ê°€ì ¸ì™€ í˜¸ë¥´ëª¬ì„ í•©ì„± ì¤‘. | **Diffuse:** ê·¸ë ˆì´ë¸ŒìŠ¤ë³‘ (Graves')  **Nodular:** ì¤‘ë…ì„± ì„ ì¢…/ë‹¤ê²°ì ˆì„± ê°‘ìƒì„ ì¢… | **Methimazole** (í˜¸ë¥´ëª¬ í•©ì„± ì°¨ë‹¨ì œ) íš¨ê³¼ ìˆìŒ. |\n| **ëˆ„ì¶œ ë˜ëŠ” ê°€ì§œ (Leak or Fake)** | **ë‚®ìŒ (Low)** | ê³µì¥ì€ ê°€ë™ ì¤‘ë‹¨(í˜¸ë¥´ëª¬ ì•ˆ ë§Œë“¦). í˜ˆì¤‘ í˜¸ë¥´ëª¬ì€ ì €ì¥ëœ ê²ƒì´ ìƒˆì–´ ë‚˜ì˜¤ê±°ë‚˜ ì™¸ë¶€ ìœ ì…. | **Thyroiditis (ì—¼ì¦):** ì €ì¥ëœ í˜¸ë¥´ëª¬ ëˆ„ì¶œ  **Exogenous:** ì•½ë¬¼ ë³µìš© (ë‹¤ì´ì–´íŠ¸ ì•½ ë“±)  **Struma Ovarii:** ë‚œì†Œ ê¸°í˜•ì¢… | **Methimazole íš¨ê³¼ ì—†ìŒ (ê¸ˆê¸°).**  ëŒ€ì¦ ì¹˜ë£Œ (Beta-blockers, NSAIDs). |\n---\n## 3. ì¹˜ë£Œì˜ ë”œë ˆë§ˆ (Treatment Options) ğŸ’Š\n### 3.1 í•­ê°‘ìƒì„ ì œ (ATDs)\n- **Methimazole:** ë¹„ì„ì‹  ì„±ì¸ì˜ ê¸°ë³¸ ì¹˜ë£Œì œ.\n    - ê¸°ì „: Thyroid Peroxidase(TPO) ì–µì œ -> í˜¸ë¥´ëª¬ í•©ì„± ì°¨ë‹¨.\n    - **ë¶€ì‘ìš©:** **ë¬´ê³¼ë¦½êµ¬ì¦(Agranulocytosis)** â˜…. (í™˜ìê°€ ì—´ì´ ë‚˜ê³  ëª©ì´ ì•„í”„ë‹¤ê³  í•˜ë©´ ì¦‰ì‹œ ì•½ì„ ì¤‘ë‹¨í•˜ê³  CBC ê²€ì‚¬).\n- **PTU (Propylthiouracil):** ì„ì‹  1ë¶„ê¸°ì—ë§Œ ì‚¬ìš© (Methimazoleì˜ ê¸°í˜• ìœ ë°œ ìœ„í—˜ ë•Œë¬¸).\n### 3.2 ë°©ì‚¬ì„± ìš”ì˜¤ë“œ ì¹˜ë£Œ (RAI) â˜¢ï¸\n- í™•ì‹¤í•œ ì¹˜ë£Œë²•(Ablation)ì´ì§€ë§Œ 90%ì—ì„œ ì˜êµ¬ì  ê°‘ìƒì„  ì €í•˜ì¦ ë°œìƒ (í‰ìƒ ì•½ ë³µìš©).\n- **â˜…ì ˆëŒ€ ê¸ˆê¸° (Contraindication):â˜… ì¤‘ë“±ë„~ì¤‘ì¦ì˜ ì•ˆêµ¬ ì§ˆí™˜(Ophthalmopathy).** RAIëŠ” ì•ˆêµ¬ ì§ˆí™˜ì„ ì•…í™”ì‹œì¼œ ì‹¤ëª…ì„ ìœ ë°œí•  ìˆ˜ ìˆìŒ. (í•„ìš” ì‹œ ìŠ¤í…Œë¡œì´ë“œ ì „ì²˜ì¹˜ í˜¹ì€ ìˆ˜ìˆ  ê³ ë ¤).\n### 3.3 ìˆ˜ìˆ  (Thyroidectomy) ğŸ”ª\n- ì ì‘ì¦: ë§¤ìš° í° ê°‘ìƒì„ ì¢…(ì••ë°• ì¦ìƒ), ì•”ì´ ì˜ì‹¬ë˜ëŠ” ê²°ì ˆ, ì„ì‹  ì¤‘ ì•½ë¬¼ ë¶€ì‘ìš©/ê±°ë¶€, ì‹¬í•œ ì•ˆêµ¬ ì§ˆí™˜ìœ¼ë¡œ RAI ë¶ˆê°€ëŠ¥í•œ ê²½ìš°.\n---\n## 4. ê°‘ìƒì„  ì¤‘ë… ë°œì‘ (Thyroid Storm) â›ˆï¸\n- **ìƒí™©:** ì¹˜ë£Œë°›ì§€ ì•Šì€ ê°‘ìƒì„  í•­ì§„ì¦ í™˜ìê°€ ìŠ¤íŠ¸ë ˆìŠ¤(ê°ì—¼, ìˆ˜ìˆ , ì™¸ìƒ, ì¶œì‚°, ì¡°ì˜ì œ ë“±)ë¥¼ ê²ªì„ ë•Œ ë°œìƒ.\n- **ì§„ë‹¨ ë‹¨ì„œ:**\n    1. **â˜…ê³ ì—´ (Hyperpyrexia):â˜…** 104Â°F~105Â°F (40Â°C ì´ìƒ). ë‹¨ìˆœ í•­ì§„ì¦ê³¼ êµ¬ë³„ë˜ëŠ” í•µì‹¬.\n    2. ì •ì‹  ìƒíƒœ ë³€í™” (Agitation, Delirium, Coma).\n    3. ì‹¬ë¶€ì „, í™©ë‹¬.\n- ë¹„êµ: ê°ˆìƒ‰ì„¸í¬ì¢…(Pheochromocytoma)ì€ ê³ í˜ˆì••/ë¹ˆë§¥ì€ ìˆì§€ë§Œ, ì´ë ‡ê²Œ ê·¹ì‹¬í•œ ê³ ì—´ì€ ë“œë¬¾.\n---","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-241"}
{"chunk_type":"transcript_chunk","text":"## 5. ê°‘ìƒì„ ì—¼ (Thyroiditis): The Leakers ğŸ’§\nì„¸ ê°€ì§€ ì£¼ìš” ìœ í˜•ì„ êµ¬ë¶„í•˜ëŠ” ê²ƒì´ ì¤‘ìš”í•©ë‹ˆë‹¤. (ëª¨ë‘ RAIU ë‚®ìŒ)\n1. **ë¬´í†µì„±(Silent/Painless) ê°‘ìƒì„ ì—¼:** í•˜ì‹œëª¨í† ì˜ ë³€í˜•.\n    1. í•­-TPO í•­ì²´ ì–‘ì„±. anti TG ab.\n    2. í†µì¦ ì—†ìŒ. 3ë‹¨ê³„ ê²½ê³¼(í•­ì§„->ì €í•˜->ì •ìƒ)ë¥¼ ê±°ì¹¨.\n2. **ì•„ê¸‰ì„±(Subacute/De Quervain's) ê°‘ìƒì„ ì—¼:**\n    - **â˜…íŠ¹ì§•: ëª©ì˜ í†µì¦/ì••í†µ (Painful/Tender neck)â˜…**. í„±ì´ë‚˜ ê·€ë¡œ ë°©ì‚¬í†µ.\n    - ë³‘ë ¥: ëª‡ ì£¼ ì „ ê°ê¸°/ë…ê°(Viral illness) ì•“ìŒ.\n    - Lab: ESR/CRP ë§¤ìš° ë†’ìŒ.\n    - ì¹˜ë£Œ: NSAIDs (í†µì¦ ì¡°ì ˆ), ì‹¬í•˜ë©´ ìŠ¤í…Œë¡œì´ë“œ. Methimazole ê¸ˆì§€.\n3. **ì‚°í›„(Postpartum) ê°‘ìƒì„ ì—¼:** ì¶œì‚° í›„ 1ë…„ ì´ë‚´ ë°œìƒ. ìê°€ë©´ì—­ì„±.\n    - *ì„ìƒì  ê³ ë¯¼:* ì¶œì‚° í›„ ê·¸ë ˆì´ë¸ŒìŠ¤ë³‘ ë°œë³‘ê³¼ êµ¬ë³„ í•„ìš”. ìˆ˜ìœ ë¶€ë¼ RAIU ëª»í•¨ -> **TRAB (TSH ìˆ˜ìš©ì²´ í•­ì²´)** ê²€ì‚¬ë¡œ ê°ë³„ (ì–‘ì„±ì´ë©´ ê·¸ë ˆì´ë¸ŒìŠ¤).\n---\n## 6. ì„ì‹ ê³¼ ê°‘ìƒì„  (Thyroid in Pregnancy) ğŸ¤°\nìƒë¦¬í•™ì  ë³€í™”ë¥¼ ì´í•´í•˜ë©´ ëœ ë¬´ì„­ìŠµë‹ˆë‹¤.\n### 6.1 ìƒë¦¬í•™ì  ë³€í™”: high total T4, slightly low TSH\n- **ì—ìŠ¤íŠ¸ë¡œê² ê¸‰ì¦:** TBG(Thyroxin Binding Globulin, ìŠ¤í€ì§€ ì—­í• ) ìƒì‚° ì¦ê°€ -> í˜ˆì¤‘ T4ë¥¼ í¡ìˆ˜ -> ê°‘ìƒì„ ì´ ë” ì¼í•´ì„œ T4 ìƒì‚° ì¦ê°€.\n    - ê²°ê³¼: **Total T4 ë†’ìŒ (ì •ìƒ), Free T4 ì •ìƒ.** (ì„ì‹ ë¶€ì˜ High Total T4ì— ì†ì§€ ë§ ê²ƒ!)\n- **hCGì˜ ì—­í• :** TSHì™€ êµ¬ì¡° ìœ ì‚¬(Alpha subunit ê³µìœ ). ì„ì‹  1ë¶„ê¸°ì— hCGê°€ ê°‘ìƒì„ ì„ ìê·¹ -> TSH ì–µì œë¨. (Gestational Transient Thyrotoxicosis). ì…ë§(Hyperemesis) ì‹¬í•œ ì‚°ëª¨ì—ì„œ í”í•¨.\n- ëŒ€ê°œ ì¹˜ë£Œ ë¶ˆí•„ìš”.\n### 6.2 ì„ì‹  ì¤‘ ê·¸ë ˆì´ë¸ŒìŠ¤ë³‘ ê´€ë¦¬ â˜…\n- **ì•½ë¬¼ ì „í™˜ ê·œì¹™:**\n    - **1ë¶„ê¸°:** **PTU** ì‚¬ìš© (Methimazoleì€ Aplasia Cutis ë“± ê¸°í˜• ìœ ë°œ).\n    - **2ë¶„ê¸°/3ë¶„ê¸°:** **Methimazole**ë¡œ ì „í™˜ (PTUëŠ” ì‚°ëª¨ì—ê²Œ ê°„ë…ì„± ìœ„í—˜).\n- **ì¹˜ë£Œ ëª©í‘œ:** ì‚°ëª¨ë¥¼ **ì•½ê°„ í•­ì§„ ìƒíƒœ(Mildly Hyperthyroid)**ë¡œ ìœ ì§€. (Free T4ë¥¼ ì •ìƒ ìƒí•œì¹˜ ë˜ëŠ” ì•½ê°„ ë†’ê²Œ). íƒœì•„ì˜ ê°‘ìƒì„  ì €í•˜ì¦ ë°©ì§€.\n### 6.3 ì„ì‹  ì¤‘ ê°‘ìƒì„  ì €í•˜ì¦ ê´€ë¦¬\n- **â˜…ì„ì‹  í™•ì¸ ì¦‰ì‹œ ì¦ëŸ‰:** ì„ì‹  í…ŒìŠ¤íŠ¸ ì–‘ì„± í™•ì¸ ì „í™”ê°€ ì˜¤ë©´, ì¦‰ì‹œ Levothyroxine ìš©ëŸ‰ì„ **30% ì¦ëŸ‰** (ì£¼ 2íšŒ ì¶”ê°€ ë³µìš©) ì§€ì‹œ.\n- ì´ìœ : íƒœì•„ì˜ ë‡Œ ë°œë‹¬ì€ 1ë¶„ê¸° ë™ì•ˆ ì „ì ìœ¼ë¡œ ì—„ë§ˆì˜ T4ì— ì˜ì¡´í•¨. TSH ê²°ê³¼ë¥¼ ê¸°ë‹¤ë¦¬ë©´ ëŠ¦ìŒ.\n---\n## 7. Hypothyroidism\n### 7.1 Hashimoto thyroiditis\n- Iodine def. ì§€ì—­\n- Anti TPO, anti TG\n- painless thyroiditisë‘ ì‚¬ì‹¤ìƒ ê°™ì€ ìŠ¤í™íŠ¸ëŸ¼ì„. painless thyroiditisê°€ ì¼ì‹œì ìœ¼ë¡œ ë°œìƒí•˜ê³  ìì—°íšŒë³µí•˜ëŠ” ë°˜ë©´, hashimotoëŠ” ë§Œì„±ì ìœ¼ë¡œ ê³„ì† ë°œí˜„ë¨.\n- long standing hashimoto thyroiditis í™˜ìì—ì„œ ê°‘ìê¸° goiter, firm, hoarseness, dysphagia\nâ†’ Primary thyroid lymphoma â˜… â˜… \nd/t chronic lymphocytic inflammation. â†’ B cell ìê·¹ â†’ non hodgkin lymphoma\n    - cf. Pamberton sign: mass effect.\n    ì†ë“¤ì–´ë³´ì„¸ìš” â†’ goiter thoracic inlet ë§‰ìŒ â†’ ì–¼êµ´ ë¹¨ê°œì§, syncope (jugular vein block)\n### 7.2 Central hypothyroidism = hypopituitarism â†’ Levothyroxineë¶€í„° ì£¼ë©´ì•ˆë¨!\n- pituitary problem\n    - also low in other hormones! : ACTH â†“ (secondary AI)\n- low TSH, low T4\n- â˜… levothyroxineë¶€í„° ì£¼ë©´ì•ˆë¨! â†’ adrenal crisis â†’ hypotension, shock\n- â˜… cortisol ë¶€í„° ì¤˜ì•¼ë¨!\n### 7.3 Levothyroxine ë³µìš© ê´€ë¦¬\n- í¡ìˆ˜ê°€ ê¹Œë‹¤ë¡œì›€: ê³µë³µ, ë¬¼ê³¼ í•¨ê»˜ ë³µìš©. ì‹ì‚¬ 30~60ë¶„ ì „.\n- **ë°©í•´ ìš”ì¸:** ì¹¼ìŠ˜, ì² ë¶„ì œ, ì œì‚°ì œ(PPI), ìš°ìœ , ì»¤í”¼ ë“±ì€ 4ì‹œê°„ ê°„ê²© í•„ìš”.\n- **ëŒ€ì‚¬ ì´‰ì§„:** Phenytoin, Carbamazepine ë“±ì€ T4 ëŒ€ì‚¬ë¥¼ ì´‰ì§„í•˜ì—¬ ë” ë†’ì€ ìš©ëŸ‰ì„ í•„ìš”ë¡œ í•¨.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-261"}
{"chunk_type":"transcript_chunk","text":"---\n## 8. íšŒìƒ‰ ì§€ëŒ€: ì§„ë‹¨ ì•Œê³ ë¦¬ì¦˜ (Diagnostic Gray Zones)\n### 8.1 ê°‘ìƒì„  ê²°ì ˆ (Thyroid Nodule) ì•Œê³ ë¦¬ì¦˜ âšª\në°˜ë“œì‹œ ì™¸ì›Œì•¼ í•˜ëŠ” ìˆœì„œì…ë‹ˆë‹¤.\n1. **Step 1: â˜…TSH ì¸¡ì •â˜…**\n2. **ê²½ë¡œ A (TSH ë‚®ìŒ):** \"Hot\" ê°€ëŠ¥ì„± -> **RAIU ìŠ¤ìº”** ì‹œí–‰.\n    - Hot Nodule: ê¸°ëŠ¥ì„±(Hyperfunctioning). ì•”ì¼ í™•ë¥  <1%. ìƒê²€ ë¶ˆí•„ìš”.\n    - Cold Nodule: ì•” ìœ„í—˜ ìˆìŒ -> ì´ˆìŒíŒŒ -> ìƒê²€(FNA).\n3. **ê²½ë¡œ B (TSH ì •ìƒ/ë†’ìŒ):** ì•” ìœ„í—˜ -> **ì´ˆìŒíŒŒ(Ultrasound)** ì‹œí–‰.\n    - ì˜ì‹¬ ì†Œê²¬: ë¶ˆê·œì¹™í•œ ê²½ê³„, ë¯¸ì„¸ì„íšŒí™”(Microcalcifications), í‚¤ê°€ ë” í° ëª¨ì–‘(Taller than wide).\n4. **Step 3: FNA (Fine Needle Aspiration):** í¬ê¸°ì™€ ì´ˆìŒíŒŒ ì†Œê²¬ì— ë”°ë¼ ê²°ì •.\n### 8.2 ë¬´ì¦ìƒ ê°‘ìƒì„  ì €í•˜ì¦ (Subclinical Hypothyroidism)\n- Lab: TSH ë†’ìŒ (ë³´í†µ <10), Free T4 ì •ìƒ.\n- **ì¹˜ë£Œ ê¸°ì¤€:**\n    - TSH > 10.\n    - TSH 7~10ì´ë©´ì„œ ì¦ìƒì´ ìˆê±°ë‚˜ ê°‘ìƒì„ ì¢…ì´ ìˆëŠ” ê²½ìš°.\n    - ì„ì‹  ì¤‘ì´ê±°ë‚˜ ì„ì‹  ì‹œë„ ì¤‘ì¼ ë•Œ.\n- ë…¸ì¸ì´ë‚˜ ê²½ë¯¸í•œ ê²½ìš°(TSH < 7)ëŠ” ì§€ì¼œë´„.\n### 8.3 ì •ìƒ ê°‘ìƒì„  ë³‘ì¦ ì¦í›„êµ° (Euthyroid Sick Syndrome) ğŸ¥\n- **ìƒí™©:** ICU í™˜ì, íŒ¨í˜ˆì¦, ëŒ€ìˆ˜ìˆ  í›„.\n- **Lab:** T3 ë‚®ìŒ, **Reverse T3 ë†’ìŒ** â˜…, TSH/T4ëŠ” ë‹¤ì–‘í•¨.\n- ê¸°ì „: ì‹ ì²´ê°€ ì—ë„ˆì§€ë¥¼ ì•„ë¼ê¸° ìœ„í•´ ëŒ€ì‚¬ìœ¨ì„ ë‚®ì¶”ëŠ” ì ì‘ ë°˜ì‘ (Metabolic Hibernation). T4ë¥¼ ë¹„í™œì„±ì¸ Reverse T3ë¡œ ì „í™˜.\n- **ê´€ë¦¬:** **â˜…í˜¸ë¥´ëª¬ ì¹˜ë£Œ í•˜ì§€ ì•ŠìŒ (Do NOT treat).â˜…** ê¸°ì € ì§ˆí™˜ ì¹˜ë£Œ ì‹œ ì •ìƒí™”ë¨.\n---\n## 9. ê¸°íƒ€ í•µì‹¬ í¬ì¸íŠ¸ (Loose Ends)\n- **ë¼ˆ ê±´ê°•:** ê°‘ìƒì„  í•­ì§„ì¦ì€ ë¼ˆë¥¼ ë…¹ì„ (Osteoclast ìê·¹). ê³¨ë‹¤ê³µì¦ ë° ê³¨ì ˆ ìœ„í—˜ ì¦ê°€. ì¥ê¸°ê°„ ì–µì œë˜ì§€ ì•Šì€ TSHëŠ” ìœ„í—˜ ìš”ì¸.\n- **ë¬´ê´€ì‹¬í•œ ê°‘ìƒì„  í•­ì§„ì¦ (Apathetic Thyrotoxicosis):** ë…¸ì¸ì—ê²Œì„œ ë°œìƒ. ì „í˜•ì  ì¦ìƒ ì—†ì´ **ìš°ìš¸ê°, ë¬´ê¸°ë ¥, í˜¼ë€, ê·¸ë¦¬ê³  â˜…ì‹¬ë°©ì„¸ë™(New onset Afib)â˜…**ìœ¼ë¡œ ë‚˜íƒ€ë‚¨. ë…¸ì¸ì˜ Afibì€ ë¬´ì¡°ê±´ TSH ì²´í¬.\n---","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-281"}
{"chunk_type":"recap_summary","text":"## ğŸ”¥ Rapid Fire Recap (í•µì‹¬ ìš”ì•½)\n1. **Hyperthyroidism:** TSH ë¨¼ì € ì²´í¬. ë‚®ìœ¼ë©´ Free T4 í™•ì¸. ê·¸ë ˆì´ë¸ŒìŠ¤ ì§•í›„(ì•ˆêµ¬ ëŒì¶œ) ì—†ìœ¼ë©´ **RAIU ìŠ¤ìº”**ìœ¼ë¡œ ê³µì¥ ê³¼ê°€ë™ vs ëˆ„ì¶œ ê°ë³„ (leak or fake)\n2. **Thyroid Storm:** ì‹¬í•œ í•­ì§„ì¦ + **ê³ ì—´(High Fever, >104F)** + ì •ì‹  ìƒíƒœ ë³€í™”.\n3. **Pregnancy:**\n    - normally total T4 high, TSH slightly low in 1st trimester.\n    - Graves: 1ë¶„ê¸° **PTU**, 2/3ë¶„ê¸° **Methimazole**.\n    - Hypo: ì„ì‹  í™•ì¸ ì¦‰ì‹œ Levothyroxine **30% ì¦ëŸ‰**.\n4. **Hypothyroid Mom:** ì–‘ì„± ë°˜ì‘ ëœ¨ìë§ˆì ì¦ëŸ‰. TSH í™•ì¸ ê¸°ë‹¤ë¦¬ì§€ ë§ ê²ƒ.\n5. **Nodule:** **TSH ë¨¼ì €.** ë‚®ìœ¼ë©´ ìŠ¤ìº”, ì •ìƒì´ë©´ ì´ˆìŒíŒŒ. Hot noduleì€ ìƒê²€ ì•ˆ í•¨.\n6. **Euthyroid Sick Syndrome (ICU):** Low T3, High Reverse T3. **ì¹˜ë£Œí•˜ì§€ ì•ŠìŒ.** ê¸°ì € ì§ˆí™˜ ì¹˜ë£Œ.\n**Takeaway:** ê°‘ìƒì„ ì€ ë…ë¦½ëœ ê¸°ê´€ì´ ì•„ë‹ˆë¼ ë¼ˆ, ì‹¬ì¥, ë‡Œ, ìƒì‹ê¸° ë“± ì „ì‹  ì‹œìŠ¤í…œì˜ ì§€íœ˜ì(Conductor)ì„ì„ ê¸°ì–µí•˜ê³  ì „ì²´ì ì¸ í™˜ìì˜ ìƒíƒœë¥¼ ë´ì•¼ í•©ë‹ˆë‹¤.","subject":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","page_title":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","episode":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","section_path":["LM_endo 1 2f346f2986ee80ca9e35c9ff88472722"],"source_doc_id":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722","source_page":null,"source_anchor":"LM_endo 1 2f346f2986ee80ca9e35c9ff88472722-294"}
{"chunk_type":"transcript_chunk","text":"# LM_cardio 1\nì œê³µëœ ì˜¤ë””ì˜¤ íŒŒì¼ì„ ë¶„ì„í•˜ì—¬ ê°•ì˜ë¡ì„ ì‘ì„±í–ˆìŠµë‹ˆë‹¤. ìš”ì²­í•˜ì‹  ëŒ€ë¡œ ì²« 30ì´ˆ êµ¬ê°„ì˜ ë°›ì•„ì“°ê¸°(Dictation)ë¥¼ ë¨¼ì € í™•ì¸í•˜ì‹  í›„, ìƒì„¸ ë‚´ìš©ì„ ì°¸ê³ í•´ ì£¼ì‹œê¸° ë°”ëë‹ˆë‹¤.\n---\n### 0. Verification: 0:00~0:30 êµ¬ê°„ ë°›ì•„ì“°ê¸°\n> \"ì•ˆë…•í•˜ì„¸ìš”. USMLE step 2 ì‹œí—˜ ì¤€ë¹„í•˜ì‹œëŠë¼ ì •ë§ ë°”ì˜ì‹œì£ ? ì˜¤ëŠ˜ ë³´ë‚´ì£¼ì‹  ìë£Œë“¤ì„ ë³´ë‹ˆê¹Œ, ìŒ ì‹¬í˜ˆê´€ íŒŒíŠ¸, ê·¸ì¤‘ì—ì„œë„ ê³ í˜ˆì••ì´ë”ë¼ê³ ìš”. ì´ê²Œ ê°€ì¥ ê¸°ë³¸ì´ ë˜ëŠ” ì£¼ì œ ê°™ìœ¼ë©´ì„œë„ íŒŒê³ ë“¤ë©´ ì •ë§ ëì´ ì—†ì–ì•„ìš”. ë§ì•„ìš”. ê±°ì˜ ëª¨ë“  í™˜ì ì¦ë¡€ì— ë­ë„ê¹Œ ê¸°ë³¸ê°’ì²˜ëŸ¼ ê¹”ë ¤ ë‚˜ì˜¤ëŠ” ê²Œ ê³ í˜ˆì••ì´ë¼ì„œìš”. ê·¸ë˜ì„œ ë‹¨ìˆœíˆ ì •ìƒ ìˆ˜ì¹˜ë¥¼ ì•„ëŠ” ê±¸ ë„˜ì–´ì„œ ì™œ ì´ëŸ° ìƒí™©ì´ ë°œìƒí–ˆê³  ê·¸ë˜ì„œ ë‹¤ìŒ ë‹¨ê³„ëŠ” ë­˜ê¹Œ? ì´ê±¸ ì¶”ë¡ í•˜ëŠ” ëŠ¥ë ¥ì´ ì •ë§ ì¤‘ìš”í•´ìš”.\"\n>\n---\n# ğŸ©º USMLE Step 2 CK: ê³ í˜ˆì••(Hypertension) ë§ˆìŠ¤í„° í´ë˜ìŠ¤\n## 1. Introduction: ìˆ«ìë¥¼ ë„˜ì–´ í™˜ìë¥¼ ì½ëŠ” ë²• ğŸ§\nê³ í˜ˆì••ì€ ë‹¨ìˆœí•œ ìˆ˜ì¹˜ ì•”ê¸°ê°€ ì•„ë‹™ë‹ˆë‹¤. **'ì™œ'** í˜ˆì••ì´ ì˜¬ëëŠ”ì§€, **'ë‹¤ìŒ ë‹¨ê³„'**ëŠ” ë¬´ì—‡ì¸ì§€ë¥¼ ì¶”ë¡ í•˜ëŠ” ê²ƒì´ USMLEì˜ í•µì‹¬ì…ë‹ˆë‹¤.\n### â˜… í˜ˆì••ì˜ ê²°ì • ìš”ì¸ (The Physiology)\ní˜ˆì•• ìˆ˜ì¹˜ë¥¼ ë‘ ê°€ì§€ ì´ì•¼ê¸°ë¡œ ë‚˜ëˆ„ì–´ í•´ì„í•´ì•¼ í•©ë‹ˆë‹¤.\n- **ì´ì™„ê¸° í˜ˆì•• (Diastolic BP):** ì „ì‹  í˜ˆê´€ ì €í•­(SVR)ì„ ë°˜ì˜. (ë§ì´ˆ í˜ˆê´€ì´ ì–¼ë§ˆë‚˜ ê½‰ ì¡°ì—¬ìˆëŠ”ê°€)\n- **ë§¥ì•• (Pulse Pressure, ìˆ˜ì¶•ê¸°-ì´ì™„ê¸°):**\n    - ì‹¬ì¥ì´ í•œ ë²ˆì— ì§œë‚´ëŠ” í”¼ì˜ ì–‘ (Stroke Volume)\n    - **ëŒ€ë™ë§¥ì˜ íƒ„ë ¥ì„± (Compliance)** â˜…\n---\n## 2. ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤ #1: ê³ ë¦½ì„± ìˆ˜ì¶•ê¸° ê³ í˜ˆì•• (Isolated Systolic HTN)\n> [Case] 65ì„¸ ë‚¨ì„± í™˜ì, í˜ˆì•• 150/90 mmHg\n> \n- **í•´ì„:**\n    - **ë§¥ì••(60)ì´ í¼:** ë‚˜ì´ê°€ ë“¤ë©´ì„œ í˜ˆê´€ì´ ë…¸í™”ë˜ì–´ **ëŒ€ë™ë§¥ ê²½ì§(Stiffness)** ë°œìƒ.\n    - ì‹¬ì¥ì´ í”¼ë¥¼ ë¿œì„ ë•Œ í˜ˆê´€ì´ ëŠ˜ì–´ë‚˜ì£¼ì§€ ëª»í•´ ìˆ˜ì¶•ê¸° í˜ˆì••ë§Œ ì„ íƒì ìœ¼ë¡œ ìƒìŠ¹í•¨.\n- **Key Point:** ê³ ë ¹ í™˜ìì—ì„œ ìˆ˜ì¶•ê¸°ë§Œ ë†’ë‹¤ë©´? ğŸ‘‰ **\"ëŒ€ë™ë§¥ ê²½ì§\"**ì„ ë°”ë¡œ ë– ì˜¬ë¦´ ê²ƒ!\n---\n## 3. ì§„ë‹¨ê³¼ ì¸¡ì •: ë³‘ì› ë°– í˜ˆì••ì´ ì§„ì§œë‹¤ ğŸ \n### â˜… ì§„ë‹¨ì˜ ë”œë ˆë§ˆ\n- **ë°±ì˜ ê³ í˜ˆì••(White Coat HTN):** ë³‘ì›ì—ì„œëŠ” ë†’ê³  ì§‘ì—ì„œëŠ” ì •ìƒì¸ ê²½ìš°.\n- **ê°€ë©´ ê³ í˜ˆì••(Masked HTN):** ë³‘ì›ì—ì„œëŠ” ì •ìƒì´ë‚˜ ì§‘ì—ì„œëŠ” ë†’ì€ ê²½ìš°.\n### â˜… í™•ì§„ ì ˆì°¨ (Hierarchy)","subject":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","page_title":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","episode":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","section_path":["LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec"],"source_doc_id":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","source_page":null,"source_anchor":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec-1"}
{"chunk_type":"transcript_chunk","text":"1. **24ì‹œê°„ í™œë™ í˜ˆì•• ì¸¡ì • (Ambulatory BP Monitoring):** ê°€ì¥ ì •í™•í•œ í‘œì¤€(Gold Standard).\n2. **ê°€ì • í˜ˆì•• ì¸¡ì • (Home BP Monitoring):** 1ì£¼ì¼ê°„ ì¸¡ì •í•˜ì—¬ ê¸°ë¡ (í˜„ì‹¤ì ì¸ ì°¨ì„ ì±…).\n3. **ì§„ë£Œì‹¤ í˜ˆì•• ì¬ì¸¡ì •:** ëª‡ ì£¼ì— ê±¸ì³ ì—¬ëŸ¬ ë²ˆ ì¸¡ì •.\n---\n## 4. ì¹˜ë£Œ ì „ëµ: ì–¸ì œ ì•½ì„ ì“¸ ê²ƒì¸ê°€? ğŸ’Š\n> [Case] í™˜ìì˜ ê°€ì • í˜ˆì••ì´ ê¾¸ì¤€íˆ 145/88 mmHgë¡œ í™•ì¸ë¨.\n>\n### 1) ë‹¨ê³„ ë¶„ë¥˜ (Staging)\n- **1ê¸° ê³ í˜ˆì••:** ìˆ˜ì¶•ê¸° 130 ~ 139 mmHg\n- **2ê¸° ê³ í˜ˆì••:** ìˆ˜ì¶•ê¸° â‰¥ 140 mmHg ğŸ‘‰ **ìš°ë¦¬ í™˜ìëŠ” ì—¬ê¸°ì— í•´ë‹¹!**\n### 2) ì¹˜ë£Œ ê²°ì • ì•Œê³ ë¦¬ì¦˜\n| ë‹¨ê³„ | í™˜ì ìƒíƒœ | ì¹˜ë£Œ ì „ëµ |\n| --- | --- | --- |\n| **1ê¸° (130-139)** | ê³ ìœ„í—˜êµ° ì•„ë‹˜ | ìƒí™œìŠµê´€ êµì • ìš°ì„  |\n| **1ê¸° (130-139)** | **ê³ ìœ„í—˜êµ°** (ë‹¹ë‡¨, ë§Œì„±ì‹ ì§ˆí™˜, â˜…ASCVD ìœ„í—˜ë„ >10%) | ìƒí™œìŠµê´€ êµì • + **ì•½ë¬¼ ì¹˜ë£Œ ë³‘í–‰** |\n| **2ê¸° (â‰¥140)** | ìœ„í—˜ë„ ë¬´ê´€ | **ìƒí™œìŠµê´€ êµì • + ì•½ë¬¼ ì¹˜ë£Œ ì¦‰ì‹œ ì‹œì‘** |\n---\n## 5. ìƒí™œìŠµê´€ êµì • (Lifestyle Modification)ê³¼ í•¨ì • ğŸ¥—\n### â˜… íš¨ê³¼ ë¹„êµ\n- **DASH ì‹ì´ìš”ë²•:** ìˆ˜ì¶•ê¸° í˜ˆì•• **~11mmHg ê°ì†Œ** íš¨ê³¼ (ì•½ 1ì•Œê³¼ ë§ë¨¹ìŒ).\n- **ì²´ì¤‘ ê°ëŸ‰:** í˜ˆì•• ê°•í•˜ì— ê°€ì¥ ì§ì ‘ì ì´ê³  íš¨ê³¼ì ì„.\n### â˜… ì‹œí—˜ ì¶œì œ í•¨ì • (Trap) âš ï¸\n- **ë¬¸ì œ:** \"í˜ˆì•• ìˆ˜ì¹˜ ìì²´ë¥¼ ë‚®ì¶”ê¸° ìœ„í•œ ë‹¤ìŒ ì¡°ì¹˜ëŠ”?\"\n    - ì˜¤ë‹µ ìœ ë„: ê¸ˆì—° (Smoking Cessation)\n    - **ì§„ì‹¤:** ê¸ˆì—°ì€ **ì¥ê¸°ì ì¸ ì‹¬í˜ˆê´€ ìœ„í—˜(ASCVD Risk)**ì„ ë‚®ì¶”ëŠ” ë° í•„ìˆ˜ì ì´ì§€ë§Œ, **í˜ˆì•• ìˆ˜ì¹˜ ìì²´ë¥¼ ê·¹ì ìœ¼ë¡œ ë–¨ì–´ëœ¨ë¦¬ì§€ëŠ” ì•ŠìŒ.**\n    - **ì •ë‹µ:** ì²´ì¤‘ ê°ëŸ‰ ë˜ëŠ” DASH ì‹ë‹¨.\n- **ì•Œì½”ì˜¬:** í•˜ë£¨ 2ì” ì´ìƒì€ ì €í•­ì„± ê³ í˜ˆì••ì˜ ì›ì¸.\n    - *Case:* ì•½ì„ 3ê°œ ì¨ë„ í˜ˆì••ì´ ì•ˆ ì¡íˆëŠ”ë° ë§¤ì¼ ì†Œì£¼ 1ë³‘ ë§ˆì‹œëŠ” í™˜ì ğŸ‘‰ ì•½ ì¶”ê°€ ì „ **ê¸ˆì£¼ ìƒë‹´**ì´ ì •ë‹µ.\n---\n## 6. ë™ë°˜ ì§ˆí™˜ì— ë”°ë¥¸ ì•½ë¬¼ ì„ íƒ (Compelling Indications) ğŸ¯\në‹¨ìˆœíˆ í˜ˆì••ì„ ë‚®ì¶”ëŠ” ê²ƒì´ ì•„ë‹ˆë¼, í™˜ìì˜ **\"ì „ì²´ì ì¸ ìƒí™©(Total Patient Care)\"**ì„ ë´ì•¼ í•©ë‹ˆë‹¤.\n| ë™ë°˜ ì§ˆí™˜ | ì¶”ì²œ ì•½ë¬¼ | ì´ìœ  (Mechanism & Benefit) |\n| --- | --- | --- |\n| **ì‹¬ê·¼ê²½ìƒ‰ (Post-MI) / ì‹¬ë¶€ì „** | **ACEi/ARB + Beta Blocker** | ì‹¬ì¥ ë¦¬ëª¨ë¸ë§ ë°©ì§€, ìƒì¡´ìœ¨ ì¦ê°€ (ì‹¬ì¥ ë³´í˜¸ íš¨ê³¼). |\n| **í†µí’ (Gout)** | **Losartan (ARB)** | ìš”ì‚° ë°°ì„¤ ì´‰ì§„(Uricosuric effect).<br>*(â€»ê¸ˆê¸°: Thiazide - ìš”ì‚° ìˆ˜ì¹˜ ë†’ì„)* |\n| **ê³¨ë‹¤ê³µì¦** | **Thiazide** | ì¹¼ìŠ˜ ë°°ì„¤ì„ ì¤„ì—¬ ë¼ˆ ê±´ê°•ì— ë„ì›€. (ì¼ì„ì´ì¡°) |\n| **í¸ë‘í†µ (ì Šì€ ì—¬ì„±)** | **Beta Blocker / CCB** | í¸ë‘í†µ ì˜ˆë°© íš¨ê³¼. |\n---\n## 7. ì´ì°¨ì„± ê³ í˜ˆì••ì˜ ë³´ë¬¼ì§€ë„ (Secondary HTN Clues) ğŸ—ºï¸","subject":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","page_title":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","episode":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","section_path":["LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec"],"source_doc_id":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","source_page":null,"source_anchor":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec-21"}
{"chunk_type":"transcript_chunk","text":"ì•½ì„ ì¨ë„ í˜ˆì••ì´ ì•ˆ ì¡íˆê±°ë‚˜(ì €í•­ì„±), íŠ¹ì • ë‹¨ì„œê°€ ë³´ì¼ ë•Œ ì˜ì‹¬í•´ì•¼ í•©ë‹ˆë‹¤.\n- **ë°°ê¼½ ì£¼ë³€ í˜ˆê´€ ì¡ìŒ (Abdominal Bruit):** ğŸ‘‰ **ì‹ ë™ë§¥ í˜‘ì°© (Renal Artery Stenosis)**\n    - *Hint:* ACEi ì‚¬ìš© í›„ í¬ë ˆì•„í‹°ë‹Œ(Cr) ìˆ˜ì¹˜ ê¸‰ìƒìŠ¹.\n    - *Hint:* ë°˜ë³µë˜ëŠ” íë¶€ì¢… (Flash Pulmonary Edema).\n- **ì €ì¹¼ë¥¨í˜ˆì¦ + ëŒ€ì‚¬ì„± ì•Œì¹¼ë¦¬ì¦:** ğŸ‘‰ **ì¼ì°¨ì„± ì•Œë„ìŠ¤í…Œë¡ ì¦ (Conn's syndrome)**\n    - Na/ë¬¼ ì €ë¥˜, K ë°°ì¶œ ê³¼ë‹¤.\n- **3ëŒ€ ì¦ìƒ (ë‘í†µ + ì‹¬ê³„í•­ì§„ + ë°œí•œ):** ğŸ‘‰ **ê°ˆìƒ‰ì„¸í¬ì¢… (Pheochromocytoma)**\n    - \"ê³µí™©ë°œì‘\"ìœ¼ë¡œ ì˜¤í•´í•˜ê¸° ì‰¬ì›€. í˜ˆì••ì´ ë°œì‘ì ìœ¼ë¡œ ì¹˜ì†ŸìŒ.\n- **íŒ”/ë‹¤ë¦¬ í˜ˆì•• ì°¨ì´:** ğŸ‘‰ **ëŒ€ë™ë§¥ ì¶•ì°© (Coarctation of the Aorta)**\n---\n## 8. ê³ í˜ˆì••ì„± ìœ„ê¸° (Hypertensive Crisis) ğŸš¨\n> [Case] ì‹¬í•œ ë‘í†µê³¼ ì‹œì•¼ íë¦¼ìœ¼ë¡œ ì‘ê¸‰ì‹¤ ë‚´ì›, BP 220/130 mmHg.\n>\n### â˜… ê¸´ê¸‰ì¦(Urgency) vs ì‘ê¸‰ì¦(Emergency) êµ¬ë¶„\ní•µì‹¬ì€ ìˆ«ìê°€ ì•„ë‹ˆë¼ **\"ê¸‰ì„± í‘œì  ì¥ê¸° ì†ìƒ(End Organ Damage)\"ì˜ ìœ ë¬´**ì…ë‹ˆë‹¤.\n| êµ¬ë¶„ | ìƒíƒœ | ì¥ê¸° ì†ìƒ ì¦ê±° | ì¹˜ë£Œ ì „ëµ |\n| --- | --- | --- | --- |\n| **ê¸´ê¸‰ì¦ (Urgency)** | í˜ˆì••ë§Œ ë§¤ìš° ë†’ìŒ | ì—†ìŒ | **ê²½êµ¬ ì•½ë¬¼**, ìˆ˜ì‹œê°„~ìˆ˜ì¼ì— ê±¸ì³ ì„œì„œíˆ ì¡°ì ˆ |\n| **ì‘ê¸‰ì¦ (Emergency)** | í˜ˆì•• ë§¤ìš° ë†’ìŒ + ì¦ìƒ | **ìˆìŒ** (ë‡Œë¶€ì¢…, ìœ ë‘ë¶€ì¢…, ì‹ ë¶€ì „, ì‹¬ë¶€ì „ ë“±) | **IV ì•½ë¬¼**, ì¦‰ê°ì ì´ê³  ì •ë°€í•œ ì¡°ì ˆ í•„ìš” |\n> Note: ì˜ì‹ í˜¼ë¯¸, ì‹œì•¼ íë¦¼ ë“±ì€ ë‡Œ/ëˆˆì˜ ì†ìƒì„ ì˜ë¯¸í•˜ë¯€ë¡œ **ì‘ê¸‰ì¦(Emergency)**ì…ë‹ˆë‹¤.\n>\n---","subject":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","page_title":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","episode":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","section_path":["LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec"],"source_doc_id":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","source_page":null,"source_anchor":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec-41"}
{"chunk_type":"recap_summary","text":"# ğŸ”¥ High Yield Summary: Rapid Fire Recap\n1. **ë…¸ì¸ ê³ í˜ˆì•• (ìˆ˜ì¶•ê¸°â†‘, ì´ì™„ê¸° ì •ìƒ/â†“):** ì›ì¸ì€ **ëŒ€ë™ë§¥ ê²½ì§(Stiffness)**.\n2. **1ê¸° ê³ í˜ˆì•• ì¹˜ë£Œ:** ê³ ìœ„í—˜êµ°(ASCVD >10%, DM, CKD)ì´ ì•„ë‹ˆë©´ **ìƒí™œìŠµê´€ êµì •**ì´ ë¨¼ì €.\n3. **í˜ˆì•• ê°•í•˜ íš¨ê³¼ 1ë“±:** **ì²´ì¤‘ ê°ëŸ‰**. (ê¸ˆì—°ì€ ì „ì²´ ì‹¬í˜ˆê´€ ìœ„í—˜ ê°ì†Œ).\n4. **ì•½ë¬¼ ì„ íƒì˜ ë¯¸í•™:**\n    - í†µí’ í™˜ì ğŸ‘‰ **Losartan** (Thiazide ê¸ˆì§€ âŒ)\n    - ê³¨ë‹¤ê³µì¦ í™˜ì ğŸ‘‰ **Thiazide**\n    - ì‹¬ê·¼ê²½ìƒ‰ ê³¼ê±°ë ¥ ğŸ‘‰ **Beta Blocker + ACEi**\n5. **ì´ì°¨ì„± ê³ í˜ˆì•• í‚¤ì›Œë“œ:**\n    - Bruit / ACEi í›„ Cr ìƒìŠ¹ / íë¶€ì¢… ğŸ‘‰ **ì‹ ë™ë§¥ í˜‘ì°©**\n    - ì €ì¹¼ë¥¨í˜ˆì¦ ğŸ‘‰ **ì•Œë„ìŠ¤í…Œë¡ ì¦**\n    - ë‘í†µ+ë•€+ë‘ê·¼ê±°ë¦¼ ğŸ‘‰ **ê°ˆìƒ‰ì„¸í¬ì¢…**\n6. **ì‘ê¸‰ì‹¤ ëŒ€ì²˜:** ì¥ê¸° ì†ìƒ(ëˆˆ, ë‡Œ, ì‹¬ì¥, ì½©íŒ¥)ì´ ìˆìœ¼ë©´ **Emergency (IV ì¹˜ë£Œ)**, ì—†ìœ¼ë©´ **Urgency (ê²½êµ¬ ì¹˜ë£Œ)**.\n# ğŸ«€ USMLE Step 2 ëŒ€ë¹„: ê°ì—¼ì„± ì‹¬ë‚´ë§‰ì—¼(IE) & ë¥˜ë§ˆí‹°ìŠ¤ì„± ì‹¬ì¥ ì§ˆí™˜(RHD) ì™„ë²½ ì •ë¦¬\n**0:00~0:30 êµ¬ê°„ ë°›ì•„ì“°ê¸° (Verification)**\n\"ì•ˆë…•í•˜ì„¸ìš”. USMLE ìŠ¤í… 2 ì‹œí—˜ ì¤€ë¹„í•˜ì‹œëŠë¼ í˜ë“œì‹œì£ ? íŠ¹íˆ ì‹¬ì¥ íŒŒíŠ¸ëŠ” ì™¸ìš¸ ê²ƒë„ ë§ê³  ì–´... ì„œë¡œ ë§‰ ë¹„ìŠ·í•´ì„œ í—·ê°ˆë¦¬ëŠ” ê°œë…ë„ ì •ë§ ë§ì–ì•„ìš”. ì˜¤ëŠ˜ ì €í¬ê°€ ë³´ë‚´ì£¼ì‹  ìë£Œë“¤ì„ ë°”íƒ•ìœ¼ë¡œ ê·¸ì¤‘ì—ì„œë„ ê°€ì¥ ê³¨ì¹˜ ì•„í”ˆ ë‘ ê°€ì§€, ê°ì—¼ì„± ì‹¬ë‚´ë§‰ì—¼ê³¼ ë¥˜ë§ˆí‹°ìŠ¤ì„± ì‹¬ì¥ ì§ˆí™˜ì„ í™•ì‹¤í•˜ê²Œ ì •ë¦¬í•´ ë“œë¦¬ë ¤ê³  í•©ë‹ˆë‹¤. ì˜¤ëŠ˜ ì €í¬ì˜ ëª©í‘œëŠ” ì´ ìë£Œë“¤ì—ì„œ í•µì‹¬ë§Œ ì™ì™ ë½‘ì•„ë“œë¦¬ëŠ” ê±°ì˜ˆìš”. ì§„ë‹¨ ê¸°ì¤€ë¶€í„° ì›ì¸ê· , í—·ê°ˆë¦¬ëŠ” ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤ê¹Œì§€ ì‹œí—˜ì— ë‚˜ì˜¤ëŠ” ê°€ì¥ ì¤‘ìš”í•œ ë‚´ìš©ë“¤ì„ ë¨¸ë¦¿ì†ì— í™•ì‹¤íˆ ë„£ì–´ë“œë¦´ê²Œìš”.\"\n---\n## 1. Introduction: ì˜¤ëŠ˜ì˜ í•™ìŠµ ëª©í‘œ ğŸ¯\nì´ ê°•ì˜ëŠ” USMLE Step 2 ì‹œí—˜ì—ì„œ ìˆ˜í—˜ìƒë“¤ì„ ê´´ë¡­íˆëŠ” ë‘ ê°€ì§€ ì£¼ìš” ì‹¬ì¥ ì§ˆí™˜, **ê°ì—¼ì„± ì‹¬ë‚´ë§‰ì—¼(Infective Endocarditis, IE)**ê³¼ **ë¥˜ë§ˆí‹°ìŠ¤ì„± ì‹¬ì¥ ì§ˆí™˜(Rheumatic Heart Disease, RHD)**ì„ ë‹¤ë£¹ë‹ˆë‹¤.\n- ë‹¨ìˆœ ì•”ê¸°ê°€ ì•„ë‹Œ **ê¸°ì „(Mechanism)** ì´í•´ë¥¼ í†µí•œ ì•”ê¸°\n- ì‹œí—˜ì— ìì£¼ ë‚˜ì˜¤ëŠ” **ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤(Clinical Scenario)** ì—°ê²°\n- *ê°ì—¼(Infection)**ê³¼ **ë©´ì—­ ë°˜ì‘(Immune Response)**ì˜ ì°¨ì´ êµ¬ë¶„\n---\n## 2. ê°ì—¼ì„± ì‹¬ë‚´ë§‰ì—¼ (Infective Endocarditis, IE) ğŸ¦ ","subject":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","page_title":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","episode":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","section_path":["LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec"],"source_doc_id":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","source_page":null,"source_anchor":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec-51"}
{"chunk_type":"transcript_chunk","text":"### 2-1. ìœ„í—˜ ìš”ì¸ (Risk Factors) âš ï¸\nê°€ì¥ ê°•ë ¥í•œ ìœ„í—˜ ìš”ì¸ì€ ì‹¬ì¥ ë‚´ë¶€ì— ì´ë¬¼ì§ˆì´ ìˆê±°ë‚˜ ì„¸ê· ì´ ì¹¨íˆ¬í•  ê²½ë¡œê°€ ìˆëŠ” ê²½ìš°ì…ë‹ˆë‹¤.\n- **â˜… ì¸ê³µ íŒë§‰ (Prosthetic valve)** ë³´ìœ ì\n- **â˜… ì´ì „ì˜ IE ë³‘ë ¥ (History of IE)**\n- ì •ë§¥ ì£¼ì‚¬ ì•½ë¬¼ ì‚¬ìš©ì (IV Drug Users)\n- ì¤‘ì‹¬ ì •ë§¥ê´€ (Central venous catheter) ë“± í˜ˆê´€ ë‚´ ì¹´í…Œí„°ë¥¼ ì˜¤ë˜ ê°€ì§„ ê²½ìš°\n### 2-2. ì¦ìƒ ë° ì§•í›„ (Signs & Symptoms) ğŸŒ¡ï¸\n- **ì¼ë°˜ì  ì¦ìƒ:** ë°œì—´(90% ì´ìƒ), ìƒˆë¡œìš´ ì‹¬ì¡ìŒ(New murmur, 85%). í•˜ì§€ë§Œ ì´ê²ƒë§Œìœ¼ë¡œëŠ” ë¹„íŠ¹ì´ì ì„.\n- **íŠ¹ì§•ì  ì§•í›„ (Classic Signs) - ê¸°ì „ì„ ì•Œë©´ ì•ˆ í—·ê°ˆë¦¼!**\n| ì§•í›„ (Sign) | ì„¤ëª… | í†µì¦ | ê¸°ì „ (Mechanism) |\n| --- | --- | --- | --- |\n| **ì œì¸ì›¨ì´ ë³‘ë³€ (Janeway lesions)** | ì†/ë°œë°”ë‹¥ì˜ ë¶‰ì€ ë°˜ì  | **ì—†ìŒ (Painless)** | **íŒ¨í˜ˆì„± ìƒ‰ì „ (Septic emboli):** ì„¸ê·  ë©ì–´ë¦¬(ìš°ì¢…)ê°€ ë–¨ì–´ì ¸ ë‚˜ê°€ í˜ˆê´€ì„ ë§‰ìŒ |\n| **ì˜¤ìŠ¬ëŸ¬ ê²°ì ˆ (Osler nodes)** | ì†/ë°œê°€ë½ ëì˜ ê²°ì ˆ | **ìˆìŒ (Painful)** | **ë©´ì—­ ë°˜ì‘ (Immune complex):** í•­ì›-í•­ì²´ ë³µí•©ì²´ê°€ í˜ˆê´€ë²½ì— ë¶™ì–´ ì—¼ì¦ ìœ ë°œ |\n| **ë¡œìŠ¤ ë°˜ì  (Roth spots)** | ë§ë§‰ ì¶œí˜ˆ | - | ë©´ì—­í•™ì  í˜„ìƒ ë“± |\n### 2-3. ì§„ë‹¨: ìˆ˜ì •ëœ ë“€í¬ ê¸°ì¤€ (Modified Duke Criteria) ğŸ“‹\n- **í™•ì§„ (Definite IE):** ì£¼ ê¸°ì¤€ 2ê°œ OR ì£¼ ê¸°ì¤€ 1ê°œ + ë¶€ ê¸°ì¤€ 3ê°œ OR ë¶€ ê¸°ì¤€ 5ê°œ\n### **â˜… ì£¼ ì§„ë‹¨ ê¸°ì¤€ (Major Criteria) - ì§ì ‘ì  ì¦ê±°**\n1. **í˜ˆì•¡ ë°°ì–‘ (Blood Culture):** ì „í˜•ì ì¸ ì›ì¸ê· ì´ 2íšŒ ì´ìƒ ê²€ì¶œ.\n2. **ì‹¬ì¥ ì´ˆìŒíŒŒ (Echocardiography):** íŒë§‰ì— ë¶™ì€ **ìš°ì¢…(Vegetation)** ì§ì ‘ í™•ì¸.\n    - *ìš°ì¢…ì´ë€?* ì„¸ê·  + í˜ˆì†ŒíŒ + í”¼ë¸Œë¦°(ì„¬ìœ ì†Œ)ì´ ì—‰ê²¨ ë¶™ì€ ë©ì–´ë¦¬.\n### **ë¶€ ì§„ë‹¨ ê¸°ì¤€ (Minor Criteria) - ì •í™© ì¦ê±°**\n- ì†Œì¸ (ì‹¬ì¥ ë³‘ë³€, IV drug use)\n- 38ë„ ì´ìƒì˜ ë°œì—´\n- í˜ˆê´€ í˜„ìƒ (ìƒ‰ì „, ì œì¸ì›¨ì´ ë³‘ë³€ ë“±)\n- ë©´ì—­í•™ì  í˜„ìƒ (ì˜¤ìŠ¬ëŸ¬ ê²°ì ˆ, ë¡œìŠ¤ ë°˜ì , ì‚¬êµ¬ì²´ì‹ ì—¼)\n---\n## 3. â˜… í•µì‹¬ ì‹œë‚˜ë¦¬ì˜¤: ì›ì¸ê· ê³¼ ìƒí™© ì—°ê²° (Bug-Scenario Match) ğŸ”—\nì‹œí—˜ ë¬¸ì œ í’€ì´ì˜ í•µì‹¬ì€ **\"ì–´ë–¤ ê· ì´ ì–´ë–¤ ìƒí™©ê³¼ ì—°ê²°ë˜ëŠ”ê°€\"**ì…ë‹ˆë‹¤.\n1. **í™©ìƒ‰í¬ë„ì•Œê·  (*Staphylococcus aureus*)** ğŸ˜ˆ\n    - **íŠ¹ì§•:** ë§¤ìš° ê³µê²©ì . ê±´ê°•í•œ íŒë§‰ë„ ì†ìƒì‹œí‚´.\n    - **ì‹œë‚˜ë¦¬ì˜¤:** **ì •ë§¥ ì£¼ì‚¬ ì•½ë¬¼ ì‚¬ìš©ì**, ì¸ê³µ íŒë§‰, ì¹´í…Œí„° ê´€ë ¨ ê°ì—¼ì˜ ì£¼ë²”.\n2. **ë¹„ë¦¬ë‹¨ìŠ¤ ì—°ì‡„êµ¬ê·  (*Viridans Streptococci*)** ğŸ¦·\n    - **íŠ¹ì§•:** êµ¬ê°• ìƒì¬ê· .\n    - **ì‹œë‚˜ë¦¬ì˜¤:** **ì¹˜ê³¼ ì‹œìˆ ** í›„ í˜ˆë¥˜ë¡œ ìœ ì…ë˜ì–´ ë°œìƒ (êµ¬ê°• ì ë§‰ ìƒì²˜).\n3. **í‘œí”¼í¬ë„ì•Œê·  (*Staphylococcus epidermidis*)** ğŸ”©\n    - **íŠ¹ì§•:** í”¼ë¶€ ìƒì¬ê· . **ë°”ì´ì˜¤í•„ë¦„(Biofilm)** í˜•ì„±.\n    - **ì‹œë‚˜ë¦¬ì˜¤:** **ì¸ê³µ íŒë§‰**, ì‹¬ë°• ì¡°ìœ¨ê¸° ë“± ì²´ë‚´ ì‚½ì… ê¸°êµ¬ í‘œë©´ì— ì˜ ìƒê¹€.\n4. **ì—”í…Œë¡œì½”ì»¤ìŠ¤ (*Enterococcus*)** ğŸš½\n    - **ì‹œë‚˜ë¦¬ì˜¤:** ë³‘ì› ë‚´ ê°ì—¼, íŠ¹íˆ **ìš”ë¡œ ê°ì—¼(UTI)** í›„ ë°œìƒ.\n5. **â˜… ìŠ¤íŠ¸ë ™í† ì½”ì»¤ìŠ¤ ê°ˆë¡œë¦¬í‹°ì¿ ìŠ¤ (*S. gallolyticus*, êµ¬ *S. bovis*)** ğŸ¦€\n    - **ì¤‘ìš” ì—°ê²° ê³ ë¦¬:** í˜ˆì•¡ ë°°ì–‘ì—ì„œ ì´ ê· ì´ ë‚˜ì˜¤ë©´ **ëŒ€ì¥ì•”(Colon cancer)** ì˜ì‹¬!\n    - **ê¸°ì „:** ìš©ì¢…ì´ë‚˜ ì•”ìœ¼ë¡œ ì¥ë²½ì´ ì•½í•´ì ¸ ê· ì´ ì¹¨íˆ¬.\n    - **ì¡°ì¹˜ (Key Action):** **ë°˜ë“œì‹œ ëŒ€ì¥ë‚´ì‹œê²½(Colonoscopy) ì‹œí–‰.**\n---\n## 4. ìš°ì‹¬ ë‚´ë§‰ì—¼ (Right-Sided IE) vs. ì¢Œì‹¬ ë‚´ë§‰ì—¼ ğŸ«\n- **í˜¸ë°œ ëŒ€ìƒ:** **ì •ë§¥ ì£¼ì‚¬ ì•½ë¬¼ ì‚¬ìš©ì** (ì£¼ì‚¬ ì‹œ ì„¸ê· ì´ ìš°ì‹¬ë°©/ìš°ì‹¬ì‹¤ë¡œ ë¨¼ì € ë„ë‹¬).\n- **í˜¸ë°œ ë¶€ìœ„:** **ì‚¼ì²¨íŒ (Tricuspid valve)** ì••ë„ì .\n- **â˜… ì„ìƒì  í•¨ì • (Clinical Trap):**\n    - ì¼ë°˜ì ì¸ IEì™€ ì–‘ìƒì´ ë‹¤ë¦„.\n    - ì‹¬ì¡ìŒì´ ì•ˆ ë“¤ë¦´ ìˆ˜ ìˆìŒ (50%).\n    - ë§ì´ˆ ì§•í›„(ì œì¸ì›¨ì´, ì˜¤ìŠ¬ëŸ¬) ë“œë­„.\n    - ì‹¬ë¶€ì „ ë“œë­„.\n- **í•©ë³‘ì¦:** **íí˜ˆì„± íìƒ‰ì „ì¦ (Septic Pulmonary Emboli)** (75% ë°œìƒ).\n    - ì¦ìƒ: ê¸°ì¹¨, í‰í†µ, í˜¸í¡ê³¤ë€ (**íë ´ê³¼ ë¹„ìŠ·í•´ ì˜¤ì§„í•˜ê¸° ì‰¬ì›€**).\n    - ì˜ìƒ ì†Œê²¬: í‰ë¶€ CTìƒ íì˜ ì—¬ëŸ¬ êµ°ë° ê²°ì ˆì´ë‚˜ **ê³µë™(Cavitation)** ë™ë°˜.\n---","subject":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","page_title":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","episode":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","section_path":["LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec"],"source_doc_id":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","source_page":null,"source_anchor":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec-61"}
{"chunk_type":"transcript_chunk","text":"## 5. ì¹˜ë£Œ ë° ìˆ˜ìˆ  ì ì‘ì¦ ğŸ’ŠğŸ”ª\n### 5-1. ì¹˜ë£Œ ì›ì¹™\n- **First Culture, Then Antibiotics:** í•­ìƒì œ íˆ¬ì—¬ ì „ ë°˜ë“œì‹œ ì„œë¡œ ë‹¤ë¥¸ ë¶€ìœ„ì—ì„œ **í˜ˆì•¡ ë°°ì–‘ 3íšŒ** ì‹œí–‰.\n- ì›ì¸ê· ì— ë§ëŠ” ì¥ê¸°ê°„ ì •ë§¥ ì£¼ì‚¬ í•­ìƒì œ ì‚¬ìš©.\n### 5-2. ìˆ˜ìˆ ì´ í•„ìš”í•œ ê²½ìš° (Indications for Surgery)\n1. í•­ìƒì œ ì¹˜ë£Œ ì¤‘ì—ë„ **ê¸‰ì„± ì‹¬ë¶€ì „(Acute HF)** ë°œìƒ.\n2. ê°ì—¼ì´ í¼ì ¸ **ë†ì–‘(Abscess)**ì´ë‚˜ ëˆ„ê³µ í˜•ì„± (ì‹¬ì „ë„ìƒ ì „ë„ ì°¨ë‹¨/Heart block ë°œìƒ ì‹œ ì˜ì‹¬).\n3. ì§„ê· (Fungal) ê°ì—¼ì´ë‚˜ ë‚´ì„±ê· .\n4. ìš°ì¢…ì´ ë„ˆë¬´ í¬ê±°ë‚˜ **ë°˜ë³µì ì¸ ìƒ‰ì „(Recurrent emboli)** ë°œìƒ ì‹œ.\n### 5-3. ë¹„ì„¸ê· ì„± í˜ˆì „ì„± ì‹¬ë‚´ë§‰ì—¼ (NBTE)\n- **íŠ¹ì§•:** ê°ì—¼ ì•„ë‹˜. ì•”(ì·Œì¥ì•” ë“±)ì´ë‚˜ ë£¨í‘¸ìŠ¤(Libman-Sacks) ê°™ì€ ë§Œì„± ì—¼ì¦ìœ¼ë¡œ ì¸í•œ **ê³¼ì‘ê³  ìƒíƒœ**ê°€ ì›ì¸.\n- **ì¹˜ë£Œ:** í•­ìƒì œ(X) â†’ ê¸°ì € ì§ˆí™˜ ì¹˜ë£Œ ë° **í•­ì‘ê³  ìš”ë²•**.\n---\n## 6. ì˜ˆë°©ì  í•­ìƒì œ ìš”ë²• (Prophylaxis) ğŸ›¡ï¸\ní˜„ëŒ€ ì˜í•™ì—ì„œëŠ” ì˜ˆë°© ìš”ë²•ì„ ì•„ì£¼ ì œí•œì ìœ¼ë¡œ ê¶Œì¥í•©ë‹ˆë‹¤.\n### 6-1. ëˆ„ê°€? (High Risk Patients)\n- ì¸ê³µ ì‹¬ì¥ íŒë§‰ ë³´ìœ ì\n- ì´ì „ IE ë³‘ë ¥ì\n- ë³µì¡í•œ ì²­ìƒ‰ì¦ì„± ì„ ì²œì„± ì‹¬ì¥ ì§ˆí™˜\n- **ì£¼ì˜:** ë¥˜ë§ˆí‹°ìŠ¤ì„± ì‹¬ì¥ ì§ˆí™˜ í™˜ìëŠ” ê³ ìœ„í—˜êµ° ì•„ë‹˜ (ì˜ˆë°©ì  í•­ìƒì œ ë¶ˆí•„ìš”).\n### 6-2. ì–¸ì œ? (High Risk Procedures)\n- **ì¹˜ê³¼:** ì‡ëª¸ì´ë‚˜ ì¹˜ì•„ ë¿Œë¦¬ ì£¼ë³€ì„ ì¡°ì‘í•˜ëŠ” ì‹œìˆ  (ì‹œìˆ  1ì‹œê°„ ì „ ì•„ëª©ì‹œì‹¤ë¦°).\n- **í˜¸í¡ê¸°:** ì ë§‰ ì ˆê°œ ìˆ˜ìˆ .\n- **í”¼ë¶€/ê·¼ìœ¡:** ê°ì—¼ ì¡°ì§ ìˆ˜ìˆ  ì‹œ.\n---\n## 7. ë¥˜ë§ˆí‹°ìŠ¤ì„± ì‹¬ì¥ ì§ˆí™˜ (Rheumatic Heart Disease, RHD) â¤ï¸â€ğŸ”¥\n### 7-1. ê¸°ì „ ë° ì§„ë‹¨\n- **ì›ì¸:** **Aêµ° ì—°ì‡„êµ¬ê· (GAS) ì¸ë‘ì—¼(Strep throat)** ì¹˜ë£Œ ì†Œí™€ ì‹œ 2-4ì£¼ ë’¤ ë°œìƒ.\n- **ê¸°ì „:** **ë¶„ì ëª¨ë°©(Molecular mimicry)**. ë©´ì—­ ì„¸í¬ê°€ ì„¸ê· ì„ ê³µê²©í•˜ë ¤ë‹¤ ë¹„ìŠ·í•˜ê²Œ ìƒê¸´ ì‹¬ì¥ íŒë§‰, ê´€ì ˆ ë“±ì„ ê³µê²©.\n- **ì§„ë‹¨ (JONES Criteria):**\n    - **J**oints (ì´ë™ì„± ë‹¤ë°œì„± ê´€ì ˆì—¼)\n    - **O** (Carditis, ì‹¬ì¥ì—¼ - ê°€ì¥ ì‹¬ê°)\n    - **N**odules (í”¼í•˜ ê²°ì ˆ)\n    - **E**rythema marginatum (ìœ ì—°ì„± í™ë°˜)\n    - **S**ydenham chorea (ë¬´ë„ë³‘)\n### 7-2. ê²½ê³¼ ë° ì‹œë‚˜ë¦¬ì˜¤\n- ì´ˆê¸°: ê¸‰ì„± ì‹¬ì¥ì—¼ â†’ ìŠ¹ëª¨íŒ ì—­ë¥˜.\n- **ë§Œì„±:** ë°˜ë³µì ì¸ ì—¼ì¦ìœ¼ë¡œ íŒë§‰ì´ ë‘êº¼ì›Œì§€ê³  êµ³ì–´ì§ â†’ **ìŠ¹ëª¨íŒ í˜‘ì°©ì¦ (Mitral Stenosis, MS)**.\n- **â˜… ì‹œë‚˜ë¦¬ì˜¤:** ê°œë°œë„ìƒêµ­ ì¶œì‹  ì Šì€ ì—¬ì„± + ì„ì‹  í›„ í˜¸í¡ê³¤ë€/í”¼ë¡œ í˜¸ì†Œ â†’ **ìŠ¹ëª¨íŒ í˜‘ì°©ì¦** ì˜ì‹¬.","subject":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","page_title":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","episode":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","section_path":["LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec"],"source_doc_id":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","source_page":null,"source_anchor":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec-81"}
{"chunk_type":"transcript_chunk","text":"### 7-3. ì˜ˆë°© (Prevention)\n- **1ì°¨ ì˜ˆë°©:** ì¸ë‘ì—¼ ë°œìƒ ì‹œ í˜ë‹ˆì‹¤ë¦° 10ì¼ ì¹˜ë£Œ (ê¸‰ì„± ë¥˜ë§ˆí‹°ìŠ¤ì—´ ìì²´ë¥¼ ë§‰ìŒ).\n- **2ì°¨ ì˜ˆë°© (ì¬ë°œ ë°©ì§€):** ì´ë¯¸ ì•“ì•˜ë˜ í™˜ìì—ê²Œ ì¥ê¸°ê°„ í˜ë‹ˆì‹¤ë¦° íˆ¬ì—¬.\n    - ì‹¬ì¥ì—¼ ì—†ìŒ: 21ì„¸ ë˜ëŠ” ë°œë³‘ í›„ 5ë…„ ì¤‘ ê¸´ ê¸°ê°„.\n    - ì‹¬ì¥ì—¼ ìˆìŒ (íŒë§‰ ì†ìƒ X): 21ì„¸ ë˜ëŠ” ë°œë³‘ í›„ 10ë…„.\n    - **ì‹¬ì¥ì—¼ + íŒë§‰ ì†ìƒ:** **40ì„¸ ë˜ëŠ” ë°œë³‘ í›„ 10ë…„ (í˜¹ì€ í‰ìƒ).**\n---\n## ğŸ”¥ Rapid Fire Recap: Must-Know Summary\n| Topic | Clinical Scenario / Key Fact | Key Action / Diagnosis |\n| --- | --- | --- |\n| **IE Symptom Trap** | **Janeway** lesions (Painless) vs **Osler** nodes (Painful) | êµ¬ë¶„ í•„ìˆ˜! (ê¸°ì „: ìƒ‰ì „ vs ë©´ì—­ë°˜ì‘) |\n| **Bug-Disease Link** | IE with **S. gallolyticus** (S. bovis) | **Colonoscopy** (R/O Colon Cancer) |\n| **Bug-Disease Link** | Dental procedure history | **Viridans Streptococci** |\n| **Right-Sided IE** | **IV Drug User** + Pneumonia-like symptoms (Cough, CP) | Suspect **Tricuspid Valve IE** + Septic Emboli |\n| **NBTE** | Sterile vegetation, Hypercoagulable state (Cancer, SLE) | Anticoagulation (No Antibiotics) |\n| **Prophylaxis Rule** | High Risk Patient (Prosthetic valve/Hx of IE) + Dental Work | **Amoxicillin** 1hr before procedure |\n| **RHD Scenario** | Young immigrant female + Pregnancy + Dyspnea | Suspect **Mitral Stenosis** due to RHD |\n| **RHD Prevention** | History of Rheumatic Fever | Long-term **Penicillin** prophylaxis (to prevent recurrence) |\n## 0:00~0:30 êµ¬ê°„ ë°›ì•„ì“°ê¸° (Dictation Verification)\n\"USMLE ì‹œí—˜ ì¤€ë¹„ í•œì°½ì´ì‹œêµ°ìš”. ë³´ë‚´ì£¼ì‹  ìë£Œ ë­‰ì¹˜ë¥¼ ë³´ë‹ˆê¹Œ ì™€, ì´ ë°©ëŒ€í•œ ì‹¬í˜ˆê´€ ì§ˆí™˜ íŒŒíŠ¸, ê·¸ì¤‘ì—ì„œë„ ì½œë ˆìŠ¤í…Œë¡¤ ë§ì´ì£ . ë„¤. ì´ê²Œ ì•Œ ê²ƒ ê°™ìœ¼ë©´ì„œë„ ë§‰ìƒ ì •ë¦¬í•˜ë ¤ë©´ ì¢€ ë§‰ë§‰í•œ ì£¼ì œì–ì•„ìš”. ë‹¨ìˆœíˆ ìˆ˜ì¹˜ë§Œ ì™¸ìš°ëŠ” ê²Œ ì•„ë‹ˆë¼ ì´ê²Œ ì‹¤ì œ í™˜ìì—ê²Œ ì–´ë–»ê²Œ ë‚˜íƒ€ë‚˜ê³  ë˜ ì–´ë–¤ ë…¼ë¦¬ë¡œ ì ‘ê·¼í•´ì•¼ í•˜ëŠ”ì§€, ê·¸ ì—°ê²°ê³ ë¦¬ë¥¼ ì°¾ê³  ì‹¶ì–´ í•˜ì‹œëŠ” ê²ƒ ê°™ì•„ìš”. ë§ì•„ìš”. ì˜¤ëŠ˜ ì´ ìë£Œë“¤ ê°€ì§€ê³  ê·¸ í•µì‹¬ íë¦„ì„ í•œë²ˆ ê°™ì´ ì¡ì•„ë³´ì£ .\"\n---\n# ğŸ©º USMLE Step 2 ëŒ€ë¹„: ì‹¬í˜ˆê´€ ì§ˆí™˜ê³¼ ì½œë ˆìŠ¤í…Œë¡¤ ì™„ì „ ì •ë³µ\n## 1. Introduction: ì‹œí—˜ì— ë‚˜ì˜¤ëŠ” ì½œë ˆìŠ¤í…Œë¡¤ì˜ ë‘ ì–¼êµ´ ğŸ­\nì½œë ˆìŠ¤í…Œë¡¤ì€ ë‹¨ìˆœí•œ ìœ„í—˜ ì¸ìê°€ ì•„ë‹™ë‹ˆë‹¤. ë•Œë¡œëŠ” ì‘ê¸‰ ìƒí™©ì„ ë§Œë“œëŠ” ì£¼ë²”ì´ê¸°ë„ í•˜ê³ , ì¹˜ë£Œì˜ ê²°ì •ì  ê¸°ì¤€ì ì´ ë˜ê¸°ë„ í•©ë‹ˆë‹¤. ì´ ê°•ì˜ë¡ì€ **ì½œë ˆìŠ¤í…Œë¡¤ ê²°ì • ìƒ‰ì „ì¦(Atheroembolism)**ì´ë¼ëŠ” ë“œë¼ë§ˆí‹±í•œ ë³‘íƒœìƒë¦¬ë¶€í„° **ìŠ¤íƒ€í‹´(Statin)** ì²˜ë°©ì˜ ì•Œê³ ë¦¬ì¦˜ê¹Œì§€ USMLEê°€ ì‚¬ë‘í•˜ëŠ” í•µì‹¬ í¬ì¸íŠ¸ë¥¼ ì •ë¦¬í•©ë‹ˆë‹¤.\n---\n## 2. ì½œë ˆìŠ¤í…Œë¡¤ ê²°ì • ìƒ‰ì „ì¦ (Atheroembolism / Cholesterol Crystal Embolism) ğŸ’\në‹¨ìˆœ ê³ ì§€í˜ˆì¦ê³¼ëŠ” ì°¨ì›ì´ ë‹¤ë¥¸, ë¬¼ë¦¬ì ì¸ í˜ˆê´€ íì‡„ ë¬¸ì œì…ë‹ˆë‹¤.\n### 2.1. ë³‘íƒœìƒë¦¬ (Pathophysiology)\n- **ì£½ìƒê²½í™”ë°˜(Plaque)ì˜ íŒŒì—´:** í˜ˆê´€ ë²½ì— ìŒ“ì—¬ìˆë˜ ê¸°ë¦„ ì°Œêº¼ê¸°(Plaque)ê°€ í„°ì§€ë©´ì„œ ì½œë ˆìŠ¤í…Œë¡¤ ê²°ì •ë“¤ì´ ì˜¨ëª¸ì˜ ì‘ì€ í˜ˆê´€ìœ¼ë¡œ ë‚ ì•„ê°€ ë°•íˆëŠ” í˜„ìƒì…ë‹ˆë‹¤.\n- **â˜… ìœ ë°œ ìš”ì¸ (Precipitating Factor):** ì‹¬ì¥ ë„ê´€ ì‚½ì…ìˆ (Cardiac catheterization) ë“± **í˜ˆê´€ ë‚´ ì‹œìˆ (Procedure) ì§í›„**ì— ì˜ ìƒê¹ë‹ˆë‹¤. ì¹´í…Œí„°ë‚˜ ì™€ì´ì–´ê°€ ëŒ€ë™ë§¥ ë²½ì„ íˆ­ ì¹˜ë©´ì„œ í”Œë¼í¬ë¥¼ í„°ëœ¨ë¦¬ëŠ” ê²ƒì´ì£ .\n- **ê²½ê³ :** ì‹œìˆ  í›„ ë©°ì¹  ë‚´ì— **ë‹¤ë°œì„± ì¥ê¸° ë¶€ì „(Multi-organ failure)** ì§•í›„ê°€ ë³´ì´ë©´ ë°˜ë“œì‹œ ì˜ì‹¬í•´ì•¼ í•©ë‹ˆë‹¤.\n### 2.2. ì„ìƒ ì¦ìƒ (Clinical Presentation)\nì¦ìƒì´ ì „ì‹ ì— ë‹¤ì±„ë¡­ê²Œ ë‚˜íƒ€ë‚˜ ì§„ë‹¨ì´ ì–´ë ¤ìš¸ ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n- **í”¼ë¶€:**\n    - **ë§ìƒ ìš°í˜ˆë°˜(Livedo reticularis):** ê·¸ë¬¼ ëª¨ì–‘ì˜ ì–¼ë£©ëœë£©í•œ í”¼ë¶€ ë³‘ë³€.\n    - **ì²­ìƒ‰ ë°œê°€ë½ ì¦í›„êµ°(Blue Toe Syndrome):** ë°œê°€ë½ ëì´ íŒŒë—ê²Œ ë³€í•¨ (ê´´ì‚¬).\n- **ì‹ ì¥:** ê¸‰ì„± ì‹ ì†ìƒ (Acute Kidney Injury, AKI).\n- **ë‡Œ:** ë‡Œì¡¸ì¤‘ (Stroke).\n- **ëˆˆ:** **ì¼ê³¼ì„± í‘ì•”ì‹œ(Amaurosis fugax)**. ë§ë§‰ í˜ˆê´€ì„ ë§‰ì•„ ê°‘ìê¸° ëˆˆì´ ì•ˆ ë³´ì„.\n    - **â˜… Hollenhorst Plaque:** ì•ˆì € ê²€ì‚¬ ì‹œ ë§ë§‰ ë™ë§¥ ê°ˆë¦¼ê¸¸ì— **ë…¸ë—ê³  ë°˜ì§ì´ëŠ” ê²°ì •**ì´ ë°•í˜€ìˆëŠ” ê²ƒì„ ì§ì ‘ í™•ì¸ ê°€ëŠ¥ (ê²°ì •ì  ì¦ê±°!).\n### 2.3. ì§„ë‹¨ í•µì‹¬ ë‹¨ì„œ (Diagnostic Triad) ğŸ§©","subject":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","page_title":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","episode":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","section_path":["LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec"],"source_doc_id":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","source_page":null,"source_anchor":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec-101"}
{"chunk_type":"transcript_chunk","text":"í˜ˆì•¡ ê²€ì‚¬ì—ì„œ ë†“ì¹˜ì§€ ë§ì•„ì•¼ í•  ë‘ ê°€ì§€ ë³€í™”ì™€ ë³‘ë ¥ì˜ ì¡°í•©ì…ë‹ˆë‹¤.\n1. **ì‹œìˆ  ë³‘ë ¥:** ìµœê·¼ í˜ˆê´€ ì‹œìˆ ì„ ë°›ìŒ.\n2. **ì‹ ì¥ ê¸°ëŠ¥ ì•…í™”:** í˜ˆì²­ í¬ë ˆì•„í‹°ë‹Œ(Creatinine) ìƒìŠ¹.\n3. **â˜… í˜¸ì‚°êµ¬ ì¦ê°€ì¦ (Eosinophilia):** ì½œë ˆìŠ¤í…Œë¡¤ ê²°ì •ì„ ì´ë¬¼ì§ˆë¡œ ì¸ì‹í•˜ì—¬ ì—¼ì¦ ë°˜ì‘ì´ ì¼ì–´ë‚¨. (í˜ˆì•¡ ë° ì†Œë³€ì—ì„œë„ ê²€ì¶œ ê°€ëŠ¥)\n### 2.4. í™•ì§„ ë° ì¹˜ë£Œ\n- **í™•ì§„ (Biopsy):** ì¹¨ë²”ëœ ì¡°ì§(í”¼ë¶€, ì‹ ì¥) ìƒê²€ ì‹œ **\"ë°”ëŠ˜ ëª¨ì–‘ ê· ì—´ (Needle-shaped clefts)\"** ê´€ì°°. (ì¡°ì§ ì²˜ë¦¬ ê³¼ì •ì—ì„œ ê²°ì •ì´ ë…¹ì•„ ì—†ì–´ì§€ê³  ë‚¨ì€ ë¹ˆ ê³µê°„)\n- **ì¹˜ë£Œ:** ì´ë¯¸ ë°•íŒ ê²°ì •ì„ ë…¹ì¼ íŠ¹íš¨ì•½ì€ ì—†ìŒ.\n    - ì§€ì§€ ìš”ë²• (í˜ˆì•• ì¡°ì ˆ, ìˆ˜ì•¡ ê³µê¸‰).\n    - **ì¬ë°œ ë°©ì§€:** **ìŠ¤íƒ€í‹´(Statin)** ìš”ë²•ìœ¼ë¡œ ì£½ìƒê²½í™”ë°˜ ì•ˆì •í™”.\n---\n## 3. ìŠ¤íƒ€í‹´(Statin) ì¹˜ë£Œ ê°€ì´ë“œë¼ì¸ ğŸ’ŠÂ - 4 groups!\n\"ëˆ„êµ¬ì—ê²Œ ì–¸ì œ ì¤„ ê²ƒì¸ê°€?\"ê°€ í•µì‹¬ì…ë‹ˆë‹¤. í¬ê²Œ **2ì°¨ ì˜ˆë°©**ê³¼ **1ì°¨ ì˜ˆë°©**ìœ¼ë¡œ ë‚˜ë‰©ë‹ˆë‹¤.\n### 3.1. 2ì°¨ ì˜ˆë°© (Secondary Prevention): ì´ë¯¸ ë³‘ì´ ìˆëŠ” ì‚¬ëŒ\n- **ëŒ€ìƒ:** ì£½ìƒê²½í™”ì„± ì‹¬í˜ˆê´€ ì§ˆí™˜(**ASCVD**) í™˜ì (ì‹¬ê·¼ê²½ìƒ‰, í˜‘ì‹¬ì¦, ë‡Œì¡¸ì¤‘, ë§ì´ˆë™ë§¥ì§ˆí™˜ ë“±).\n- **ì¡°ì¹˜:** LDL ìˆ˜ì¹˜ì™€ ìƒê´€ì—†ì´ **ë¬´ì¡°ê±´** ìŠ¤íƒ€í‹´ ì‹œì‘.\n- **ê°•ë„:**\n    - **â‰¤ 75ì„¸:** ê³ ê°•ë„(High-intensity) ìŠ¤íƒ€í‹´.\n    - **> 75ì„¸:** ë¶€ì‘ìš© ê³ ë ¤í•˜ì—¬ ì¤‘ê°•ë„(Moderate-intensity) ìŠ¤íƒ€í‹´.\n### 3.2. 1ì°¨ ì˜ˆë°© (Primary Prevention): ì•„ì§ ë³‘ì€ ì—†ëŠ” ì‚¬ëŒ\nìœ„í—˜ë„ì— ë”°ë¼ 3ê°€ì§€ ê·¸ë£¹ìœ¼ë¡œ ë‚˜ë‰©ë‹ˆë‹¤.\n| ê·¸ë£¹ | ê¸°ì¤€ (Criteria) | ì¡°ì¹˜ (Action) |\n| --- | --- | --- |\n| **LDL í­íƒ„í˜•** | **LDL â‰¥ 190 mg/dL** | ìœ ì „ì  ì†Œì¸ ì˜ì‹¬. **ì¦‰ì‹œ ê³ ê°•ë„ ìŠ¤íƒ€í‹´**. |\n| **ë‹¹ë‡¨ë³‘ í™˜ì** | **40~75ì„¸ + ë‹¹ë‡¨ë³‘ (DM)** | **ë¬´ì¡°ê±´ ìŠ¤íƒ€í‹´**. (10ë…„ ìœ„í—˜ë„ â‰¥ 20%ë©´ ê³ ê°•ë„, ì•„ë‹ˆë©´ ì¤‘ê°•ë„) |\n| **ê³ ìœ„í—˜êµ°** | **40~75ì„¸ + ë‹¹ë‡¨ ì—†ìŒ** | **10ë…„ ASCVD ìœ„í—˜ë„ ê³„ì‚°.\nâ‰¥ 7.5%:** ìŠ¤íƒ€í‹´ ê³ ë ¤.\n**â‰¥ 20%:** ê³ ê°•ë„ ìŠ¤íƒ€í‹´ ê¶Œê³ . |\n---\n## 4. ìŠ¤íƒ€í‹´ ë¶€ì‘ìš© ê´€ë¦¬ (Adverse Effects) âš ï¸\n### 4.1. ê·¼ìœ¡í†µ (Myalgia) - í”í•¨\n- **ì¦ìƒ:** ê·¼ìœ¡ë§Œ ì•„í””. ê·¼ìœ¡ íš¨ì†Œ ìˆ˜ì¹˜(CK)ëŠ” ì •ìƒ.\n- **ëŒ€ì²˜:** ì•½ì„ ë°”ë¡œ ëŠì§€ ì•ŠìŒ.\n    - ë‹¤ë¥¸ ì¢…ë¥˜ì˜ ìŠ¤íƒ€í‹´ìœ¼ë¡œ ë³€ê²½ (ì˜ˆ: Atorvastatin $\\rightarrow$ Rosuvastatin).\n    - ìš©ëŸ‰ì„ ì¤„ì´ê±°ë‚˜ ê²©ì¼ ë³µìš© ì‹œë„.\n### 4.2. íš¡ë¬¸ê·¼ìœµí•´ì¦ (Rhabdomyolysis) - ë“œë¬¼ì§€ë§Œ ì‹¬ê°\n- **ì¦ìƒ:** ê·¹ì‹¬í•œ ê·¼ìœ¡í†µ + ì½œë¼ìƒ‰ ì†Œë³€.\n- **ì§„ë‹¨:** **CK ìˆ˜ì¹˜ê°€ ì •ìƒì˜ 10ë°° ì´ìƒ ìƒìŠ¹** + ì‹ ë¶€ì „ ë™ë°˜.\n- **ëŒ€ì²˜:** **ì¦‰ì‹œ íˆ¬ì—¬ ì¤‘ë‹¨** (ì˜êµ¬ì  ì¤‘ë‹¨).\n- *Tip:* ê²©í•œ ìš´ë™(ë§ˆë¼í†¤ ë“±) í›„ ì¼ì‹œì  CK ìƒìŠ¹ì€ íš¡ë¬¸ê·¼ìœµí•´ì¦ê³¼ êµ¬ë³„ í›„ ì¬íˆ¬ì—¬ ê°€ëŠ¥.\n---\n## 5. ì¤‘ì„±ì§€ë°© (Triglyceride, TG) ê´€ë¦¬ ì „ëµ ğŸ”","subject":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","page_title":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","episode":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","section_path":["LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec"],"source_doc_id":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","source_page":null,"source_anchor":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec-121"}
{"chunk_type":"transcript_chunk","text":"ê´€ë¦¬ì˜ ëª©í‘œê°€ ì‹¬ì¥ì´ ì•„ë‹ ìˆ˜ë„ ìˆìŠµë‹ˆë‹¤.\n- **TG > 1000 mg/dL:**\n    - **â˜… ìµœìš°ì„  ëª©í‘œ:** **ê¸‰ì„± ì·Œì¥ì—¼(Acute Pancreatitis)** ì˜ˆë°©. (ì‹¬ì¥ë³‘ ì˜ˆë°©ë³´ë‹¤ ì‹œê¸‰í•¨)\n    - **ì¹˜ë£Œ:** Fibrates, ì˜¤ë©”ê°€-3(Fish oil), ê¸ˆì£¼, ì²´ì¤‘ ê°ëŸ‰.\n- **TG 150 ~ 500 mg/dL:**\n    - **ì¹˜ë£Œ:** ìƒí™œìŠµê´€ êµì •(ì²´ì¤‘ ê°ëŸ‰, ìš´ë™, **ì ˆì£¼**)ì´ ì™•ë„.\n    - ì¡°ì ˆ ì•ˆ ë˜ê±°ë‚˜ ê³ ìœ„í—˜êµ°ì¸ ê²½ìš° ìŠ¤íƒ€í‹´ ì¶”ê°€ ê³ ë ¤.\n---\n## 6. ê¸‰ì„± ê´€ìƒë™ë§¥ ì¦í›„êµ° (ACS)ê³¼ ìŠ¤íƒ€í‹´ ğŸš‘\nì‘ê¸‰ì‹¤ì— ì˜¨ ì‹¬ê·¼ê²½ìƒ‰(ACS) í™˜ìì—ê²Œ ê³ ìš©ëŸ‰ ìŠ¤íƒ€í‹´ì„ ì“°ëŠ” ì§„ì§œ ì´ìœ .\n- **ëª©ì :** ë‹¨ìˆœ LDL ì €í•˜ê°€ ì•„ë‹˜.\n- **ê¸°ì „:** **í”Œë¼í¬ ì•ˆì •í™” (Plaque Stabilization).**\n    - ê°•ë ¥í•œ **í•­ì—¼ì¦ ì‘ìš©(Anti-inflammatory)**ìœ¼ë¡œ í˜ˆê´€ ë‚´ ì—¼ì¦ì„ ì–µì œ.\n    - í”Œë¼í¬ì˜ ê»ì§ˆ(Cap)ì„ ë‘ê»ê²Œ ë§Œë“¤ì–´ ì¶”ê°€ íŒŒì—´ì„ ë§‰ìŒ (\"ì†Œë°©ìˆ˜ ì—­í• \" ğŸš’).\n- **ê²°ë¡ :** LDL ìˆ˜ì¹˜ í™•ì¸ ì „ì´ë¼ë„ ACS í™˜ìì—ê²ŒëŠ” **ì¦‰ì‹œ ê³ ìš©ëŸ‰ ìŠ¤íƒ€í‹´** íˆ¬ì—¬.\n---\n## 7. ìƒí™œìŠµê´€ êµì • (Lifestyle Modifications) ğŸ¥—\n- **ì§€ì¤‘í•´ì‹ ì‹ë‹¨ (Mediterranean Diet):** ì˜¬ë¦¬ë¸Œìœ , ìƒì„ , ê²¬ê³¼ë¥˜ ì¤‘ì‹¬. ì‹¬í˜ˆê´€ ê±´ê°•ì— ì¢‹ìŒ.\n- **DASH ì‹ë‹¨:** ì§€ì¤‘í•´ì‹ê³¼ ìœ ì‚¬ + **ì €ë‚˜íŠ¸ë¥¨ (Low Sodium)**. ê³ í˜ˆì•• í™˜ìì—ê²Œ íŠ¹í™”.\n---","subject":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","page_title":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","episode":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","section_path":["LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec"],"source_doc_id":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","source_page":null,"source_anchor":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec-141"}
{"chunk_type":"recap_summary","text":"# ğŸ”¥ Rapid Fire Recap: Must-Know High Yield Summary\n### 1. Atheroembolism (Cholesterol Crystal Embolism)\n- **Scenario:** ìµœê·¼ í˜ˆê´€ ì‹œìˆ (Angio) ë°›ìŒ $\\rightarrow$ ë°œê°€ë½ íŒŒë˜ì§(Blue toe) + ì½©íŒ¥ ë§ê°€ì§(AKI).\n- **Key Triad:** Procedure history + AKI + **Eosinophilia**.\n- **Pathology:** Needle-shaped clefts.\n- **Eye Find:** Hollenhorst plaque (retinal cholesterol crystal).\n### 2. Statin Indications (4 Groups)\n1. **ASCVD History:** ë¬´ì¡°ê±´ Start (â‰¤75ì„¸ High, >75ì„¸ Moderate).\n2. **LDL â‰¥ 190:** ë¬´ì¡°ê±´ High intensity.\n3. **Diabetes (40-75ì„¸):** ë¬´ì¡°ê±´ Start.\n4. **High Risk (40-75ì„¸):** 10-year risk â‰¥ 7.5%ë©´ ê³ ë ¤.\n### 3. Hypertriglyceridemia\n- **TG > 1000:** **Pancreatitis** ì˜ˆë°©ì´ 1ìˆœìœ„. (Rx: Fibrates).\n- **TG 150-500:** Lifestyle (íŠ¹íˆ **ê¸ˆì£¼**) $\\rightarrow$ Statin.\n### 4. ACS Management\n- **Action:** ER ì˜¤ìë§ˆì High-dose Statin.\n- **Why?** **Plaque Stabilization** (Anti-inflammatory effect), not just lipid lowering.\n# ğŸ«€ USMLE Step 2: ì‹¬í˜ˆê´€ ê³ ì†ë„ë¡œ ì™„ì „ ì •ë³µ (Aorta & Carotid)","subject":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","page_title":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","episode":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","section_path":["LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec"],"source_doc_id":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","source_page":null,"source_anchor":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec-151"}
{"chunk_type":"transcript_chunk","text":"### ğŸ§ 0. Verification (ë°›ì•„ì“°ê¸°)\n**0:00 ~ 0:30 êµ¬ê°„ ë°›ì•„ì“°ê¸°:**\n\"USMLE Step 2 ì‹œí—˜ì„ ì¤€ë¹„í•˜ê³  ê³„ì‹  ë‹¹ì‹ ì„ ìœ„í•œ ë§ì¶¤í˜• ë¶„ì„, ì§€ê¸ˆ ë°”ë¡œ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ë³´ë‚´ì£¼ì‹  ë°©ëŒ€í•œ ì‹¬í˜ˆê´€ ìë£Œë¥¼ ë³´ë‹ˆê¹ìš”, ì´ê²Œ ê¼­ ìš°ë¦¬ ëª¸ì†ì˜ ê±°ëŒ€í•œ ê³ ì†ë„ë¡œ ì§€ë„ë¥¼ ë³´ëŠ” ê²ƒ ê°™ë”ë¼ê³ ìš”. ì•„, ê·¸ê±° ì•„ì£¼ ì¢‹ì€ ë¹„ìœ ë„¤ìš”. ê·¸ë ‡ì£ . ê·¸ë˜ì„œ ì˜¤ëŠ˜ì€ ê·¸ì¤‘ì—ì„œë„ ê°€ì¥ ì¤‘ìš”í•œ ê°„ì„ ë„ë¡œ ë°”ë¡œ ëŒ€ë™ë§¥ê³¼ ë‡Œë¡œ í–¥í•˜ëŠ” í•µì‹¬ ë‚˜ë“¤ëª©ì´ì£ , ê²½ë™ë§¥ì— ë”± ì§‘ì¤‘í•´ ë³´ë ¤ê³  í•©ë‹ˆë‹¤. ë„¤ ë§ìŠµë‹ˆë‹¤. ë‹¨ìˆœíˆ ì§ˆë³‘ ì´ë¦„ë§Œ ì™¸ìš°ëŠ” ê²Œ ì•„ë‹ˆë¼...\"\n---\n## 1. Introduction: ìš°ë¦¬ ëª¸ì˜ ê³ ì†ë„ë¡œì™€ ì‚¬ê³  ìœ í˜• ğŸ›£ï¸\nì´ë²ˆ ê°•ì˜ëŠ” ì‹¬í˜ˆê´€ê³„ë¥¼ **'ê³ ì†ë„ë¡œ ì§€ë„'**ì— ë¹„ìœ í•˜ì—¬ ì„¤ëª…í•©ë‹ˆë‹¤. ë‹¨ìˆœíˆ ë³‘ëª…ì„ ì™¸ìš°ëŠ” ê²ƒì´ ì•„ë‹ˆë¼, ë„ë¡œì—ì„œ ë²Œì–´ì§€ëŠ” **ì‚¬ê³ ì˜ ìœ í˜•(ë³‘íƒœìƒë¦¬)**ì„ ì´í•´í•˜ë©´ ê³µë¶€ê°€ í›¨ì”¬ ì‰¬ì›Œì§‘ë‹ˆë‹¤.\n- **ë„ë¡œê°€ ì°¢ì–´ì§:** ë°•ë¦¬ (Dissection)\n- **ë„ë¡œê°€ ì•½í•´ì ¸ì„œ í’ì„ ì²˜ëŸ¼ ë¶€í’‚:** ë™ë§¥ë¥˜ (Aneurysm)\n- **êµí†µ ì²´ì¦ìœ¼ë¡œ ê½‰ ë§‰í˜:** íì‡„/í˜‘ì°© (Occlusion/Stenosis)\n---\n## 2. ëŒ€ë™ë§¥ ë°•ë¦¬ (Aortic Dissection) âš¡\nëŒ€ë™ë§¥ ë²½ì˜ ë‚´ë§‰(Intima)ì´ ì°¢ì–´ì ¸ í˜ˆì•¡ì´ íŒŒê³ ë“¤ë©° **ê°€ì§œ í†µë¡œ(False Lumen)**ë¥¼ ë§Œë“œëŠ” ì§ˆí™˜ì…ë‹ˆë‹¤.\n### ğŸš© í•µì‹¬ ì¦ìƒ ë° ìœ„í—˜ ì¸ì\n- **ì „í˜•ì  ì¦ìƒ:** ë“±(Back)ìœ¼ë¡œ ë»—ì¹˜ëŠ” ì°¢ì–´ì§€ëŠ” ë“¯í•œ í‰í†µ.\n- **ìœ„í—˜ ì¸ì:** ê³ í˜ˆì••, ë§ˆë¥´íŒ ì¦í›„êµ°(Marfan Syndrome).\n- **â˜… USMLE TRAP (í•¨ì •): ë§¥ë°• ê²°ì†(Pulse Deficit)**\n    - ì–‘íŒ” í˜ˆì•• ì°¨ì´(>20mmHg)ë‚˜ ë§¥ë°• ì•½í™”ëŠ” **í™˜ìì˜ 20~30%ì—ì„œë§Œ ê´€ì°°**ë¨.\n    - ë§¥ë°• ê²°ì†ì´ ì—†ë‹¤ê³  í•´ì„œ ë°•ë¦¬ë¥¼ ë°°ì œí•˜ë©´ **ì˜¤ì§„ì˜ ëŠª**ì— ë¹ ì§!\n### ğŸ¥ ì§„ë‹¨ ì „ëµ: í˜ˆì—­í•™ì  ì•ˆì •ì„±(Hemodynamic Stability)ì´ ê¸°ì¤€!\ní™˜ìê°€ ì§€ê¸ˆ ë‹¹ì¥ ì£½ëŠëƒ ì‚¬ëŠëƒ(Shock ìƒíƒœ)ì— ë”°ë¼ ê²€ì‚¬ë²•ì´ ê°ˆë¦½ë‹ˆë‹¤.\n| í™˜ì ìƒíƒœ | ì¶”ì²œ ê²€ì‚¬ | ì´ìœ  |\n| --- | --- | --- |\n| **ë¶ˆì•ˆì • (Unstable)** | **ê²½ì‹ë„ ì‹¬ì´ˆìŒíŒŒ (Bedside TEE)** | ì‘ê¸‰ì‹¤/ìˆ˜ìˆ ì‹¤ì—ì„œ ë°”ë¡œ ì‹œí–‰ ê°€ëŠ¥. CT ì°ìœ¼ëŸ¬ ê°ˆ ì‹œê°„ ì—†ìŒ! |\n| **ì•ˆì • (Stable)** | **í‰ë¶€ CT (Angio)** | ê°€ì¥ ì •í™•í•˜ê³  ë¹ ë¦„. ëŒ€ë™ë§¥ ì „ì²´ ì¡°ë§ ê°€ëŠ¥. |\n| **ì•ˆì • + ì˜ˆì™¸** | **MRI** | ì•„ì£¼ ë¹„ì‘ê¸‰ ìƒí™©, ì¥ì‹œê°„ ëˆ„ì›Œìˆì„ ìˆ˜ ìˆì„ ë•Œë§Œ ì œí•œì  ì‚¬ìš©. |\n### âš ï¸ ë¬´ì„œìš´ í•©ë³‘ì¦ (ê°€ì§œ í†µë¡œê°€ ì–´ë””ë¥¼ ë§‰ëŠëƒ?)\n- **ì‹ ì¥ ë™ë§¥:** ê¸‰ì„± ì‹ ë¶€ì „\n- **ì¥ê°„ë§‰ ë™ë§¥:** ì¥ í—ˆí˜ˆ (ê·¹ì‹¬í•œ ë³µí†µ)\n- **ì²™ìˆ˜ í˜ˆê´€:** í•˜ë°˜ì‹  ë§ˆë¹„\n---\n## 3. ë³µë¶€ ëŒ€ë™ë§¥ë¥˜ (AAA: Abdominal Aortic Aneurysm) ğŸˆ\nì˜¤ë˜ëœ íƒ€ì´ì–´ì²˜ëŸ¼ í˜ˆê´€ë²½ì´ ì•½í•´ì ¸ ë¶€í’€ì–´ ì˜¤ë¥´ëŠ” ì§ˆí™˜ì…ë‹ˆë‹¤.\n### ğŸš© ì¦ìƒ ë° ì§„ë‹¨","subject":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","page_title":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","episode":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","section_path":["LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec"],"source_doc_id":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","source_page":null,"source_anchor":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec-161"}
{"chunk_type":"transcript_chunk","text":"- **ì¦ìƒ:** ëŒ€ë¶€ë¶„ ë¬´ì¦ìƒ (ê±´ê°•ê²€ì§„ ë°œê²¬). ë°•ë™ì„± ë³µë¶€ ì¢…ê´´(Pulsatile Mass)ê°€ ë§Œì ¸ì§ˆ ìˆ˜ ìˆìŒ.\n- **â˜… ì—°ê´€ ì§ˆí™˜:** ë¬´ë¦ ë’¤ ì˜¤ê¸ˆë™ë§¥(Popliteal)ì´ë‚˜ í—ˆë²…ì§€ ëŒ€í‡´ë™ë§¥(Femoral)ì˜ ë™ë§¥ë¥˜ë„ í•¨ê»˜ ìˆì„ ê°€ëŠ¥ì„± ë†’ìŒ.\n### ğŸš¨ íŒŒì—´ ì˜ì‹¬ ì‹œë‚˜ë¦¬ì˜¤ (Rupture)\n- **ì¦ìƒ:** ë³µí†µ + ì €í˜ˆì••(Hypotension) = **ì‹œí•œí­íƒ„ì´ í„°ì§„ ê²ƒ!**\n- **ì¡°ì¹˜:** **ì¦‰ì‹œ ìˆ˜ìˆ ì‹¤ ì´ë™** (CT ì°ì§€ ì•ŠìŒ!) â¡ï¸ ì´ë™ ì¤‘ ì¹¨ìƒ ì˜† ë³µë¶€ ì´ˆìŒíŒŒ(FAST)ë¡œ ì¶œí˜ˆ/ë™ë§¥ë¥˜ í™•ì¸.\n### ğŸ“ í¬ê¸°ë³„ ê´€ë¦¬ ì „ëµ (ì•ˆì •ì ì¸ í™˜ì)\nì•ˆì •ì ì¸ í™˜ìë¼ë©´ **ë³µë¶€ CT**ë¡œ ì •í™•í•œ í¬ê¸°ì™€ ëª¨ì–‘ì„ íŒŒì•… í›„ ê³„íšì„ ì„¸ì›ë‹ˆë‹¤.\n| ë™ë§¥ë¥˜ í¬ê¸° / ìƒíƒœ | ì¡°ì¹˜ ì „ëµ |\n| --- | --- |\n| **> 5.5 cm** | **ìˆ˜ìˆ  (Surgery)** |\n| **ë¹ ë¥¸ ì„±ì¥** | **ìˆ˜ìˆ ** (6ê°œì›” ë‚´ 0.5cm ì´ìƒ ì„±ì¥ ì‹œ) |\n| **ìœ ì¦ìƒ** | **ìˆ˜ìˆ ** (ë³µí†µ ë“± ì¦ìƒì´ ìˆìœ¼ë©´ íŒŒì—´ ì „ì¡°) |\n| **4.0 ~ 5.4 cm** | 6~12ê°œì›”ë§ˆë‹¤ ì´ˆìŒíŒŒ ì¶”ì  ê´€ì°° |\n| **< 4.0 cm** | 2~3ë…„ë§ˆë‹¤ ì´ˆìŒíŒŒ ì¶”ì  ê´€ì°° |\n---\n## 4. ëŒ€ë™ë§¥ ì¶•ì°© (Coarctation of the Aorta) â°\n\"ì •ì› í˜¸ìŠ¤ê°€ ì¤‘ê°„ì— ë°Ÿí˜€ì„œ ê¼¬ì¸ ìƒí™©\"ê³¼ ê°™ìŠµë‹ˆë‹¤. ê¼¬ì¸ ë¶€ë¶„ ì „í›„ë¡œ ì••ë ¥ ì°¨ì´ê°€ ë°œìƒí•©ë‹ˆë‹¤.\n### ğŸš© ë³‘íƒœìƒë¦¬ ë° ì¦ìƒ\n- **ìƒì²´ (High Pressure):** ë‘í†µ, ì½”í”¼ (ê³ í˜ˆì••)\n- **í•˜ì²´ (Low Pressure):** ë‹¤ë¦¬ íŒŒí–‰ (í˜ˆì•¡ ê³µê¸‰ ë¶€ì¡±)\n- **ì§„ë‹¨ ë‹¨ì„œ:**\n    - ìƒì²´ í˜ˆì•• > í•˜ì²´ í˜ˆì••\n    - ìš”ê³¨-ëŒ€í‡´ ë§¥ë°• ì§€ì—° (Radio-femoral delay)\n    - **Rib Notching (ëŠ‘ê³¨ í•¨ëª°):** ìš°íšŒë„ë¡œ(Collateral)ê°€ ì»¤ì ¸ì„œ ëŠ‘ê³¨ ì•„ë˜ë¥¼ íŒŒë¨¹ìŒ (CXR ì†Œê²¬).\n    - **3 Sign:** ëŒ€ë™ë§¥ì˜ 3ì ëª¨ì–‘ ìŒì˜.\n- **ê´€ë ¨ ì§ˆí™˜:** í„°ë„ˆ ì¦í›„êµ°(Turner Syndrome), ì´ì²¨íŒ ëŒ€ë™ë§¥íŒë§‰(Bicuspid Aortic Valve).\n### ğŸ‘¶ ì‹ ìƒì•„ vs ì„±ì¸\n- **ì‹ ìƒì•„:** ë™ë§¥ê´€(PDA)ì— ì˜ì¡´í•˜ì—¬ í•˜ì²´ë¡œ í”¼ë¥¼ ë³´ëƒ„. ì¶œìƒ í›„ ë™ë§¥ê´€ì´ ë§‰íˆë©´ ì‡¼í¬/ì‚¬ë§ ìœ„í—˜.\n    - **ì¹˜ë£Œ:** **PGE1 (Prostaglandin E1)** íˆ¬ì—¬í•˜ì—¬ ë™ë§¥ê´€ì„ ë‹¤ì‹œ ì—´ì–´ì¤˜ì•¼ í•¨.\n- **ì„±ì¸:** ì£¼ë¡œ ìƒì²´ ê³ í˜ˆì••ìœ¼ë¡œ ë°œê²¬ë¨.\n---\n## 5. ë¥´ë¦¬ìŠˆ ì¦í›„êµ° (Leriche Syndrome) ğŸ›‘\nëŒ€ë™ë§¥ì´ ë‘ ë‹¤ë¦¬ë¡œ ê°ˆë¼ì§€ëŠ” ëë¶€ë¶„(ì¢…ì°©ì§€)ì´ ê½‰ ë§‰íŒ ë§Œì„± ì§ˆí™˜ì…ë‹ˆë‹¤ (Aortoiliac Occlusion).\n### ğŸš© 3ëŒ€ ì¦ìƒ (Classic Triad) - â˜… ì•”ê¸° í•„ìˆ˜\n1. **ì—‰ë©ì´/í—ˆë²…ì§€ íŒŒí–‰ (Claudication):** ê±¸ì„ ë•Œ ì•„í””.\n2. **ë°œê¸° ë¶€ì „ (Erectile Dysfunction/Impotence)**\n3. **ëŒ€í‡´ ë™ë§¥ ë§¥ë°• ì†Œì‹¤:** ë‹¤ë¦¬ê°€ ì°¨ê°‘ê³  ìœ„ì¶•ë¨.\n---\n## 6. ê²½ë™ë§¥ í˜‘ì°© (Carotid Artery Stenosis) ğŸ§ ","subject":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","page_title":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","episode":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","section_path":["LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec"],"source_doc_id":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","source_page":null,"source_anchor":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec-181"}
{"chunk_type":"transcript_chunk","text":"ë‡Œë¡œ ê°€ëŠ” ê¸¸ëª©ì´ ì¢ì•„ì§. ëª©í‘œëŠ” **ë‡Œì¡¸ì¤‘(Stroke) ì˜ˆë°©**ì…ë‹ˆë‹¤.\n### ğŸ’‰ ì¹˜ë£Œ ê²°ì •: ì–¸ì œ ëš«ì–´ì£¼ëŠ”ê°€? (CEA: ë‚´ë§‰ ì ˆì œìˆ )\nì¦ìƒ ìœ ë¬´ì™€ í˜‘ì°© ì •ë„(%)ê°€ ê²°ì •ì  ê¸°ì¤€ì…ë‹ˆë‹¤.\n| í™˜ì êµ¬ë¶„ | ìˆ˜ìˆ /ì‹œìˆ  ê¸°ì¤€ | ì¹˜ë£Œ ì „ëµ |\n| --- | --- | --- |\n| **ìœ ì¦ìƒ (Symptomatic)** | **70~99% í˜‘ì°©** | **ì ê·¹ì  ìˆ˜ìˆ  (CEA) ê¶Œì¥**. (50~69%ëŠ” ë‚¨ì„±ì—ì„œ ì´ë“ì´ ë” í¼) |\n| **ë¬´ì¦ìƒ (Asymptomatic)** | **> 80% í˜‘ì°©** | ë§¤ìš° ì‹¬í•œ ê²½ìš°ì—ë§Œ ì œí•œì ìœ¼ë¡œ ìˆ˜ìˆ  ê³ ë ¤. |\n| **ê¸°ë³¸ ì¹˜ë£Œ** | ëª¨ë“  í™˜ì | ì•„ìŠ¤í”¼ë¦°, ìŠ¤íƒ€í‹´, í˜ˆì•• ì¡°ì ˆ (ì•½ë¬¼ ì¹˜ë£Œê°€ ê¸°ë³¸). |\n- *Note:* ìœ ì¦ìƒì´ë€ TIA(ì¼ê³¼ì„± í—ˆí˜ˆ ë°œì‘)ë‚˜ ë‡Œì¡¸ì¤‘ì„ ì´ë¯¸ ê²½í—˜í•œ ê²½ìš°ë¥¼ ë§í•˜ë©°, ì¬ë°œ ìœ„í—˜ì´ ë§¤ìš° ë†’ìŒ.\n---\n## 7. ê²½ë™ë§¥ ë°•ë¦¬ (Carotid Artery Dissection) âœï¸ğŸ§˜â€â™€ï¸\ní˜ˆê´€ë²½ì´ ì°¢ì–´ì§€ëŠ” ê²ƒì¸ë°, ì›ì¸ê³¼ ì¦ìƒì´ ë§¤ìš° ë…íŠ¹í•©ë‹ˆë‹¤.\n### ğŸš© ì›ì¸ ë° ì‹œë‚˜ë¦¬ì˜¤\n- **ì™¸ìƒ(Trauma):** ì…ì— ì¹«ì†”/ì—°í•„ì„ ë¬¼ê³  ë„˜ì–´ì§„ ì•„ì´, ìš”ê°€ë‚˜ ëª©ì„ ë¹„íŠ¸ëŠ” í–‰ìœ„ í›„ ë°œìƒ.\n- **ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤:** ì™¸ìƒ í›„ ëª‡ ì‹œê°„ ë’¤, ë°˜ì‹  ë§ˆë¹„ë‚˜ ì–¸ì–´ ì¥ì• (Stroke ì¦ìƒ) ë°œìƒ.\n### ğŸ‘ï¸ íŠ¹ì§•ì  ì¦ìƒ: ë¶€ë¶„ì  í˜¸ë„ˆ ì¦í›„êµ° (Partial Horner's Syndrome)\n- ì¦ìƒ: ì•ˆê²€í•˜ìˆ˜(Ptosis) + ë™ê³µìˆ˜ì¶•(Miosis)\n- **â˜… ì°¨ì´ì : ë¬´í•œì¦(Anhidrosis, ë•€ ì•ˆ ë‚¨)ì€ ì—†ìŒ!**\n    - *ì´ìœ :* ì–¼êµ´ ë•€ ë¶„ë¹„ ì‹ ê²½ì€ ì™¸ê²½ë™ë§¥ì„ ë”°ë¼ê°€ê³ , ëˆˆ ê´€ë ¨ ì‹ ê²½ì€ ë‚´ê²½ë™ë§¥ì„ ë”°ë¼ê°€ê¸° ë•Œë¬¸. (ë°•ë¦¬ëŠ” ì£¼ë¡œ ë‚´ê²½ë™ë§¥ì—ì„œ ë°œìƒ)\n### ğŸ¥ ì§„ë‹¨ ë° ì¹˜ë£Œ\n- **ì§„ë‹¨:** **CT Angio** (ê°€ì¥ ë¹ ë¥´ê³  ì •í™•).\n- **ì¹˜ë£Œ:** **í•­ì‘ê³ ì œ/í•­í˜ˆì†ŒíŒì œ** (ì°¢ì–´ì§„ ë²½ì— ìƒê¸´ í˜ˆì „ì´ ë‡Œë¡œ ë‚ ì•„ê°€ëŠ” ê²ƒì„ ë°©ì§€).\n---","subject":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","page_title":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","episode":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","section_path":["LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec"],"source_doc_id":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","source_page":null,"source_anchor":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec-201"}
{"chunk_type":"recap_summary","text":"## ğŸ”¥ Rapid Fire Recap: Must-Know Summary\n1. **Aortic Dissection (ëŒ€ë™ë§¥ ë°•ë¦¬)**\n    - ì°¢ì–´ì§€ëŠ” í‰í†µ + **Unstable** ğŸ‘‰ **Bedside TEE**\n    - ì°¢ì–´ì§€ëŠ” í‰í†µ + **Stable** ğŸ‘‰ **CT Angio**\n    - Trap: **Pulse Deficit**ì€ ì—†ëŠ” ê²½ìš°ê°€ ë” ë§ë‹¤!\n2. **AAA (ë³µë¶€ ëŒ€ë™ë§¥ë¥˜)**\n    - ë³µí†µ + ì €í˜ˆì•• (Rupture) ğŸ‘‰ **ì¦‰ì‹œ ìˆ˜ìˆ ì‹¤ + Bedside US** (CT âŒ)\n    - ìˆ˜ìˆ  ê¸°ì¤€: **>5.5cm**, ë¹ ë¥¸ ì„±ì¥(>0.5cm/6mo), ìœ ì¦ìƒ.\n3. **Coarctation (ëŒ€ë™ë§¥ ì¶•ì°©)**\n    - **íŒ” í˜ˆì•• > ë‹¤ë¦¬ í˜ˆì••**, Rib Notching.\n    - Neonate Shock ğŸ‘‰ **PGE1** (ë™ë§¥ê´€ ì—´ì–´ë¼!)\n4. **Leriche Syndrome**\n    - **Triad:** ì—‰ë©ì´ í†µì¦ + ë°œê¸°ë¶€ì „ + ëŒ€í‡´ë§¥ë°• ì†Œì‹¤.\n5. **Carotid Stenosis (ê²½ë™ë§¥ í˜‘ì°©)**\n    - **Symptomatic (ìœ ì¦ìƒ)**: 70% ì´ìƒ ë§‰íˆë©´ **CEA (ìˆ˜ìˆ )**.\n    - Asymptomatic (ë¬´ì¦ìƒ): ì•½ë¬¼ì¹˜ë£Œ ìš°ì„ , 80% ì´ìƒì¼ ë•Œë§Œ ìˆ˜ìˆ  ê³ ë ¤.\n6. **Carotid Dissection (ê²½ë™ë§¥ ë°•ë¦¬)**\n    - Trauma (ì—°í•„, ìš”ê°€) + **Partial Horner's** (ë•€ì€ ë‚¨!) + Stroke ì¦ìƒ.\n    - ì§„ë‹¨: CT Angio / ì¹˜ë£Œ: í•­ì‘ê³ ì œ.\n> ğŸ’¡ Core Philosophy: ì‘ê¸‰ ìƒí™©ì—ì„œì˜ ì§„ë‹¨ ì•Œê³ ë¦¬ì¦˜ì€ \"ê°€ì¥ ì •í™•í•œ ê²€ì‚¬\"ê°€ ì•„ë‹ˆë¼ **\"ìƒëª…ì„ ì‚´ë¦¬ëŠ” ê°€ì¥ ë¹ ë¥´ê³  ì•ˆì „í•œ ê²€ì‚¬\"**ê°€ ì •ë‹µì´ ë©ë‹ˆë‹¤. (e.g., Unstable Patient -> Bedside Tool)\n>","subject":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","page_title":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","episode":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","section_path":["LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec"],"source_doc_id":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec","source_page":null,"source_anchor":"LM_cardio 1 2f346f2986ee80e3baf9e27d823f4aec-215"}
{"chunk_type":"transcript_chunk","text":"# LM_cardio 2 5~\n**Verification: Audio Dictation (0:00 ~ 0:30)**\n> \"USMLE Step 2 ì‹œí—˜ì—ì„œ ì–´... ì •ë§ ì¤‘ìš”í•œ ê³ ë¹„ ì¤‘ í•˜ë‚˜ì£ . ì‹¬ê·¼ê²½ìƒ‰, MIì— ëŒ€í•´ ì•„ì£¼ ê¹Šì´ íŒŒê³ ë“¤ì–´ë³´ê² ìŠµë‹ˆë‹¤. ì§€ê¸ˆ ë‹¹ì‹ ì´ ì‘ê¸‰ì‹¤ì— ìˆë‹¤ê³  í•œë²ˆ ìƒìƒí•´ë³´ì„¸ìš”. í‰í†µì„ í˜¸ì†Œí•˜ëŠ” í™˜ìê°€ ë§‰ ë“¤ì–´ì™”ê³ , ì´ì œ ëª¨ë“  ê²°ì • í•˜ë‚˜í•˜ë‚˜ê°€ í™˜ìì˜ ìƒëª…ê³¼ ì§ê²°ë˜ëŠ” ê·¸ëŸ° ê¸´ë°•í•œ ìƒí™©ì…ë‹ˆë‹¤. ì˜¤ëŠ˜ë¶€í„° ë‘ ë²ˆì— ê±¸ì³ì„œ ì´ ì‹¬ê·¼ê²½ìƒ‰ì„ ë¶„ì„í•´ë³¼ í…ë°, ê·¸ ì²« ì‹œê°„ì€ ë°”ë¡œ ì´ ì‘ê¸‰ ìƒí™©ì—ì„œ ì‹œì‘í•˜ê² ìŠµë‹ˆë‹¤. ì§„ë‹¨ë¶€í„° ê¸‰ì„±ê¸° ì¹˜ë£Œ...\"\n>\n---\n# ğŸ©º USMLE Step 2 ì‹¬ì¥ë‚´ê³¼: ì‹¬ê·¼ê²½ìƒ‰(MI) ì™„ì „ ì •ë³µ (Part 1. ê¸‰ì„±ê¸° ê´€ë¦¬)\n## 1. Introduction: ì‘ê¸‰ì‹¤ ì‹œë‚˜ë¦¬ì˜¤ì™€ ì§„ë‹¨ì˜ ê°ˆë¦¼ê¸¸ ğŸš‘\ní™˜ìê°€ í‰í†µ(Chest Pain)ì„ í˜¸ì†Œí•˜ë©° ì‘ê¸‰ì‹¤ì— ë„ì°©í–ˆìŠµë‹ˆë‹¤. ì „í˜•ì ì¸ í‰í†µ ì™¸ì—ë„ í˜¸í¡ê³¤ë€, ë©”ìŠ¤êº¼ì›€ ê°™ì€ ë¹„ì „í˜•ì  ì¦ìƒë„ ìˆì„ ìˆ˜ ìˆìŠµë‹ˆë‹¤. ì´ë•Œ ê°€ì¥ ë¨¼ì € í•´ì•¼ í•  ì¼ì€ ë¬´ì—‡ì¼ê¹Œìš”?\n### ğŸš© ì§„ë‹¨ì˜ ê±°ëŒ€í•œ ë¶„ê¸°ì \nëª¨ë“  ê²ƒì€ **ECG(ì‹¬ì „ë„)**ì™€ **Troponin(ì‹¬ì¥ íš¨ì†Œ)** ìˆ˜ì¹˜ì—ì„œ ì‹œì‘ë©ë‹ˆë‹¤.\n- **ECG ì°ìë§ˆì ê²°ì •ë˜ëŠ” ìš´ëª…**\n    - **ST ë¶„ì ˆ ìƒìŠ¹ (ST Elevation)** ë˜ëŠ” **ìƒˆë¡œìš´ ì¢Œê°ì°¨ë‹¨(New LBBB)** ë°œê²¬ ğŸ“‰\n    - ğŸ‘‰ **STEMI (ST-Elevation MI)** ì§„ë‹¨!\n    - ğŸ‘‰ **Action:** ì¦‰ì‹œ 'Code Red'. ë§‰íŒ í˜ˆê´€ì„ ëš«ê¸° ìœ„í•œ ê¸´ê¸‰ ì¬ê´€ë¥˜ ìš”ë²•(Reperfusion) íŒ€ í˜¸ì¶œ. ê³ ë¯¼í•  ì‹œê°„ ì—†ìŒ!\n- **ST ìƒìŠ¹ì´ ì—†ë‹¤ë©´?** (Code RedëŠ” ì•„ë‹˜, ì •êµí•œ ì§„ë‹¨ í•„ìš”)\n    - **Troponin ìƒìŠ¹ â¬†ï¸:** ì‹¬ì¥ ê·¼ìœ¡ ì†ìƒì˜ ì¦ê±° ìˆìŒ ğŸ‘‰ **NSTEMI** (Non-ST-Elevation MI)\n    - **Troponin ì •ìƒ â†”ï¸** but **ECGìƒ í—ˆí˜ˆì„± ë³€í™”(ST í•˜ê°• ë“±):** ğŸ‘‰ **ë¶ˆì•ˆì • í˜‘ì‹¬ì¦ (Unstable Angina)**\n> ğŸ’¡ ê°œë… ì •ë¦¬: ê¸‰ì„± ê´€ìƒë™ë§¥ ì¦í›„êµ° (ACS)\n> \n> - **STEMI**\n> - **NSTEMI**\n> - **ë¶ˆì•ˆì • í˜‘ì‹¬ì¦ (Unstable Angina)**\n> ì´ 3ê°€ì§€ë¥¼ í†µí‹€ì–´ **ACS**ë¼ê³  ë¶€ë¦…ë‹ˆë‹¤.\n---\n## 2. ì´ˆê¸° ì•½ë¬¼ ì¹˜ë£Œ: í™”ì¬ í˜„ì¥ì˜ ì†Œë°© í˜¸ìŠ¤ë“¤ ğŸš’ğŸ’Š\nì§„ë‹¨(STEMI vs NSTEMI/UA)ê³¼ ìƒê´€ì—†ì´ **ì´ˆê¸° ì•½ë¬¼ ì¹˜ë£ŒëŠ” ê±°ì˜ ë™ì¼**í•˜ê²Œ ë“¤ì–´ê°‘ë‹ˆë‹¤. ê° ì•½ë¬¼ì€ ì„œë¡œ ë‹¤ë¥¸ ê°ë„ì—ì„œ ì‹¬ì¥ì„ ê³µê²©í•˜ëŠ” ë¬¸ì œë“¤ì„ í•´ê²°í•©ë‹ˆë‹¤.\n| ì•½ë¬¼ (Drug) | ì‘ìš© ê¸°ì „ (Mechanism) | â˜… ì£¼ì˜ì‚¬í•­/ì„ìƒì  ì˜ë¯¸ |\n| --- | --- | --- |\n| **ì§ˆì‚°ì—¼ (Nitrates)** | ê´€ìƒë™ë§¥ í™•ì¥ â†’ í˜ˆë¥˜ ê°œì„ , ì‹¬ì¥ ë¶€ë‹´ ê°ì†Œ | ì €í˜ˆì••ì´ë‚˜ **ìš°ì‹¬ì‹¤(RV) ê²½ìƒ‰** ì˜ì‹¬ ì‹œ ê¸ˆê¸° ğŸš« |\n| **ë² íƒ€ ì°¨ë‹¨ì œ (Beta-blockers)** | ì‹¬ë°•ìˆ˜/ìˆ˜ì¶•ë ¥ ê°ì†Œ â†’ **ì‹¬ê·¼ ì‚°ì†Œ ìš”êµ¬ëŸ‰ ê°ì†Œ** (í˜ì´ìŠ¤ ì¡°ì ˆ) | ì‹¬ì¸ì„± ì‡¼í¬, ì‹¬ë°•ìˆ˜ê°€ ë„ˆë¬´ ëŠë¦¬ê±°ë‚˜ ì‹¬ë¶€ì „ ì‹¬í•  ë•Œ ê¸ˆê¸° |\n| **í•­í˜ˆì†ŒíŒì œ (Anti-platelets)** | í˜ˆì „ì˜ 'ë²½ëŒ' í˜•ì„± ì–µì œ (Aspirin + P2Y12 ì–µì œì œ) | í˜ˆì†ŒíŒ í™œì„± ì°¨ë‹¨ |\n| **í•­ì‘ê³ ì œ (Anti-coagulants)** | í˜ˆì „ì˜ 'ê·¸ë¬¼(Fibrin)' í˜•ì„± ì–µì œ (Heparin ë“±) | í˜ˆì „ì´ ë” ì»¤ì§€ê±°ë‚˜ ìƒˆë¡œ ìƒê¸°ëŠ” ê²ƒ ì›ì²œ ë´‰ì‡„ |\n| **â˜… ìŠ¤íƒ€í‹´ (High-dose Statin)** | **Plaque ì•ˆì •í™” (Stabilization)** | ë‹¨ìˆœ ì½œë ˆìŠ¤í…Œë¡¤ ì €í•˜ ëª©ì  ì•„ë‹˜! ì—¼ì¦ì„ ê°€ë¼ì•‰íˆê³  **í„°ì§€ê¸° ì§ì „ì˜ í”Œë¼í¬ ê»ì§ˆì„ ë‹¨ë‹¨í•˜ê²Œ** ë§Œë“¦. |\n---\n## 3. ì¹˜ë£Œ ì „ëµì˜ ê°ˆë¦¼ê¸¸: ì‹œê°„ê³¼ì˜ ì‹¸ì›€ vs íƒì • ìˆ˜ì‚¬ ğŸ•µï¸â€â™‚ï¸\n### A. STEMI: ì‹œê°„ì€ ê³§ ê·¼ìœ¡ì´ë‹¤ (Time is Muscle) ğŸ’ª\në§‰íŒ í˜ˆê´€ì„ ë¬¼ë¦¬ì ìœ¼ë¡œ ëš«ëŠ” ê²ƒì´ ìœ ì¼í•œ í•´ë‹µì…ë‹ˆë‹¤.\n1. **Gold Standard: PCI (ê²½í”¼ì  ê´€ìƒë™ë§¥ ì¤‘ì¬ìˆ )**\n    - í’ì„ ê³¼ ìŠ¤í…íŠ¸ë¡œ í˜ˆê´€ ë„“íˆê¸°.\n    - **ëª©í‘œ ì‹œê°„:** ì˜ë£Œì§„ ì ‘ì´‰ í›„ **90ë¶„ ì´ë‚´**!\n2. **Plan B: í˜ˆì „ ìš©í•´ìˆ  (Thrombolytics)**\n    - PCI ì‹œì„¤ì´ ì—†ê±°ë‚˜ ì´ì†¡ì— **120ë¶„ ì´ìƒ** ì†Œìš”ë  ë•Œ.\n    - ì•½ë¬¼ë¡œ í˜ˆì „ì„ ë…¹ì„ (ì¶œí˜ˆ ìœ„í—˜ ê°ìˆ˜).","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-1"}
{"chunk_type":"transcript_chunk","text":"### B. NSTEMI / Unstable Angina: ìœ„í—˜ë„ í‰ê°€ (Risk Stratification)\nECGê°€ ëª…í™•í•œ ë‹µì„ ì£¼ì§€ ì•Šìœ¼ë¯€ë¡œ, í™˜ìì˜ **ìœ„í—˜ë„**ë¥¼ ë¨¼ì € í‰ê°€í•´ì•¼ í•©ë‹ˆë‹¤. ì´ë•Œ ì‚¬ìš©í•˜ëŠ” ë„êµ¬ê°€ **TIMI Risk Score**ì…ë‹ˆë‹¤.\n### ğŸ“Š TIMI Risk Score (0~7ì ) - 7ê°€ì§€ í•­ëª©\n1. ë‚˜ì´ **65ì„¸** ì´ìƒ\n2. CAD ìœ„í—˜ì¸ì **3ê°œ** ì´ìƒ (ê³ í˜ˆì••, ë‹¹ë‡¨, í¡ì—° ë“±)\n3. ê¸°ì¡´ ê´€ìƒë™ë§¥ í˜‘ì°© **50%** ì´ìƒ\n4. ìµœê·¼ 7ì¼ ë‚´ **ì•„ìŠ¤í”¼ë¦°** ë³µìš©\n5. 24ì‹œê°„ ë‚´ ì‹¬í•œ **í˜‘ì‹¬ì¦ 2íšŒ** ì´ìƒ\n6. **Troponin** ìƒìŠ¹\n7. ECGìƒ **ST í¸ìœ„ > 0.5mm**\n### ğŸš¦ ì ìˆ˜ì— ë”°ë¥¸ ì „ëµ\n- **ì €ìœ„í—˜êµ° (0~2ì ):** ì•½ë¬¼ ì¹˜ë£Œ + ë¹„ì¹¨ìŠµì  ê²€ì‚¬(ì‹¬ì¥ì´ˆìŒíŒŒ, ìŠ¤íŠ¸ë ˆìŠ¤ í…ŒìŠ¤íŠ¸)ë¡œ ê´€ì°°.\n- **ê³ ìœ„í—˜êµ° (3ì  ì´ìƒ):** **24ì‹œê°„ ë‚´ ê´€ìƒë™ë§¥ ì¡°ì˜ìˆ ** â†’ í•„ìš”ì‹œ PCI.\n- **â˜… ì˜ˆì™¸ (ì´ˆê³ ìœ„í—˜):** ì ìˆ˜ì™€ ìƒê´€ì—†ì´ **í˜ˆì—­í•™ì  ë¶ˆì•ˆì •(ì‡¼í¬, ë¶€ì •ë§¥, ë‚œì¹˜ì„± í‰í†µ)**ì´ ìˆìœ¼ë©´ ì§€ì²´ ì—†ì´ **ì‘ê¸‰ PCI**!\n---\n## 4. ECGì™€ ì‹¬ì¥ í•´ë¶€í•™ì˜ ì—°ê²° (Localization) ğŸ—ºï¸\nì–´ëŠ í˜ˆê´€ì´ ë§‰í˜”ëŠ”ì§€ ECG ë¦¬ë“œë¡œ ì•Œ ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n| ê²½ìƒ‰ ë¶€ìœ„ | ê´€ë ¨ í˜ˆê´€ (Artery) | ECG ë¦¬ë“œ (Leads) |\n| --- | --- | --- |\n| **ì „ë²½ (Anterior)** | ì¢Œì „í•˜í–‰ì§€ (**LAD**) | **V1 ~ V6** (ê´‘ë²”ìœ„í•œ ST ìƒìŠ¹) |\n| **í•˜ë²½ (Inferior)** | ìš°ê´€ìƒë™ë§¥(**RCA**) or ì¢ŒíšŒì„ ì§€(LCX) | **II, III, aVF** |\n| **ì¸¡ë²½ (Lateral)** | ì¢ŒíšŒì„ ì§€ (**LCX** or branches) | **I, aVL, V5, V6** |\n| **í›„ë²½ (Posterior)** | - | **V1~V3**ì—ì„œ ê±°ìš¸ìƒ(Mirror image)ì¸ **ST í•˜ê°•** |\n---\n## 5. â˜… ìš°ì‹¬ì‹¤ ê²½ìƒ‰ (RV MI): USMLE ê³ ë“ì ì˜ ì—´ì‡  ğŸ”‘\n**í•˜ë²½ ê²½ìƒ‰(Inferior MI)** í™˜ìì˜ 50%ì—ì„œ ë™ë°˜ë©ë‹ˆë‹¤. **ì¹˜ë£Œë²•ì´ ì •ë°˜ëŒ€**ì´ë¯€ë¡œ ë°˜ë“œì‹œ êµ¬ë³„í•´ì•¼ í•©ë‹ˆë‹¤!\n- **ê¸°ì „:** ìš°ì‹¬ì‹¤ íŒí”„ ê³ ì¥ â†’ íë¡œ í”¼ë¥¼ ëª» ë³´ëƒ„ â†’ ì¢Œì‹¬ì‹¤ë¡œ ë“¤ì–´ì˜¤ëŠ” í”¼(Preload) ê°ì†Œ â†’ **ì €í˜ˆì•• ì‡¼í¬**.\n- **íŠ¹ì§•:** íëŠ” ê¹¨ë—í•¨(Clear lungs) + ëª© ì •ë§¥ í™•ì¥(JVD).\n- **ì§„ë‹¨:** **ìš°ì¸¡ í‰ë¶€ ìœ ë„ (V4R)**ì—ì„œ ST ìƒìŠ¹ í™•ì¸.\n- **â˜… ì¹˜ë£Œì˜ í•µì‹¬ (Trap):**\n    - **ê¸ˆê¸° ğŸš«:** Nitrates, Diuretics (ì „ë¶€í•˜ë¥¼ ê¹ì•„ë¨¹ìœ¼ë©´ í™˜ì ì‚¬ë§ ìœ„í—˜).\n    - **ì¹˜ë£Œ âœ…:** **ìˆ˜ì•¡(Saline) ê³µê¸‰!** (ê°•ì œë¡œ ë°€ì–´ ë„£ì–´ì„œ ì „ë¶€í•˜ ìœ ì§€).\n---\n## 6. í‡´ì› í›„ ì¥ê¸° ê´€ë¦¬: 5ê°€ì§€ ë°©ì–´ ìš”ìƒˆ (The Fortress) ğŸ°\nì¬ë°œ ë°©ì§€ë¥¼ ìœ„í•œ ìµœì ì˜ ì•½ë¬¼ ê´€ë¦¬ (Optimal Medical Therapy).\n1. **ì´ì¤‘ í•­í˜ˆì†ŒíŒ ìš”ë²• (DAPT):** Aspirin(í‰ìƒ) + P2Y12 ì–µì œì œ(12ê°œì›”). í•´ì(Moat)ë¥¼ íŒŒì„œ í˜ˆì „ ìƒì„± ì°¨ë‹¨.\n2. **ë² íƒ€ ì°¨ë‹¨ì œ (Beta-blockers):** ì„±ë²½ ìœ„ì˜ íŒŒìˆ˜ê¾¼. ë¶€ì •ë§¥ ê°ì‹œ ë° ì‹¬ì¥ ê³¼ë¶€í•˜ ë°©ì§€.\n3. **ACEi / ARB:** ì‹¬ì¥ **ë¦¬ëª¨ë¸ë§(Remodeling)** ë°©ì§€. ì‹¬ì¥ êµ¬ì¡° ë³€í˜•(ë²½ ì–‡ì•„ì§, í’ì„ ì²˜ëŸ¼ ëŠ˜ì–´ë‚¨)ì„ ë§‰ì•„ ì‹¬ë¶€ì „ ì˜ˆë°©. (íŠ¹íˆ LVEF ì €í•˜ ì‹œ í•„ìˆ˜).\n4. **ê³ ìš©ëŸ‰ ìŠ¤íƒ€í‹´ (High-intensity Statin):** ë¬´ë„ˆì§„ ì„±ë²½ ë³´ìˆ˜. ì „ì‹ ì˜ ë™ë§¥ê²½í™”ë°˜ ì•ˆì •í™”.\n5. **ì•Œë„ìŠ¤í…Œë¡  ê¸¸í•­ì œ (MRA):** ì‹¬ë¶€ì „/ë‹¹ë‡¨ ë™ë°˜ ì‹œ ì¶”ê°€í•˜ì—¬ ë¦¬ëª¨ë¸ë§ ì´ì¤‘ ì–µì œ.\n---","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-21"}
{"chunk_type":"recap_summary","text":"## ğŸ”¥ Rapid Fire Recap: High Yield Summary\n- **ì§„ë‹¨:** ST ìƒìŠ¹ ìˆë‚˜ìš”?\n    - **YES** â†’ **STEMI** â†’ **90ë¶„ ë‚´ PCI** (ì•ˆë˜ë©´ 120ë¶„ ë‚´ í˜ˆì „ìš©í•´ì œ).\n    - **NO** â†’ Troponin í™•ì¸ â†’ ìƒìŠ¹ì‹œ **NSTEMI** / ì •ìƒì´ë©´ **UA** â†’ **TIMI Score**ë¡œ ì‹œìˆ  ì‹œê¸° ê²°ì •.\n- **ì´ˆê¸° ì•½ë¬¼ (MONA-BS):** Morphine(í•„ìš”ì‹œ), O2(ì €ì‚°ì†Œì‹œ), **Nitrates**, **Aspirin**, **Beta-blocker**, **Statin**.\n- **â˜… í•¨ì • (RV MI):** II, III, aVF ìƒìŠ¹(í•˜ë²½ ê²½ìƒ‰) + ì €í˜ˆì••? â†’ **RV MI ì˜ì‹¬!** â†’ **Nitroglycerin ì ˆëŒ€ ê¸ˆê¸° âŒ** â†’ **ìˆ˜ì•¡(Fluid) ì¤˜ë¼ ğŸ’§**.\n- **ì¥ê¸° ì˜ˆí›„:** ì‹¬ì¥ ë¦¬ëª¨ë¸ë§ ë°©ì§€ì•½ë¬¼ = **ACE inhibitors / ARBs**.\n**(ë‹¤ìŒ í™” ì˜ˆê³ )**: ê¸°ê³„ì  í•©ë³‘ì¦(ì‹¬ì¥ë²½ êµ¬ë©, íŒë§‰ íŒŒì—´)ê³¼ ì „ê¸°ì  í•©ë³‘ì¦(ë¶€ì •ë§¥), ê·¸ë¦¬ê³  ST ìƒìŠ¹ì´ ì‚¬ë¼ì§€ì§€ ì•ŠëŠ” ê²½ìš°(ì‹¬ì‹¤ë¥˜)ì— ëŒ€í•´ ë‹¤ë£¹ë‹ˆë‹¤.\n# ì‹¬ê·¼ê²½ìƒ‰ ì‹œë¦¬ì¦ˆ Part 2: í­í’ ì „ì˜ ê³ ìš”, ì•ˆì •í˜• í˜‘ì‹¬ì¦ (Stable Angina) ì •ë³µí•˜ê¸°\n**0:00~0:30 êµ¬ê°„ ë°›ì•„ì“°ê¸° (Verification)**\n\"ì•ˆë…•í•˜ì„¸ìš”, ì‹¬ê·¼ ê²½ìƒ‰ ì‹œë¦¬ì¦ˆ ê·¸ ë‘ ë²ˆì§¸ ì‹œê°„ì…ë‹ˆë‹¤. ë„¤, ì•ˆë…•í•˜ì„¸ìš”. ì§€ë‚œë²ˆì—ëŠ” ì €í¬ê°€ ì‹¬ê·¼ ê²½ìƒ‰ì˜ ì•„ì£¼ í° ê·¸ë¦¼ì„ í•œë²ˆ ê·¸ë ¤ë´¤ë‹¤ë©´, ì˜¤ëŠ˜ì€ ê·¸ í­í’ì „ì˜ ê³ ìš”ë¼ê³  í• ê¹Œìš”? ì•„, ì¢‹ì€ í‘œí˜„ì´ë„¤ìš”. ë„¤, ì–¸ì œë“  í­í’ìœ¼ë¡œ ë³€í•  ìˆ˜ ìˆëŠ” ì•ˆì •í˜• í˜‘ì‹¬ì¦ì„ ì œëŒ€ë¡œ í•œë²ˆ íŒŒí—¤ì³ë³´ê² ìŠµë‹ˆë‹¤. ì¢‹ìŠµë‹ˆë‹¤. USMLE ì‹œí—˜ì—ì„œ, ìŒ, ì˜ˆë¥¼ ë“¤ì–´ 58ì„¸ ë‚¨ì„± í™˜ìê°€ ê³„ë‹¨ë§Œ ì˜¤ë¥´ë©´ ê°€ìŠ´ì´ ë»ê·¼í•´ìš”ë¼ê³  í•  ë•Œ ë¨¸ë¦¿ì†ì´ í•˜ì–˜ì¡Œë˜ ê²½í—˜ ë‹¤ë“¤ ìˆìœ¼ì‹œì£ ?\"\n---\n## 1. Introduction: í­í’ ì „ì˜ ê³ ìš” ğŸŒªï¸\nì´ ê°•ì˜ëŠ” ê¸‰ì„± ê´€ìƒë™ë§¥ ì¦í›„êµ°(ACS)ì´ë¼ëŠ” 'í­í’'ì´ ì˜¤ê¸° ì „, **ì•ˆì •í˜• í˜‘ì‹¬ì¦(Stable Angina)** ë‹¨ê³„ì—ì„œ í™˜ìë¥¼ ì–´ë–»ê²Œ ì§„ë‹¨í•˜ê³  ê´€ë¦¬í•´ì•¼ í•˜ëŠ”ì§€ì— ëŒ€í•œ ëª…í™•í•œ ë¡œë“œë§µì„ ì œì‹œí•©ë‹ˆë‹¤. ì‘ê¸‰ ìƒí™©ì€ ì•„ë‹ˆì§€ë§Œ, ê¸¸ì„ ì˜ëª» ë“¤ë©´ ë°”ë¡œ ì‘ê¸‰ìœ¼ë¡œ ì´ì–´ì§ˆ ìˆ˜ ìˆëŠ” ì¤‘ìš”í•œ ë‹¨ê³„ì…ë‹ˆë‹¤.\n---","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-40"}
{"chunk_type":"transcript_chunk","text":"## 2. ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤ ë° í†µì¦ì˜ ê°ë³„ ğŸ¥\n**ğŸ“ í™˜ì ì¼€ì´ìŠ¤:**\n- **í™˜ì:** 58ì„¸ ë‚¨ì„±\n- **ê³¼ê±°ë ¥:** ê³ í˜ˆì••, í¡ì—° ğŸš¬\n- **ì£¼í˜¸ì†Œ:** ì–¸ë•ì„ ì˜¤ë¥¼ ë•Œë§ˆë‹¤ ê°€ìŠ´ì„ ì¥ì–´ì§œëŠ” ëŠë‚Œ. 5ë¶„ ì‰¬ë©´ ê´œì°®ì•„ì§.\n### 2-1. í‰í†µ í‰ê°€ì˜ 3ê°€ì§€ ì²´í¬ë¦¬ìŠ¤íŠ¸ (Diamond-Forrester Classification)\nì´ ì„¸ ê°€ì§€ê°€ 'ë§ŒëŠ¥ ì—´ì‡ 'ì…ë‹ˆë‹¤. ğŸ—ï¸\n1. **í†µì¦ì˜ ìœ„ì¹˜ì™€ ì–‘ìƒ:** ê°€ìŠ´ ì¤‘ì•™ì´ ë»ê·¼í•˜ê³  ì¥ì–´ì§œëŠ” ë“¯í•œê°€? (Substernal, Squeezing)\n2. **ìœ ë°œ ìš”ì¸:** ìš´ë™ì´ë‚˜ ìŠ¤íŠ¸ë ˆìŠ¤ ìƒí™©ì—ì„œ ìƒê¸°ëŠ”ê°€? (Exertion) ğŸƒ\n3. **ì™„í™” ìš”ì¸:** ì‰¬ë©´ ë‚˜ì•„ì§€ëŠ”ê°€? (Rest/Nitroglycerin) ğŸ›Œ\n| ë¶„ë¥˜ | ê¸°ì¤€ ì¶©ì¡± ìˆ˜ | ì„ìƒì  ì˜ë¯¸ |\n| --- | --- | --- |\n| **ì „í˜•ì  í˜‘ì‹¬ì¦ (Typical Angina)** | **3ê°€ì§€ ëª¨ë‘** | ì‹¬ì¥ ë¬¸ì œì¼ ê°€ëŠ¥ì„± ë§¤ìš° ë†’ìŒ (êµê³¼ì„œì  ì‚¬ë¡€) |\n| **ë¹„ì „í˜•ì  í˜‘ì‹¬ì¦ (Atypical Angina)** | 2ê°€ì§€ | ì‹¬ì¥ ë¬¸ì œ ê°€ëŠ¥ì„± ê³ ë ¤ |\n| **ë¹„í˜‘ì‹¬ì¦ì„± í‰í†µ (Non-anginal Pain)** | 1ê°€ì§€ ì´í•˜ | ì‹¬ì¥ ë¬¸ì œ ì•„ë‹ ê°€ëŠ¥ì„± ë†’ìŒ |\n### 2-2. ê°ë³„í•´ì•¼ í•  ë‹¤ë¥¸ ì§ˆí™˜ë“¤ (Differential Diagnosis)\ní‰í†µì˜ ì›ì¸ì€ ë‹¤ì–‘í•˜ë¯€ë¡œ ì–‘ìƒì— ë”°ë¼ ê°ë³„ì´ í•„ìš”í•©ë‹ˆë‹¤.\n- **ëŒ€ë™ë§¥ ë°•ë¦¬ (Aortic Dissection):** í†µì¦ì´ ì°¢ì–´ì§€ëŠ” ë“¯í•˜ë©° ë“± ìª½ìœ¼ë¡œ ë»—ì¹¨. âš¡\n- **ì‹ë„ ì—­ë¥˜ (GERD):** ì‹ì‚¬ í›„ë‚˜ ëˆ„ì› ì„ ë•Œ ì‹¬í•´ì§. ì œì‚°ì œë¡œ í˜¸ì „. ğŸ’Š\n- **ê·¼ê³¨ê²©ê³„ ì§ˆí™˜:** ì›€ì§ì„ì´ë‚˜ ì••í†µê³¼ ê´€ë ¨.\n---\n## 3. ìœ„í—˜ ì¸ìì™€ ìœ„í—˜ ë“±ê°€ë¬¼ (Risk Factors & Equivalents) âš ï¸\n### 3-1. í™•ë¦½ëœ ìœ„í—˜ ì¸ì\n- ë‚˜ì´ (ë‚¨ì„± >45ì„¸, ì—¬ì„± >55ì„¸), ê³ í˜ˆì••, í¡ì—°, ê°€ì¡±ë ¥, ì´ìƒì§€ì§ˆí˜ˆì¦.\n### 3-2. â˜… ìœ„í—˜ ë“±ê°€ë¬¼ (Risk Equivalents) â˜…\nì´ ì§ˆí™˜ì´ ìˆìœ¼ë©´ **\"ì´ë¯¸ ê´€ìƒë™ë§¥ ì§ˆí™˜ì´ ìˆëŠ” ê²ƒê³¼ ë™ê¸‰\"**ìœ¼ë¡œ ì·¨ê¸‰í•˜ì—¬ ê°•ë ¥í•˜ê²Œ ê´€ë¦¬í•´ì•¼ í•©ë‹ˆë‹¤.\n- **ë‹¹ë‡¨ë³‘ (Diabetes):** ğŸ­\n    - *ë¹„ìœ :* ë†’ì€ í˜ˆë‹¹ì´ í˜ˆê´€ ë‚´ë²½ì„ **'ì‚¬í¬'**ì²˜ëŸ¼ ê¸ì–´ëŒ€ì–´ ë¯¸ì„¸í•œ ì†ìƒê³¼ ì—¼ì¦ì„ ëŠì„ì—†ì´ ì¼ìœ¼í‚´.\n- ë§Œì„± ì‹ ì¥ ì§ˆí™˜ (CKD)\n- ë§ì´ˆ ë™ë§¥ ì§ˆí™˜ (PAD)\n---\n## 4. â˜… ì§„ë‹¨ ì•Œê³ ë¦¬ì¦˜ì˜ í•µì‹¬: ì‚¬ì „ ê²€ì‚¬ í™•ë¥  (Pre-test Probability) ğŸ“Š\nUSMLEê°€ í…ŒìŠ¤íŠ¸í•˜ê³ ì í•˜ëŠ” í•µì‹¬ ì—­ëŸ‰ì…ë‹ˆë‹¤. ë¬´ì¡°ê±´ ê²€ì‚¬ë¥¼ í•˜ëŠ” ê²ƒì´ ì•„ë‹ˆë¼, **í™˜ìì˜ ë‚˜ì´, ì„±ë³„, ì¦ìƒì˜ ì „í˜•ì„±**ì„ ì¢…í•©í•˜ì—¬ í™•ë¥ ì„ ë¨¼ì € ì˜ˆì¸¡í•´ì•¼ í•©ë‹ˆë‹¤.","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-50"}
{"chunk_type":"transcript_chunk","text":"1. **ì €ìœ„í—˜êµ° (Low Probability):** ì¦ìƒ ì—†ëŠ” ì Šì€ ì—¬ì„± ë“± â†’ ê²€ì‚¬ ë¶ˆí•„ìš” (ìœ„ì–‘ì„± ê°€ëŠ¥ì„±).\n2. **ê³ ìœ„í—˜êµ° (High Probability):** 50ëŒ€ ì´ìƒ ë‚¨ì„± + ì „í˜•ì  ì¦ìƒ â†’ **ì§„ë‹¨ì´ ê±°ì˜ ë‚´ë ¤ì§„ ê²ƒê³¼ ê°™ìŒ.** ë°”ë¡œ ì•½ë¬¼ ì¹˜ë£Œ ì‹œì‘ Â± ê´€ìƒë™ë§¥ ì¡°ì˜ìˆ  ê³ ë ¤.\n3. **â˜… ì¤‘ê°„ í™•ë¥ êµ° (Intermediate Probability):** ì§„ë‹¨ ê²€ì‚¬ê°€ ê°€ì¥ í•„ìš”í•œ ì§‘ë‹¨. â†’ **ë¶€í•˜ ê²€ì‚¬(Stress Test)** ì‹œí–‰.\n---\n## 5. ë¶€í•˜ ê²€ì‚¬ (Stress Test) ì„ íƒ ê°€ì´ë“œ ğŸƒâ€â™‚ï¸ğŸ’“\n\"ì–´ë–¤ ë¶€í•˜ ê²€ì‚¬ë¥¼ í•  ê²ƒì¸ê°€?\"ëŠ” ë”± **ë‘ ê°€ì§€ ì§ˆë¬¸**ìœ¼ë¡œ ê²°ì •ë©ë‹ˆë‹¤.\n| ì§ˆë¬¸ 1: ìš´ë™ ê°€ëŠ¥í•œê°€? (Running machine) | ì§ˆë¬¸ 2: ì•ˆì • ì‹œ ì‹¬ì „ë„(ECG)ê°€ ê¹¨ë—í•œê°€? | ì„ íƒí•´ì•¼ í•  ê²€ì‚¬ | ë¹„ê³  |\n| --- | --- | --- | --- |\n| **YES** ğŸ™†â€â™‚ï¸ | **YES** ğŸ™†â€â™‚ï¸ | **ìš´ë™ ë¶€í•˜ ì‹¬ì „ë„ (Exercise ECG)** | ê°€ì¥ ê¸°ë³¸, ì €ë ´í•¨ |\n| **YES** ğŸ™†â€â™‚ï¸ | **NO** ğŸ™…â€â™‚ï¸ (ì´ë¯¸ ì´ìƒ ìˆìŒ) | **ìš´ë™ ë¶€í•˜ + ì˜ìƒ ê²€ì‚¬** | ì‹¬ì´ˆìŒíŒŒ(Echo) or í•µì˜í•™ ì˜ìƒ |\n| **NO** ğŸ™…â€â™‚ï¸ (ê´€ì ˆì—¼ ë“±) | ìƒê´€ì—†ìŒ | **ì•½ë¬¼ ë¶€í•˜ + ì˜ìƒ ê²€ì‚¬** | ì•½ë¬¼ë¡œ ì‹¬ì¥ì„ ë›°ê²Œ í•¨ |\n### ğŸš¨ ì¤‘ìš” ê²½ê³  (The Trap) ğŸš¨\n- **ê²€ì‚¬ ì „ 48ì‹œê°„ ì¤‘ë‹¨ ì•½ë¬¼:** ë² íƒ€ ì°¨ë‹¨ì œ(BB), ì¹¼ìŠ˜ ì±„ë„ ì°¨ë‹¨ì œ(CCB), ì§ˆì‚°ì—¼ ì œì œ(Nitrates).\n    - *ì´ìœ :* ì´ ì•½ë“¤ì€ ì‹¬ë°•ìˆ˜ë‚˜ í˜ˆì••ì„ ë‚®ì¶° **ê²€ì‚¬ ê²°ê³¼(í—ˆí˜ˆ ì†Œê²¬)ë¥¼ ìœ„ìŒì„±(False Negative)ìœ¼ë¡œ ë§Œë“¤ ìˆ˜ ìˆìŒ.** ğŸ’ŠğŸš«\n- **ê³ ìœ„í—˜ ì†Œê²¬ ë°œìƒ ì‹œ:** ë‚®ì€ ê°•ë„ì˜ ìš´ë™ì—ë„ ì‹¬ì „ë„ ë³€í™”(ST ë¶„ì ˆ ë³€í™”)ë‚˜ í˜ˆì•• ì €í•˜ ë°œìƒ ì‹œ â†’ **ì¦‰ì‹œ ê´€ìƒë™ë§¥ ì¡°ì˜ìˆ (Coronary Angiography) ì‹œí–‰.**\n---\n## 6. ì¹˜ë£Œ ì „ëµ: Two Track Attack âš”ï¸\n### Track 1: ì†Œë°©ìˆ˜ (Firefighter) ğŸš’\n- **ì—­í• :** ë‹¹ì¥ ë°œìƒí•œ í‰í†µ(ë¶ˆ)ì„ ë„ëŠ” ì—­í• .\n- **ì•½ë¬¼:** **ì„¤í•˜ ë‹ˆíŠ¸ë¡œê¸€ë¦¬ì„¸ë¦° (Sublingual Nitroglycerin).**\n### Track 2: ê±´ì„¤íŒ€ (Construction Team) ğŸ‘·â€â™‚ï¸\n- **ì—­í• :** 24ì‹œê°„ ë‚´ë‚´ í˜ˆê´€ë²½ì„ ë³´ê°•í•˜ê³ , í˜ˆì••ì„ ë‚®ì¶”ê³ , í˜ˆì „ ìƒì„±ì„ ë§‰ì•„ 'ì§‘ì´ ë¬´ë„ˆì§€ëŠ” ê²ƒ(ì‹¬ê·¼ê²½ìƒ‰)'ì„ ì˜ˆë°©.\n- **í•µì‹¬ ì¸ë ¥ (1ì°¨ ì¹˜ë£Œì œ): â˜… ë² íƒ€ ì°¨ë‹¨ì œ (Beta-Blocker) â˜…**\n    - *í˜„ì¥ ì´ê°ë…:* ì‹¬ë°•ìˆ˜ì™€ ìˆ˜ì¶•ë ¥ì„ ì¤„ì—¬ ì‹¬ì¥ì˜ ì‚°ì†Œ ìš”êµ¬ëŸ‰ì„ ë‚®ì¶¤. ìƒì¡´ë¥  í–¥ìƒ ì…ì¦.\n- **ëŒ€ì²´ ì¸ë ¥ (ë² íƒ€ ì°¨ë‹¨ì œ ë¶ˆê°€ ì‹œ): ì¹¼ìŠ˜ ì±„ë„ ì°¨ë‹¨ì œ (CCB)**\n    1. **Non-Dihydropyridine ê³„ì—´ (Verapamil, Diltiazem):** *ì‹¬ì¥ ì „ë¬¸ ìƒë‹´ì‚¬.* ì‹¬ì¥ì— ì§ì ‘ ì‘ìš©í•´ ì§„ì •ì‹œí‚´ (ì‹¬ë°•ìˆ˜/ìˆ˜ì¶•ë ¥ ê°ì†Œ).\n    2. **Dihydropyridine ê³„ì—´ (Amlodipine ë“±):** *ë„ë¡œ êµí†µ ì •ë¦¬ ì „ë¬¸ê°€.* ë§ì´ˆ í˜ˆê´€ì„ í™•ì¥í•´ í˜ˆì••ì„ ë‚®ì¶¤.\n- **ì¶”ê°€ ìš”ì›:** ì§ˆì‚°ì—¼ ì œì œ (ì¥ê¸° ë³µìš©ìš©), ë¼ë†€ë¼ì§„ (Ranolazine, ë¶ˆì‘ì„±ì¼ ë•Œ).\n---\n## 7. íŠ¹ë³„ ì¼€ì´ìŠ¤: ë³€ì´í˜• í˜‘ì‹¬ì¦ (Vasospastic/Prinzmetal's Angina) ğŸ©¸\nì•ˆì •í˜• í˜‘ì‹¬ì¦ê³¼ëŠ” **ì™„ì „íˆ ë‹¤ë¥¸ ë³‘**ì…ë‹ˆë‹¤.\n- **ì›ì¸:** í˜ˆê´€ ë‚´ í”Œë¼í¬(ê¸°ë¦„ë•Œ)ê°€ ì•„ë‹ˆë¼ **í˜ˆê´€ íŒŒì´í”„ ìì²´ê°€ ì¥ì–´ì§œë“¯ ìˆ˜ì¶•(Spasm)**í•˜ëŠ” ê²ƒ. ğŸ’«\n- **íŠ¹ì§•:**\n    - ì Šì€ í™˜ì, í¡ì—°ì ğŸš¬.\n    - ìš´ë™ê³¼ ë¬´ê´€í•˜ê²Œ **ìƒˆë²½ì´ë‚˜ ì•„ì¹¨, ì‰¬ê³  ìˆì„ ë•Œ** í‰í†µ ë°œìƒ.\n    - ê´€ìƒë™ë§¥ ì¡°ì˜ìˆ  ìƒ í˜ˆê´€ì€ ê¹¨ë—í•¨.\n    - í†µì¦ ì‹œ ì¼ì‹œì  **ST ë¶„ì ˆ ìƒìŠ¹ (ST Elevation).** ğŸ“ˆ\n- **ì¹˜ë£Œ:**\n    - **ì¹¼ìŠ˜ ì±„ë„ ì°¨ë‹¨ì œ (CCB):** í˜ˆê´€ ìˆ˜ì¶• ì˜ˆë°©.\n    - ë‹ˆíŠ¸ë¡œê¸€ë¦¬ì„¸ë¦° (ê¸‰ì„±ê¸°).\n- **â˜ ï¸ ì¹˜ëª…ì  í•¨ì • (USMLE Trap):**\n    - **â˜… ë² íƒ€ ì°¨ë‹¨ì œ (Beta-Blocker) ê¸ˆê¸° â˜…**\n    - *ì´ìœ :* ë² íƒ€ ìˆ˜ìš©ì²´ë¥¼ ë§‰ìœ¼ë©´ ìƒëŒ€ì ìœ¼ë¡œ ì•ŒíŒŒ ìˆ˜ìš©ì²´ì˜ ì‘ìš©ì´ ê°•í•´ì ¸ **í˜ˆê´€ ìˆ˜ì¶•ì„ ì˜¤íˆë ¤ ì•…í™”**ì‹œí‚¬ ìˆ˜ ìˆìŒ (Propranolol ë“± ì£¼ì˜).\n---","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-70"}
{"chunk_type":"recap_summary","text":"## 8. Rapid Fire Recap (Must-Know Summary) ğŸ”¥\n1. **ì§„ë‹¨ í”„ë ˆì„ì›Œí¬:** í‰í†µì˜ 3ìš”ì†Œ(ìœ„ì¹˜/ì–‘ìƒ, ìœ ë°œ, ì™„í™”) í™•ì¸ â†’ **3/3ì´ë©´ Typical Angina.**\n2. **ì§„ë‹¨ ê²€ì‚¬ ê²°ì •:** ì‚¬ì „ ê²€ì‚¬ í™•ë¥ (Pre-test Probability)ì´ **ì¤‘ê°„(Intermediate)**ì¸ í™˜ìì—ê²Œ **ë¶€í•˜ ê²€ì‚¬(Stress Test)** ì‹œí–‰.\n3. **ë¶€í•˜ ê²€ì‚¬ ì„ íƒë²•:**\n    - ìš´ë™ ê°€ëŠ¥? ECG ì •ìƒ? â†’ ë‘˜ ë‹¤ YESë©´ **Exercise ECG.**\n    - í•˜ë‚˜ë¼ë„ NOë©´ â†’ Imaging ì¶”ê°€ í˜¹ì€ ì•½ë¬¼ ë¶€í•˜.\n4. **ê²€ì‚¬ ì „ ì£¼ì˜:** **BB, CCB, Nitrates 48ì‹œê°„ ì¤‘ë‹¨** (ìœ„ìŒì„± ë°©ì§€).\n5. **ì¹˜ë£Œì˜ í•µì‹¬:**\n    - ì¦ìƒ ì¡°ì ˆ(ì†Œë°©ìˆ˜) â†’ **Nitroglycerin.**\n    - ì‚¬ë§ë¥  ê°ì†Œ/ì˜ˆë°©(ê±´ì„¤íŒ€) â†’ **Beta-Blocker** (1st line).\n6. **ë³€ì´í˜• í˜‘ì‹¬ì¦(Vasospastic):** ìƒˆë²½ íœ´ì‹ ì‹œ í†µì¦ + ST ìƒìŠ¹. ì¹˜ë£ŒëŠ” **CCB**. **BBëŠ” ì ˆëŒ€ ê¸ˆê¸°!** âŒ\n**ë‹¤ìŒ ì‹œê°„ ì˜ˆê³ :** ì•ˆì •ì ì¸ ìƒíƒœê°€ ê¹¨ì§€ê³  ì˜ˆì¸¡ ë¶ˆê°€ëŠ¥í•œ ê³µí¬ë¡œ ë°”ë€ŒëŠ” **ê¸‰ì„± ê´€ìƒë™ë§¥ ì¦í›„êµ°(ACS)**, ê·¸ì¤‘ì—ì„œë„ ë¶ˆì•ˆì • í˜‘ì‹¬ì¦ê³¼ ì‹¬ê·¼ê²½ìƒ‰ì— ëŒ€í•´ ë‹¤ë£¹ë‹ˆë‹¤.\n# USMLE Step 2 ì‹¬ê·¼ê²½ìƒ‰(MI) ì™„ì „ ì •ë³µ: í•©ë³‘ì¦, ì§„ë‹¨, ê·¸ë¦¬ê³  ê´€ë¦¬ (3ë¶€ì‘ì˜ ì™„ê²°)\n**[0:00~0:30 êµ¬ê°„ ë°›ì•„ì“°ê¸° ê²€ì¦]**\n\"ì•ˆë…•í•˜ì„¸ìš”. ì‹¬ê·¼ê²½ìƒ‰ì— ëŒ€í•œ ì €í¬ì˜ 3ë¶€ì‘ ì—¬ì •. ê·¸ ì„¸ ë²ˆì§¸ì´ì ë§ˆì§€ë§‰ ì‹œê°„ì— ì˜¤ì‹  ê²ƒì„ í™˜ì˜í•©ë‹ˆë‹¤. íŠ¹íˆ USMLE Step 2 ì‹œí—˜ì„ ì¤€ë¹„í•˜ì‹œëŠ” ë°”ë¡œ ë‹¹ì‹ ì„ ìœ„í•´ ì¤€ë¹„í•œ ì‹œê°„ì´ì£ ? ì €í¬ê°€ ì§€ë‚œ ë‘ ë²ˆì— ê±¸ì³ì„œ ì‹¬ê·¼ê²½ìƒ‰ì´ ëŒ€ì²´ ë­ê³ , ë˜ ì–´ë–»ê²Œ ì§„ë‹¨í•˜ê³  ê¸‰ì„±ê¸°ì— ì¹˜ë£Œí•˜ëŠ”ì§€ ì•Œì•„ë´¤ì–ì•„ìš”? ì˜¤ëŠ˜ì€ ê·¸ ì´í›„ì˜ ì´ì•¼ê¸°ì…ë‹ˆë‹¤. ê·¸ëŸ¬ë‹ˆê¹Œ ì‹¬ê·¼ê²½ìƒ‰ì´ë¼ëŠ” í° í­í’ì´ ì§€ë‚˜ê°„ ìë¦¬ì— ë‚¨ì„ ìˆ˜ ìˆëŠ” ì–´... ê·¸ëŸ° ìœ„í—˜í•œ í•©ë³‘ì¦ë“¤ë¶€í„° ì‹œì‘í•´ ë³¼ ê±°ê³ ìš”.\"\n---\n## 1. ì„œë¡ : í­í’ì´ ì§€ë‚˜ê°„ ìë¦¬ë¥¼ ê´€ë¦¬í•˜ë‹¤ ğŸŒªï¸\nì˜¤ëŠ˜ ê°•ì˜ëŠ” ì‹¬ê·¼ê²½ìƒ‰(MI) ê¸‰ì„±ê¸° ì¹˜ë£Œ ì´í›„ì˜ ìƒí™©ì„ ë‹¤ë£¹ë‹ˆë‹¤. í™˜ìë¥¼ ì‚´ë¦° ê²ƒì´ ëì´ ì•„ë‹ˆë¼, **ê·¸ ì´í›„ì— ë²Œì–´ì§ˆ ìˆ˜ ìˆëŠ” ì¼ë“¤ì„ ì˜ˆì¸¡í•˜ê³  ê´€ë¦¬í•˜ëŠ” ê²ƒ**ì´ USMLE Step 2ì˜ í•µì‹¬ í¬ì¸íŠ¸ì…ë‹ˆë‹¤.\nì£¼ìš” í† í”½:\n- ê¸°ê³„ì  í•©ë³‘ì¦ (Mechanical Complications)\n- ì¥ê¸°ì  ì‹¬ì‹¤ ë¦¬ëª¨ë¸ë§ ë° ì•½ë¬¼ ê´€ë¦¬\n- ê¸‰ì„± ê´€ìƒë™ë§¥ ì¦í›„êµ°(ACS) ë° ì•ˆì •í˜• í˜‘ì‹¬ì¦ì˜ ì§„ë‹¨ ì•Œê³ ë¦¬ì¦˜\n- í‰í†µì˜ ê°ë³„ ì§„ë‹¨\n---","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-88"}
{"chunk_type":"transcript_chunk","text":"## 2. ì‹œí•œí­íƒ„ê³¼ ê°™ì€ ê¸°ê³„ì  í•©ë³‘ì¦ (Mechanical Complications) ğŸ’£\nì‹¬ê·¼ê²½ìƒ‰ ë°œìƒ í›„ **3ì¼ ~ 5ì¼ ì‚¬ì´**ê°€ ê°€ì¥ ìœ„í—˜í•œ ì‹œê¸°ì…ë‹ˆë‹¤. ê´´ì‚¬ëœ ì‹¬ì¥ ê·¼ìœ¡ì´ ì•½í•´ì§€ë©´ì„œ êµ¬ì¡°ì ì¸ íŒŒì—´ì´ ì¼ì–´ë‚  ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n| í•©ë³‘ì¦ ì¢…ë¥˜ | ë°œìƒ ê¸°ì „ ë° íŠ¹ì§• | ì„ìƒì  ë‹¨ì„œ (Clue) â˜… |\n| --- | --- | --- |\n| **1. ìœ ë‘ê·¼ íŒŒì—´**(Papillary Muscle Rupture) | â€¢ ìŠ¹ëª¨íŒì„ ì¡ê³  ìˆëŠ” ìœ ë‘ê·¼ì´ ëŠì–´ì§ (ë°§ì¤„ì´ ëŠì–´ì§€ëŠ” ê²ƒê³¼ ìœ ì‚¬)\nâ€¢ **í›„ë‚´ì¸¡ ìœ ë‘ê·¼**ì€ ìš°ê´€ìƒë™ë§¥(RCA) **ë‹¨ë… ê³µê¸‰(ì™¸ì¤„íƒ€ê¸°)**ì„ ë°›ìœ¼ë¯€ë¡œ íŠ¹íˆ ì·¨ì•½í•¨. | â€¢ í•˜ë²½ ê²½ìƒ‰(Inferior MI) í›„ ë°œìƒ\nâ€¢ ì‹¬í•œ í˜¸í¡ ê³¤ë€ (íë¶€ì¢…)\nâ€¢ ì²­ì§„ ì‹œ **ìƒˆë¡œìš´ ì‹¬ì¡ìŒ (MR)** |\n| **2. ì‹¬ì‹¤ ì¤‘ê²© íŒŒì—´**(Ventricular Septal Rupture) | â€¢ ì¢Œì‹¬ì‹¤ê³¼ ìš°ì‹¬ì‹¤ ì‚¬ì´ì˜ ë²½(Septum)ì´ í„°ì§.\nâ€¢ ì‚°ì†Œê°€ í’ë¶€í•œ ì¢Œì‹¬ì‹¤ í”¼ê°€ ìš°ì‹¬ì‹¤ë¡œ ì½¸ì½¸ ìŸì•„ì§. | â€¢ ì²­ì§„ ì‹œ ìƒˆë¡œìš´ ì‹¬ì¡ìŒ\nâ€¢ **ìš°ì‹¬ë„ììˆ  ì‹œ ì‚°ì†Œ í¬í™”ë„ ê¸‰ìƒìŠ¹ (Step-up)** í˜„ìƒ ê´€ì°° (ìœ ë‘ê·¼íŒŒì—´ê³¼ ê°ë³„ì  â˜… ) |\n| **3. ììœ ë²½ íŒŒì—´**(Free Wall Rupture) | â€¢ ì‹¬ì¥ ë°”ê¹¥ìª½ ë²½ì— êµ¬ë©ì´ ëš«ë¦¼.\nâ€¢ ì‹¬ë‚­(Pericardial sac)ì— í”¼ê°€ ì°¨ë©´ì„œ ì‹¬ì¥ì„ ëˆ„ë¦„ â†’ **ì‹¬ì¥ ëˆŒë¦¼ì¦ (Tamponade)** | â€¢ **ê°€ì¥ ì¹˜ëª…ì  (ìµœì•…ì˜ ìƒí™©)**\nâ€¢ ê°‘ì‘ìŠ¤ëŸ¬ìš´ ì €í˜ˆì••, ì‡¼í¬, ì‹¬ì •ì§€\nâ€¢ ìˆœì‹ê°„ì— ë°œìƒ |\n> ğŸš¨ í•µì‹¬ í¬ì¸íŠ¸: 3ê°€ì§€ ëª¨ë‘ ê°‘ì‘ìŠ¤ëŸ¬ìš´ ì €í˜ˆì••(Hypotension)ê³¼ ì‡¼í¬ë¥¼ ìœ ë°œí•˜ë©°, ì²­ì§„ ì‹œ ìƒˆë¡œìš´ ì¡ìŒì´ ë“¤ë¦´ ìˆ˜ ìˆë‹¤ëŠ” ê³µí†µì ì´ ìˆìŠµë‹ˆë‹¤. í•˜ì§€ë§Œ ì‚°ì†Œ í¬í™”ë„ Step-upì€ VSRë§Œì˜ íŠ¹ì§•ì…ë‹ˆë‹¤.\n>\n---\n## 3. ì„œì„œíˆ ë‹¤ê°€ì˜¤ëŠ” ìœ„í˜‘: ì¢Œì‹¬ì‹¤ ë™ë§¥ë¥˜ (LV Aneurysm) ğŸˆ\nê¸‰ì„±ê¸°ê°€ ì§€ë‚˜ê³  **ëª‡ ë‹¬ ë’¤**ì— ë‚˜íƒ€ë‚  ìˆ˜ ìˆëŠ” í•©ë³‘ì¦ì…ë‹ˆë‹¤.\n- **ê¸°ì „:** ê´´ì‚¬ëœ ì‹¬ì¥ ê·¼ìœ¡ì´ í‰í„° ì¡°ì§ìœ¼ë¡œ ë³€í•˜ë©´ì„œ ì••ë ¥ì„ ì´ê¸°ì§€ ëª»í•˜ê³  í’ì„ ì²˜ëŸ¼ ì–‡ê²Œ ëŠ˜ì–´ë‚¨.\n- **íŠ¹ì§•:** ëŠ˜ì–´ë‚œ ë¶€ìœ„ê°€ ìˆ˜ì¶•í•˜ì§€ ì•Šê³  ë°–ìœ¼ë¡œ íŠ€ì–´ë‚˜ì˜¤ëŠ” **ì´ìƒ ìš´ë™ (Dyskinetic motion)**ì„ ë³´ì„.\n- **ìœ„í—˜ì„±:** í˜ˆë¥˜ ì •ì²´(Stasis)ë¡œ ì¸í•´ **í˜ˆì „(Thrombus, í”¼ë–¡)**ì´ ì˜ ìƒê¹€ â†’ ë‡Œí˜ˆê´€ì„ ë§‰ìœ¼ë©´ **ë‡Œì¡¸ì¤‘(Stroke)** ìœ ë°œ.\n- **â˜… USMLE Tip:** MI ë³‘ë ¥ì´ ìˆëŠ” í™˜ìê°€ ëª‡ ë‹¬ ë’¤ ë‡Œì¡¸ì¤‘ ì¦ìƒì„ ë³´ì´ë©´ LV Aneurysmì— ì˜í•œ í˜ˆì „ì„ ì˜ì‹¬í•´ì•¼ í•©ë‹ˆë‹¤.\n---\n## 4. ì‹¬ì‹¤ ë¦¬ëª¨ë¸ë§ ë°©ì§€ì™€ ì•½ë¬¼ ê´€ë¦¬ ğŸ’Š\nì‹¬ì¥ì€ ìƒì²˜ë¥¼ ì…ìœ¼ë©´ í˜¸ë¥´ëª¬(**Angiotensin II**)ì„ ë¶„ë¹„í•˜ì—¬ ë”±ë”±í•˜ê³  ë¹„ëŒ€í•´ì§€ë ¤ëŠ” ì„±ì§ˆ(**Remodeling**)ì´ ìˆìŠµë‹ˆë‹¤. ì´ëŠ” ì¥ê¸°ì ìœ¼ë¡œ ì˜ˆí›„ë¥¼ ì•…í™”ì‹œí‚µë‹ˆë‹¤.\n### â˜… í•„ìˆ˜ ì•½ë¬¼ ì¡°í•©: \"B A S S M\"\nì‹¬ê·¼ê²½ìƒ‰ í›„ ê±°ì˜ ëª¨ë“  í™˜ìì—ê²Œ í‰ìƒ í•„ìš”í•œ ì•½ë¬¼ë“¤ì…ë‹ˆë‹¤.\n1. **B (Beta-blockers):** ì‹¬ì¥ ë¶€ë‹´ ê°ì†Œ, ë¶€ì •ë§¥ ì˜ˆë°©.\n2. **A (Aspirin/Antiplatelet):** í˜ˆì „ ìƒì„± ì–µì œ.\n3. **S (Statins):** ì½œë ˆìŠ¤í…Œë¡¤ ì €í•˜ + í˜ˆê´€ ì—¼ì¦ ì™„í™” ë° ë™ë§¥ê²½í™”ë°˜ ì•ˆì •í™”.\n4. **S (Spironolactone):** Mineralocorticoid ê¸¸í•­ì œ (í•„ìš”ì‹œ ì¶”ê°€, ë¦¬ëª¨ë¸ë§ ë°©ì§€).\n5. **M (ACE Inhibitors - \"M\"odulators of remodeling):**\n    - Angiotensin II ìƒì„±ì„ ë§‰ì•„ ì‹¬ì¥ ê·¼ìœ¡ì˜ ë³€í˜•(ë¦¬ëª¨ë¸ë§)ì„ ì°¨ë‹¨.\n    - ì¥ê¸°ì  ìƒì¡´ìœ¨ ê°œì„ ì— ê²°ì •ì  ì—­í• .\n### ğŸš« ì ˆëŒ€ ê¸ˆê¸° ì•½ë¬¼\n- **NSAIDs (ì˜ˆ: ì´ë¶€í”„ë¡œíœ ë“±):** ì‹¬í˜ˆê´€ê³„ ë¶€ì‘ìš© ìœ„í—˜ì„ ê¸‰ê²©íˆ ë†’ì„. ì§„í†µì œê°€ í•„ìš”í•˜ë”ë¼ë„ NSAIDsëŠ” í”¼í•´ì•¼ í•¨ (ì‹œí—˜ì˜ í•¨ì •!).\n---\n## 5. ì§„ë‹¨ ì•Œê³ ë¦¬ì¦˜: ì‘ê¸‰ì‹¤ë¶€í„° ì™¸ë˜ê¹Œì§€ ğŸ¥\n### A. ê¸‰ì„± í‰í†µ í™˜ì (ì‘ê¸‰ì‹¤)\n1. **ì´ˆê¸° ê²€ì‚¬ (10ë¶„ ì´ë‚´):** **ì‹¬ì „ë„ (ECG)** âš¡ï¸\n    - **ST ë¶„ì ˆ ìƒìŠ¹ (STEMI):** ì¦‰ì‹œ í˜ˆê´€ì„ ëš«ì–´ì£¼ëŠ” ì¬ê´€ë¥˜ ì¹˜ë£Œ(Revascularization) ì‹œí–‰.\n2. **ì‹¬ì „ë„ê°€ ì •ìƒì´ê±°ë‚˜ ë¹„ì§„ë‹¨ì ì¼ ë•Œ:**\n    - **ì‹¬ì¥ íš¨ì†Œ ê²€ì‚¬ (Troponin):**\n        - Troponin ìƒìŠ¹: **NSTEMI**\n        - Troponin ì •ìƒ: **ë¶ˆì•ˆì • í˜‘ì‹¬ì¦ (Unstable Angina)**\n    - **â˜… ì£¼ì˜:** ì´ˆê¸° ì‹¬ì „ë„/íš¨ì†Œ ìˆ˜ì¹˜ê°€ ì •ìƒì´ë¼ê³  í•´ì„œ MIë¥¼ ë°°ì œí•˜ë©´ ì•ˆ ë¨. **ì‹œê°„ì„ ë‘ê³  ë°˜ë³µ ê²€ì‚¬(Follow-up) í•„ìˆ˜!**\n3. **ë¹„ì „í˜•ì  ì¦ìƒ (Atypical Symptoms):**\n    - ëŒ€ìƒ: ì—¬ì„±, ê³ ë ¹, ë‹¹ë‡¨ í™˜ì.\n    - ì¦ìƒ: ì²´í•œ ëŠë‚Œ, ìˆ¨ì´ ì°¸, ê·¹ì‹¬í•œ í”¼ë¡œê° ë“±. (í‰í†µì´ ì—†ì„ ìˆ˜ë„ ìˆìŒ)","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-98"}
{"chunk_type":"transcript_chunk","text":"### B. ì•ˆì •í˜• í‰í†µ í™˜ì (ì™¸ë˜)\nìš´ë™í•  ë•Œë§Œ ê°€ìŠ´ì´ ì•„í”ˆ ê²½ìš°, **ìœ„í—˜ë„(Pre-test probability)**ë¥¼ ë¨¼ì € í‰ê°€í•©ë‹ˆë‹¤.\n- **ì¤‘ë“±ë„ ìœ„í—˜êµ° (ëŒ€ë‹¤ìˆ˜ í™˜ì):** **ë¶€í•˜ ê²€ì‚¬ (Stress Test)** ì‹œí–‰.\n### ğŸƒâ€â™‚ï¸ ë¶€í•˜ ê²€ì‚¬ ì„ íƒ ê°€ì´ë“œ (ì‹œí—˜ ë‹¨ê³¨ ë¬¸ì œ)\n| í™˜ì ìƒíƒœ | ì¶”ì²œ ê²€ì‚¬ | ì›ë¦¬ ë° ì£¼ì˜ì‚¬í•­ |\n| --- | --- | --- |\n| **ê±¸ì„ ìˆ˜ ìˆìŒ + ECG ì •ìƒ** | **ìš´ë™ ë¶€í•˜ ì‹¬ì „ë„**(Exercise ECG) | â€¢ ê°€ì¥ ê¸°ë³¸ ê²€ì‚¬ |\n| **ëª» ê±¸ìŒ (ë¬´ë¦ í†µì¦ ë“±) OR ECG ì´ìƒ** | **ì•½ë¬¼ ë¶€í•˜ ê²€ì‚¬**(Pharmacologic Stress Test) | â€¢ ì•½ë¬¼ë¡œ ì‹¬ì¥ì„ ë›°ê²Œ í•˜ê±°ë‚˜ í˜ˆê´€ì„ í™•ì¥ì‹œí‚´ |\n### ğŸ’Š ì•½ë¬¼ ë¶€í•˜ ê²€ì‚¬ì˜ ì¢…ë¥˜\n1. **í˜ˆê´€ í™•ì¥ì œ (Adenosine, Dipyridamole):**\n    - **ì›ë¦¬:** ì •ìƒ í˜ˆê´€ì€ í™•ì¥ë˜ì§€ë§Œ, ë³‘ë“  í˜ˆê´€ì€ í™•ì¥ë˜ì§€ ì•Šì•„ í˜ˆë¥˜ê°€ ì •ìƒ í˜ˆê´€ ìª½ìœ¼ë¡œ ì ë¦¼ â†’ **ê´€ìƒë™ë§¥ ë„ë¥˜ í˜„ìƒ (Coronary Steal Phenomenon)**. ì´ë¥¼ ì˜ìƒìœ¼ë¡œ í¬ì°©.\n    - **â˜… ê¸ˆê¸°:** **ì²œì‹(Asthma)**, ê¸°ê´€ì§€ ê²½ë ¨ í™˜ì (ê¸°ê´€ì§€ ìˆ˜ì¶• ìœ ë°œ ê°€ëŠ¥).\n2. **ë„ë¶€íƒ€ë¯¼ (Dobutamine Stress Echo):**\n    - **ì›ë¦¬:** ì‹¬ì¥ì„ ë¹ ë¥´ê³  ê°•í•˜ê²Œ ë›°ê²Œ ë§Œë“¦ (ìš´ë™ íš¨ê³¼).\n    - **ì ì‘ì¦:** **ì²œì‹ ë“± íì§ˆí™˜ì´ ìˆëŠ” í™˜ì**ì—ê²Œ ì•ˆì „í•œ ëŒ€ì•ˆ.\n---\n## 6. í˜‘ì‹¬ì¦ì˜ ëª…í™•í•œ ì •ì˜ì™€ ê°ë³„ ğŸ”\n### í˜‘ì‹¬ì¦(Angina) ì§„ë‹¨ ê¸°ì¤€ 3ê°€ì§€ (USMLE Definition)\n1. ì „í˜•ì ì¸ í†µì¦ ìœ„ì¹˜ì™€ ì–‘ìƒ (í‰ê³¨ í•˜ë¶€, ì¥ì–´ì§œëŠ” ë“¯í•¨).\n2. ìš´ë™ì´ë‚˜ ìŠ¤íŠ¸ë ˆìŠ¤ì— ì˜í•´ ìœ ë°œë¨.\n3. íœ´ì‹ì´ë‚˜ ë‹ˆíŠ¸ë¡œê¸€ë¦¬ì„¸ë¦°(Nitroglycerin) ë³µìš© ì‹œ ì™„í™”ë¨.\n- **3ê°œ ì¶©ì¡±:** ì „í˜•ì  í˜‘ì‹¬ì¦ (Typical Angina)\n- **2ê°œ ì¶©ì¡±:** ë¹„ì „í˜•ì  í˜‘ì‹¬ì¦ (Atypical Angina)\n- **0~1ê°œ ì¶©ì¡±:** ë¹„í˜‘ì‹¬ì¦ì„± í‰í†µ (Non-anginal chest pain)\n### ì£¼ìš” ê°ë³„ ì§ˆí™˜ (Differential Diagnosis)\n| ì§ˆí™˜ëª… | í•µì‹¬ íŠ¹ì§• (Buzzwords) |\n| --- | --- |\n| **ëŒ€ë™ë§¥ ë°•ë¦¬** (Aortic Dissection) | â€¢ ê°‘ìê¸° ë“±(Back)ì´ **ì°¢ì–´ì§€ëŠ” ë“¯í•œ(Tearing)** ê·¹ì‹¬í•œ í†µì¦ |\n| **íìƒ‰ì „ì¦** (PE) | â€¢ ë‚ ì¹´ë¡œìš´ í†µì¦, í˜¸í¡ê³¤ë€, ìˆ¨ ì‰´ ë•Œ ì‹¬í•´ì§ |\n| **ì—­ë¥˜ì„± ì‹ë„ì—¼** (GERD) | â€¢ íƒ€ëŠ” ë“¯í•œ í†µì¦(Burning), ëˆ•ê±°ë‚˜ ì‹ì‚¬ í›„ ì•…í™”, ì œì‚°ì œì— í˜¸ì „ |\n| **ë³€ì´í˜• í˜‘ì‹¬ì¦** (Prinzmetal's) | â€¢ **í˜ˆê´€ ê²½ë ¨(Vasospasm)**ì´ ì›ì¸ (í˜ˆê´€ ë§‰í˜ X)\nâ€¢ **ì Šì€ í™˜ì**, **ìƒˆë²½/ì•ˆì • ì‹œ** ë°œìƒ, í¡ì—°ì\nâ€¢ ì¼ì‹œì  ST ìƒìŠ¹ í›„ ì •ìƒí™”ë¨ |\n---\n## 7. ë§Œì„± ì•ˆì •í˜• í˜‘ì‹¬ì¦ ê´€ë¦¬\n- **ëª©í‘œ:** ì¦ìƒ ì¡°ì ˆ ë° MI ì§„í–‰ ë°©ì§€.\n- **1ì°¨ ì¹˜ë£Œì œ:** **ë² íƒ€ ì°¨ë‹¨ì œ (Beta-blockers)** - ì‹¬ì¥ ë¶€ë‹´ ê²½ê°.\n- **ì¶”ê°€ ì•½ì œ:** ì¹¼ìŠ˜ ì±„ë„ ì°¨ë‹¨ì œ(CCB), ì§ˆì‚°ì—¼ ì œì œ(Nitrates).\n---","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-118"}
{"chunk_type":"recap_summary","text":"## ğŸš€ Rapid Fire Recap: Must-Know High Yields\n### 1. Post-MI Complications Timeline & Clues\n- **3~5ì¼ì°¨ (ê¸°ê³„ì  í•©ë³‘ì¦):**\n    - **Papillary Muscle Rupture:** Inferior MI + Pulmonary Edema + New Murmur.\n    - **VSD (Septal Rupture):** New Murmur + **O2 Saturation Step-up (RV)**.\n    - **Free Wall Rupture:** Cardiac Tamponade + Sudden Shock/Arrest.\n- **ìˆ˜ê°œì›” í›„:**\n    - **LV Aneurysm:** Dyskinetic motion + Thrombus/Stroke Risk.\n### 2. Long-term Meds (BASS M)\n- **B**eta-blocker, **A**spirin, **S**tatin, **S**pironolactone, **ACE** Inhibitor.\n- **Trap:** Do NOT use **NSAIDs**! â˜ ï¸\n### 3. Stress Test Selection Framework\n- **Can exercise?** â†’ Yes: **Exercise ECG**.\n- **Can't exercise?** â†’ Pharmacologic.\n    - **Asthma/Bronchospasm present?**\n        - Yes: **Dobutamine Echo** (Adenosine is contraindicated!).\n        - No: **Adenosine/Dipyridamole** (Coronary Steal mechanism).\n### 4. Chest Pain Differentiation\n- **Prinzmetal's Angina:** Young, rest/morning pain, transient ST elevation. (Cause: Vasospasm).\n- **Typical Angina:** Meets all 3 criteria (Location, Provocation by stress, Relief by rest/NTG).\n### 5. Clinical Management Trap","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-135"}
{"chunk_type":"transcript_chunk","text":"- **Normal initial ECG/Troponin:** Never rule out ACS immediately. **Observation & Repeat testing** is mandatory.\n![image.png](LM_cardio%202%205~/image.png)\n![image.png](LM_cardio%202%205~/image%201.png)\n# ğŸ” USMLE Step 2 ëŒ€ë¹„: ì‹¬ì¥ íŒë§‰ í˜‘ì°©ì¦ì˜ ëª¨ë“  ê²ƒ (Aortic & Mitral Stenosis) â¤ï¸\n### ğŸ§ 0:00 ~ 0:30 ë°›ì•„ì“°ê¸° (Dictation)\nì, ì—¬ëŸ¬ë¶„ì´ ë³´ë‚´ì£¼ì‹  ì´ ìë£Œ ë¬¶ìŒ ì§€ê¸ˆ ì œ ì†ì— ë”± ë“¤ë ¤ ìˆìŠµë‹ˆë‹¤. ì´ë²ˆì—ëŠ” ì‹¬ì¥ì„ í•œë²ˆ ì œëŒ€ë¡œ íŒŒí—¤ì³ ë³¼ í…ë°ìš”. ì˜¤ëŠ˜ì€ ìš°ë¦¬ê°€ ë­ë„ê¹Œ, ì‹¬ì¥ íƒì •ì´ ë˜ì–´ ë³´ëŠ” ì‹œê°„ì…ë‹ˆë‹¤. ì•„, ì‹¬ì¥ íƒì •ì´ìš”? ë„¤. ìš°ë¦¬ì˜ ì‚¬ê±´ íŒŒì¼ì€ ë°”ë¡œ ì´ ìë£Œë“¤ì´ê³ ìš”. ë‹¨ì„œëŠ” ì‹¬ì¥ì—ì„œ ë“¤ë ¤ì˜¤ëŠ” ì•„ì£¼ ë¯¸ì„¸í•œ ì†Œë¦¬, ì´ìƒí•œ ë°•ë™ ê°™ì€ ì‹ í˜¸ë“¤ì…ë‹ˆë‹¤. ì¬ë°ŒëŠ” ì ‘ê·¼ì¸ë°ìš”? ì‹¬ì¥ì˜ ì¤‘ìš”í•œ ë¬¸ë“¤ì´ ê³ ì¥ ë‚¬ì„ ë•Œ ë³´ë‚´ëŠ” ì‹ í˜¸ë“¤ì´ì£ . ë„¤ ë§ìŠµë‹ˆë‹¤.\n---\n## ğŸ“‹ ëª©ì°¨\n- **1. Introduction: ì‹¬ì¥ íŒë§‰ ì§ˆí™˜ì˜ ë‘ ì–¼êµ´**\n- **2. ì‹¬ì¥ ì¡ìŒ(Murmur) ìˆ˜ì‚¬ì˜ ê¸°ì´ˆ: ì–‘ì„± vs ë³‘ì  ì¡ìŒ**\n- **3. ì¶”ê°€ ë‹¨ì„œ: S3ì™€ S4 ê°¤ëŸ½ìŒ(Gallop)**\n- **4. ì„ìƒì  ê³ ë¯¼: íŒë§‰ ì§ˆí™˜ í™˜ìì˜ ë¹„ì‹¬ì¥ ìˆ˜ìˆ  ê²°ì •**\n- **5. ì‚¬ê±´ íŒŒì¼ #1: ëŒ€ë™ë§¥íŒë§‰ í˜‘ì°©ì¦ (Aortic Stenosis, AS)**\n- **6. ì‚¬ê±´ íŒŒì¼ #2: ìŠ¹ëª¨íŒë§‰ í˜‘ì°©ì¦ (Mitral Stenosis, MS)**\n- **7. âš¡ Rapid Fire Recap: Must-Know High Yield Summary**\n---\n## 1. Introduction: ì‹¬ì¥ íŒë§‰ ì§ˆí™˜ì˜ ë‘ ì–¼êµ´ ğŸšª\nì‹¬ì¥ íŒë§‰ì€ í˜ˆì•¡ì´ í•œ ë°©í–¥ìœ¼ë¡œë§Œ íë¥´ê²Œ í•˜ëŠ” 'ë¬¸' ì—­í• ì„ í•©ë‹ˆë‹¤. ì´ ë¬¸ì— ë¬¸ì œê°€ ìƒê¸°ëŠ” ê²½ìš°ëŠ” í¬ê²Œ ë‘ ê°€ì§€ì…ë‹ˆë‹¤.\n- **í˜‘ì°©ì¦(Stenosis):** ë¬¸ì´ ë»‘ë»‘í•˜ê²Œ ë…¹ìŠ¬ì–´ ì˜ ì•ˆ ì—´ë¦¬ëŠ” ìƒíƒœ â˜…\n- **ì—­ë¥˜ì¦(Regurgitation):** ë¬¸ì´ í—ê±°ì›Œì ¸ì„œ ê½‰ ì•ˆ ë‹«íˆê³  í”¼ê°€ ìƒˆëŠ” ìƒíƒœ\nì˜¤ëŠ˜ì€ ê·¸ì¤‘ì—ì„œë„ **'í˜‘ì°©ì¦'** ì‚¬ê±´ íŒŒì¼ì— ì§‘ì¤‘í•´ ë´…ë‹ˆë‹¤! ğŸ”\n---\n## 2. ì‹¬ì¥ ì¡ìŒ(Murmur) ìˆ˜ì‚¬ì˜ ê¸°ì´ˆ: ì–‘ì„± vs ë³‘ì  ì¡ìŒ ğŸ”Š\nì˜ì‚¬ê°€ ì²­ì§„ê¸°ë¥¼ ëŒ”ì„ ë•Œ ë“¤ë¦¬ëŠ” 'ì¡ìŒ'ì´ ëª¨ë‘ ìœ ì£„ëŠ” ì•„ë‹™ë‹ˆë‹¤.\n| êµ¬ë¶„ ë‹¨ì„œ | ë³‘ì  ì¡ìŒ (ìœ„í—˜ ì‹ í˜¸! âš ï¸) | ì–‘ì„± ì¡ìŒ (ë¬´í•´í•¨) |\n| --- | --- | --- |\n| **íƒ€ì´ë°** | **ë²”ìˆ˜ì¶•ê¸°(Holosystolic)** ë˜ëŠ” **ì´ì™„ê¸°(Diastolic)** ì— ë“¤ë¦¼ â˜… | ì£¼ë¡œ ìˆ˜ì¶•ê¸°ì— ì§§ê²Œ ë“¤ë¦¼ |\n| **ë³¼ë¥¨(ê°•ë„)** | 3ë“±ê¸‰(Grade 3) ì´ìƒìœ¼ë¡œ ê½¤ í¬ê²Œ ë“¤ë¦¼ | ì†Œë¦¬ê°€ ì‘ìŒ |\n| **ìì„¸ ë³€í™”** | **ìì„¸ë¥¼ ë°”ê¿”ë„ ì†Œë¦¬ê°€ ì‚¬ë¼ì§€ì§€ ì•Šê³  ëˆì§ˆê¸°ê²Œ ë‚¨ìŒ** â˜… | ëˆ„ì›Œìˆë‹¤ ì¼ì–´ì„œê±°ë‚˜ ë°œì‚´ë°” í˜¸í¡ ì‹œ ì†Œë¦¬ê°€ ì‘ì•„ì§ |\n- **ì¶”ê°€ ì¦ê±°:** ì²­ìƒ‰ì¦, ì•½í•´ì§„ ë§¥ë°• ë“±ì´ ë™ë°˜ë˜ë©´ ë” í™•ì‹¤í•œ ë³‘ì  ì‹ í˜¸ì…ë‹ˆë‹¤.\n---\n## 3. ì¶”ê°€ ë‹¨ì„œ: S3ì™€ S4 ê°¤ëŸ½ìŒ(Gallop) ğŸ","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-145"}
{"chunk_type":"transcript_chunk","text":"ë§ì´ ë‹¬ë¦¬ëŠ” ì†Œë¦¬ì²˜ëŸ¼ ë“¤ë¦°ë‹¤ê³  í•´ì„œ ë¶™ì—¬ì§„ ì´ë¦„ì…ë‹ˆë‹¤.\n- **S3 (ì§€ì¹œ ì‹¬ì¥ì˜ ì†Œë¦¬):**\n    - **íƒ€ì´ë°:** S2 ì§í›„ (ì¿µ-ì§-**í„±**)\n    - **ì´ë¯¸ì§€:** íƒ„ë ¥ì„ ìƒê³  ì¶• ëŠ˜ì–´ì§„ **ë‚¡ì€ ë¬¼í’ì„ **ì— ë¬¼ì´ ì±„ì›Œì§ˆ ë•Œ ë‚˜ëŠ” 'ì°°í‘¸ë•' ì†Œë¦¬ ğŸˆ\n    - **ì˜ë¯¸:** ì‹¬ë¶€ì „ì´ë‚˜ íŒë§‰ ì—­ë¥˜ë¡œ ì¸í•´ ì¢Œì‹¬ì‹¤ì´ ëŠ˜ì–´ë‚˜ ìˆì„ ë•Œ ë°œìƒ.\n- **S4 (ì €í•­í•˜ëŠ” ì‹¬ì¥ì˜ ì†Œë¦¬):**\n    - **íƒ€ì´ë°:** S1 ì§ì „ (**í„±**ì¿µ-ì§) â˜…\n    - **ì´ë¯¸ì§€:** ë”±ë”±í•œ **ì½˜í¬ë¦¬íŠ¸ ë²½**ì— ë¬¼ì„ ì„¸ê²Œ ë˜ì§ˆ ë•Œ ë‚˜ëŠ” 'í½' ì†Œë¦¬ ğŸ§±\n    - **ì˜ë¯¸:** ê³ í˜ˆì••ìœ¼ë¡œ ì‹¬ì¥ ê·¼ìœ¡ì´ ë‘êº¼ì›Œì¡Œê±°ë‚˜, ê¸‰ì„± ì‹¬ê·¼ê²½ìƒ‰ìœ¼ë¡œ ê·¼ìœ¡ì´ ë»£ë»£í•´ì¡Œì„ ë•Œ ì‹ ë°©ì´ í”¼ë¥¼ ì§œë‚´ë©° ë‚´ëŠ” ì €í•­ì˜ ì†Œë¦¬.\n---\n## 4. ì„ìƒì  ê³ ë¯¼: íŒë§‰ ì§ˆí™˜ í™˜ìì˜ ë¹„ì‹¬ì¥ ìˆ˜ìˆ  ê²°ì • ğŸ¥\níŒë§‰ ì§ˆí™˜ì´ ìˆëŠ” í™˜ìê°€ ë¬´ë¦ ìˆ˜ìˆ  ê°™ì€ ë‹¤ë¥¸ ìˆ˜ìˆ ì„ ë°›ì•„ì•¼ í•œë‹¤ë©´?\n1. **ê²½ë¯¸(Mild)í•œ ê²½ìš°:** ìˆ˜ìˆ  ì§„í–‰ ê°€ëŠ¥.\n2. **ì¤‘ë“±ë„~ì¤‘ì¦(Moderate to Severe)ì¸ ê²½ìš°:** **'ì¦ìƒ ìœ ë¬´'**ê°€ í•µì‹¬! â˜…\n    - **ì¦ìƒ ìˆìŒ (í˜¸í¡ê³¤ë€, í‰í†µ):** ë¬´ì¡°ê±´ **íŒë§‰ ìˆ˜ìˆ ì„ ë¨¼ì €** í•´ì•¼ í•¨. âš ï¸\n    - **ì¦ìƒ ì—†ìŒ:** ìˆ˜ìˆ ì˜ ìœ„í—˜ë„ë¥¼ ë”°ì§.\n        - ì €ìœ„í—˜ ìˆ˜ìˆ (ë‚´ì‹œê²½ ë“±): ì§„í–‰ ê°€ëŠ¥.\n        - ê³ ìœ„í—˜ ìˆ˜ìˆ (ë³µë¶€ ìˆ˜ìˆ  ë“±): ì¢Œì‹¬ì‹¤ ë°•ì¶œë¥ (EF < 50%)ì´ë‚˜ íë™ë§¥ ì••ë ¥ì„ í™•ì¸í•˜ì—¬ ì‹¬ì¥ì˜ ì—¬ë ¥ì„ í‰ê°€ í›„ ê²°ì •.\n---\n## 5. ì‚¬ê±´ íŒŒì¼ #1: ëŒ€ë™ë§¥íŒë§‰ í˜‘ì°©ì¦ (Aortic Stenosis, AS) ğŸ“‰\nì‹¬ì¥ì—ì„œ ì˜¨ëª¸ìœ¼ë¡œ ë‚˜ê°€ëŠ” ìµœì¢… ì¶œêµ¬ê°€ ì¢ì•„ì§€ëŠ” ë³‘ì…ë‹ˆë‹¤.\n- **ë²”ì¸(ì›ì¸):**\n    - 70ì„¸ ì´ìƒ ê³ ë ¹: ì˜¤ëœ ì„¸ì›” ì¹¼ìŠ˜ì´ ìŒ“ì¸ **ì„íšŒí™”** â˜…\n    - ì Šì€ í™˜ì: ì„ ì²œì„± **ì´ì—½ì„± ëŒ€ë™ë§¥íŒë§‰(Bicuspid AV)**\n- **â˜… 3ëŒ€ ê²½ê³  ì¦ìƒ (ë°˜ë“œì‹œ ì•”ê¸°!):**\n    1. **ìš´ë™ ì‹œ í˜¸í¡ê³¤ë€** (Dyspnea)\n    2. **í˜‘ì‹¬ì¦** (Angina - í‰í†µ)\n    3. **ì‹¤ì‹ ** (Syncope) -> ì´ ì¦ìƒë“¤ì´ ë‚˜íƒ€ë‚˜ë©´ ì‹¬ì¥ì´ ë¹„ëª…ì„ ì§€ë¥´ëŠ” ê²ƒ! ğŸ˜±\n- **ë¬¼ë¦¬ì  ì¦ê±° (ì§„ì°°):**\n    - **ì²­ì§„:** ì˜¤ë¥¸ìª½ ê°€ìŠ´ ìœ„ìª½ì—ì„œ 'ìŠˆ-í›…' í•˜ê³  ì»¤ì¡Œë‹¤ê°€ ì‘ì•„ì§€ëŠ” **ë‹¤ì´ì•„ëª¬ë“œ ëª¨ì–‘ ì¡ìŒ** (Crescendo-Decrescendo). ëª© ìª½ìœ¼ë¡œ ì†Œë¦¬ê°€ ë»—ì–´ë‚˜ê°. ğŸ”ˆ\n    - **ë§¥ë°•:** **Pulsus Parvus et Tardus** (ì‘ê³  ëŠë¦° ë§¥ë°•). ëª©ì˜ ê²½ë™ë§¥ì—ì„œ ì•½í•˜ê²Œ ìŠ¥~ ë°€ë ¤ì˜¤ëŠ” ëŠë‚Œ.\n- **ì •ë°€ ì¡°ì‚¬ (Echo):**\n    - í˜ˆë¥˜ ì†ë„ > 4m/s ë˜ëŠ” í‰ê·  ì••ë ¥ì°¨ > 40mmHg ì´ë©´ **ì¤‘ì¦(Severe)** ì§„ë‹¨. â˜…\n- **ì¹˜ë£Œ(íŒë§‰ êµì²´) ì¡°ê±´:**\n    1. ì¤‘ì¦ + 3ëŒ€ ê²½ê³  ì¦ìƒ ë°œí˜„\n    2. ì¦ìƒ ì—†ì–´ë„ EF < 50% í•˜ë½\n    3. ë‹¤ë¥¸ ì‹¬ì¥ ìˆ˜ìˆ  ì‹œ ë³‘í–‰\n- **âš ï¸ ì ˆëŒ€ ê¸ˆê¸°:** ì¤‘ì¦ AS í™˜ìì—ê²Œ **ìš´ë™ ë¶€í•˜ ê²€ì‚¬(Running machine)**ëŠ” ê¸ˆì§€! (í˜ˆì•• ì €í•˜ ë° ë¶€ì •ë§¥ ìœ„í—˜) â˜…\n---\n## 6. ì‚¬ê±´ íŒŒì¼ #2: ìŠ¹ëª¨íŒë§‰ í˜‘ì°©ì¦ (Mitral Stenosis, MS) ğŸŒ¬ï¸\nì¢Œì‹¬ë°©ì—ì„œ ì¢Œì‹¬ì‹¤ë¡œ ë“¤ì–´ê°€ëŠ” ë°©ë¬¸ì´ ì¢ì•„ì ¸ í”¼ê°€ ì¢Œì‹¬ë°©ì— ê³ ì´ëŠ” ë³‘ì…ë‹ˆë‹¤.\n- **ì„ìƒì  íŠ¹ì§•:**\n    - í”¼ê°€ ê³ ì´ë©´ì„œ íìª½ ì••ë ¥ì´ ë†’ì•„ì§ -> í˜¸í¡ê³¤ë€, **ê¸°ì¢Œí˜¸í¡**(ëˆ„ìš°ë©´ ë” ìˆ¨ì°¸), **ê°í˜ˆ**(í”¼ ì„ì¸ ê°€ë˜). ğŸ©¸\n    - **ì˜¤íŠ¸ë„ˆ ì¦í›„êµ°(Ortner's syndrome):** ê±°ëŒ€í•´ì§„ ì¢Œì‹¬ë°©ì´ ì„±ëŒ€ ì‹ ê²½ì„ ëˆŒëŸ¬ **ëª©ì†Œë¦¬ê°€ ì‰¼**. â˜…\n    - **ìŠ¹ëª¨íŒ ì–¼êµ´(Mitral Facies):** ì‚°ì†Œ ê³µê¸‰ ë¶€ì¡±ìœ¼ë¡œ ëº¨ì´ ë¶„í™/ë³´ëë¹›ì„ ë°.\n- **ë…íŠ¹í•œ ì†Œë¦¬:**\n    - **ê°œë°©ìŒ (Opening Snap, OS):** ì´ì™„ê¸°ì— êµ³ì€ íŒë§‰ì´ ì–µì§€ë¡œ 'íƒ' í•˜ê³  í´ì§€ëŠ” ì†Œë¦¬ (íŒ½íŒ½í•œ ë›ì´ ë°”ëŒì„ ë°›ëŠ” ì†Œë¦¬). â˜…\n    - ì§í›„ì— 'ìš°ë¥´ë¥´' í•˜ëŠ” **ë‚®ì€ ì´ì™„ê¸° ëŸ¼ë¸”(Rumbe)** ì†Œë¦¬ ë™ë°˜.\n- **ì§„ë‹¨:**\n    - ì‹¬ì „ë„(EKG)ì—ì„œ ë„“ê³  ì›€í‘¹ íŒ¬ **P-mitrale** (ì¢Œì‹¬ë°© ê³¼ë¶€í•˜ ì‹ í˜¸) ê´€ì°°. â˜…\n- **ì¹˜ë£Œ:**\n    - ìƒíƒœê°€ ê´œì°®ìœ¼ë©´ **í’ì„  ì¹´í…Œí„°**ë¡œ ë„“í˜€ì£¼ëŠ” ì‹œìˆ ì„ ë¨¼ì € ê³ ë ¤, ì‹¬í•˜ë©´ ìˆ˜ìˆ /êµì²´.\n---","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-165"}
{"chunk_type":"recap_summary","text":"## âš¡ Rapid Fire Recap: Must-Know High Yield Summary\n| êµ¬ë¶„ | **Aortic Stenosis (AS)** | **Mitral Stenosis (MS)** |\n| --- | --- | --- |\n| **í•µì‹¬ ê¸°ì „** | LVì—ì„œ ëŒ€ë™ë§¥ìœ¼ë¡œ ë‚˜ê°€ëŠ” ë¬¸ì´ ì¢ì•„ì§ | LAì—ì„œ LVë¡œ ë“¤ì–´ì˜¤ëŠ” ë¬¸ì´ ì¢ì•„ì§ |\n| **ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤** | ê³ ë ¹ì, ìš´ë™ ì¤‘ ì‹¤ì‹ /í‰í†µ ğŸƒâ€â™‚ï¸â¡ï¸ğŸ˜µ | í˜¸í¡ê³¤ë€, ê¸°ì¢Œí˜¸í¡, ëª©ì†Œë¦¬ ì‰¼ ğŸ—£ï¸ |\n| **Key Sound â˜…** | **Systolic** Crescendo-Decrescendo (Neck radiation) | **Diastolic** Rumble + **Opening Snap** |\n| **íŠ¹ì§•ì  ì§•í›„** | Pulsus Parvus et Tardus (ì•½í•˜ê³  ëŠ¦ì€ ë§¥) | Mitral Facies (ë³´ëë¹› ëº¨), Ortner's syndrome |\n| **ì‹¬í•œ ì •ë„ ê¸°ì¤€** | Velocity > 4m/s, Mean Gradient > 40mmHg | P-mitrale (EKG), LA enlargement |\n| **High Yield Trap** | **ì¤‘ì¦ ASì—ì„œ Stress TestëŠ” ì ˆëŒ€ ê¸ˆì§€!** ğŸš« | ìˆ˜ìˆ  ì „ í’ì„  ì‹œìˆ (PMBV) ìš°ì„  ê³ ë ¤ ê°€ëŠ¥ |\n| **High Yield Fact** | S4ëŠ” ê³ í˜ˆì••/MI(ë»£ë»£í•œ ë²½), S3ëŠ” ì‹¬ë¶€ì „(ëŠ˜ì–´ë‚œ í’ì„ ) | ê°¤ëŸ½ìŒì€ 3ì¤‘ì£¼(ì‚¼ì¤‘ì£¼)ì²˜ëŸ¼ ë“¤ë¦¼ ğŸ |\n**ë‹¤ìŒ ì˜ˆê³ :** ë¬¸ì´ ì œëŒ€ë¡œ ë‹«íˆì§€ ì•ŠëŠ” **ì—­ë¥˜ì„± íŒë§‰ ì§ˆí™˜** ìˆ˜ì‚¬ ì˜ˆì •! ğŸ”œ\n**ê²€ì¦ (Verification): 0:00~0:30 ë°›ì•„ì“°ê¸°**\n\"ì•ˆë…•í•˜ì„¸ìš”. íŒë§‰ ì§ˆí™˜ì— ëŒ€í•œ ì €í¬ ë‘ ë²ˆì§¸ ì‹¬ì¸µ ë¶„ì„ ì‹œê°„ì— ì˜¤ì‹  ê±¸ í™˜ì˜í•©ë‹ˆë‹¤. ë„¤, ì•ˆë…•í•˜ì„¸ìš”. ì§€ë‚œ ì‹œê°„ì—ëŠ” ì €í¬ê°€ ì‹¬ì¥ì˜ ë¬¸ì´ ì¢ì•„ì§€ëŠ” í˜‘ì°©ì¦, ê·¸ì¤‘ì—ì„œë„ íŠ¹íˆ ëŒ€ë™ë§¥íŒ í˜‘ì°©ì¦ì„ ë‹¤ë¤˜ì–ì•„ìš”. ë„¤ ë§ìŠµë‹ˆë‹¤. ì‹¬ì¥ì— ê°€í•´ì§€ëŠ” ê·¸ ì—„ì²­ë‚œ ì••ë ¥ ë¶€í•˜ì— ëŒ€í•œ ì´ì•¼ê¸°ì˜€ì£ . ë§ì•„ìš”. ê·¸ë˜ì„œ ì˜¤ëŠ˜ì€ ì–´, ê·¸ ì •ë°˜ëŒ€ ìƒí™©. ê·¸ëŸ¬ë‹ˆê¹Œ ë¬¸ì´ ì œëŒ€ë¡œ ë‹«íˆì§ˆ ì•Šì•„ì„œ í”¼ê°€ ì—­ë¥˜í•˜ëŠ”, ë§í•˜ìë©´ ìƒˆëŠ” ë¬¸ì˜ ë¬¸ì œë¥¼ í•œë²ˆ íŒŒí—¤ì³ ë³´ë ¤ê³  í•©ë‹ˆë‹¤.\"\n---\n# ğŸ«€ USMLE Step 2 íŒë§‰ ì—­ë¥˜ ì§ˆí™˜(Regurgitant Valve Diseases) ì‹¬ì¸µ ë¶„ì„\n## 1. Introduction: ì—­ë¥˜ì„± ì§ˆí™˜ì˜ ê¸°ë³¸ ê°œë…\nì´ë²ˆ ì—í”¼ì†Œë“œì—ì„œëŠ” **ì‹¬ì¥ì˜ ë¬¸ì´ ì œëŒ€ë¡œ ë‹«íˆì§€ ì•Šì•„ í”¼ê°€ ìƒˆëŠ” 'ì—­ë¥˜ì„±(Regurgitant)' ì§ˆí™˜**ì„ ë‹¤ë£¹ë‹ˆë‹¤. í•µì‹¬ì€ ì••ë ¥ ì°¨ì´ì™€ ê·¸ì— ë”°ë¥¸ ì‹¬ì¥ì˜ ì ì‘ ê³¼ì •ì…ë‹ˆë‹¤.\n- **ì™¼ìª½ ì‹¬ì¥ (Left Heart):** ê±°ëŒ€í•œ ì••ë ¥ì„ ê²¬ë””ì§€ ëª»í•˜ê³  ìƒˆëŠ” ë¬¸.\n- **ì˜¤ë¥¸ìª½ ì‹¬ì¥ (Right Heart):** ë¹„êµì  ë‚®ì€ ì••ë ¥ì—ì„œ ë°œìƒí•˜ëŠ” ë¬¸ì œë“¤.","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-180"}
{"chunk_type":"transcript_chunk","text":"---\n## 2. ëŒ€ë™ë§¥íŒ ì—­ë¥˜ (Aortic Regurgitation, AR) ğŸ©¸\nì‹¬ì¥ì´ í”¼ë¥¼ ë¿œì–´ë‚¸ ì§í›„, íŒë§‰ì´ í—ê±°ì›Œì ¸ í”¼ê°€ ë‹¤ì‹œ ì¢Œì‹¬ì‹¤(LV)ë¡œ ìŸì•„ì ¸ ë“¤ì–´ì˜¤ëŠ” ìƒí™©ì…ë‹ˆë‹¤.\n### ğŸŒŠ ë³‘íƒœìƒë¦¬: ë”ì°í•œ ìš©ì  ë¶€í•˜ (Volume Overload)\n- **ì´í™˜ê¸°(Diastole)ì˜ ì¬ì•™:** ì‹¬ì¥ì´ ì‰¬ì–´ì•¼ í•  ë•Œ ëŒ€ë™ë§¥ìœ¼ë¡œ ë‚˜ê°”ë˜ í”¼ì˜ ìƒë‹¹ëŸ‰ì´ ì¢Œì‹¬ì‹¤ë¡œ 'ì™€ë¥´ë¥´' ë‹¤ì‹œ ìŸì•„ì ¸ ë“¤ì–´ì˜µë‹ˆë‹¤.\n- **ëë‚´ì•¼ í•  ì¼ì´ ì•ˆ ëë‚¨:** ì¢Œì‹¬ì‹¤ì€ ë§¤ ë°•ë™ë§ˆë‹¤ ì—„ì²­ë‚œ ì–‘ì˜ í”¼ë¥¼ ì¶”ê°€ë¡œ ë°›ê²Œ ë©ë‹ˆë‹¤.\n- **ì‹¬ì¥ì˜ ì ì‘:** **í¸ì‹¬ì„± ë¹„ëŒ€ (Eccentric Hypertrophy)**\n    - ë§ˆì¹˜ í’ì„ ì„ ê³„ì† ë¶ˆì–´ì„œ í¬ê²Œ ë§Œë“œëŠ” ê²ƒê³¼ ê°™ìŠµë‹ˆë‹¤.\n    - ë‹¹ì¥ì€ ë§ì€ í”¼ë¥¼ ë‹´ì„ ìˆ˜ ìˆì§€ë§Œ, í’ì„  ë²½ì´ ì–‡ì•„ì§€ê³  íë¬¼íë¬¼í•´ì§€ëŠ” ê²ƒì²˜ëŸ¼ ê²°êµ­ ì‹¬ì¥ ê·¼ìœ¡ë„ ì§€ì³ íŒí”„ ê¸°ëŠ¥ì„ ìƒì‹¤í•©ë‹ˆë‹¤.\n### ğŸ©º ì‹ ì²´ ì§„ì°° (Physical Exam) - \"ì˜í™” ê°™ì€ ì§•í›„ë“¤\"\nê·¹ë‹¨ì ì¸ í˜ˆë¥˜ëŸ‰ì˜ ì´ë™ ë•Œë¬¸ì— ë§¤ìš° ë“œë¼ë§ˆí‹±í•œ ì§•í›„ë“¤ì´ ë‚˜íƒ€ë‚©ë‹ˆë‹¤.\n1. **ë¬¼ë§ì¹˜ ë§¥ë°• (Water-hammer pulse / Corrigan's pulse):**\n    - ê°•í•˜ê²Œ 'ì¿µ' í•˜ê³  ë•Œë¦¬ëŠ” ë“¯í•œ ë§¥ë°•.\n2. **ë„“í˜€ì§„ ë§¥ì•• (Widened Pulse Pressure):**\n    - **ìˆ˜ì¶•ê¸°:** ê±°ëŒ€í•´ì§„ ì‹¬ì¥ì´ ë§ì€ í”¼ë¥¼ ë¿œì–´ë‚´ì–´ í˜ˆì••ì´ **ê¸‰ìƒìŠ¹**.\n    - **ì´ì™„ê¸°:** í”¼ê°€ ì‹¬ì¥ìœ¼ë¡œ ë‹¤ì‹œ ì‘¥ ë¹ ì ¸ë‚˜ê°€ë©´ì„œ í˜ˆì••ì´ **ê¸‰í•˜ê°•**.\n    - ì´ ê·¹ë‹¨ì ì¸ ì°¨ì´ê°€ ì†ëª©ì—ì„œ íŒŒë™ìœ¼ë¡œ ëŠê»´ì§‘ë‹ˆë‹¤.\n### â˜… High-Yield Tip: ì²­ì§„ ìœ„ì¹˜ë¡œ ì›ì¸ ê°ë³„í•˜ê¸°\nëŒ€ë™ë§¥íŒ ì—­ë¥˜ì˜ ì¡ìŒì€ **ì ì  ì•½í•´ì§€ëŠ” ì´ì™„ê¸° ì¡ìŒ (Decrescendo Diastolic Murmur)**ì…ë‹ˆë‹¤. í•˜ì§€ë§Œ ì¡ìŒì´ *ì–´ë””ì„œ* ë“¤ë¦¬ëŠëƒê°€ ì¤‘ìš”í•©ë‹ˆë‹¤.\n| ì²­ì§„ ìœ„ì¹˜ | ì˜ì‹¬ ì›ì¸ (Etiology) | í˜ˆë¥˜ ì œíŠ¸(Jet)ì˜ ë°©í–¥ |\n| --- | --- | --- |\n| **ìš°ì¸¡ í‰ê³¨ì—° (Right Sternal Border)** | **ëŒ€ë™ë§¥ ë¿Œë¦¬ (Aortic Root) í™•ì¥**<br>(ì˜ˆ: ë§ˆë¥´íŒ¡ ì¦í›„êµ°, ë§¤ë… ë“±) | í”¼ê°€ ì¤‘ì•™ì—ì„œ ì—­ë¥˜í•˜ì—¬ ìš°ì¸¡ìœ¼ë¡œ í–¥í•¨ |\n| **ì¢Œì¸¡ í‰ê³¨ì—° (Left Sternal Border)** | **íŒë§‰ ìì²´ (Valvular Leaflet) ë¬¸ì œ**<br>(ì˜ˆ: ì‹¬ë‚´ë§‰ì—¼, ì´ì—½ì„± ëŒ€ë™ë§¥íŒ) | íŒë§‰ì´ ë„ˆëœë„ˆëœí•´ì ¸ì„œ ì œíŠ¸ ê¸°ë¥˜ê°€ ì¢Œì‹¬ì‹¤ ë²½ì„ ë•Œë¦¼ |\n---\n## 3. ìŠ¹ëª¨íŒ ì—­ë¥˜ (Mitral Regurgitation, MR) ğŸŒªï¸\nì‹¬ì¥ì´ ì˜¨ í˜ì„ ë‹¤í•´ ì§œë‚´ëŠ” ìˆ˜ì¶•ê¸° ì••ë ¥ì„ ê²¬ëŒì•¼ í•˜ëŠ” ìŠ¹ëª¨íŒì´ ìƒˆëŠ” ìƒí™©ì…ë‹ˆë‹¤.\n### ğŸˆ ìŠ¹ëª¨íŒ íƒˆì¶œì¦ (Mitral Valve Prolapse, MVP)\n- ê°€ì¥ í”í•œ ì›ì¸ ì¤‘ í•˜ë‚˜. íŒë§‰ ì¡°ì§ì´ ì•½í•´ì ¸ ìˆ˜ì¶•ê¸° ë•Œ ì¢Œì‹¬ë°© ìª½ìœ¼ë¡œ í’ì„ ì²˜ëŸ¼ ë¶€í’€ì–´ ì˜¤ë¦„.\n- **ì²­ì§„ ì†Œê²¬:** **ìˆ˜ì¶•ê¸° ì¤‘ê¸° í´ë¦­ìŒ (Mid-systolic click)**. 'ë”¸ê¹' í•˜ëŠ” ì†Œë¦¬ê°€ ë“¤ë¦¬ë©°, ë” ì‹¬í•´ì§€ë©´ ì—­ë¥˜ê°€ ì‹œì‘ë©ë‹ˆë‹¤.\n### âš ï¸ ê¸‰ì„± vs ë§Œì„±: \"ê°€ì§œ ì •ìƒ\"ì˜ í•¨ì • (The Trap)\nìŠ¹ëª¨íŒ ì—­ë¥˜ëŠ” ì‹œê¸°ì— ë”°ë¼ ì–‘ìƒì´ ì™„ì „íˆ ë‹¤ë¦…ë‹ˆë‹¤.\n### 1) ê¸‰ì„± ìŠ¹ëª¨íŒ ì—­ë¥˜ (Acute MR) - *Medical Emergency* ğŸš¨\n- **ì‹œë‚˜ë¦¬ì˜¤:** ì‹¬ê·¼ê²½ìƒ‰(MI) í›„ **ìœ ë‘ê·¼ íŒŒì—´(Papillary muscle rupture)**ë¡œ íŒë§‰ ì§€ì§€ëŒ€ê°€ ëŠì–´ì§.\n- **ìƒí™©:** ì¤€ë¹„ë˜ì§€ ì•Šì€(ì‘ê³  ë”±ë”±í•œ) ì¢Œì‹¬ë°©ìœ¼ë¡œ í”¼ê°€ ì—­ë¥˜.\n- **í˜ˆì—­í•™:**\n    - í”¼ê°€ ì €í•­ì´ ë‚®ì€ ì¢Œì‹¬ë°©ìœ¼ë¡œ ë„ë§ê° $\\rightarrow$ **í›„ë¶€í•˜(Afterload) ê°ì†Œ**.\n    - **â˜… ë°•ì¶œë¥ (LVEF)ì˜ í•¨ì •:** LVEF ìˆ˜ì¹˜ëŠ” ì˜¬ë¼ê°„ ê²ƒì²˜ëŸ¼ ë³´ì„ (**Supranormal EF**).\n    - **ì‹¤ì œ ìƒí™©:** ëŒ€ë™ë§¥ìœ¼ë¡œ ë‚˜ê°€ëŠ” í”¼ëŠ” ë¶€ì¡± $\\rightarrow$ **ì‡¼í¬(Shock)** & **íë¶€ì¢…(Pulmonary Edema)**.\n- **Lesson:** ê¸‰ì„± MR í™˜ìì—ê²Œì„œ LVEFê°€ ì •ìƒì´ê±°ë‚˜ ë†’ì•„ ë³´ì´ëŠ” ê²ƒì€ í™˜ìê°€ ê´œì°®ë‹¤ëŠ” ëœ»ì´ ì•„ë‹˜. ì‹¤ì œë¡œëŠ” ì‹¬ê°í•œ ìƒíƒœì„.","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-190"}
{"chunk_type":"transcript_chunk","text":"### 2) ë§Œì„± ìŠ¹ëª¨íŒ ì—­ë¥˜ (Chronic MR)\n- **ìˆ˜ìˆ  íƒ€ì´ë°ì˜ ì—­ì„¤:**\n    - **ê¸°ì¤€:** ì¦ìƒì´ ì—†ë”ë¼ë„ **LVEFê°€ 60% ë¯¸ë§Œ**ìœ¼ë¡œ ë–¨ì–´ì§€ë©´ ìˆ˜ìˆ  ê³ ë ¤ (Range 30~60%).\n    - **ì´ìœ :** ì—­ë¥˜ ë•Œë¬¸ì— LVEFëŠ” \"ë»¥íŠ€ê¸°\"ëœ ìˆ˜ì¹˜ì„. 60% ë¯¸ë§Œì´ë¼ëŠ” ê²ƒì€ ì´ë¯¸ ì‹¬ì¥ ìˆ˜ì¶• ê¸°ëŠ¥ì´ ë§ê°€ì§€ê¸° ì‹œì‘í–ˆë‹¤ëŠ” **ê°•ë ¥í•œ ì ì‹ í˜¸**.\n    - ì¦ìƒì´ ë‚˜íƒ€ë‚  ë•Œê¹Œì§€ ê¸°ë‹¤ë¦¬ë©´ ì´ë¯¸ ëŠ¦ìŒ (ë¹„ê°€ì—­ì  ì†ìƒ).\n- **ì¹˜ë£Œ:** ê°€ëŠ¥í•˜ë‹¤ë©´ **íŒë§‰ ì„±í˜•ìˆ (Repair)**ì´ ì¹˜í™˜ìˆ (Replacement)ë³´ë‹¤ ì„ í˜¸ë¨ (í•­ì‘ê³ ì œ ë¶ˆí•„ìš”, ë‚´êµ¬ì„± ì¢‹ìŒ).\n---\n## 4. ìš°ì‹¬ì¥ íŒë§‰ ì§ˆí™˜ (Right Heart Valvular Diseases) ğŸ«\nìš°ì‹¬ì¥ ì§ˆí™˜ì˜ ê°ë³„ í¬ì¸íŠ¸ëŠ” **\"í˜¸í¡(Respiration)\"**ì…ë‹ˆë‹¤.\n### â˜… í˜¸í¡ê³¼ ì¡ìŒì˜ ê´€ê³„ (Carvallo's Sign)\n- **ìˆ¨ì„ ë“¤ì´ë§ˆì‹¤ ë•Œ (Inspiration):**\n    - í‰ê°• ë‚´ ì••ë ¥ ê°ì†Œ $\\rightarrow$ ìš°ì‹¬ì¥ìœ¼ë¡œ ë“¤ì–´ì˜¤ëŠ” ì •ë§¥ í™˜ë¥˜ëŸ‰(Venous Return) ì¦ê°€.\n    - **ê²°ê³¼:** ì¢ì€ ë¬¸ì„ í†µê³¼í•˜ê±°ë‚˜ ìƒˆëŠ” í”¼ì˜ ì–‘ì´ ë§ì•„ì§ $\\rightarrow$ **ìš°ì‹¬ì¥ ì¡ìŒ(TR, PR, PS)ì´ ì»¤ì§**.\n    - ë°˜ëŒ€ë¡œ ì¢Œì‹¬ì¥ ì¡ìŒì€ ë³€í™”ê°€ ì—†ê±°ë‚˜ ì‘ì•„ì§.\n    - *ì´ê²ƒì´ ì¢Œì‹¬ì¥/ìš°ì‹¬ì¥ ì¡ìŒì„ êµ¬ë³„í•˜ëŠ” ê°€ì¥ í™•ì‹¤í•œ ì²­ì§„ íŒ!*\n### ì£¼ìš” ì§ˆí™˜ë“¤\n1. **íë™ë§¥íŒ í˜‘ì°©ì¦ (Pulmonic Stenosis):** Crescendo-decrescendo ì¡ìŒ (í¡ê¸° ì‹œ ì¦ê°€).\n2. **íë™ë§¥íŒ ì—­ë¥˜ (Pulmonic Regurgitation):**\n    - ì›ì¸: ì£¼ë¡œ ì˜ì¸ì„± (TOF ìˆ˜ìˆ  ë“± ì¹˜ë£Œ ê³¼ì • í›„ ë°œìƒ).\n    - ì¡ìŒ: Decrescendo diastolic murmur (í¡ê¸° ì‹œ ì¦ê°€).\n3. **ì‚¼ì²œíŒ ì—­ë¥˜ (Tricuspid Regurgitation):**\n    - ì›ì¸: ì£¼ë¡œ ìš°ì‹¬ì‹¤ í™•ì¥ì— ì˜í•œ 2ì°¨ì (ê¸°ëŠ¥ì ) ì›ì¸.\n---\n## 5. ì‚¼ì²œíŒ íì‡„ì¦ (Tricuspid Atresia) ğŸ‘¶\nì‹ ìƒì•„ ì‹¬ì „ë„(ECG) í•˜ë‚˜ë¡œ ì§„ë‹¨í•  ìˆ˜ ìˆëŠ” ê²°ì •ì  ë‹¨ì„œê°€ ìˆìŠµë‹ˆë‹¤.\n### ğŸ§© ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤\n- ì²­ìƒ‰ì¦(Cyanosis)ì´ ìˆëŠ” ì‹ ìƒì•„.\n### â˜… ê²°ì •ì  ë‹¨ì„œ: ì¢Œì¶• í¸ìœ„ (Left Axis Deviation, LAD)\n- **ì •ìƒ ì‹ ìƒì•„:** íƒœì•„ ìˆœí™˜ íŠ¹ì„±ìƒ ìš°ì‹¬ì‹¤ì´ ì¢Œì‹¬ì‹¤ë³´ë‹¤ ìš°ì„¸ $\\rightarrow$ **ìš°ì¶• í¸ìœ„(RAD)**ê°€ ì •ìƒ.\n- **ì‚¼ì²œíŒ íì‡„ì¦:**\n    - ì‚¼ì²œíŒì´ ì•„ì˜ˆ ë§‰í˜ $\\rightarrow$ ìš°ì‹¬ì‹¤ë¡œ í”¼ê°€ ëª» ê° $\\rightarrow$ ìš°ì‹¬ì‹¤ ë°œë‹¬ ì €í•˜ (Hypoplastic RV).\n    - ëª¨ë“  í”¼ëŠ” ASD/VSDë¥¼ í†µí•´ ì¢Œì‹¬ì‹¤ë¡œë§Œ ìˆœí™˜.\n    - **ê²°ê³¼:** ì¢Œì‹¬ì‹¤ë§Œ ì¼ì„ í•¨ $\\rightarrow$ ì „ê¸°ì  ì¶•ì´ ì™¼ìª½ìœ¼ë¡œ ì ë¦¼ (**LAD**).\n    - **ECG íŠ¹ì§•:** **Tall P waves** (ìš°ì‹¬ë°© ë¹„ëŒ€) + **LAD**.\n- **ê²°ë¡ :** ì²­ìƒ‰ì¦ ì‹ ìƒì•„ì—ì„œ LADê°€ ë³´ì´ë©´ **ì‚¼ì²œíŒ íì‡„ì¦**ì„ ê°•ë ¥íˆ ì‹œì‚¬.\n---","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-210"}
{"chunk_type":"recap_summary","text":"# ğŸš€ Rapid Fire Recap: Must-Know High Yield Summary\n## 1. Aortic Regurgitation (AR)\n- **Mechanism:** Volume Overload $\\rightarrow$ Eccentric Hypertrophy.\n- **Signs:** Water-hammer pulse, Widened Pulse Pressure.\n- **Differentiation (Location):**\n    - **Right** Sternal Border murmur $\\rightarrow$ **Aortic Root** issue (Marfan).\n    - **Left** Sternal Border murmur $\\rightarrow$ **Valve Leaflet** issue (Endocarditis).\n## 2. Mitral Regurgitation (MR)\n- **The Trap (Acute MR):** **Normal/High LVEF** is a sign of severe hemodynamic collapse (Shock/Pulmonary Edema). Don't be fooled by the number.\n- **Surgery Timing (Chronic MR):** Operate when **LVEF < 60%** (even if asymptomatic). EF < 60% means LV dysfunction represents significant damage.\n- **Pathology:** MVP causes Mid-systolic click.\n## 3. Right Sided Murmurs\n- **Key Action:** Ask patient to breathe in (**Inspiration**).\n- **Rule:** Inspiration increases venous return $\\rightarrow$ **Right-sided murmurs get LOUDER**. (Left-sided murmurs do not).\n## 4. Tricuspid Atresia\n- **Clinical Picture:** Cyanotic Newborn.\n- **Key ECG Finding:** **Left Axis Deviation (LAD)**. (Since normal newborns have RAD, LAD implies a hypoplastic RV due to atresia).\n**Verification: Audio Dictation (0:00 ~ 0:30)**","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-227"}
{"chunk_type":"transcript_chunk","text":"\"USMLE Step 2 ì‹œí—˜ì„ ì¤€ë¹„í•˜ê³  ê³„ì‹  ì²­ì·¨ìë¶„ë“¤ì„ ìœ„í•´ ì €í¬ê°€ ëŒ€ì‹  ìë£Œë¥¼ ê¹Šê²Œ íŒŒê³ ë“œëŠ” ì‹œê°„ì…ë‹ˆë‹¤. ë³´ë‚´ì£¼ì‹  ë°©ëŒ€í•œ ì‹¬ì¥í•™ ìë£Œ ì¤‘ì—ì„œ ì˜¤ëŠ˜ì€ ê°€ì¥ í•µì‹¬ì´ë¼ê³  í•  ìˆ˜ ìˆëŠ” ì‹¬ì „ë„ íŒë…ì— í•œë²ˆ ì§‘ì¤‘í•´ ë³´ë ¤ê³  í•©ë‹ˆë‹¤.\në„¤, ì•„ì£¼ ì¤‘ìš”í•œ ë¶€ë¶„ì´ì£ .\nëª©í‘œëŠ” ì´ ë³µì¡í•œ íŒŒí˜•ë“¤ì„ ê·¸ëƒ¥ ì™¸ìš°ëŠ” ê²Œ ì•„ë‹ˆë¼ ê·¸ ë…¼ë¦¬ë¥¼ ì´í•´í•´ì„œ ì–´ë–¤ ìƒí™©ì—ì„œë„ ìì‹  ìˆê²Œ ë¶„ì„í•  ìˆ˜ ìˆë„ë¡ ë•ëŠ” ê²ë‹ˆë‹¤. ì, ê·¸ëŸ¼ ì‹¬ì¥ì˜ ì „ê¸° ì‹ í˜¸ë¥¼ ë”°ë¼ê°€ëŠ” ì—¬ì •, ë°”ë¡œ ì‹œì‘í•´ ë³¼ê¹Œìš”?\"\n---\n# ğŸ«€ USMLE Step 2 Cardiology Deep Dive: ì‹¬ì „ë„(ECG)ì™€ ë¶€ì •ë§¥ ë§ˆìŠ¤í„°í•˜ê¸°\n## 1. Introduction: ì‹¬ì „ë„ëŠ” ì‹¬ì¥ì˜ ì–¸ì–´ë‹¤ ğŸ—£ï¸\n- **í•µì‹¬ ëª©í‘œ:** íŒŒí˜•ì„ ë‹¨ìˆœ ì•”ê¸°í•˜ëŠ” ê²ƒì´ ì•„ë‹ˆë¼, ë…¼ë¦¬ë¥¼ ì´í•´í•˜ì—¬ ì–´ë–¤ ìƒí™©ì—ì„œë„ ë¶„ì„ ê°€ëŠ¥í•˜ê²Œ í•˜ëŠ” ê²ƒ.\n- **ì ‘ê·¼ ë°©ì‹:** ì‹¬ì¥ì˜ ìœ„ì¸µ(ì‹¬ë°©) â†’ ì•„ë˜ì¸µ(ì‹¬ì‹¤) â†’ ëŠë¦¬ê²Œ ë›°ëŠ” ë¬¸ì œ(ì„œë§¥) ìˆœì„œë¡œ ì²´ê³„ì  ì ‘ê·¼.\n- **ì„ìƒì  ì˜ì˜:** ë¶€ì •ë§¥ ì§„ë‹¨ì˜ ì‹œì‘ì ì´ì, ì‹¬ì¥ì˜ ìƒíƒœë¥¼ íŒŒì•…í•˜ëŠ” ë„êµ¬.\n---\n## 2. ì‹¬ë°©ì—ì„œ ì‹œì‘ë˜ëŠ” ë¬¸ì œ (Supraventricular Arrhythmias) âš¡ï¸\n### 2.1. ë°œì‘ì„± ìƒì‹¬ì‹¤ì„± ë¹ˆë§¥ (PSVT)\n- **ğŸ’¬ ì„ìƒ ì‹œë‚˜ë¦¬ì˜¤:** ì Šì€ í™˜ìê°€ \"ê°€ìŠ´ì´ ë¯¸ì¹œ ë“¯ì´ ë›´ë‹¤\"ë©° ì‘ê¸‰ì‹¤ ë‚´ì›.\n- **ğŸ“‰ ECG íŠ¹ì§•:**\n    - Heart Rate > 150íšŒ/ë¶„ (ë§¤ìš° ë¹ ë¦„).\n    - RR ê°„ê²©: ì¹¼ë¡œ ì° ë“¯ ê·œì¹™ì  (Regular).\n    - QRS íŒŒí˜•: ì¢ìŒ (Narrow).\n    - **â˜… PíŒŒ:** ë³´ì´ì§€ ì•ŠìŒ (ë„ˆë¬´ ë¹¨ë¼ì„œ QRS íŒŒí˜• ì•ˆìœ¼ë¡œ ìˆ¨ì–´ë²„ë¦¼).\n- **âš™ï¸ ë°œìƒ ê¸°ì „ (Mechanism):** ë°©ì‹¤ê²°ì ˆ(AV node) ë‚´ì˜ **ì¬ì§„ì… íšŒë¡œ(Re-entry circuit)**.\n    - ì„ ì²œì ìœ¼ë¡œ ë¹ ë¥¸ ê¸¸(Fast pathway)ê³¼ ëŠë¦° ê¸¸(Slow pathway) ë‘ ê°€ì§€ë¥¼ ê°€ì§„ ì‚¬ëŒì´ íŠ¹ì • ê³„ê¸°ë¡œ ì „ê¸°ê°€ ë±…ê¸€ë±…ê¸€ ëŒê²Œ ë¨.\n- **ğŸ’Š ì¹˜ë£Œ ì „ëµ (Treatment):**\n    - **1ì°¨ ì‹œë„:** **ë¯¸ì£¼ì‹ ê²½ ìê·¹ë²• (Vagal Maneuvers)** - ë°œì‚´ë°”(Valsalva), ê²½ë™ë§¥ ë§ˆì‚¬ì§€.\n    - **ì›ë¦¬:** ë¯¸ì£¼ì‹ ê²½(ë¸Œë ˆì´í¬ ì—­í• )ì„ ìê·¹ â†’ ë°©ì‹¤ê²°ì ˆ ì „ë„ ì†ë„ ì €í•˜ â†’ íšŒë¡œ ì°¨ë‹¨ â†’ ì •ìƒ ë¦¬ë“¬ ë³µê·€.\n### 2.2. ì‹¬ë°©ì„¸ë™ (Atrial Fibrillation) ğŸŒªï¸\n- **ì„¤ëª…:** \"ë¶ˆê·œì¹™í•˜ê²Œ ë¶ˆê·œì¹™í•œ (Irregularly Irregular)\" ë¶€ì •ë§¥. ì˜ˆì¸¡ ë¶ˆê°€.\n- **ğŸ“‰ ECG íŠ¹ì§•:** RR ê°„ê²©ì´ ì œë©‹ëŒ€ë¡œ, PíŒŒ ì†Œì‹¤(ê¸°ì €ì„ ì´ ìê¸€ìê¸€ ë–¨ë¦¼).\n- **âš™ï¸ ë°œìƒ ì›ì¸:** íì •ë§¥ ì£¼ë³€ì—ì„œ ë¬´ì§ˆì„œí•œ ì „ê¸° ì‹ í˜¸ê°€ í­í’ì²˜ëŸ¼ ìŸì•„ì ¸ ë°©ì‹¤ê²°ì ˆì„ í­ê²©í•¨.\n- **âš ï¸ ìœ„í—˜ ìš”ì¸ (Risk Factors):**\n    - **â˜… ê³ í˜ˆì•• (ê°€ì¥ ì¤‘ìš”/í”í•¨)**.\n    - ê³ ë ¹, ì‹¬ë¶€ì „.\n- **ğŸ§ª í•„ìˆ˜ ê²€ì‚¬:** **ê°‘ìƒì„  ê¸°ëŠ¥ ê²€ì‚¬ (TSH)**.\n    - ì´ìœ : ê°‘ìƒì„ ê¸°ëŠ¥í•­ì§„ì¦ì€ **êµì • ê°€ëŠ¥í•œ(Correctable)** ì‹¬ë°©ì„¸ë™ì˜ ì›ì¸ì´ê¸° ë•Œë¬¸.\n- **ğŸ’Š ê´€ë¦¬ ì „ëµ (Management):**\n    - **Rate Control (ì‹¬ë°•ìˆ˜ ì¡°ì ˆ) vs. Rhythm Control (ë¦¬ë“¬ ì¡°ì ˆ)**\n    - **â˜… ì—°êµ¬ ê²°ê³¼:** ë‘ ì „ëµ ê°„ ìƒì¡´ìœ¨ì´ë‚˜ ë‡Œì¡¸ì¤‘ ì˜ˆë°© ì¸¡ë©´ì—ì„œ í° ì°¨ì´ê°€ ì—†ìŒ.\n    - **ì ‘ê·¼ë²•:** í™˜ì ë§ì¶¤í˜•.\n        - ì¦ìƒì´ ì‹¬í•¨ â†’ Rhythm Control ê³ ë ¤.\n        - ì¦ìƒì´ ê²½ë¯¸/ë¬´ì¦ìƒ â†’ ë¶€ì‘ìš©ì´ ì ì€ **Rate Control ìš°ì„ **.\n### 2.3. ê¸°íƒ€ ì‹¬ë°© ë¶€ì •ë§¥\n- **ì‹¬ë°© ì¡°ê¸° ìˆ˜ì¶• (PAC):** ì •ìƒ ë¦¬ë“¬ ì¤‘ê°„ì— í†¡ íŠ€ì–´ë‚˜ì˜´. ëŒ€ë¶€ë¶„ ë¬´ì¦ìƒ. ê¸ˆì—°/ê¸ˆì£¼ ë“± ìƒí™œìŠµê´€ ê´€ë¦¬ ê¶Œê³ .\n- **ë‹¤í˜•ì„± ì‹¬ë°© ë¹ˆë§¥ (Multifocal Atrial Tachycardia, MAT) ğŸ«**\n    - **ğŸ“‰ ECG íŠ¹ì§•:** ì‹¬ë°©ì„¸ë™ì²˜ëŸ¼ ë¶ˆê·œì¹™í•´ ë³´ì´ì§€ë§Œ, **â˜… ëª¨ì–‘ì´ ë‹¤ë¥¸ PíŒŒê°€ 3ê°€ì§€ ì´ìƒ** ê´€ì°°ë¨ (ì—¬ëŸ¬ ëª…ì˜ ë¦¬ë”ê°€ ì‹ í˜¸ë¥¼ ë³´ë‚´ëŠ” 'ë°˜ë€êµ°' ìƒíƒœ).\n    - **â˜… ì„ìƒì  ì—°ê²°ê³ ë¦¬:** **COPD (ë§Œì„± íì‡„ì„± íì§ˆí™˜)** ë“± ë§Œì„± íì§ˆí™˜ í™˜ìì—ì„œ í”í•¨.\n    - **Action:** MATê°€ ë³´ì´ë©´ **í ìƒíƒœ**ë¥¼ í™•ì¸í•˜ë¼!\n---\n## 3. ì‹¬ì‹¤ì—ì„œ ìƒê¸°ëŠ” ë¬¸ì œ (Ventricular Arrhythmias) ğŸ’¥\n- **íŠ¹ì§•:** ì‹¬ì‹¤ì€ ì£¼ íŒí”„ì´ë¯€ë¡œ ë¬¸ì œê°€ ìƒê¸°ë©´ í˜ˆì•¡ ìˆœí™˜ì´ ìœ„íƒœë¡œì›€. ë„“ì€ QRS (Wide Complex Tachycardia).\n### 3.1. ì‹¬ì‹¤ ë¹ˆë§¥ (Ventricular Tachycardia)\n- **ğŸš¨ ì¹˜ë£Œ ê²°ì •ì˜ í•µì‹¬ (Algorithm):** **í™˜ìê°€ ì•ˆì •í•œê°€(Stable) vs. ë¶ˆì•ˆì •í•œê°€(Unstable)?**\n    - **Stable (í˜ˆì•• ìœ ì§€, ì˜ì‹ ëª…ë£Œ):** ì•½ë¬¼ ì¹˜ë£Œ.\n    - **Unstable (ì €í˜ˆì••, ì˜ì‹ ì†Œì‹¤):** **ì¦‰ì‹œ ì „ê¸° ì¶©ê²© (Synchronized Cardioversion)**. ê¸°ë‹¤ë¦´ ì‹œê°„ ì—†ìŒ.\n- **ğŸ” í™•ì§„ ë‹¨ì„œ (Diagnostic Clues):**\n    - **í¬íšíŒŒ (Capture beat):** ì •ìƒ ì‹ í˜¸ê°€ ìš´ ì¢‹ê²Œ ì¢ì€ QRSë¥¼ ë§Œë“¦.\n    - **ìœµí•©íŒŒ (Fusion beat):** ì •ìƒ ì‹ í˜¸ì™€ ì‹¬ì‹¤ ì‹ í˜¸ê°€ ì„ì—¬ ì–´ì¤‘ê°„í•œ ëª¨ì–‘ì„ ë§Œë“¦.\n    - â†’ ì´ ë‘ ê°€ì§€ê°€ ë³´ì´ë©´ ì‹¬ì‹¤ ë¹ˆë§¥ í™•ì§„ ê°€ëŠ¥ (ë°©ì‹¤ í•´ë¦¬ ì¦ê±°).\n### 3.2. í† ë¥´ì‚¬ë“œ ë“œ í¬ì¸íŠ¸ (Torsades de Pointes) ğŸ¥¨\n- **ì´ë¦„ì˜ ëœ»:** \"ì ë“¤ì˜ ë¹„í‹€ë¦¼\" (íŒŒí˜•ì´ ê¸°ì €ì„ ì„ ì¤‘ì‹¬ìœ¼ë¡œ ê¼¬ì„).\n- **ğŸ“‰ íŠ¹ì§•:** QT ê°„ê²© ì—°ì¥(Prolonged QT)ì— ì˜í•´ ë°œìƒ.\n- **ğŸ’Š ì¹˜ë£Œ (Treatment):**\n    - **â˜… 1ì°¨ ì¹˜ë£Œì œ: ì •ë§¥ ì£¼ì‚¬ ë§ˆê·¸ë„¤ìŠ˜ (IV Magnesium).**\n    - **ì›ë¦¬:** ì‹¬ì¥ ì„¸í¬ë§‰ì˜ ì´ì˜¨ ì±„ë„ ì•ˆì •í™”.\n    - **ì£¼ì˜:** ì¼ë°˜ í•­ë¶€ì •ë§¥ì œëŠ” QTë¥¼ ë” ëŠ˜ë¦¬ë¯€ë¡œ ê¸ˆê¸°.\n    - **Unstable:** ì œì„¸ë™ (Defibrillation).","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-237"}
{"chunk_type":"transcript_chunk","text":"---\n## 4. ëŠë¦¬ê²Œ ë›°ëŠ” ë¬¸ì œ (Bradycardia & AV Blocks) ğŸ¢\n### 4.1. ì„œë§¥ì˜ ê¸°ë³¸ (Bradycardia Basics)\n- **ì›ì¹™:** ì¦ìƒ(ì–´ì§€ëŸ¬ì›€, ì‹¤ì‹ )ì´ ì—†ìœ¼ë©´ ì¹˜ë£Œí•˜ì§€ ì•ŠìŒ (ì˜ˆ: ìš´ë™ì„ ìˆ˜).\n- **ğŸ’Š ì¦ìƒì´ ìˆê³  ë¶ˆì•ˆì •í•œ ê²½ìš° (Symptomatic Unstable):**\n    - **1st Line:** **ì•„íŠ¸ë¡œí•€ (Atropine)**.\n        - **ì›ë¦¬:** ë¶€êµê°ì‹ ê²½(ë¸Œë ˆì´í¬) ì°¨ë‹¨ = ê°€ì† í˜ë‹¬ íš¨ê³¼.\n    - **ë°˜ì‘ ì—†ìŒ:** Pacing (ì‹¬ë°• ì¡°ìœ¨).\n### 4.2. ë°©ì‹¤ ì°¨ë‹¨ (AV Block) - ë¹„ìœ ë¥¼ í†µí•œ ì´í•´ ğŸš§\n| ì¢…ë¥˜ | íŠ¹ì§• ë° ë¹„ìœ  | ì˜ˆí›„ ë° ì¹˜ë£Œ |\n| --- | --- | --- |\n| **1ë„ (1st Degree)** | PR ê°„ê²© ì¼ì •í•˜ê²Œ ê¸¸ì–´ì§. <br> *\"ì§€ê°í•˜ì§€ë§Œ ë§¤ì¼ ì¶œê·¼í•˜ëŠ” ì§ì›\"* | ì–‘í˜¸. ê´€ì°°. |\n| **2ë„ 1í˜• (Wenckebach)** | PRì´ ì ì  ê¸¸ì–´ì§€ë‹¤ê°€ QRS íƒˆë½. <br> *\"ì ì  ì§€ì¹˜ë‹¤ê°€ í•˜ë£¨ ê²°ê·¼í•˜ëŠ” ì§ì›\"* | ë¹„êµì  ì–‘í˜¸. ê´€ì°°. |\n| **2ë„ 2í˜• (Mobitz II)** | **â˜… PR ì •ìƒ, ê°‘ìê¸° QRS íƒˆë½.** <br> *\"ì˜ˆê³  ì—†ì´ ê°‘ìê¸° ê²°ê·¼í•˜ëŠ” ì§ì›\"* | **ìœ„í—˜.** ì˜ˆì¸¡ ë¶ˆê°€í•˜ë©° ì™„ì „ ì°¨ë‹¨ìœ¼ë¡œ ì§„í–‰ ê°€ëŠ¥. <br> **â˜… Pacemaker ê³ ë ¤.** |\n| **3ë„ (Complete)** | PíŒŒì™€ QRSê°€ ë”°ë¡œ ë†‚ (ë°©ì‹¤ í•´ë¦¬). <br> *\"ë™ì—…ìê°€ ê°ˆë¼ì„œì„œ ë”°ë¡œ ë…¸ëŠ” ìƒíƒœ\"* | **ë§¤ìš° ìœ„í—˜.** ì‹¬ì‹¤ ì´íƒˆ ë¦¬ë“¬ì€ ë„ˆë¬´ ëŠë¦¼. <br> **â˜… Permanent Pacemaker í•„ìˆ˜.** |\n### 4.3. ë™ê¸°ëŠ¥ ë¶€ì „ ì¦í›„êµ° (Sick Sinus Syndrome) ğŸ‘´\n- **íŠ¹ì§•:** ë…¸ì¸ í™˜ì. ë°œì „ì†Œ(SA node) ë…¸í›„í™”.\n- **ì¦ìƒ:** ì„œë§¥-ë¹ˆë§¥ ì¦í›„êµ° (ëŠë ¸ë‹¤ê°€ ë¹¨ëë‹¤ê°€ ë°˜ë³µ).\n- **ì¹˜ë£Œ:** ëŠë¦° ë§¥ì„ ìœ„í•´ Pacemaker ì‚½ì… + ë¹ ë¥¸ ë§¥ ì¡°ì ˆì„ ìœ„í•œ ì•½ë¬¼ ë³‘ìš©.\n---\n## 5. Rapid Fire Recap: High Yield Summary ğŸ”¥\në¹ ë¥¸ ë³µìŠµì„ ìœ„í•œ í•µì‹¬ ìš”ì•½ì…ë‹ˆë‹¤.\n1. **PSVT:** ì Šì€ í™˜ì + ê°‘ì‘ìŠ¤ëŸ¬ìš´ ë‘ê·¼ê±°ë¦¼ + PíŒŒ ì•ˆ ë³´ì„ â†’ **Vagal Maneuver** (1st step).\n2. **A-Fib:** ê³ í˜ˆì•• í™˜ì + Irregularly Irregular â†’ **TSH ì²´í¬** (êµì • ê°€ëŠ¥ ì›ì¸), ì¦ìƒ ê²½ë¯¸í•˜ë©´ **Rate Control**.\n3. **MAT (Multifocal Atrial Tachycardia):** ë¶ˆê·œì¹™ + PíŒŒ ëª¨ì–‘ 3ê°œ ì´ìƒ â†’ **COPD/íì§ˆí™˜** ì˜ì‹¬.\n4. **V-Tach:** ê°€ì¥ ì¤‘ìš”í•œ ê±´ **Vital Sign**. Unstableí•˜ë©´ **Cardioversion**.\n5. **Torsades de Pointes:** QT ì—°ì¥ + ê¼¬ì¸ íŒŒí˜• â†’ **Magnesium Sulfate**.\n6. **Mobitz II Block:** ì˜ˆê³  ì—†ëŠ” QRS íƒˆë½ â†’ **Pacemaker** (Hiss-Purkinje ì‹œìŠ¤í…œ ë¬¸ì œë¡œ ê³ ìœ„í—˜).\n7. **Symptomatic Bradycardia:** ì¦ìƒ ìˆëŠ” ì„œë§¥ 1ì°¨ ì•½ë¬¼ â†’ **Atropine**.\n**â˜… Final Clinical Pearl:** ì‹¬ì „ë„ íŒŒí˜• ì•”ê¸°ë³´ë‹¤ ì¤‘ìš”í•œ ê²ƒì€, **í™˜ìì˜ ìƒíƒœ(ì¦ìƒ, í˜ˆì••)**ì™€ **ì „ì²´ì ì¸ ë§¥ë½(ê¸°ì €ì§ˆí™˜)** ì†ì—ì„œ íŒë‹¨í•˜ëŠ” ê²ƒì…ë‹ˆë‹¤. ëª¨ë¹„ì¸  1í˜•ê³¼ 2í˜•ì„ êµ¬ë¶„í•˜ëŠ” ê²ƒì€ ë‹¨ìˆœí•œ íŒŒí˜• ë¶„ì„ì´ ì•„ë‹ˆë¼, í™˜ìì˜ ì¥ê¸°ì  ì˜ˆí›„(ì•ˆì • vs ìœ„í—˜)ë¥¼ ê²°ì •ì§“ëŠ” ì¤‘ëŒ€í•œ ì„ìƒì  íŒë‹¨ì…ë‹ˆë‹¤.","subject":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","page_title":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","episode":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","section_path":["LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f"],"source_doc_id":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f","source_page":null,"source_anchor":"LM_cardio 2 5~ 2f346f2986ee8091a918d9958d59899f-257"}
{"chunk_type":"transcript_chunk","text":"# LM_cardio 3\n# ğŸ«€ USMLE Step 2 Heart Failure (ì‹¬ë¶€ì „) ì™„ë²½ ì •ë¦¬\n## 0. Verification (0:00 ~ 0:30 ë°›ì•„ì“°ê¸°)\n\"ì•ˆë…•í•˜ì„¸ìš”, USMLE ìŠ¤í…íˆ¬ ì‹œí—˜ ì¤€ë¹„í•˜ì‹œëŠ” ì²­ì·¨ìë¶„ê»˜ì„œ ì‹¬ë¶€ì „ ìë£Œë¥¼ ë³´ë‚´ì£¼ì…¨ëŠ”ë°, ì™€ ì–‘ì´ ì •ë§ ë°©ëŒ€í•˜ë„¤ìš”. ì´ê±¸ ë³´ë‹ˆê¹Œ ì‹¬ë¶€ì „ì´ë¼ëŠ” ê²Œ ê·¸ëƒ¥ ì‹¬ì¥ì´ ê³ ì¥ ë‚¬ë‹¤ ì´ê²Œ ì „í˜€ ì•„ë‹ˆë”ë¼ê³ ìš”. ìë£Œë¥¼ ë³´ë©´ ì‹¬ì¥ì´ ì•½í•´ì„œ ë¬¸ì œì¸ ê²½ìš°ë„ ìˆê³  ë„ˆë¬´ ë»£ë»£í•´ì„œ, ì‹¬ì§€ì–´ëŠ” ì¼ì„ ë„ˆë¬´ ë§ì´ í•´ì„œ ë¬¸ì œê°€ ë˜ê¸°ë„ í•˜ê³ ìš”. ê·¸ë˜ì„œ ì˜¤ëŠ˜ ì €í¬ì˜ ëª©í‘œëŠ” ì´ ë³µì¡í•œ ì‹¬ë¶€ì „ì˜ ì—¬ëŸ¬ ì–¼êµ´ë“¤ì„ ëª…í™•íˆ êµ¬ë¶„í•´ì„œ ì§„ë‹¨ë¶€í„° ì¹˜ë£Œê¹Œì§€ í•µì‹¬ë§Œ ë”±ë”± ì •ë¦¬í•´ ë“œë¦¬ëŠ” ê²ë‹ˆë‹¤. ì, ê·¸ëŸ¼ í•œë²ˆ ì œëŒ€ë¡œ ë“¤ì–´ê°€ ë³¼ê¹Œìš”?\"\n---\n## 1. Introduction: ì‹¬ë¶€ì „ì˜ ì •ì˜ì™€ 4ê°€ì§€ ì–¼êµ´\nì‹¬ë¶€ì „(Heart Failure)ì€ ë‹¨ìˆœí•œ ê³ ì¥ì´ ì•„ë‹ˆë¼, **ì‹¬ì¥ì´ ìš°ë¦¬ ëª¸ì˜ ëŒ€ì‚¬ ìš”êµ¬ëŸ‰ì„ ê°ë‹¹í•˜ì§€ ëª»í•˜ëŠ” ìƒíƒœ**ë¡œ ê·€ê²°ë˜ëŠ” ì¦í›„êµ°ì…ë‹ˆë‹¤. íŒŸìºìŠ¤íŠ¸ì—ì„œëŠ” ì‹¬ë¶€ì „ì„ í¬ê²Œ 4ê°€ì§€ ê·¸ë¦¼ìœ¼ë¡œ ë¶„ë¥˜í–ˆìŠµë‹ˆë‹¤.\n1. **HFrEF (ìˆ˜ì¶•ê¸° ê¸°ëŠ¥ ë¶€ì „):** íŒí”„ê°€ ì•½í•´ì§„ ìƒíƒœ ğŸ“‰\n2. **HFpEF (ì´ì™„ê¸° ê¸°ëŠ¥ ë¶€ì „):** íŒí”„ëŠ” ê´œì°®ì€ë° ê³µê°„ì´ ë»£ë»£í•´ì„œ í”¼ë¥¼ ëª» ì±„ìš°ëŠ” ìƒíƒœ ğŸ§±\n3. **íì„±ì‹¬ (Cor Pulmonale):** í ë•Œë¬¸ì— ìš°ì‹¬ì‹¤ì´ ë§ê°€ì§€ëŠ” ìƒíƒœ ğŸ«\n4. **ê³ ë°•ì¶œì„± ì‹¬ë¶€ì „ (High-output HF):** ì—”ì§„ì´ ê³¼ì—´ë  ì •ë„ë¡œ ì¼ì„ ë„ˆë¬´ ë§ì´ í•˜ëŠ” ìƒíƒœ ğŸ”¥\n---\n## 2. ì§„ë‹¨(Diagnosis): ë¯¼ê°ë„ vs íŠ¹ì´ë„ ê²Œì„ ğŸ•µï¸â€â™‚ï¸\nì‹œí—˜ì—ì„œ í•¨ì •ìœ¼ë¡œ ë‚´ê¸° ì¢‹ì€ ë¶€ë¶„ì…ë‹ˆë‹¤. ì¦ìƒë§Œ ë³´ê³  íŒë‹¨í•˜ì§€ ë§ê³  **íŠ¹ì´ë„(Specificity)**ê°€ ë†’ì€ ì†Œê²¬ì„ ì°¾ì•„ì•¼ í•©ë‹ˆë‹¤.\n| ì†Œê²¬ | íŠ¹ì§• | ì„ìƒì  ì˜ë¯¸ |\n| --- | --- | --- |\n| **í˜¸í¡ ê³¤ë€ (Dyspnea)** | ë¯¼ê°ë„ ë†’ìŒ / íŠ¹ì´ë„ ë‚®ìŒ | íë ´, ë¶ˆì•ˆì¥ì•  ë“± ì›ì¸ì´ ë‹¤ì–‘í•˜ì—¬ ì´ê²ƒë§Œìœ¼ë¡œëŠ” í™•ì§„ ë¶ˆê°€ |\n| **â˜… S3 ì‹¬ìŒ (Gallop)** | ë¯¼ê°ë„ ë‚®ìŒ / **íŠ¹ì´ë„ ë§¤ìš° ë†’ìŒ** | \"ì¼„í„°í‚¤(Ken-tuc-ky)\" ë¦¬ë“¬. ë“¤ë¦¬ë©´ ê±°ì˜ í™•ì‹¤íˆ ì‹¬ë¶€ì „ (ê¸ˆë§¥ì„ ìº” ê²ƒê³¼ ê°™ìŒ!) |\n| **â˜… ê¸°ì¢Œí˜¸í¡ (Orthopnea)** | ë¯¼ê°ë„ ë‚®ìŒ / **íŠ¹ì´ë„ ë§¤ìš° ë†’ìŒ** | ëˆ„ìš°ë©´ ìˆ¨ì´ ì°¨ëŠ” ì¦ìƒ. ì‹¬ë¶€ì „ì˜ ê°•ë ¥í•œ ì¦ê±° |\n| **í˜ˆì²­ BNP** | 100 ì´ìƒ ì‹œ ìœ ì˜ë¯¸ | ë¯¼ê°ë„ ë†’ê³  íŠ¹ì´ë„ë„ ì–´ëŠ ì •ë„ ìˆì–´ ê°•ë ¥í•œ ë‹¨ì„œê°€ ë¨ |\n---\n## 3. ì‹¬ê°ë„ í‰ê°€: NYHA ë¶„ë¥˜ (Prognosis)\nì¦ìƒì˜ ì‹¬ê°ë„ë¥¼ ë„˜ì–´ **ì¹˜ë£Œ ë°©í–¥ê³¼ ì˜ˆí›„(Prognosis)**ë¥¼ ê²°ì •í•˜ëŠ” ê¸°ì¤€ì…ë‹ˆë‹¤.\n- **Class I:** ì¦ìƒì´ ì•„ì˜ˆ ì—†ëŠ” ìƒíƒœ (ë¬´ì¦ìƒ)\n- **Class II:** ê³„ë‹¨ ì˜¤ë¥´ê¸° ë“± ì¼ìƒ í™œë™ì—ì„œ ìˆ¨ì´ ì°¸\n- **Class III:** ì§‘ì•ˆì¼ ê°™ì€ ê°€ë²¼ìš´ í™œë™ì—ë„ ì¦ìƒ ë°œìƒ (ì‚¶ì˜ ì§ˆ ì €í•˜ ğŸ“‰)\n- **Class IV:** ê°€ë§Œíˆ ìˆì–´ë„ ìˆ¨ì´ ì°¨ëŠ” ìƒíƒœ (ìµœì•…ì˜ ì˜ˆí›„)\n    - ğŸ‘‰ **í•µì‹¬:** NYHA ë“±ê¸‰ì´ ë†’ì„ìˆ˜ë¡ ì˜ˆí›„ëŠ” ë‚˜ì©ë‹ˆë‹¤.\n---\n## 4. HFrEF (ìˆ˜ì¶•ê¸° ì‹¬ë¶€ì „) ì‹¬ì¸µ ë¶„ì„\n### 4-1. ë‚˜ìœ ì˜ˆí›„ ì¸ì (Bad Prognostic Factors) âš ï¸\në‹¤ìŒ ì†Œê²¬ë“¤ì´ ë³´ì´ë©´ í™˜ìì˜ ìƒíƒœê°€ ë§¤ìš° ìœ„í—˜í•¨ì„ ì•”ì‹œí•©ë‹ˆë‹¤.","subject":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","page_title":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","episode":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","section_path":["LM_cardio 3 2f346f2986ee80d9a857eb6585776d49"],"source_doc_id":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","source_page":null,"source_anchor":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49-1"}
{"chunk_type":"transcript_chunk","text":"- ë†’ì€ NYHA ë“±ê¸‰\n- ì²­ì§„ ì‹œ S3 Gallop\n- ëª©ì •ë§¥ì••(JVD) ìƒìŠ¹\n- ì €í˜ˆì••\n- ë†’ì€ Pro-BNP ìˆ˜ì¹˜\n- ì‹¬ì „ë„ìƒ QRS í­ > 120ms (ë˜ëŠ” LBBB)\n- **â˜… ì €ë‚˜íŠ¸ë¥¨í˜ˆì¦ (Hyponatremia)**\n### 4-2. ì €ë‚˜íŠ¸ë¥¨í˜ˆì¦ì˜ ì—­ì„¤ (Mechanism) ğŸ’§\n- **ìƒí™©:** ì‹¬ë°•ì¶œëŸ‰ ê°ì†Œ â†’ ì‹ ì¥ í˜ˆë¥˜ ê°ì†Œ\n- **ì˜¤í•´:** ëª¸ì€ ì´ë¥¼ 'íƒˆìˆ˜/í˜ˆì•¡ ë¶€ì¡±'ìœ¼ë¡œ ì°©ê°\n- **ë°˜ì‘:** í•­ì´ë‡¨í˜¸ë¥´ëª¬(ADH) ë¶„ë¹„ í­ë°œ ğŸ’¥\n- **ê²°ê³¼:** ìˆ˜ë¶„ ì¬í¡ìˆ˜ ì¦ê°€ â†’ í˜ˆì•¡ í¬ì„ â†’ **ì €ë‚˜íŠ¸ë¥¨í˜ˆì¦**\n    - ğŸ‘‰ ì¦‰, Na ìˆ˜ì¹˜ê°€ ë‚®ë‹¤ëŠ” ê²ƒì€ ëª¸ì´ ì‹¬ê°í•œ ìœ„ê¸° ìƒí™©ìœ¼ë¡œ ì¸ì‹í•˜ê³  ìˆë‹¤ëŠ” **ì¤‘ì¦ë„ì˜ ê°•ë ¥í•œ ì§€í‘œ**ì…ë‹ˆë‹¤. (í˜ˆì¤‘ Na < 130 ì´ë©´ 1ë…„ ìƒì¡´ìœ¨ ê¸‰ê°)\n---\n## 5. ê¸‰ì„± ì•…í™” ì‹¬ë¶€ì „ (Acute Decompensated HF) ëŒ€ì²˜ ğŸš‘\ní™˜ìê°€ ìˆ¨ì„ í—ë–¡ì´ê³  íë¶€ì¢…(Flash Pulmonary Edema)ì´ ì˜¨ ì‘ê¸‰ ìƒí™©ì—ì„œì˜ ëŒ€ì²˜ë²•ì…ë‹ˆë‹¤.\n### **í•µì‹¬ ì²´í¬ë¦¬ìŠ¤íŠ¸: LMNOP**\n- **L (Lasix):** ì´ë‡¨ì œ. ëª¸ì˜ ì „ì²´ ìˆ˜ë¶„ëŸ‰ì„ ì¤„ì„.\n- **M (Morphine):** ë¶ˆì•ˆê° ê°ì†Œ ë° í˜ˆê´€ í™•ì¥ íš¨ê³¼.\n- **N (Nitrates):** ì§ˆì‚°ì—¼. í˜ˆê´€ì„ í™•ì¥ì‹œì¼œ ì‹¬ì¥ìœ¼ë¡œ ëŒì•„ì˜¤ëŠ” í”¼(Preload)ë¥¼ ì¤„ì„.\n- **O (Oxygen):** ë¶€ì¡±í•œ ì‚°ì†Œ ê³µê¸‰.\n- **P (Position/Posture):** í™˜ìë¥¼ ì•‰í˜€ì„œ ì¤‘ë ¥ìœ¼ë¡œ í”¼ë¥¼ í•˜ì²´ë¡œ ì ë¦¬ê²Œ í•¨ (ì‹¬ì¥ ë¶€ë‹´ ê²½ê°).\n> ğŸ’¡ ì¶”ê°€ ì¡°ì¹˜:\n> \n> - Wet/Dry, Cold/Warm(ì‡¼í¬ ì—¬ë¶€) í‰ê°€\n> - ì •ë§¥ì£¼ì‚¬(ì´ë‡¨ì œ, í˜ˆê´€í™•ì¥ì œ) íˆ¬ì—¬í•˜ë©° ì‹¬ì „ë„, ì‹¬ì´ˆìŒíŒŒ ë“±ìœ¼ë¡œ ì›ì¸ íŒŒì•…\n---\n## 6. ë§Œì„± HFrEFì˜ ê´€ë¦¬ (Chronic Management) ğŸ’Š\n### 6-1. ì•½ë¬¼ ì¹˜ë£Œ (The Big Pillars)\në‹¨ìˆœ ì¦ìƒ ì™„í™”ê°€ ì•„ë‹ˆë¼ **ì‚¬ë§ë¥ (Mortality)ì„ ë‚®ì¶”ëŠ” ê²ƒ**ì´ ëª©í‘œì…ë‹ˆë‹¤.\n1. **1ë‹¨ê³„ (Foundation):**\n    - **ARNI** (Angiotensin Receptor-Neprilysin Inhibitor) ë˜ëŠ” ACEi/ARB\n    - **Beta-blockers** (ë² íƒ€ì°¨ë‹¨ì œ): í•´ë¡œìš´ ì‹ ê²½ í˜¸ë¥´ëª¬ ì‘ìš© ì°¨ë‹¨.\n2. **2ë‹¨ê³„ (Fibrosis Prevention):**\n    - **Aldosterone Antagonist** (ì˜ˆ: Spironolactone): ì‹¬ì¥ ì„¬ìœ í™” ë°©ì§€, ì…ì›ìœ¨/ì‚¬ë§ë¥  ê°ì†Œ.\n3. **3ë‹¨ê³„ (Metabolic & Remodeling):**\n    - **â˜… SGLT2 Inhibitor:** ì›ë˜ ë‹¹ë‡¨ì•½ì´ì—ˆìœ¼ë‚˜ ì‹¬ì¥ ë³´í˜¸ íš¨ê³¼ íƒì›”. ì‹¬ì¥ ë¶€ë‹´ ê°ì†Œ, ë¦¬ëª¨ë¸ë§ ë°©ì§€, ëŒ€ì‚¬ ê°œì„ . ì´ì œëŠ” í•µì‹¬ ì¶•!\n> ì°¸ê³ : Digoxin (ë””ê³¡ì‹ )\n> \n> - ì‚¬ë§ë¥  ê°œì„  íš¨ê³¼ ì—†ìŒ âŒ\n> - í•µì‹¬ ì¹˜ë£Œì—ë„ ì¦ìƒì´ ì¡°ì ˆ ì•ˆ ë  ë•Œ ì“°ëŠ” 'ë³´ì¡° ì„ ìˆ˜'. ì¦ìƒ ì™„í™” ë° ì…ì›ìœ¨ ê°ì†Œ ëª©ì .\n### 6-2. ê¸°ê¸° ì¹˜ë£Œ (Device Therapy) âš™ï¸\nì•½ë¬¼(ì†Œí”„íŠ¸ì›¨ì–´)ë¡œ ì•ˆ ë˜ë©´ í•˜ë“œì›¨ì–´ë¥¼ ì†ë´ì•¼ í•©ë‹ˆë‹¤.\n- **ICD (ì‚½ì…í˜• ì œì„¸ë™ê¸°):** ì‹¬ê¸°ëŠ¥ì´ ë§ì´ ë–¨ì–´ì ¸ ê¸‰ì‚¬ ìœ„í—˜(ì¹˜ëª…ì  ë¶€ì •ë§¥)ì´ ë†’ì€ í™˜ìì—ê²Œ 'ë³´í—˜'ìœ¼ë¡œ ì‚½ì….\n- **CRT (ì‹¬ì¥ ì¬ë™ê¸°í™” ì¹˜ë£Œ):**\n    - **ëŒ€ìƒ:** ì¢Œì‹¬ì‹¤/ìš°ì‹¬ì‹¤ ë°•ìê°€ ì•ˆ ë§ëŠ” ê²½ìš° (ECGìƒ LBBB íŒ¨í„´, QRS í­ > 150ms).\n    - **ì›ë¦¬:** ì–‘ì‹¬ì‹¤ì— ì „ê·¹ì„ ì‹¬ì–´ ë°•ìë¥¼ ë§ì¶°ì¤Œ â†’ íŒí”„ íš¨ìœ¨ ìƒìŠ¹ ğŸ“ˆ\n---\n## 7. HFpEF (ë°•ì¶œë¥  ë³´ì¡´ ì‹¬ë¶€ì „) ğŸˆ","subject":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","page_title":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","episode":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","section_path":["LM_cardio 3 2f346f2986ee80d9a857eb6585776d49"],"source_doc_id":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","source_page":null,"source_anchor":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49-21"}
{"chunk_type":"transcript_chunk","text":"- **ë¹„ìœ :** í¬ê³  íë¬¼íë¬¼í•œ í’ì„ (HFrEF) vs **ì‘ê³  ë”±ë”±í•œ ìƒˆ í’ì„ (HFpEF)**. ë°”ëŒ(í”¼)ì„ ë„£ê¸°ê°€ ë„ˆë¬´ í˜ë“¦.\n- **í™˜ìêµ°:** ë§Œì„± ê³ í˜ˆì••(ì˜¤ë˜ ì•“ì•„ì„œ ì‹¬ì¥ ê·¼ìœ¡ì´ í—¬ìŠ¤ ì„ ìˆ˜ì²˜ëŸ¼ ë‘êº¼ì›Œì§), ê³ ë ¹, ë¹„ë§Œ.\n- **ì¹˜ë£Œ:**\n    - ê³¼ê±°ì—” ì´ë‡¨ì œë¡œ ë¶“ê¸°ë§Œ ëºìŒ.\n    - ìµœê·¼ íŒ¨ëŸ¬ë‹¤ì„ ë³€í™”: **MRA (ì•Œë„ìŠ¤í…Œë¡  ê¸¸í•­ì œ)**ë‚˜ **SGLT2 Inhibitor**ê°€ íš¨ê³¼ì ì´ë¼ëŠ” ì—°êµ¬ ê²°ê³¼ ì¶•ì  ì¤‘.\n---\n## 8. íì„±ì‹¬ (Cor Pulmonale) ğŸ«â¡ï¸â¤ï¸\n- **ì •ì˜:** í ì§ˆí™˜(íŠ¹íˆ **COPD**)ìœ¼ë¡œ ì¸í•´ íë™ë§¥ ì••ë ¥ì´ ë†’ì•„ì ¸ ìš°ì‹¬ì‹¤ì´ ì§€ì³ ì“°ëŸ¬ì§„ ìƒíƒœ.\n- **ê°ë³„ í¬ì¸íŠ¸:** ì¢Œì‹¬ì‹¤ì€ ë©€ì©¡í•¨.\n- **ì„ìƒ ì†Œê²¬ (ìš°ì‹¬ë¶€ì „ ì§•í›„):**\n    - ê²½ì •ë§¥ í™•ì¥ (JVD)\n    - ê°„ ë¹„ëŒ€ (Hepatomegaly)\n    - í•˜ì§€ ë¶€ì¢…\n- **ì§„ë‹¨:** ECG (ìš°ê° ì°¨ë‹¨-RBBB, ìš°ì¶• í¸ìœ„), ì‹¬ì´ˆìŒíŒŒ(íë™ë§¥ ê³ í˜ˆì•• í™•ì¸).\n---\n## 9. ê³ ë°•ì¶œì„± ì‹¬ë¶€ì „ (High-Output HF) ğŸ”¥\n- **ê°œë…:** ì‹¬ì¥ íŒí”„ ê¸°ëŠ¥ì€ ì •ìƒ(ì‹¬ì§€ì–´ í•­ì§„)ì´ë‚˜, ëª¸ì˜ ìš”êµ¬ëŸ‰ì´ ë¹„ì •ìƒì ìœ¼ë¡œ ê³¼ë„í•œ ìƒíƒœ. (ìŠˆí¼ì¹´ì—ê²Œ ì‹œì† 400km ìœ ì§€ë¥¼ ê°•ìš”í•˜ëŠ” ê¼´)\n- **ì›ì¸:**\n    - **ë™ì •ë§¥ë£¨ (AV Fistula):** ëª¨ì„¸í˜ˆê´€ ì—†ì´ ë™ë§¥-ì •ë§¥ì´ ë°”ë¡œ ì—°ê²°ë˜ì–´ í”¼ê°€ ë„ˆë¬´ ë¹¨ë¦¬ ì‹¬ì¥ìœ¼ë¡œ ë³µê·€.\n    - **ì‹¬í•œ ë¹ˆí˜ˆ:** ì‚°ì†Œ ìš´ë°˜ ëŠ¥ë ¥ ì €í•˜ë¡œ ì‹¬ì¥ì´ ë” ë§ì´ ëœ€.\n    - **ê°‘ìƒì„  ê¸°ëŠ¥ í•­ì§„ì¦:** ì‹ ì§„ëŒ€ì‚¬ í­ë°œ.\n    - **ê°ê¸°ë³‘ (Beriberi):** í‹°ì•„ë¯¼(Thiamine) ê²°í•.\n- **í•µì‹¬:** ìˆ˜ìš”ì™€ ê³µê¸‰ì˜ ë¶ˆê· í˜• (Demand > Supply).\n---\n## 10. ê¸°íƒ€ ê³ ë ¤ ì‚¬í•­ (Thought Provoking) ğŸ¤”\nì‹¬ë¶€ì „ì€ ê¸°ê³„ì  ê³ ì¥ë¿ë§Œ ì•„ë‹ˆë¼ ì™¸ë¶€ ìš”ì¸ì— ì˜í•´ì„œë„ ë°œìƒí•  ìˆ˜ ìˆìŠµë‹ˆë‹¤.\n- **ì£¼ì‚°ê¸° ì‹¬ê·¼ë³‘ì¦ (Peripartum Cardiomyopathy):** ì„ì‹ ì´ë¼ëŠ” ìƒë¦¬ì  ìŠ¤íŠ¸ë ˆìŠ¤.\n- **íƒ€ì½”ì¸ ë³´ ì‹¬ê·¼ë³‘ì¦ (Takotsubo):** ê·¹ì‹¬í•œ ê°ì •ì  ìŠ¤íŠ¸ë ˆìŠ¤ë¡œ ë©€ì©¡í•˜ë˜ ì‹¬ì¥ì´ í•˜ë£¨ì•„ì¹¨ì— ë§ê°€ì§.\n    - ğŸ‘‰ ì‹¬ë¶€ì „ì€ í™˜ìì˜ ì‚¶, ìŠ¤íŠ¸ë ˆìŠ¤, í™˜ê²½ì„ í¬í•¨í•œ í•˜ë‚˜ì˜ 'ì´ì•¼ê¸°'ë¡œ ì ‘ê·¼í•´ì•¼ í•¨.\n---","subject":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","page_title":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","episode":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","section_path":["LM_cardio 3 2f346f2986ee80d9a857eb6585776d49"],"source_doc_id":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","source_page":null,"source_anchor":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49-41"}
{"chunk_type":"recap_summary","text":"# ğŸ”¥ Rapid Fire Recap: Must-Know High Yield Summary\n1. **Diagnosis:** í˜¸í¡ê³¤ë€(Dyspnea)ì€ í”í•˜ì§€ë§Œ, **S3 Gallop**ê³¼ **ê¸°ì¢Œí˜¸í¡(Orthopnea)**ì´ ë“¤ë¦¬ë©´ **Heart Failure**ë¥¼ ê°•ë ¥íˆ ì‹œì‚¬í•œë‹¤! (íŠ¹ì´ë„ High)\n2. **Prognosis:** **Hyponatremia** (ì €ë‚˜íŠ¸ë¥¨í˜ˆì¦) = í¬ì„ì„± = ì‹¬ê°í•œ ì¤‘ì¦ë„ & ë‚˜ìœ ì˜ˆí›„.\n3. **Acute Rx:** ê¸‰ì„± íë¶€ì¢…ì—” **LMNOP** (Lasix, Morphine, Nitrates, Oxygen, Position).\n4. **Chronic Rx (HFrEF):** ìƒì¡´ìœ¨(Mortality)ì„ ë†’ì´ëŠ” ì•½ë¬¼ 3ëŒ€ì¥ = **ARNI/ACEi + BB + MRA (+ SGLT2i)**. (Digoxinì€ ì¦ìƒ ì¡°ì ˆìš©ì¼ ë¿!)\n5. **Device:** **Wide QRS/LBBB** (>150ms) í™˜ìëŠ” íŒí”„ íš¨ìœ¨ì„ ë†’ì´ê¸° ìœ„í•´ **CRT**ë¥¼ ê³ ë ¤í•œë‹¤.\n6. **HFpEF:** **ê³ í˜ˆì••** ë³‘ë ¥ í™•ì¸! ì¹˜ë£Œì— **SGLT2i**ê°€ ì¤‘ìš”í•´ì§€ê³  ìˆë‹¤.\n7. **Cor Pulmonale:** **COPD** í™˜ì + **ìš°ì‹¬ë¶€ì „** ì†Œê²¬ (JVD, Edema) + ì¢Œì‹¬ì‹¤ ì •ìƒ.\n8. **High-Output:** ì‹¬ì¥ì€ ì˜ ë›°ëŠ”ë°(EF ì •ìƒ/ì¦ê°€) ì‹¬ë¶€ì „ ì¦ìƒ? **ë¹ˆí˜ˆ, ê°‘ìƒì„ í•­ì§„, AV Fistula, í‹°ì•„ë¯¼ ê²°í•** ì˜ì‹¬!\n**0:00~0:30 êµ¬ê°„ ë°›ì•„ì“°ê¸° (Verification)**\n\"ì USMLE Step 2 ì‹œí—˜ ì¤€ë¹„í•˜ì‹œëŠ” ë¶„ë“¤, ì˜¤ëŠ˜ ë°”ë¡œ ì—¬ëŸ¬ë¶„ì„ ìœ„í•œ ì‹œê°„ì…ë‹ˆë‹¤. ë³´ë‚´ì£¼ì‹  ìë£Œë“¤ì„ ì­‰ ë³´ë‹ˆê¹Œìš”, í•˜ë‚˜ì˜ í° ê·¸ë¦¼ì´ ê·¸ë ¤ì§€ë”ë¼ê³ ìš”. ì´ê²Œ ë‹¨ìˆœíˆ ë‹¤ë¦¬ê°€ ì•„í”„ë‹¤, ë¶“ëŠ”ë‹¤, ì´ëŸ° ë§ì´ˆ ì¦ìƒì´ìš”. ì‚¬ì‹¤ì€ ìš°ë¦¬ ëª¸ì˜ ì¤‘ì‹¬, ê·¸ëŸ¬ë‹ˆê¹Œ ì‹¬ì¥ì´ë‚˜ ì „ì‹  í˜ˆê´€ ìƒíƒœë¥¼ ì•Œë ¤ì£¼ëŠ” ì•„ì£¼ ì¤‘ìš”í•œ ì‹ í˜¸ì¼ ìˆ˜ ìˆë‹¤ëŠ” ì  ë§ì´ì£ .\"\n---\n# ğŸ«€ ë§ì´ˆí˜ˆê´€ì§ˆí™˜(PVD) ì‹¬ì¸µ ë¶„ì„: ë‹¤ë¦¬ëŠ” ì‹¬ì¥ì˜ ê±°ìš¸ì´ë‹¤\n## 1. Introduction: ë§ì´ˆí˜ˆê´€ì§ˆí™˜ì˜ í° ê·¸ë¦¼\nì´ ê°•ì˜ì˜ í•µì‹¬ì€ ë§ì´ˆí˜ˆê´€ì§ˆí™˜(PVD)ì„ ë‹¨ìˆœíˆ ë‹¤ë¦¬ì˜ ë³‘ìœ¼ë¡œë§Œ ë³´ì§€ ì•ŠëŠ” ê²ƒì…ë‹ˆë‹¤. ë‹¤ë¦¬ì˜ í˜ˆê´€ ìƒíƒœëŠ” **ì „ì‹  í˜ˆê´€ ìƒíƒœ(ì‹¬ì¥, ë‡Œí˜ˆê´€)ë¥¼ ëŒ€ë³€í•˜ëŠ” ê±°ìš¸**ì…ë‹ˆë‹¤. ë”°ë¼ì„œ ì§„ë‹¨ëª… ì•”ê¸°ë³´ë‹¤ **ë³‘íƒœìƒë¦¬ì™€ ì„ìƒì  ì‚¬ê³  ê³¼ì •**ì´ ì¤‘ìš”í•©ë‹ˆë‹¤.\n---\n## 2. ë§ì´ˆ ë™ë§¥ ì§ˆí™˜ (PAD: Peripheral Artery Disease)","subject":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","page_title":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","episode":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","section_path":["LM_cardio 3 2f346f2986ee80d9a857eb6585776d49"],"source_doc_id":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","source_page":null,"source_anchor":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49-53"}
{"chunk_type":"transcript_chunk","text":"### ğŸ©¸ ê¸°ë³¸ ê°œë…: ë¹™ì‚°ì˜ ì¼ê°\n- **ì˜ë¯¸:** ë‹¤ë¦¬ í˜ˆê´€ì— ë™ë§¥ê²½í™”ê°€ ìˆë‹¤ëŠ” ê²ƒì€ ì‹¬ì¥ì´ë‚˜ ë‡Œí˜ˆê´€ë„ ë¬´ì‚¬í•˜ì§€ ì•Šì„ ê°€ëŠ¥ì„±ì´ ë§¤ìš° ë†’ë‹¤ëŠ” ëœ»ì…ë‹ˆë‹¤.\n- **ìœ„í—˜ì„±:** PAD í™˜ìëŠ” 5ë…„ ë‚´ ì‹¬ê·¼ê²½ìƒ‰(MI)ì´ë‚˜ ë‡Œì¡¸ì¤‘ì„ ê²ªì„ í™•ë¥ ì´ 20%, ì‹¬í˜ˆê´€ ì§ˆí™˜ìœ¼ë¡œ ì‚¬ë§í•  í™•ë¥ ì´ 15~30%ì— ë‹¬í•©ë‹ˆë‹¤. ì´ëŠ” ë‹¨ìˆœí•œ ë‹¤ë¦¬ í†µì¦ì´ ì•„ë‹Œ **ê°•ë ¥í•œ ê²½ê³ ë“±**ì…ë‹ˆë‹¤.\n### ğŸ“‰ ì§„ë‹¨: ë°œëª© ìƒì™„ ì§€ìˆ˜ (ABI, Ankle-Brachial Index)\në°œëª© í˜ˆì••ì„ íŒ” í˜ˆì••ìœ¼ë¡œ ë‚˜ëˆˆ ìˆ˜ì¹˜ì…ë‹ˆë‹¤. ì´ ìˆ˜ì¹˜ í•´ì„ì— **ì‹œí—˜ì— ë‚˜ì˜¬ë§Œí•œ í•¨ì •**ì´ ìˆ¨ì–´ìˆìŠµë‹ˆë‹¤.\n- **ê¸°ë³¸ í•´ì„:** ABI < 0.9 ì´ë©´ PADë¡œ ì§„ë‹¨.\n- **â˜… Critical Trap (í•¨ì •): ABI ìˆ˜ì¹˜ê°€ 1.4 ì²˜ëŸ¼ ë†’ê²Œ ë‚˜ì˜¨ë‹¤ë©´?**\n- **ì˜¤ë‹µ:** í˜ˆê´€ì´ íŠ¼íŠ¼í•˜ë‹¤? (X)\n- **ì •ë‹µ:** í˜ˆê´€ì´ ë„ˆë¬´ ë”±ë”±í•˜ê²Œ ì„íšŒí™”ë˜ì–´ ì°Œê·¸ëŸ¬ì§€ì§€ ì•ŠëŠ” ìƒíƒœ. **'ì½˜í¬ë¦¬íŠ¸ íŒŒì´í”„'** ê°™ë‹¤. (O)\n- **ì˜ë¯¸:** ë‹¹ë‡¨ë‚˜ ë§Œì„± ì‹ ë¶€ì „ í™˜ìì—ê²Œì„œ ì£¼ë¡œ ë³´ì´ë©°, **ì¸¡ì • ë¶ˆê°€ ë° ì‹ ë¢°ë„ ì—†ìŒ**ì„ ì˜ë¯¸í•˜ëŠ” ì‹¬ê°í•œ ì‹ í˜¸ì…ë‹ˆë‹¤. ABI > 1.3 ì´ˆê³¼ëŠ” ì •ìƒë³´ë‹¤ ë” ì•ˆ ì¢‹ì€ ì ì‹ í˜¸ì…ë‹ˆë‹¤. ì´ë•ŒëŠ” ë„í”ŒëŸ¬ ì´ˆìŒíŒŒ ë“± ë‹¤ë¥¸ ê²€ì‚¬ë¡œ ë„˜ì–´ê°€ì•¼ í•©ë‹ˆë‹¤.\n### ğŸ’Š ì¹˜ë£Œ ì•Œê³ ë¦¬ì¦˜ (Treatment Paradigm)\në‹¤ë¦¬ í†µì¦ ì¹˜ë£Œë³´ë‹¤ **í™˜ì ì „ì²´(ì‹¬ì¥/ë‡Œ)ë¥¼ ë³´í˜¸**í•˜ëŠ” ê²ƒì´ ìš°ì„ ì…ë‹ˆë‹¤.\n1. **ëª¨ë“  í™˜ì ê³µí†µ (Life-saving):**\n- **ì•„ìŠ¤í”¼ë¦° (Aspirin):** í•­í˜ˆì†ŒíŒì œ.\n- **ìŠ¤íƒ€í‹´ (Statin):** ê³ ì§€í˜ˆì¦ ì•½.\n- â˜… ë‹¤ë¦¬ ì ˆë‹¨ë³´ë‹¤ ì‹¬ê·¼ê²½ìƒ‰/ë‡Œì¡¸ì¤‘ìœ¼ë¡œ ì¸í•œ ì‚¬ë§ì„ ë§‰ëŠ” ê²ƒì´ í˜„ëŒ€ ì˜í•™ì˜ í•µì‹¬ì…ë‹ˆë‹¤.\n1. **ìƒí™œ ìŠµê´€ ê°œì„  & ìš´ë™ ìš”ë²• (Limb-saving):**\n- **ê°ë…í•˜ ìš´ë™ í”„ë¡œê·¸ë¨ (Supervised Exercise):** ê°€ì¥ íš¨ê³¼ì ì¸ ì¹˜ë£Œë²• ì¤‘ í•˜ë‚˜.\n- **ì›ë¦¬:** ê±·ê¸° ìš´ë™ì„ í†µí•´ ë‹¤ë¦¬ì— ì•½ê°„ì˜ í—ˆí˜ˆ ìƒíƒœë¥¼ ë°˜ë³µì ìœ¼ë¡œ ì£¼ë©´, ìš°ë¦¬ ëª¸ì´ ìŠ¤ìŠ¤ë¡œ **ê³ìˆœí™˜ í˜ˆê´€(Collateral Circulation)**ì„ ë§Œë“¤ì–´ëƒ…ë‹ˆë‹¤. (ëª¸ì´ ìŠ¤ìŠ¤ë¡œ ë§Œë“œëŠ” ìš°íšŒë¡œ/Bypass ìˆ˜ìˆ  íš¨ê³¼).\n- **ê¸ˆì—°:** í•„ìˆ˜.\n1. **ì•½ë¬¼ & ìˆ˜ìˆ  (Symptom Relief):**\n- **ì‹¤ë¡œìŠ¤íƒ€ì¡¸ (Cilostazol):** ê°„í—ì  íŒŒí–‰ì¦(ê±·ë‹¤ê°€ ì•„íŒŒì„œ ì‰¬ëŠ” ì¦ìƒ)ì´ ë„ˆë¬´ ì‹¬í•  ë•Œ ì¦ìƒ ì™„í™” ëª©ì ìœ¼ë¡œ ê³ ë ¤.\n- ìˆ˜ìˆ /ì‹œìˆ : ì•½ë¬¼/ìš´ë™ìœ¼ë¡œ í•´ê²°ë˜ì§€ ì•Šì„ ë•Œ ê³ ë ¤.\n---\n## 3. ì •ë§¥ ë¶€ì „ (Venous Insufficiency)\n### ğŸŒŠ ê°œë…: ë°°ìˆ˜ ë¬¸ì œ (í•˜ìˆ˜ë„ ë§‰í˜)\në™ë§¥ì´ ìƒìˆ˜ë„ ê³µê¸‰ ë¬¸ì œë¼ë©´, ì •ë§¥ì€ í•˜ìˆ˜ë„ ë°°ìˆ˜ ë¬¸ì œì…ë‹ˆë‹¤. ì‹¬ì¥ìœ¼ë¡œ í”¼ë¥¼ ëŒë ¤ë³´ë‚´ëŠ” íŒë§‰(Valve)ì´ ê³ ì¥ ë‚˜ í”¼ê°€ ë‹¤ë¦¬ì— ê³ ì´ëŠ” í˜„ìƒì…ë‹ˆë‹¤.\n### ğŸ¦µ ì„ìƒ ì–‘ìƒ ë° íŠ¹ì§•\n- **ì‹œê°„ì  íŒ¨í„´:** ì•„ì¹¨ì—ëŠ” ê´œì°®ë‹¤ê°€, í•˜ë£¨ ì¢…ì¼ ì„œì„œ ì¼í•˜ê³  ë‚œ **ì €ë…ì— ì½”ë¼ë¦¬ ë‹¤ë¦¬ì²˜ëŸ¼ í‰í‰ ë¶“ê³  ë¬´ê±°ì›Œì§**.\n- **í”¼ë¶€ ë³€í™” (ìš¸ì²´ í”¼ë¶€ì—¼, Stasis Dermatitis):**\n- **ëŠª(Swamp)ì˜ ë¹„ìœ :** ë¬¼ì´ ë¹ ì§€ì§€ ì•Šê³  ê³ ì´ë©´ ëŠªì´ ë˜ë“¯, í˜ˆì•¡ì´ ì •ì²´ë˜ë©´ ì í˜ˆêµ¬ê°€ í˜ˆê´€ ë°–ìœ¼ë¡œ ìƒˆì–´ ë‚˜ì˜µë‹ˆë‹¤.\n- **í—¤ëª¨ì‹œë°ë¦° ì¹¨ì°©:** ê¹¨ì§„ ì í˜ˆêµ¬ì˜ ì²  ì„±ë¶„ì´ í”¼ë¶€ë¥¼ **ë…¹ìŠ¨ ê²ƒì²˜ëŸ¼ ì ê°ˆìƒ‰**ìœ¼ë¡œ ë¬¼ë“¤ì…ë‹ˆë‹¤.\n- **ì§ˆê°:** í”¼ë¶€ì™€ í”¼í•˜ ì¡°ì§ì´ ì„¬ìœ í™”ë˜ì–´ **ë‚˜ë¬´ì²˜ëŸ¼ ë‹¨ë‹¨í•œ(Woody induration)** ì§ˆê°ìœ¼ë¡œ ë³€í•©ë‹ˆë‹¤.\n### ğŸ›  ì¹˜ë£Œ: ì¤‘ë ¥ì„ ì´ê¸°ëŠ” ê¸°ê³„ì  ë°©ë²•\nì´ë‡¨ì œ(Diuretics)ëŠ” ê¸°ê³„ì  íŒë§‰ ê³ ì¥ì—ëŠ” í° íš¨ê³¼ê°€ ì—†ìŠµë‹ˆë‹¤. ë¬¼ë¦¬ì ì¸ ë°©ë²•ì´ í•µì‹¬ì…ë‹ˆë‹¤.\n1. **ë‹¤ë¦¬ ì˜¬ë¦¬ê¸° (Leg Elevation):** ì¤‘ë ¥ì„ ì´ìš©í•´ í”¼ë¥¼ ì‹¬ì¥ìœ¼ë¡œ ë³´ëƒ„.\n2. **ì••ë°• ìŠ¤íƒ€í‚¹ (Compression Stockings):** ë°–ì—ì„œ ì§œì£¼ëŠ” í˜.\n3. **ê±·ê¸°/ë°œëª© ìš´ë™:** ì¢…ì•„ë¦¬ ê·¼ìœ¡ íŒí”„(Calf pump)ë¥¼ í™œì„±í™”ì‹œì¼œ ì •ë§¥ë¥˜ë¥¼ ìœ„ë¡œ ì˜ì•„ ì˜¬ë¦¼.\n---\n## 4. ì‘ê¸‰ ìƒí™©: ê¸‰ì„± ì‚¬ì§€ í—ˆí˜ˆ (Acute Limb Ischemia)\n### ğŸš¨ ë³‘íƒœìƒë¦¬: 6 Ps","subject":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","page_title":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","episode":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","section_path":["LM_cardio 3 2f346f2986ee80d9a857eb6585776d49"],"source_doc_id":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49","source_page":null,"source_anchor":"LM_cardio 3 2f346f2986ee80d9a857eb6585776d49-63"}
